{"6f92b5c2f59a67b3ef85474d09e0a1ce8477f7d5": [["Running Head: Social media in outbreaksOpportunities and challenges of social media in outbreaks: A concern for COVID-19Opportunit\u00e9s et d\u00e9fis des m\u00e9dias sociaux dans les \u00e9pid\u00e9mies : Une pr\u00e9occupation pour COVID-19Amir Abdoli 1\u20f0 , Seyede Manizhe Heidarnejadi 2 1 According to a recent systematic review, the most popular social media platforms for circulation of information about the emerging infectious diseases (EID) were Facebook, Twitter, and YouTube [2] .", [["infectious diseases", "DISEASE", 393, 412], ["EID", "DISEASE", 414, 417], ["COVID", "TEST", 112, 117], ["Une pr\u00e9occupation pour COVID", "TREATMENT", 182, 210], ["Abdoli", "TREATMENT", 218, 224], ["Head", "ANATOMY", 8, 12], ["infectious", "OBSERVATION", 393, 403]]], ["Analysis of social media during the outbreaks of MERS-CoV and the H7N9 influenza in China have shown the usefulness of these platforms for measurement of the level of public awareness [3] .", [["influenza", "DISEASE", 71, 80], ["MERS-CoV", "ORGANISM", 49, 57], ["H7N9 influenza", "ORGANISM", 66, 80], ["MERS-CoV", "SPECIES", 49, 57], ["social media", "TREATMENT", 12, 24], ["CoV", "PROBLEM", 54, 57], ["the H7N9 influenza", "PROBLEM", 62, 80], ["these platforms", "TEST", 119, 134]]], ["Another research regarding the Zika virus outbreak has demonstrated that social media can be used as a complementary way for forecasting the disease incidence and assessment of the dynamics of the outbreak [4] .", [["Zika virus", "ORGANISM", 31, 41], ["Zika virus", "SPECIES", 31, 41], ["the Zika virus outbreak", "PROBLEM", 27, 50], ["social media", "TREATMENT", 73, 85], ["the disease incidence", "PROBLEM", 137, 158], ["assessment", "TEST", 163, 173]]], ["The World Health Organization (WHO) has recently reported 12 myths about the COVID-19 pandemic [5] that swiftly disseminated in the websites and social media platforms.", [["the COVID", "TEST", 73, 82], ["disseminated", "OBSERVATION_MODIFIER", 112, 124]]], ["Hence, the internet and social media platforms can be used as a helpful tool for dissemination of information during outbreaks by health authorities [1, 6] .Opportunit\u00e9s et d\u00e9fis des m\u00e9dias sociaux dans les \u00e9pid\u00e9mies : Une pr\u00e9occupation pour COVID-19Besides the mentioned advantages, it seems that gossip and rumors are more contagious than contagious diseases in outbreaks.", [["COVID-19Besides", "CHEMICAL", 242, 257], ["social media platforms", "TREATMENT", 24, 46], ["rumors", "PROBLEM", 309, 315], ["contagious diseases", "PROBLEM", 341, 360]]], ["For instance, two speculative treatment methods of Ebola, including ingestion of Nano Silver and bathing in or drinking saltwater was spread during the Ebola outbreak in Twitter and Weibo (a Chines social media application) [7] .", [["Ebola", "DISEASE", 51, 56], ["Silver", "CHEMICAL", 86, 92], ["Ebola", "DISEASE", 152, 157], ["Ebola", "ORGANISM", 51, 56], ["Ebola", "PROBLEM", 51, 56], ["Nano Silver", "TREATMENT", 81, 92], ["a Chines social media application", "TREATMENT", 189, 222], ["Ebola", "OBSERVATION", 51, 56]]], ["For instance, consumption of garlic, onion, and ginger as well as smoking frankincense and harmala (Peganum harmala) have been suggested for prevention of the COVID-19 in websites and social media platforms.", [["onion", "ANATOMY", 37, 42], ["garlic, onion, and ginger", "CHEMICAL", 29, 54], ["smoking", "CHEMICAL", 66, 73], ["garlic", "SIMPLE_CHEMICAL", 29, 35], ["onion", "ORGANISM_SUBDIVISION", 37, 42], ["ginger", "ORGANISM_SUBDIVISION", 48, 54], ["harmala", "ORGANISM_SUBDIVISION", 91, 98], ["Peganum harmala", "ORGANISM", 100, 115], ["garlic", "SPECIES", 29, 35], ["onion", "SPECIES", 37, 42], ["ginger", "SPECIES", 48, 54], ["Peganum harmala", "SPECIES", 100, 115], ["garlic", "SPECIES", 29, 35], ["Peganum harmala", "SPECIES", 100, 115], ["garlic", "TREATMENT", 29, 35], ["harmala (Peganum harmala", "TREATMENT", 91, 115], ["harmala", "ANATOMY", 91, 98]]], ["An online survey among Chinese populations (4872 participants from 31 provinces of China) during the COVID-19 outbreak has shown that 22.6%, 48.3%, and 19.4% of the participants reported to experienced anxiety, depression and a combination of them, respectively [8] .", [["anxiety", "DISEASE", 202, 209], ["depression", "DISEASE", 211, 221], ["participants", "ORGANISM", 165, 177], ["participants", "SPECIES", 49, 61], ["participants", "SPECIES", 165, 177], ["the COVID", "TEST", 97, 106], ["anxiety", "PROBLEM", 202, 209], ["depression", "PROBLEM", 211, 221]]], ["As such, more than 80% of participants have been used social media.", [["participants", "ORGANISM", 26, 38], ["participants", "SPECIES", 26, 38]]], ["Social media exposure (SME) was positively associated with high rate of anxiety (OR=1.72) and combination of anxiety and depression (OR=1.91) compared with less SME exposure [8] .", [["anxiety", "DISEASE", 72, 79], ["anxiety", "DISEASE", 109, 116], ["depression", "DISEASE", 121, 131], ["SME", "CHEMICAL", 161, 164], ["high rate of anxiety", "PROBLEM", 59, 79], ["anxiety", "PROBLEM", 109, 116], ["depression", "PROBLEM", 121, 131]]], ["Another survey among the Chinese populations regarding the social media use and mental health status during the COVID-19 outbreak have shown that about one-fifth of the respondents had anxiety and depression.", [["anxiety", "DISEASE", 185, 192], ["depression", "DISEASE", 197, 207], ["anxiety", "PROBLEM", 185, 192], ["depression", "PROBLEM", 197, 207]]], ["Moreover, the anxiety and depression were associated with spending \u2265 2 hours daily on COVID-19 news via social media [9] .", [["anxiety", "DISEASE", 14, 21], ["depression", "DISEASE", 26, 36], ["the anxiety", "PROBLEM", 10, 21], ["depression", "PROBLEM", 26, 36], ["COVID", "TREATMENT", 86, 91]]], ["Also, studies about the association of social media use and mental health status revealed that the depressive symptoms were higher in young girls than boys [10] .Opportunit\u00e9s et d\u00e9fis des m\u00e9dias sociaux dans les \u00e9pid\u00e9mies : Une pr\u00e9occupation pour COVID-19Increasing pandemic fears due to fake news and misinformation is another challenge of the social media platforms that should be managed by health authorities or governments.Opportunit\u00e9s et d\u00e9fis des m\u00e9dias sociaux dans les \u00e9pid\u00e9mies : Une pr\u00e9occupation pour COVID-19Taken together, the pros and cons of the internet and social media should be more considered by the health authorities or governments for the management and control of outbreaks.", [["depressive", "DISEASE", 99, 109], ["girls", "SPECIES", 140, 145], ["boys", "SPECIES", 151, 155], ["the depressive symptoms", "PROBLEM", 95, 118], ["the social media platforms", "TREATMENT", 341, 367], ["social media", "TREATMENT", 575, 587], ["the management", "TREATMENT", 659, 673]]]], "PMC7382329": [["IntroductionThe emerging coronavirus disease 2019 (COVID-19) is a recent pandemic which has been recently declared as a public health emergency by the World Health Organization (WHO).", [["coronavirus disease", "DISEASE", 25, 44], ["COVID-19", "CHEMICAL", 51, 59], ["coronavirus", "ORGANISM", 25, 36], ["coronavirus disease 2019 (COVID-19", "SPECIES", 25, 59], ["The emerging coronavirus disease", "PROBLEM", 12, 44], ["COVID", "TEST", 51, 56], ["a recent pandemic", "PROBLEM", 64, 81], ["coronavirus disease", "OBSERVATION", 25, 44], ["pandemic", "OBSERVATION", 73, 81]]], ["Since its first appearance in visitors of the Wuhan\u2019s seafood and meat market, China, reported in December 2019, COVID-19 has now a large-scale socioeconomic impact [1].", [["meat", "ORGANISM_SUBDIVISION", 66, 70], ["COVID", "TEST", 113, 118]]], ["According to WHO, till 6 April 2020, the infection has spread over to at least 170 countries and territories, where there have been more than 1.21 million confirmed cases, with more than 67,000 deaths due to COVID-19.", [["infection", "DISEASE", 41, 50], ["deaths", "DISEASE", 194, 200], ["the infection", "PROBLEM", 37, 50], ["COVID", "TEST", 208, 213], ["infection", "OBSERVATION", 41, 50]]], ["One should also keep in mind that these data on the COVID-19 spread and related casualties are rapidly becoming outdated, almost with the speed of typing of these sentences [2].IntroductionAccording to the International Committee on Taxonomy of Viruses (ICTV), SARS-CoV-2 comes under the coronavirinae sub-family of coronaviridae family of order nidovirales.", [["SARS", "DISEASE", 261, 265], ["SARS-CoV-2", "ORGANISM", 261, 271], ["coronaviridae", "ORGANISM", 316, 329], ["ICTV", "SPECIES", 254, 258], ["these data", "TEST", 34, 44], ["the COVID", "TEST", 48, 57]]], ["Viruses of the nidovirales order are enveloped, non-segmented positive-sense, single-stranded RNA viruses [3].", [["single-stranded RNA viruses", "PROBLEM", 78, 105]]], ["The family coronaviridae comprises of vertebrate infecting viruses that transmit horizontally, mainly through the oral/fecal route and cause gastrointestinal and respiratory problems to the host [4].", [["oral", "ANATOMY", 114, 118], ["gastrointestinal", "ANATOMY", 141, 157], ["respiratory", "ANATOMY", 162, 173], ["gastrointestinal and respiratory problems", "DISEASE", 141, 182], ["oral", "ORGANISM_SUBDIVISION", 114, 118], ["gastrointestinal", "ORGANISM_SUBDIVISION", 141, 157], ["vertebrate infecting viruses", "PROBLEM", 38, 66], ["the oral/fecal route", "TREATMENT", 110, 130], ["gastrointestinal and respiratory problems", "PROBLEM", 141, 182], ["infecting viruses", "OBSERVATION", 49, 66], ["fecal", "ANATOMY", 119, 124], ["gastrointestinal", "ANATOMY", 141, 157], ["respiratory", "ANATOMY", 162, 173]]], ["Sub-family coronavirinae consists of four genera, namely: alpha, beta, gamma, and delta coronaviruses based on the phylogenetic clustering of viruses [5, 6].", [["alpha, beta", "GENE_OR_GENE_PRODUCT", 58, 69], ["gamma", "GENE_OR_GENE_PRODUCT", 71, 76], ["delta coronaviruses", "ORGANISM", 82, 101], ["alpha, beta, gamma", "PROTEIN", 58, 76], ["alpha, beta, gamma", "TREATMENT", 58, 76], ["delta coronaviruses", "PROBLEM", 82, 101], ["the phylogenetic clustering of viruses", "PROBLEM", 111, 149], ["gamma", "ANATOMY", 71, 76], ["viruses", "OBSERVATION", 142, 149]]], ["Coronavirinae having the largest genomes among the RNA viruses incorporate their ~ 30 kb genomes inside an enveloped capsid [7].IntroductionSARS-coronavirus genomic RNA includes a 5\u2032 cap, leader sequence, UTR, a replicase gene, genes for structural and accessory proteins, 3\u2032 UTR, and a poly-A tail (Fig. 1).", [["Coronavirinae", "CHEMICAL", 0, 13], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 0, 13], ["coronavirus", "ORGANISM", 145, 156], ["~ 30 kb genomes", "DNA", 81, 96], ["coronavirus genomic RNA", "RNA", 145, 168], ["5\u2032 cap", "DNA", 180, 186], ["leader sequence", "DNA", 188, 203], ["UTR", "DNA", 205, 208], ["replicase gene", "DNA", 212, 226], ["\u2032 UTR", "DNA", 274, 279], ["poly-A tail", "DNA", 287, 298], ["Coronavirinae", "TREATMENT", 0, 13], ["the RNA viruses", "PROBLEM", 47, 62], ["IntroductionSARS", "TEST", 128, 144], ["coronavirus genomic RNA", "PROBLEM", 145, 168], ["a 5\u2032 cap", "TREATMENT", 178, 186], ["leader sequence", "TEST", 188, 203], ["UTR", "PROBLEM", 205, 208], ["structural and accessory proteins", "PROBLEM", 238, 271], ["largest", "OBSERVATION_MODIFIER", 25, 32], ["RNA viruses", "OBSERVATION", 51, 62], ["coronavirus genomic RNA", "OBSERVATION", 145, 168], ["tail", "ANATOMY", 294, 298]]], ["Two-third of the genome codes for the replicase polyproteins (~ 20 kb) containing all non-structural viral proteins, while the remaining part of the genome (~ 10 kb) contains genes for accessory proteins interspersed between the genes responsible for coding structural proteins [7, 8].", [["replicase polyproteins", "PROTEIN", 38, 60], ["non-structural viral proteins", "PROTEIN", 86, 115], ["accessory proteins", "PROTEIN", 185, 203], ["structural proteins", "PROTEIN", 258, 277], ["the replicase polyproteins", "PROBLEM", 34, 60], ["all non-structural viral proteins", "PROBLEM", 82, 115], ["accessory proteins", "PROBLEM", 185, 203], ["coding structural proteins", "PROBLEM", 251, 277], ["non-structural viral proteins", "OBSERVATION", 86, 115]]], ["The ~ 20 kb (replicase gene) ssRNA is translated first into two long polyproteins: replicase polyprotein 1a and 1ab inside host cells.", [["cells", "ANATOMY", 128, 133], ["replicase polyprotein 1a", "GENE_OR_GENE_PRODUCT", 83, 107], ["1", "GENE_OR_GENE_PRODUCT", 112, 113], ["host cells", "CELL", 123, 133], ["replicase gene", "DNA", 13, 27], ["long polyproteins", "DNA", 64, 81], ["replicase polyprotein 1a", "PROTEIN", 83, 107], ["host cells", "CELL_TYPE", 123, 133], ["The ~ 20 kb (replicase gene) ssRNA", "TREATMENT", 0, 34], ["two long polyproteins", "PROBLEM", 60, 81], ["replicase polyprotein 1a", "TREATMENT", 83, 107], ["host cells", "OBSERVATION", 123, 133]]], ["The newly formed polyproteins, after cleavage by two viral proteases, result in 16 non-structural proteins (Nsps) that perform a wide range of functions for viruses inside the host cell [9, 10].", [["cell", "ANATOMY", 181, 185], ["Nsps", "GENE_OR_GENE_PRODUCT", 108, 112], ["cell", "CELL", 181, 185], ["viral proteases", "PROTEIN", 53, 68], ["16 non-structural proteins", "PROTEIN", 80, 106], ["Nsps", "PROTEIN", 108, 112], ["The newly formed polyproteins", "PROBLEM", 0, 29], ["cleavage", "TREATMENT", 37, 45], ["two viral proteases", "TEST", 49, 68], ["16 non-structural proteins (Nsps", "PROBLEM", 80, 112], ["viruses", "PROBLEM", 157, 164], ["polyproteins", "OBSERVATION", 17, 29], ["host cell", "OBSERVATION", 176, 185]]], ["The genomic sequence of SARS-CoV-2 is reported to have 29,903 nucleotides with GenBank accession number NC_045512 [11].IntroductionIn this study, we analysed the dark side of SARS-CoV-2 proteome (i.e. a part of a proteome that includes proteins or protein regions, which are not amenable to experimental structure determination by existing means and inaccessible to homology modeling), to better understand an interplay between the ordered and disordered components of the proteome.", [["nucleotides", "CHEMICAL", 62, 73], ["SARS-CoV-2", "ORGANISM", 24, 34], ["protein regions", "PROTEIN", 248, 263], ["SARS-CoV-2", "SPECIES", 24, 34], ["SARS-CoV", "SPECIES", 175, 183], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["this study", "TEST", 134, 144], ["SARS", "TEST", 175, 179], ["CoV", "TEST", 180, 183], ["proteins or protein regions", "PROBLEM", 236, 263]]], ["According to the \u201cheretic\u201d viewpoint of the \u201cpresence of functional intrinsic disorder in proteins\u201d, a noticeable amount of biologically active proteins (of protein regions) fail to fold into the well-defined structures and instead remain disordered, existing as highly dynamic ensembles of rapidly interconverting conformations under the physiological conditions.", [["disorder", "DISEASE", 78, 86], ["protein regions", "PROTEIN", 157, 172], ["functional intrinsic disorder in proteins", "PROBLEM", 57, 98], ["biologically active proteins (of protein regions)", "PROBLEM", 124, 173], ["intrinsic disorder", "OBSERVATION", 68, 86], ["active", "OBSERVATION_MODIFIER", 137, 143], ["proteins", "OBSERVATION", 144, 152]]], ["These proteins and protein regions are known now as intrinsically disordered proteins (IDPs) and intrinsically disordered protein regions (IDPRs), respectively.", [["protein regions", "PROTEIN", 19, 34], ["intrinsically disordered proteins", "PROTEIN", 52, 85], ["IDPs", "PROTEIN", 87, 91], ["intrinsically disordered protein regions", "PROTEIN", 97, 137], ["IDPRs", "PROTEIN", 139, 144], ["These proteins and protein regions", "PROBLEM", 0, 34], ["intrinsically disordered proteins (IDPs)", "PROBLEM", 52, 92], ["intrinsically disordered protein regions", "PROBLEM", 97, 137], ["protein regions", "OBSERVATION", 19, 34]]], ["The propensity of being functional intrinsically disordered proteins (similar to the propensity of forming unique biologically active structures of ordered proteins) is determined by the amino acid sequences [12\u201314].", [["amino acid", "CHEMICAL", 187, 197], ["amino acid", "CHEMICAL", 187, 197], ["amino acid", "AMINO_ACID", 187, 197], ["intrinsically disordered proteins", "PROTEIN", 35, 68], ["ordered proteins", "PROTEIN", 148, 164], ["amino acid sequences", "PROTEIN", 187, 207], ["functional intrinsically disordered proteins", "PROBLEM", 24, 68], ["the amino acid sequences", "TEST", 183, 207]]], ["IDPs exhibit their biological functions in numerous biological processes commonly associated with cellular signalling, gene regulation, and control by interacting with their physiological partners [15\u201319].", [["cellular", "ANATOMY", 98, 106], ["cellular", "CELL", 98, 106], ["cellular signalling", "PROBLEM", 98, 117]]], ["These functions of IDPs and IDPRs are regulated by their protein\u2013protein, protein\u2013RNA, and protein\u2013DNA interactions [20, 21].", [["IDPs", "GENE_OR_GENE_PRODUCT", 19, 23], ["IDPRs", "GENE_OR_GENE_PRODUCT", 28, 33], ["protein\u2013", "GENE_OR_GENE_PRODUCT", 74, 82], ["IDPs", "PROTEIN", 19, 23], ["IDPRs", "PROTEIN", 28, 33], ["protein\u2013protein, protein\u2013RNA", "RNA", 57, 85], ["IDPs", "TEST", 19, 23]]], ["Molecular recognition features (MoRFs) are the regions in IDPs implicated in the regulation of IDP function by protein\u2013protein interactions and serve as the primary stage in molecular recognition.IntroductionIt is known that the IDPs/IDPRs are present in all three kingdoms of life, and viral proteins often contain unstructured regions that have been strongly correlated with their virulence [22\u201325].", [["MoRFs", "GENE_OR_GENE_PRODUCT", 32, 37], ["IDP", "GENE_OR_GENE_PRODUCT", 95, 98], ["IDPs", "GENE_OR_GENE_PRODUCT", 229, 233], ["IDPRs", "GENE_OR_GENE_PRODUCT", 234, 239], ["MoRFs", "PROTEIN", 32, 37], ["IDPs", "PROTEIN", 58, 62], ["IDPs", "PROTEIN", 229, 233], ["IDPRs", "PROTEIN", 234, 239], ["viral proteins", "PROTEIN", 287, 301], ["protein\u2013protein interactions", "PROBLEM", 111, 139], ["the IDPs/IDPRs", "TREATMENT", 225, 239], ["viral proteins", "PROBLEM", 287, 301], ["molecular recognition", "OBSERVATION", 174, 195]]], ["In this report, we have investigated the disordered side of SARS-CoV-2 proteome using a complementary set of computational approaches to check the prevalence of IDPRs in its proteins and to shed some light on their disorder-related functions.", [["disorder", "DISEASE", 215, 223], ["IDPRs", "GENE_OR_GENE_PRODUCT", 161, 166], ["IDPRs", "PROTEIN", 161, 166], ["their disorder", "PROBLEM", 209, 223]]], ["We also have comprehensively analysed IDPRs among the closely related viruses, human SARS and bat SARS-like CoVs.", [["SARS", "DISEASE", 85, 89], ["SARS", "DISEASE", 98, 102], ["IDPRs", "GENE_OR_GENE_PRODUCT", 38, 43], ["human", "ORGANISM", 79, 84], ["bat SARS-like CoVs", "ORGANISM", 94, 112], ["IDPRs", "PROTEIN", 38, 43], ["human SARS and bat SARS-like CoVs", "DNA", 79, 112], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["the closely related viruses", "PROBLEM", 50, 77], ["human SARS", "PROBLEM", 79, 89], ["bat SARS", "PROBLEM", 94, 102], ["CoVs", "PROBLEM", 108, 112]]], ["Furthermore, we have also identified protein functions related to protein\u2013protein interactions, RNA binding, and DNA binding from all three viruses.", [["DNA", "CELLULAR_COMPONENT", 113, 116], ["protein functions", "PROBLEM", 37, 54], ["protein\u2013protein interactions", "PROBLEM", 66, 94], ["RNA binding", "PROBLEM", 96, 107], ["DNA binding", "PROBLEM", 113, 124], ["protein functions", "OBSERVATION", 37, 54]]], ["Since these three viruses are closely related, our study provides an important means for a better understanding of the sequence and structural peculiarities of their evolution.Sequence retrieval and multiple sequence alignment ::: Materials and methodsThe protein sequences of bat CoV (SARS-like) and human SARS CoV were retrieved from UniProt (UniProt IDs for individual proteins are listed in Table 1).", [["bat CoV", "ORGANISM", 277, 284], ["SARS-like)", "GENE_OR_GENE_PRODUCT", 286, 296], ["human", "ORGANISM", 301, 306], ["SARS CoV", "ORGANISM", 307, 315], ["bat CoV", "PROTEIN", 277, 284], ["human SARS CoV", "PROTEIN", 301, 315], ["bat CoV", "SPECIES", 277, 284], ["human", "SPECIES", 301, 306], ["bat CoV", "SPECIES", 277, 284], ["human SARS CoV", "SPECIES", 301, 315], ["our study", "TEST", 47, 56], ["the sequence", "TEST", 115, 127], ["Sequence retrieval", "TEST", 176, 194], ["The protein sequences", "TEST", 252, 273], ["bat CoV", "TEST", 277, 284], ["human SARS CoV", "PROBLEM", 301, 315], ["UniProt (UniProt IDs", "TREATMENT", 336, 356], ["individual proteins", "TREATMENT", 361, 380], ["viruses", "OBSERVATION", 18, 25]]], ["The translated sequences of SARS-CoV-2 proteins [GenBank database [26] (Accession ID: NC_045512.2)] were obtained from GenBank.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["SARS-CoV-2 proteins", "DNA", 28, 47], ["SARS-CoV", "SPECIES", 28, 36], ["The translated sequences", "TEST", 0, 24], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36], ["GenBank database", "TEST", 49, 65]]], ["We used these sequences for performing multiple sequence alignment (MSA) and predicting the IDPRs.", [["IDPRs", "DNA", 92, 97], ["these sequences", "TEST", 8, 23], ["multiple sequence alignment", "TEST", 39, 66]]], ["We have used Clustal Omega [27] for protein sequence alignment and Esprit 3.0 [28] for constructing the aligned images.Per-residue predictions of intrinsic disorder predisposition ::: Materials and methodsFor the prediction of the intrinsic disorder predisposition of CoV proteomes, we used multiple predictors, such as members of the PONDR\u00ae (Predictor of Natural Disordered Regions) family including PONDR\u00aeVLS2 [29], PONDR\u00aeVL3 [30], PONDR\u00aeFIT [31], and PONDR\u00ae VLXT [32], as well as the IUPred platform for predicting long (\u2265 30 residues) and short IDPRs (< 30 residues) [33].", [["intrinsic disorder", "DISEASE", 146, 164], ["CoV", "ORGANISM", 268, 271], ["PONDR", "PROTEIN", 335, 340], ["PONDR", "PROTEIN", 401, 406], ["IDPRs", "PROTEIN", 549, 554], ["Clustal Omega", "TREATMENT", 13, 26], ["protein sequence alignment", "TEST", 36, 62], ["Esprit", "TEST", 67, 73], ["constructing the aligned images", "TEST", 87, 118], ["methods", "TREATMENT", 198, 205], ["VLS2", "TEST", 407, 411], ["FIT", "TEST", 440, 443], ["PONDR", "TEST", 454, 459], ["VLXT", "TEST", 461, 465], ["the IUPred platform", "TEST", 483, 502], ["residues", "TEST", 529, 537], ["short IDPRs", "TEST", 543, 554], ["intrinsic disorder", "OBSERVATION", 146, 164]]], ["Residues with disorder scores exceeding the threshold value of 0.5 are considered as intrinsically disordered residues, whereas residues with the predicted disorder scores between 0.2 and 0.5 are considered flexible.", [["disorder", "DISEASE", 14, 22], ["disorder scores", "PROBLEM", 14, 29], ["the threshold value", "TEST", 40, 59], ["intrinsically disordered residues", "PROBLEM", 85, 118], ["the predicted disorder scores", "PROBLEM", 142, 171]]], ["Complete predicted percent of intrinsic disorder (PPID) in a query protein was calculated for every protein of all the three viruses from outputs of six predictors.", [["intrinsic disorder", "DISEASE", 30, 48], ["intrinsic disorder (PPID)", "PROBLEM", 30, 55], ["a query protein", "TEST", 59, 74], ["intrinsic disorder", "OBSERVATION", 30, 48]]], ["The detailed methodology has been given in our previous reports [34, 35].Combined CH\u2013CDF analysis to predict disorder predisposition of proteins ::: Materials and methodsThe charge hydropathy plot [36] and PONDR\u00ae VLXT-based cumulative distribution function are two binary predictors of disorder (i.e. tool evaluating entire protein as mostly ordered or mostly disordered), which are available on the PONDR web server (https://www.pondr.com).", [["disorder predisposition", "DISEASE", 109, 132], ["disorder", "DISEASE", 286, 294], ["VLXT", "PROTEIN", 213, 217], ["Combined CH\u2013CDF analysis", "TEST", 73, 97], ["The charge hydropathy plot", "TEST", 170, 196], ["PONDR", "TEST", 206, 211], ["VLXT", "TEST", 213, 217], ["disorder", "PROBLEM", 286, 294], ["entire protein", "TEST", 317, 331]]], ["Combining the result from these binary predictors helps to classify the proteins into different groups, depending on their global disorder [37].Molecular recognition feature (MoRF) determination in CoV proteomes ::: Materials and methodsThe authentic online bioinformatics predictors that use a different set of algorithms for the prediction of MoRFs were used.", [["CoV", "ORGANISM", 198, 201], ["MoRFs", "GENE_OR_GENE_PRODUCT", 345, 350], ["MoRFs", "PROTEIN", 345, 350], ["their global disorder", "PROBLEM", 117, 138], ["MoRFs", "TREATMENT", 345, 350]]], ["These include MoRFchibi_web [38], ANCHOR [39, 40], MoRFPred [41], and DISOPRED3 [42].", [["ANCHOR", "TEST", 34, 40]]], ["The protein residues with ANCHOR, MoRFPred, and DISOPRED3 scores above the threshold value of 0.5 and MoRFchibi_web score above the threshold value of 0.725 are considered MoRF regions.Identification of DNA- and RNA-binding regions in CoV proteomes ::: Materials and methodsOften, IDPs and IDPRs facilitate interactions with RNAs and DNAs and regulate many cellular functions [43].", [["cellular", "ANATOMY", 357, 365], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["CoV", "ORGANISM", 235, 238], ["IDPRs", "GENE_OR_GENE_PRODUCT", 290, 295], ["DNAs", "CELLULAR_COMPONENT", 334, 338], ["cellular", "CELL", 357, 365], ["ANCHOR", "PROTEIN", 26, 32], ["MoRFPred", "PROTEIN", 34, 42], ["DISOPRED3", "PROTEIN", 48, 57], ["MoRF regions", "DNA", 172, 184], ["RNA-binding regions", "DNA", 212, 231], ["IDPs", "PROTEIN", 281, 285], ["IDPRs", "PROTEIN", 290, 295], ["RNAs", "RNA", 325, 329], ["DISOPRED3 scores", "TEST", 48, 64], ["the threshold value", "TEST", 71, 90], ["MoRFchibi_web score", "TEST", 102, 121], ["the threshold value", "TEST", 128, 147], ["DNA", "TEST", 203, 206], ["methodsOften", "TREATMENT", 267, 279], ["IDPs", "TREATMENT", 281, 285], ["IDPRs", "TREATMENT", 290, 295], ["RNAs and DNAs", "TREATMENT", 325, 338], ["protein residues", "OBSERVATION", 4, 20], ["ANCHOR", "OBSERVATION_MODIFIER", 26, 32], ["DNA", "OBSERVATION", 203, 206]]], ["Thus, for predicting the DNA-binding residues in CoV proteins, we used two online servers: DRNAPred [20] and DisoRDPbind [43].", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["CoV proteins", "PROTEIN", 49, 61], ["the DNA-binding residues in CoV proteins", "PROBLEM", 21, 61]]], ["For RNA-binding residues, we used PPRInt (Prediction of Protein RNA- Interaction) [44] and DisoRDPbind servers [43].Comprehensive computational analysis of intrinsic disorder in structural and accessory proteins of SARS-CoV-2, human SARS and bat CoV (SARS-like) ::: Results and discussionThe mean values of the predicted percentage of intrinsic disorder scores (mean PPIDs) that were obtained by averaging the predicted disorder scores from six disorder predictors (Tables S1\u2013S3) for structural and accessory proteins of SARS-CoV-2 as well as human SARS, and bat CoV are represented in Table 1.Comprehensive computational analysis of intrinsic disorder in structural and accessory proteins of SARS-CoV-2, human SARS and bat CoV (SARS-like) ::: Results and discussionFigure 2a\u2013c are 2D-disordered plots generated for SARS-CoV-2, human SARS and bat CoV proteins, respectively, and represent the PPIDPONDR-FIT vs. PPIDMean plots.", [["intrinsic disorder", "DISEASE", 156, 174], ["SARS", "DISEASE", 215, 219], ["SARS", "DISEASE", 233, 237], ["disorder", "DISEASE", 420, 428], ["disorder", "DISEASE", 445, 453], ["SARS", "DISEASE", 549, 553], ["intrinsic disorder", "DISEASE", 634, 652], ["SARS", "DISEASE", 693, 697], ["SARS", "DISEASE", 711, 715], ["SARS-CoV-2", "ORGANISM", 215, 225], ["human", "ORGANISM", 227, 232], ["bat CoV", "ORGANISM", 242, 249], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 521, 531], ["human", "ORGANISM", 543, 548], ["bat CoV", "ORGANISM", 559, 566], ["SARS-CoV-2", "ORGANISM", 693, 703], ["human", "ORGANISM", 705, 710], ["bat CoV", "ORGANISM", 720, 727], ["human", "ORGANISM", 828, 833], ["bat CoV", "ORGANISM", 843, 850], ["PPRInt", "PROTEIN", 34, 40], ["accessory proteins", "PROTEIN", 193, 211], ["accessory proteins", "PROTEIN", 499, 517], ["CoV", "PROTEIN", 526, 529], ["accessory proteins", "PROTEIN", 671, 689], ["SARS-CoV-2, human SARS and bat CoV proteins", "PROTEIN", 816, 859], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 543, 548], ["human", "SPECIES", 705, 710], ["human", "SPECIES", 828, 833], ["SARS-CoV", "SPECIES", 215, 223], ["human", "SPECIES", 227, 232], ["bat CoV", "SPECIES", 242, 249], ["SARS-CoV", "SPECIES", 521, 529], ["human", "SPECIES", 543, 548], ["bat CoV", "SPECIES", 559, 566], ["SARS-CoV", "SPECIES", 693, 701], ["human", "SPECIES", 705, 710], ["bat CoV", "SPECIES", 720, 727], ["SARS-CoV", "SPECIES", 816, 824], ["human", "SPECIES", 828, 833], ["bat CoV", "SPECIES", 843, 850], ["RNA-binding residues", "PROBLEM", 4, 24], ["Comprehensive computational analysis", "TEST", 116, 152], ["intrinsic disorder", "PROBLEM", 156, 174], ["SARS", "PROBLEM", 215, 219], ["CoV", "TEST", 220, 223], ["human SARS", "PROBLEM", 227, 237], ["bat CoV", "TEST", 242, 249], ["The mean values", "TEST", 288, 303], ["intrinsic disorder scores", "PROBLEM", 335, 360], ["mean PPIDs", "TEST", 362, 372], ["the predicted disorder scores", "PROBLEM", 406, 435], ["six disorder predictors", "PROBLEM", 441, 464], ["structural and accessory proteins of SARS", "PROBLEM", 484, 525], ["CoV", "TEST", 526, 529], ["human SARS", "PROBLEM", 543, 553], ["Comprehensive computational analysis", "TEST", 594, 630], ["intrinsic disorder", "PROBLEM", 634, 652], ["SARS", "PROBLEM", 693, 697], ["CoV", "TEST", 698, 701], ["human SARS", "PROBLEM", 705, 715], ["2D-disordered plots", "TEST", 782, 801], ["SARS", "TEST", 816, 820], ["CoV", "TEST", 821, 824], ["human SARS", "TEST", 828, 838], ["bat CoV proteins", "TEST", 843, 859], ["the PPIDPONDR", "TEST", 889, 902], ["PPIDMean plots", "PROBLEM", 911, 925], ["intrinsic disorder", "OBSERVATION", 156, 174], ["mean values", "OBSERVATION_MODIFIER", 292, 303], ["intrinsic disorder", "OBSERVATION", 335, 353]]], ["Based on their predicted levels of intrinsic disorder, proteins can be classified as highly ordered (PPID < 10%), moderately disordered (10% \u2264 PPID < 30%) and highly disordered (PPID \u2265 30%) [46].", [["intrinsic disorder", "DISEASE", 35, 53], ["intrinsic disorder", "PROBLEM", 35, 53], ["PPID", "TEST", 101, 105], ["moderately disordered", "PROBLEM", 114, 135], ["PPID", "TEST", 143, 147], ["highly disordered (PPID", "PROBLEM", 159, 182]]], ["From the data in Table 1, Fig. 2a\u2013c, as well as the PPID based classification, we conclude that the nucleocapsid protein from all three CoVs possess the highest percentage of disorder and, therefore, is classified as a highly disordered protein.", [["disorder", "DISEASE", 175, 183], ["CoVs", "GENE_OR_GENE_PRODUCT", 136, 140], ["PPID", "PROTEIN", 52, 56], ["nucleocapsid protein", "PROTEIN", 100, 120], ["CoVs", "PROTEIN", 136, 140], ["highly disordered protein", "PROTEIN", 219, 244], ["the nucleocapsid protein", "PROBLEM", 96, 120], ["disorder", "PROBLEM", 175, 183], ["a highly disordered protein", "PROBLEM", 217, 244], ["highest", "OBSERVATION_MODIFIER", 153, 160], ["percentage", "OBSERVATION_MODIFIER", 161, 171]]], ["The ORF3b protein in bat CoV, ORF6 protein of all three CoVs, and ORF9b proteins of SARS-CoV-2 and bat CoV belongs to the class of moderately disordered proteins.", [["ORF3b", "GENE_OR_GENE_PRODUCT", 4, 9], ["bat CoV", "ORGANISM", 21, 28], ["ORF6", "GENE_OR_GENE_PRODUCT", 30, 34], ["CoVs", "GENE_OR_GENE_PRODUCT", 56, 60], ["ORF9b", "GENE_OR_GENE_PRODUCT", 66, 71], ["SARS-CoV-2", "ORGANISM", 84, 94], ["bat CoV", "ORGANISM", 99, 106], ["ORF3b protein", "PROTEIN", 4, 17], ["bat CoV, ORF6 protein", "PROTEIN", 21, 42], ["CoVs", "PROTEIN", 56, 60], ["ORF9b proteins", "PROTEIN", 66, 80], ["SARS-CoV-2 and bat CoV", "PROTEIN", 84, 106], ["moderately disordered proteins", "PROTEIN", 131, 161], ["bat CoV", "SPECIES", 21, 28], ["SARS-CoV", "SPECIES", 84, 92], ["bat CoV", "SPECIES", 99, 106], ["The ORF3b protein", "TEST", 0, 17], ["bat CoV", "TEST", 21, 28], ["ORF6 protein", "TEST", 30, 42], ["ORF9b proteins", "TEST", 66, 80], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["bat CoV", "TEST", 99, 106], ["moderately disordered proteins", "PROBLEM", 131, 161]]], ["While the structured proteins, namely, spike glycoprotein (S), envelope protein (E) and membrane protein (M) as well as accessory proteins ORF3a, ORF7a, ORF8 (ORF8a and ORF8b in case of human SARS) of all three strains of CoVs are ordered proteins.", [["SARS", "DISEASE", 192, 196], ["spike glycoprotein (S)", "GENE_OR_GENE_PRODUCT", 39, 61], ["envelope protein (E)", "GENE_OR_GENE_PRODUCT", 63, 83], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["ORF3a", "GENE_OR_GENE_PRODUCT", 139, 144], ["ORF7a", "GENE_OR_GENE_PRODUCT", 146, 151], ["ORF8", "GENE_OR_GENE_PRODUCT", 153, 157], ["ORF8a", "GENE_OR_GENE_PRODUCT", 159, 164], ["ORF8b", "GENE_OR_GENE_PRODUCT", 169, 174], ["human", "ORGANISM", 186, 191], ["CoVs", "GENE_OR_GENE_PRODUCT", 222, 226], ["spike glycoprotein", "PROTEIN", 39, 57], ["S", "PROTEIN", 59, 60], ["envelope protein", "PROTEIN", 63, 79], ["E", "PROTEIN", 81, 82], ["membrane protein", "PROTEIN", 88, 104], ["M", "PROTEIN", 106, 107], ["accessory proteins", "PROTEIN", 120, 138], ["ORF3a", "PROTEIN", 139, 144], ["ORF7a", "PROTEIN", 146, 151], ["ORF8", "PROTEIN", 153, 157], ["ORF8a", "PROTEIN", 159, 164], ["ORF8b", "PROTEIN", 169, 174], ["CoVs", "PROTEIN", 222, 226], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 186, 191], ["the structured proteins", "TEST", 6, 29], ["human SARS", "PROBLEM", 186, 196], ["CoVs", "PROBLEM", 222, 226]]], ["ORF14 and ORF10 proteins are also ordered proteins.Comprehensive computational analysis of intrinsic disorder in structural and accessory proteins of SARS-CoV-2, human SARS and bat CoV (SARS-like) ::: Results and discussionTo further investigate the nature of the disorder in proteins of all three CoVs, we utilized the combined CH\u2013CDF tool that uses the outputs of two binary classifiers of disorder: charge hydropathy (CH) plot and cumulative distribution function (CDF) plot.", [["intrinsic disorder", "DISEASE", 91, 109], ["SARS", "DISEASE", 150, 154], ["SARS", "DISEASE", 168, 172], ["disorder", "DISEASE", 264, 272], ["disorder", "DISEASE", 392, 400], ["ORF14", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF10", "GENE_OR_GENE_PRODUCT", 10, 15], ["SARS-CoV-2", "ORGANISM", 150, 160], ["human", "ORGANISM", 162, 167], ["bat CoV", "ORGANISM", 177, 184], ["ORF14", "PROTEIN", 0, 5], ["ORF10 proteins", "PROTEIN", 10, 24], ["accessory proteins", "PROTEIN", 128, 146], ["CoVs", "PROTEIN", 298, 302], ["human", "SPECIES", 162, 167], ["SARS-CoV", "SPECIES", 150, 158], ["human", "SPECIES", 162, 167], ["bat CoV", "SPECIES", 177, 184], ["Comprehensive computational analysis", "TEST", 51, 87], ["intrinsic disorder", "PROBLEM", 91, 109], ["SARS", "PROBLEM", 150, 154], ["CoV", "TEST", 155, 158], ["human SARS", "PROBLEM", 162, 172], ["bat CoV", "TEST", 177, 184], ["the disorder", "PROBLEM", 260, 272], ["the combined CH\u2013CDF tool", "PROBLEM", 316, 340], ["disorder", "PROBLEM", 392, 400], ["charge hydropathy (CH) plot", "PROBLEM", 402, 429], ["intrinsic disorder", "OBSERVATION", 91, 109]]], ["This helped in retrieving more detailed characterization of the global disorder predisposition of query proteins and their classification according to the disorder \u201cfavors\u201d.", [["disorder", "DISEASE", 71, 79], ["disorder", "DISEASE", 155, 163], ["the global disorder", "PROBLEM", 60, 79], ["query proteins", "PROBLEM", 98, 112]]], ["The CH plot is a linear classifier that differentiates between proteins that are predisposed to extended disordered conformations which includes random coils and pre-molten globules from proteins that have compact conformations (ordered proteins and molten globule-like proteins).", [["molten globule-like proteins", "GENE_OR_GENE_PRODUCT", 250, 278], ["ordered proteins", "PROTEIN", 229, 245], ["molten globule-like proteins", "PROTEIN", 250, 278], ["extended disordered conformations", "PROBLEM", 96, 129], ["random coils", "TREATMENT", 145, 157], ["pre-molten globules from proteins", "PROBLEM", 162, 195]]], ["The other binary predictor, CDF, is a nonlinear classifier that uses PONDR\u00aeVLXT scores to discriminate ordered globular proteins from all disordered conformations, which include native molten globules, pre-molten globules, and random coils.", [["pre-molten globules", "ANATOMY", 202, 221], ["PONDR", "PROTEIN", 69, 74], ["VLXT", "PROTEIN", 75, 79], ["globular proteins", "PROTEIN", 111, 128], ["globular proteins", "PROBLEM", 111, 128], ["all disordered conformations", "PROBLEM", 134, 162], ["native molten globules", "TREATMENT", 178, 200], ["pre-molten globules", "TREATMENT", 202, 221], ["random coils", "TREATMENT", 227, 239], ["molten globules", "OBSERVATION", 185, 200]]], ["The CH\u2013CDF plot can be divided into four quadrants: Q1 (bottom right quadrant) containing ordered proteins; Q2 (bottom left quadrant) includes proteins predicted to be disordered by CDF and compact by CH (i.e. native molten globules and hybrid proteins containing high levels of both ordered and disordered regions); Q3 (top left quadrant) contains proteins that are predicted to be disordered by both CH and CDF analysis (i.e. highly disordered proteins with the extended disorder); and Q4 (top right quadrant) possesses proteins disordered according to CH but ordered according to CDF analysis [34].", [["CH", "CHEMICAL", 402, 404], ["CH", "CHEMICAL", 555, 557], ["CDF", "GENE_OR_GENE_PRODUCT", 182, 185], ["Q1", "PROTEIN", 52, 54], ["ordered proteins", "PROTEIN", 90, 106], ["Q2", "PROTEIN", 108, 110], ["bottom left quadrant", "PROTEIN", 112, 132], ["CDF", "PROTEIN", 182, 185], ["CH", "PROTEIN", 201, 203], ["hybrid proteins", "PROTEIN", 237, 252], ["disordered regions", "PROTEIN", 296, 314], ["Q3", "PROTEIN", 317, 319], ["CDF", "PROTEIN", 409, 412], ["Q4", "PROTEIN", 488, 490], ["The CH\u2013CDF plot", "TREATMENT", 0, 15], ["ordered proteins", "TREATMENT", 90, 106], ["proteins", "PROBLEM", 143, 151], ["native molten globules", "TREATMENT", 210, 232], ["hybrid proteins", "TREATMENT", 237, 252], ["CDF analysis", "TEST", 409, 421], ["the extended disorder", "PROBLEM", 460, 481], ["proteins disordered", "PROBLEM", 522, 541], ["CDF analysis", "TEST", 583, 595], ["right", "ANATOMY_MODIFIER", 63, 68], ["quadrant", "ANATOMY", 69, 77], ["left", "ANATOMY_MODIFIER", 119, 123], ["quadrant", "ANATOMY", 124, 132], ["left", "ANATOMY_MODIFIER", 325, 329], ["quadrant", "ANATOMY", 330, 338], ["right", "ANATOMY_MODIFIER", 496, 501], ["quadrant", "ANATOMY", 502, 510]]], ["Figure 2d\u2013f represent the CH\u2013CDF analysis of proteins of SARS-CoV-2, human SARS, and bat CoV and shows that all the proteins are located within the two quadrants Q1 and Q2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["human", "ORGANISM", 69, 74], ["SARS", "ORGANISM", 75, 79], ["bat CoV", "ORGANISM", 85, 92], ["bat CoV", "PROTEIN", 85, 92], ["Q1", "PROTEIN", 162, 164], ["Q2", "PROTEIN", 169, 171], ["human", "SPECIES", 69, 74], ["SARS-CoV", "SPECIES", 57, 65], ["human", "SPECIES", 69, 74], ["bat CoV", "SPECIES", 85, 92], ["the CH\u2013CDF analysis", "TEST", 22, 41], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["human SARS", "TEST", 69, 79], ["bat CoV", "TEST", 85, 92]]], ["The CH\u2013CDF analysis leads to the conclusion that all proteins of all three CoVs are ordered except nucleocapsid protein, which is predicted to be disordered by CDF as well as CH and hence lies in Q3.Comprehensive computational analysis of intrinsic disorder in structural and accessory proteins of SARS-CoV-2, human SARS and bat CoV (SARS-like) ::: Results and discussionMolecular recognition features (MoRFs) are short interaction-prone disordered regions found within IDPs/IDPRs that commence a disorder-to-order transition upon binding to their partners [47, 48].", [["intrinsic disorder", "DISEASE", 239, 257], ["SARS", "DISEASE", 298, 302], ["SARS", "DISEASE", 316, 320], ["disorder", "DISEASE", 497, 505], ["CH", "CHEMICAL", 175, 177], ["CoVs", "GENE_OR_GENE_PRODUCT", 75, 79], ["CDF", "GENE_OR_GENE_PRODUCT", 160, 163], ["SARS-CoV-2", "ORGANISM", 298, 308], ["human", "ORGANISM", 310, 315], ["bat CoV", "ORGANISM", 325, 332], ["CH\u2013CDF", "PROTEIN", 4, 10], ["CoVs", "PROTEIN", 75, 79], ["nucleocapsid protein", "PROTEIN", 99, 119], ["CDF", "PROTEIN", 160, 163], ["Q3", "PROTEIN", 196, 198], ["accessory proteins", "PROTEIN", 276, 294], ["MoRFs", "PROTEIN", 403, 408], ["IDPs", "PROTEIN", 470, 474], ["IDPRs", "PROTEIN", 475, 480], ["human", "SPECIES", 310, 315], ["SARS-CoV", "SPECIES", 298, 306], ["human", "SPECIES", 310, 315], ["bat CoV", "SPECIES", 325, 332], ["The CH\u2013CDF analysis", "TEST", 0, 19], ["nucleocapsid protein", "PROBLEM", 99, 119], ["Comprehensive computational analysis", "TEST", 199, 235], ["intrinsic disorder", "PROBLEM", 239, 257], ["SARS", "PROBLEM", 298, 302], ["CoV", "TEST", 303, 306], ["human SARS", "PROBLEM", 310, 320], ["short interaction", "PROBLEM", 414, 431], ["prone disordered regions", "PROBLEM", 432, 456], ["a disorder", "PROBLEM", 495, 505]]], ["In this study, we have analysed and compared MoRFs (protein-binding regions) in SARS-CoV-2 with human SARS and bat CoVs.", [["SARS", "DISEASE", 102, 106], ["MoRFs", "GENE_OR_GENE_PRODUCT", 45, 50], ["SARS-CoV-2", "ORGANISM", 80, 90], ["human", "ORGANISM", 96, 101], ["bat", "ORGANISM", 111, 114], ["CoVs", "GENE_OR_GENE_PRODUCT", 115, 119], ["MoRFs", "PROTEIN", 45, 50], ["protein-binding regions", "PROTEIN", 52, 75], ["human SARS and bat CoVs", "PROTEIN", 96, 119], ["human", "SPECIES", 96, 101], ["SARS-CoV", "SPECIES", 80, 88], ["human", "SPECIES", 96, 101], ["this study", "TEST", 3, 13], ["SARS", "TEST", 80, 84], ["CoV", "TEST", 85, 88], ["human SARS", "PROBLEM", 96, 106]]], ["The results of this analysis are summarized in Table 2, which clearly shows that most of the SARS-CoV-2 proteins contain at least one MoRF.", [["SARS", "DISEASE", 93, 97], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 93, 103], ["MoRF", "GENE_OR_GENE_PRODUCT", 134, 138], ["SARS-CoV-2 proteins", "PROTEIN", 93, 112], ["MoRF", "PROTEIN", 134, 138], ["SARS-CoV", "SPECIES", 93, 101], ["this analysis", "TEST", 15, 28], ["the SARS", "TEST", 89, 97], ["CoV", "TEST", 98, 101]]], ["This is indicative of an important role played by disorder in functionality of these viral proteins.", [["disorder", "DISEASE", 50, 58], ["viral proteins", "PROTEIN", 85, 99], ["these viral proteins", "PROBLEM", 79, 99], ["indicative of", "UNCERTAINTY", 8, 21]]], ["All of the SARS-CoV-2 proteins have been predicted to contain MoRFs except ORF7b and Nsp13 proteins.", [["SARS", "DISEASE", 11, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 11, 21], ["MoRFs", "GENE_OR_GENE_PRODUCT", 62, 67], ["ORF7b", "GENE_OR_GENE_PRODUCT", 75, 80], ["Nsp13", "GENE_OR_GENE_PRODUCT", 85, 90], ["SARS-CoV-2 proteins", "PROTEIN", 11, 30], ["MoRFs", "PROTEIN", 62, 67], ["ORF7b", "PROTEIN", 75, 80], ["Nsp13 proteins", "PROTEIN", 85, 99], ["SARS-CoV", "SPECIES", 11, 19], ["the SARS", "TEST", 7, 15]]], ["MoRFs in human SARS and bat CoV proteomes are listed in Tables S7 and S8.", [["SARS", "DISEASE", 15, 19], ["MoRFs", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 9, 14], ["bat CoV", "ORGANISM", 24, 31], ["MoRFs", "PROTEIN", 0, 5], ["S8", "PROTEIN", 70, 72], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["bat CoV", "SPECIES", 24, 31]]], ["Similar to SARS-CoV-2 proteome, bat CoV proteins ORF7b, and Nsp13 are not predicted to have any MoRF by any of the servers used.", [["SARS", "DISEASE", 11, 15], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 11, 21], ["bat CoV", "ORGANISM", 32, 39], ["ORF7b", "GENE_OR_GENE_PRODUCT", 49, 54], ["Nsp13", "GENE_OR_GENE_PRODUCT", 60, 65], ["MoRF", "GENE_OR_GENE_PRODUCT", 96, 100], ["SARS-CoV-2 proteome", "DNA", 11, 30], ["bat CoV proteins", "PROTEIN", 32, 48], ["ORF7b", "PROTEIN", 49, 54], ["Nsp13", "PROTEIN", 60, 65], ["MoRF", "PROTEIN", 96, 100], ["SARS-CoV", "SPECIES", 11, 19], ["bat CoV", "SPECIES", 32, 39], ["SARS", "TEST", 11, 15], ["CoV", "TEST", 16, 19], ["bat CoV proteins ORF7b", "TEST", 32, 54]]], ["In human SARS proteome, proteins ORF7b, Nsp13, Nsp2, and Nsp15 do not show the presence of any MoRF.", [["human", "ORGANISM", 3, 8], ["ORF7b", "GENE_OR_GENE_PRODUCT", 33, 38], ["Nsp13", "GENE_OR_GENE_PRODUCT", 40, 45], ["Nsp2", "GENE_OR_GENE_PRODUCT", 47, 51], ["Nsp15", "GENE_OR_GENE_PRODUCT", 57, 62], ["MoRF", "GENE_OR_GENE_PRODUCT", 95, 99], ["ORF7b", "PROTEIN", 33, 38], ["Nsp13", "PROTEIN", 40, 45], ["Nsp2", "PROTEIN", 47, 51], ["Nsp15", "PROTEIN", 57, 62], ["MoRF", "PROTEIN", 95, 99], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["human SARS proteome", "TEST", 3, 22], ["proteins ORF7b", "TEST", 24, 38], ["Nsp13", "TEST", 40, 45], ["Nsp2", "TEST", 47, 51], ["Nsp15", "TEST", 57, 62]]], ["Interestingly, the N protein from SARS-CoV-2, human SARS, and bat CoV shows high number of variable MoRFs, signifying its central role in virus pathogenesis.Nucleotide-binding propensity in proteins of coronaviruses ::: Results and discussionIn addition to protein\u2013protein interactions/protein-binding functions, IDPs and IDRs also mediate functions by facilitating their interactions with nucleotides (DNA and RNA) [21, 49].", [["Nucleotide", "CHEMICAL", 157, 167], ["Nucleotide", "CHEMICAL", 157, 167], ["nucleotides", "CHEMICAL", 390, 401], ["SARS-CoV-2", "ORGANISM", 34, 44], ["human", "ORGANISM", 46, 51], ["SARS", "ORGANISM", 52, 56], ["bat CoV", "ORGANISM", 62, 69], ["MoRFs", "GENE_OR_GENE_PRODUCT", 100, 105], ["coronaviruses", "ORGANISM", 202, 215], ["IDPs", "GENE_OR_GENE_PRODUCT", 313, 317], ["IDRs", "GENE_OR_GENE_PRODUCT", 322, 326], ["DNA", "CELLULAR_COMPONENT", 403, 406], ["N protein", "PROTEIN", 19, 28], ["MoRFs", "PROTEIN", 100, 105], ["IDPs", "PROTEIN", 313, 317], ["IDRs", "PROTEIN", 322, 326], ["human", "SPECIES", 46, 51], ["SARS-CoV", "SPECIES", 34, 42], ["human", "SPECIES", 46, 51], ["bat CoV", "SPECIES", 62, 69], ["the N protein", "TEST", 15, 28], ["SARS", "TEST", 34, 38], ["CoV", "TEST", 39, 42], ["human SARS", "TEST", 46, 56], ["bat CoV", "TEST", 62, 69], ["variable MoRFs", "PROBLEM", 91, 105], ["virus pathogenesis", "PROBLEM", 138, 156], ["nucleotides (DNA and RNA", "TEST", 390, 414], ["high number", "OBSERVATION_MODIFIER", 76, 87], ["central", "OBSERVATION_MODIFIER", 122, 129], ["virus", "OBSERVATION", 138, 143], ["coronaviruses", "OBSERVATION", 202, 215]]], ["Therefore, we have used a combination of two different online servers for locating protein residues that show the propensity to bind with DNA as well as RNA.", [["DNA", "CELLULAR_COMPONENT", 138, 141], ["RNA", "RNA", 153, 156], ["locating protein residues", "TREATMENT", 74, 99], ["DNA", "PROBLEM", 138, 141], ["DNA", "OBSERVATION", 138, 141]]], ["The nucleotide-binding residues in proteins of the three studied coronaviruses are listed in Tables S9\u2013S11.", [["nucleotide", "CHEMICAL", 4, 14], ["nucleotide", "CHEMICAL", 4, 14], ["coronaviruses", "ORGANISM", 65, 78], ["S9", "PROTEIN", 100, 102], ["The nucleotide-binding residues", "TREATMENT", 0, 31], ["binding residues", "OBSERVATION", 15, 31]]], ["Interestingly, all the viral proteins of SARS-CoV-2, human SARS, and bat CoV have shown the propensity to bind to nucleic acids.", [["nucleic acids", "CHEMICAL", 114, 127], ["SARS-CoV-2", "ORGANISM", 41, 51], ["human", "ORGANISM", 53, 58], ["SARS", "ORGANISM", 59, 63], ["bat CoV", "ORGANISM", 69, 76], ["nucleic acids", "SIMPLE_CHEMICAL", 114, 127], ["viral proteins", "PROTEIN", 23, 37], ["human SARS, and bat CoV", "PROTEIN", 53, 76], ["human", "SPECIES", 53, 58], ["bat CoV", "SPECIES", 69, 76], ["SARS-CoV", "SPECIES", 41, 49], ["human", "SPECIES", 53, 58], ["bat CoV", "SPECIES", 69, 76], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["human SARS", "TEST", 53, 63], ["bat CoV", "TEST", 69, 76], ["nucleic acids", "TREATMENT", 114, 127]]], ["In particular, structural (S, M, and N proteins) and non-structural (Nsp 2, 3, 4, 5, 6, 12, 13, 14, 15, and 16) proteins of all three viruses display a large number of RNA-binding residues.", [["Nsp 2", "GENE_OR_GENE_PRODUCT", 69, 74], ["3", "GENE_OR_GENE_PRODUCT", 76, 77], ["4", "GENE_OR_GENE_PRODUCT", 79, 80], ["5", "GENE_OR_GENE_PRODUCT", 82, 83], ["15", "GENE_OR_GENE_PRODUCT", 100, 102], ["structural (S, M, and N proteins", "PROTEIN", 15, 47], ["non-structural (Nsp 2, 3, 4, 5, 6, 12, 13, 14, 15, and 16) proteins", "PROTEIN", 53, 120], ["structural (S, M, and N proteins", "TEST", 15, 47], ["non-structural (Nsp", "TEST", 53, 72], ["RNA-binding residues", "PROBLEM", 168, 188], ["large", "OBSERVATION_MODIFIER", 152, 157], ["number", "OBSERVATION_MODIFIER", 158, 164], ["binding residues", "OBSERVATION", 172, 188]]], ["However, ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, and ORF14 proteins show less RNA-binding and more DNA-binding residues.Spike (S) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionThe S protein is a large multifunctional protein forming the exterior of the CoV particles [50, 51].", [["Intrinsic disorder", "DISEASE", 147, 165], ["ORF3a", "GENE_OR_GENE_PRODUCT", 9, 14], ["ORF3b", "GENE_OR_GENE_PRODUCT", 16, 21], ["ORF6", "GENE_OR_GENE_PRODUCT", 23, 27], ["ORF7a", "GENE_OR_GENE_PRODUCT", 29, 34], ["ORF7b", "GENE_OR_GENE_PRODUCT", 36, 41], ["ORF8", "GENE_OR_GENE_PRODUCT", 43, 47], ["ORF14", "GENE_OR_GENE_PRODUCT", 53, 58], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["Spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 120, 142], ["coronaviruses", "ORGANISM", 201, 214], ["ORF3a", "PROTEIN", 9, 14], ["ORF3b", "PROTEIN", 16, 21], ["ORF6", "PROTEIN", 23, 27], ["ORF7a", "PROTEIN", 29, 34], ["ORF7b", "PROTEIN", 36, 41], ["ORF8", "PROTEIN", 43, 47], ["ORF14 proteins", "PROTEIN", 53, 67], ["Spike (S) glycoprotein", "PROTEIN", 120, 142], ["structural proteins", "PROTEIN", 178, 197], ["S protein", "PROTEIN", 245, 254], ["multifunctional protein", "PROTEIN", 266, 289], ["ORF7b", "TEST", 36, 41], ["ORF8", "TEST", 43, 47], ["ORF14 proteins", "TEST", 53, 67], ["less RNA-binding", "PROBLEM", 73, 89], ["binding residues", "PROBLEM", 103, 119], ["Intrinsic disorder analysis", "PROBLEM", 147, 174], ["a large multifunctional protein", "TREATMENT", 258, 289], ["less RNA", "OBSERVATION", 73, 81], ["binding residues", "OBSERVATION", 103, 119], ["disorder", "OBSERVATION", 157, 165], ["coronaviruses", "OBSERVATION", 201, 214]]], ["It forms surface homotrimers and contains two distinct ectodomain known as S1 and S2.", [["surface homotrimers", "ANATOMY", 9, 28], ["S2", "GENE_OR_GENE_PRODUCT", 82, 84], ["surface homotrimers", "PROTEIN", 9, 28], ["ectodomain", "PROTEIN", 55, 65], ["S1", "PROTEIN", 75, 77], ["S2", "PROTEIN", 82, 84], ["surface homotrimers", "OBSERVATION", 9, 28], ["two", "OBSERVATION_MODIFIER", 42, 45], ["distinct", "OBSERVATION_MODIFIER", 46, 54], ["ectodomain", "OBSERVATION", 55, 65], ["S1", "ANATOMY_MODIFIER", 75, 77], ["S2", "ANATOMY", 82, 84]]], ["Subunit S1 initiates viral infection by binding to the host cell receptors, while S2 acts as a class I viral fusion protein that mediates the fusion of the virion and cellular membranes and thereby promotes the viral entry into the host cells [52, 53].", [["cell", "ANATOMY", 60, 64], ["virion", "ANATOMY", 156, 162], ["cellular membranes", "ANATOMY", 167, 185], ["cells", "ANATOMY", 237, 242], ["viral infection", "DISEASE", 21, 36], ["Subunit S1", "GENE_OR_GENE_PRODUCT", 0, 10], ["cell", "CELL", 60, 64], ["S2", "GENE_OR_GENE_PRODUCT", 82, 84], ["virion", "CELLULAR_COMPONENT", 156, 162], ["cellular membranes", "CELLULAR_COMPONENT", 167, 185], ["cells", "CELL", 237, 242], ["Subunit S1", "PROTEIN", 0, 10], ["host cell receptors", "PROTEIN", 55, 74], ["S2", "PROTEIN", 82, 84], ["class I viral fusion protein", "PROTEIN", 95, 123], ["host cells", "CELL_TYPE", 232, 242], ["viral infection", "PROBLEM", 21, 36], ["a class I viral fusion protein", "PROBLEM", 93, 123], ["viral", "OBSERVATION_MODIFIER", 21, 26], ["infection", "OBSERVATION", 27, 36], ["fusion", "OBSERVATION", 142, 148], ["virion", "ANATOMY", 156, 162], ["cellular membranes", "OBSERVATION", 167, 185]]], ["It binds to specific surface receptor angiotensin-converting enzyme 2 (ACE2) on host cell plasma membrane through its N-terminal receptor-binding domain (RBD) [54].Spike (S) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionS protein consists of an N-terminal signal peptide, a long extracellular domain, a single-pass transmembrane domain, and a short intracellular domain [55].", [["surface", "ANATOMY", 21, 28], ["cell plasma membrane", "ANATOMY", 85, 105], ["extracellular", "ANATOMY", 344, 357], ["intracellular", "ANATOMY", 414, 427], ["angiotensin", "CHEMICAL", 38, 49], ["Intrinsic disorder", "DISEASE", 191, 209], ["N", "CHEMICAL", 118, 119], ["N", "CHEMICAL", 310, 311], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 38, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 71, 75], ["host cell", "CELL", 80, 89], ["plasma membrane", "CELLULAR_COMPONENT", 90, 105], ["Spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 164, 186], ["coronaviruses", "ORGANISM", 245, 258], ["long", "CELLULAR_COMPONENT", 339, 343], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 344, 357], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 414, 427], ["surface receptor angiotensin-converting enzyme 2", "PROTEIN", 21, 69], ["ACE2", "PROTEIN", 71, 75], ["N-terminal receptor-binding domain", "PROTEIN", 118, 152], ["RBD", "PROTEIN", 154, 157], ["Spike (S) glycoprotein", "PROTEIN", 164, 186], ["structural proteins", "PROTEIN", 222, 241], ["discussionS protein", "PROTEIN", 275, 294], ["long extracellular domain", "PROTEIN", 339, 364], ["single-pass transmembrane domain", "PROTEIN", 368, 400], ["short intracellular domain", "PROTEIN", 408, 434], ["angiotensin", "TEST", 38, 49], ["converting enzyme", "TEST", 50, 67], ["ACE2", "TEST", 71, 75], ["host cell plasma membrane", "TEST", 80, 105], ["Intrinsic disorder analysis", "PROBLEM", 191, 218], ["discussionS protein", "TEST", 275, 294], ["an N-terminal signal peptide", "PROBLEM", 307, 335], ["a long extracellular domain", "PROBLEM", 337, 364], ["a short intracellular domain", "PROBLEM", 406, 434], ["disorder", "OBSERVATION", 201, 209], ["coronaviruses", "OBSERVATION", 245, 258]]], ["A 3.60 \u00c5 resolution structure (PDB ID: 6ACC) of human SARS S protein complexed with its host-binding partner ACE2 is obtained using cryo-electron microscopy (cryo-EM) (Fig. 3b).", [["human", "ORGANISM", 48, 53], ["SARS S protein", "GENE_OR_GENE_PRODUCT", 54, 68], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["human SARS S protein", "PROTEIN", 48, 68], ["ACE2", "PROTEIN", 109, 113], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["human SARS S protein complexed", "PROBLEM", 48, 78], ["cryo-electron microscopy", "TEST", 132, 156]]], ["In this PDB structure, few residues (1\u201317, 240\u2013243, 661\u2013673, 812\u2013831 and 1120\u20131203) are missing [56], suggesting their flexible nature.", [["PDB", "ANATOMY", 8, 11], ["few", "OBSERVATION_MODIFIER", 23, 26], ["residues", "OBSERVATION_MODIFIER", 27, 35], ["flexible nature", "OBSERVATION", 119, 134]]], ["Also, the structure of S protein (3.5 \u00c5) from SARS-CoV-2 has been recently deduced by Wrapp et al. using electron microscopy (PDB ID: 6VSB) [57] (Fig. 3a).", [["SARS", "DISEASE", 46, 50], ["S protein", "GENE_OR_GENE_PRODUCT", 23, 32], ["S protein", "PROTEIN", 23, 32], ["S protein", "TEST", 23, 32], ["SARS", "PROBLEM", 46, 50], ["CoV", "TEST", 51, 54], ["electron microscopy", "TEST", 105, 124]]], ["In this structure, residues 1\u201326, 67\u201378, 96\u201398, 143\u2013155, 177\u2013186, 247\u2013260, 329\u2013334, 444\u2013448, 455\u2013490, 501\u2013502, 621\u2013639, 673\u2013686, 812\u2013814, 829\u2013851, 1147\u20131288 are observed to be missing, again corresponding to the high conformational flexibility regions.", [["conformational flexibility regions", "PROTEIN", 217, 251], ["the high conformational flexibility regions", "PROBLEM", 208, 251]]], ["Biophysical analysis of SARS-CoV-2 S protein has revealed a higher binding affinity with ACE2 receptor than S protein from human SARS [57].Spike (S) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionMSA analysis among all three coronaviruses demonstrates that the S protein of SARS-CoV-2 has a 77.71% sequence identity with bat CoV and 77.14% identity with human SARS (Fig. S1).", [["SARS", "DISEASE", 129, 133], ["Intrinsic disorder", "DISEASE", 166, 184], ["SARS", "DISEASE", 424, 428], ["SARS-CoV-2 S", "GENE_OR_GENE_PRODUCT", 24, 36], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 89, 102], ["S protein", "GENE_OR_GENE_PRODUCT", 108, 117], ["human", "ORGANISM", 123, 128], ["Spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 139, 161], ["coronaviruses", "ORGANISM", 220, 233], ["SARS-CoV-2", "ORGANISM", 338, 348], ["bat CoV", "ORGANISM", 385, 392], ["human", "ORGANISM", 418, 423], ["S1", "GENE_OR_GENE_PRODUCT", 435, 437], ["SARS-CoV-2 S protein", "PROTEIN", 24, 44], ["ACE2 receptor", "PROTEIN", 89, 102], ["S protein", "PROTEIN", 108, 117], ["Spike (S) glycoprotein", "PROTEIN", 139, 161], ["structural proteins", "PROTEIN", 197, 216], ["S protein", "PROTEIN", 325, 334], ["S1", "PROTEIN", 435, 437], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 418, 423], ["SARS-CoV", "SPECIES", 24, 32], ["human", "SPECIES", 123, 128], ["SARS-CoV", "SPECIES", 338, 346], ["bat CoV", "SPECIES", 385, 392], ["human", "SPECIES", 418, 423], ["Biophysical analysis", "TEST", 0, 20], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["S protein", "TEST", 35, 44], ["a higher binding affinity", "PROBLEM", 58, 83], ["ACE2 receptor", "TEST", 89, 102], ["human SARS", "TEST", 123, 133], ["Intrinsic disorder analysis", "PROBLEM", 166, 193], ["discussionMSA analysis", "TEST", 250, 272], ["the S protein", "TEST", 321, 334], ["SARS", "TEST", 338, 342], ["CoV", "TEST", 343, 346], ["bat CoV", "TEST", 385, 392], ["human SARS (Fig", "PROBLEM", 418, 433], ["disorder", "OBSERVATION", 176, 184], ["coronaviruses", "OBSERVATION", 220, 233]]], ["As observed, there is a significant sequence variation in RBD located at the N-terminal region which might affect its virulence, receptor-mediated binding and entry into the host cell.Spike (S) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionAccording to our intrinsic disorder propensity analysis, the S protein from all three CoVs are found to be highly structured (Table 1).", [["cell", "ANATOMY", 179, 183], ["Intrinsic disorder", "DISEASE", 211, 229], ["N", "CHEMICAL", 77, 78], ["RBD", "GENE_OR_GENE_PRODUCT", 58, 61], ["host cell", "CELL", 174, 183], ["Spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 184, 206], ["coronaviruses", "ORGANISM", 265, 278], ["CoVs", "GENE_OR_GENE_PRODUCT", 391, 395], ["RBD", "PROTEIN", 58, 61], ["N-terminal region", "DNA", 77, 94], ["host cell", "CELL_TYPE", 174, 183], ["Spike (S) glycoprotein", "PROTEIN", 184, 206], ["structural proteins", "PROTEIN", 242, 261], ["S protein", "PROTEIN", 366, 375], ["CoVs", "PROTEIN", 391, 395], ["a significant sequence variation in RBD", "PROBLEM", 22, 61], ["Intrinsic disorder analysis", "PROBLEM", 211, 238], ["our intrinsic disorder propensity analysis", "TEST", 318, 360], ["the S protein", "TEST", 362, 375], ["all three CoVs", "PROBLEM", 381, 395], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["variation", "OBSERVATION_MODIFIER", 45, 54], ["RBD", "OBSERVATION", 58, 61], ["terminal", "ANATOMY_MODIFIER", 79, 87], ["region", "ANATOMY_MODIFIER", 88, 94], ["virulence", "OBSERVATION_MODIFIER", 118, 127], ["host cell", "OBSERVATION", 174, 183], ["disorder", "OBSERVATION", 221, 229], ["coronaviruses", "OBSERVATION", 265, 278]]], ["The mean PPID scores of SARS-CoV-2, human SARS, and bat CoVs are calculated to be 1.41%, 1.12%, and 1.85%, respectively.", [["SARS", "DISEASE", 24, 28], ["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "ORGANISM", 24, 34], ["human", "ORGANISM", 36, 41], ["bat", "ORGANISM", 52, 55], ["CoVs", "GENE_OR_GENE_PRODUCT", 56, 60], ["PPID", "PROTEIN", 9, 13], ["human", "SPECIES", 36, 41], ["SARS-CoV", "SPECIES", 24, 32], ["human", "SPECIES", 36, 41], ["The mean PPID scores", "TEST", 0, 20], ["SARS", "TEST", 24, 28], ["CoV", "TEST", 29, 32], ["human SARS", "TEST", 36, 46], ["bat CoVs", "TEST", 52, 60]]], ["Figure 3c\u2013e represent the intrinsic disorder profiles of S proteins from SARS-CoV-2, human SARS and bat CoV obtained from six disorder predictors.", [["SARS", "DISEASE", 73, 77], ["SARS", "DISEASE", 91, 95], ["SARS-CoV-2", "ORGANISM", 73, 83], ["human", "ORGANISM", 85, 90], ["bat CoV", "ORGANISM", 100, 107], ["S proteins", "PROTEIN", 57, 67], ["human", "SPECIES", 85, 90], ["SARS-CoV", "SPECIES", 73, 81], ["human", "SPECIES", 85, 90], ["bat CoV", "SPECIES", 100, 107], ["the intrinsic disorder", "PROBLEM", 22, 44], ["S proteins", "TEST", 57, 67], ["SARS", "TEST", 73, 77], ["CoV", "TEST", 78, 81], ["human SARS", "TEST", 85, 95], ["bat CoV", "TEST", 100, 107], ["intrinsic disorder", "OBSERVATION", 26, 44]]], ["Finally, Fig. 3f shows aligned disorder profiles of S proteins from these CoVs and illustrates remarkable similarity in their disorder propensity, especially in the C-terminal region.Spike (S) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionIt is of interest to map known functional regions of S proteins to their corresponding disorder profiles.", [["disorder", "DISEASE", 31, 39], ["disorder", "DISEASE", 126, 134], ["Intrinsic disorder", "DISEASE", 210, 228], ["C", "CHEMICAL", 165, 166], ["S proteins", "GENE_OR_GENE_PRODUCT", 52, 62], ["CoVs", "GENE_OR_GENE_PRODUCT", 74, 78], ["Spike (S) glycoprotein", "GENE_OR_GENE_PRODUCT", 183, 205], ["coronaviruses", "ORGANISM", 264, 277], ["S proteins", "GENE_OR_GENE_PRODUCT", 357, 367], ["S proteins", "PROTEIN", 52, 62], ["CoVs", "PROTEIN", 74, 78], ["C-terminal region", "PROTEIN", 165, 182], ["Spike (S) glycoprotein", "PROTEIN", 183, 205], ["structural proteins", "PROTEIN", 241, 260], ["S proteins", "PROTEIN", 357, 367], ["aligned disorder profiles", "PROBLEM", 23, 48], ["S proteins", "PROBLEM", 52, 62], ["these CoVs", "PROBLEM", 68, 78], ["their disorder propensity", "PROBLEM", 120, 145], ["Intrinsic disorder analysis", "PROBLEM", 210, 237], ["their corresponding disorder profiles", "PROBLEM", 371, 408], ["S proteins", "OBSERVATION_MODIFIER", 52, 62], ["C", "ANATOMY_MODIFIER", 165, 166], ["terminal", "ANATOMY_MODIFIER", 167, 175], ["region", "ANATOMY_MODIFIER", 176, 182], ["disorder", "OBSERVATION", 220, 228], ["coronaviruses", "OBSERVATION", 264, 277]]], ["The maturation of S protein requires specific post-translational modifications (PTM), proteolytic cleavage that happens at two stages.", [["S protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["S protein", "PROTEIN", 18, 27], ["specific post-translational modifications (PTM)", "TREATMENT", 37, 84], ["proteolytic cleavage", "TREATMENT", 86, 106]]], ["First, host cell furin or another cellular protease nicks the S precursor to generate S1 and S2 proteins, whereas the second cleavage takes place after the viral attachment to host cell receptors which leads to the release of a fusion peptide generating the S2\u2032 subunit.", [["cell", "ANATOMY", 12, 16], ["cellular", "ANATOMY", 34, 42], ["cell", "ANATOMY", 181, 185], ["host cell", "CELL", 7, 16], ["furin", "GENE_OR_GENE_PRODUCT", 17, 22], ["cellular", "CELL", 34, 42], ["S1", "GENE_OR_GENE_PRODUCT", 86, 88], ["S2", "GENE_OR_GENE_PRODUCT", 93, 95], ["host cell", "CELL", 176, 185], ["S2\u2032 subunit", "GENE_OR_GENE_PRODUCT", 258, 269], ["furin", "PROTEIN", 17, 22], ["cellular protease", "PROTEIN", 34, 51], ["S precursor", "PROTEIN", 62, 73], ["S1", "PROTEIN", 86, 88], ["S2 proteins", "PROTEIN", 93, 104], ["host cell receptors", "PROTEIN", 176, 195], ["S2\u2032 subunit", "PROTEIN", 258, 269], ["host cell furin", "TREATMENT", 7, 22], ["another cellular protease nicks", "PROBLEM", 26, 57], ["S1 and S2 proteins", "PROBLEM", 86, 104], ["the second cleavage", "PROBLEM", 114, 133], ["the viral attachment to host cell receptors", "TREATMENT", 152, 195], ["a fusion peptide", "TREATMENT", 226, 242], ["host cell furin", "OBSERVATION", 7, 22], ["S2", "ANATOMY", 93, 95], ["host cell", "OBSERVATION", 176, 185], ["fusion", "OBSERVATION", 228, 234]]], ["In human SARS, the first and second cleavage site are located at residues R667 and R797, respectively, whereas in bat CoV, the corresponding cleavage sites are residues R654 and R784.", [["SARS", "DISEASE", 9, 13], ["R784", "CHEMICAL", 178, 182], ["human", "ORGANISM", 3, 8], ["R797", "AMINO_ACID", 83, 87], ["bat CoV", "ORGANISM", 114, 121], ["first and second cleavage site", "DNA", 19, 49], ["bat CoV", "PROTEIN", 114, 121], ["cleavage sites", "PROTEIN", 141, 155], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["bat CoV", "SPECIES", 114, 121], ["second cleavage site", "PROBLEM", 29, 49], ["SARS", "OBSERVATION", 9, 13]]], ["As it follows from Fig. 3, these cleavage sites are located within the IDPRs.", [["Fig. 3", "GENE_OR_GENE_PRODUCT", 19, 25], ["IDPRs", "GENE_OR_GENE_PRODUCT", 71, 76], ["IDPRs", "DNA", 71, 76], ["these cleavage sites", "PROBLEM", 27, 47]]], ["In human SARS S protein, fusion peptide (residues 770\u2013788) located within a flexible region is characterized by a mean disorder score of 0.232 \u00b1 0.053.", [["residues 770\u2013788", "CHEMICAL", 41, 57], ["human", "ORGANISM", 3, 8], ["SARS S protein", "GENE_OR_GENE_PRODUCT", 9, 23], ["human SARS S protein", "PROTEIN", 3, 23], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["fusion peptide", "TREATMENT", 25, 39], ["a mean disorder score", "TEST", 112, 133], ["flexible", "ANATOMY_MODIFIER", 76, 84], ["mean disorder", "OBSERVATION", 114, 127]]], ["Similarly, in bat CoV S protein, fusion peptide (residues 757\u2013775) has a mean disorder score of 0.320 \u00b1 0.046.", [["bat CoV S", "GENE_OR_GENE_PRODUCT", 14, 23], ["bat CoV S protein", "PROTEIN", 14, 31], ["bat CoV", "SPECIES", 14, 21], ["bat CoV S protein", "TEST", 14, 31], ["fusion peptide", "TREATMENT", 33, 47], ["a mean disorder score", "TEST", 71, 92]]], ["It contains two heptad repeat regions that form coiled-coil structure during viral and target cell membrane fusion, assuming a trimer-of-hairpins structure needed for the functional positioning of fusion peptide.", [["cell membrane", "ANATOMY", 94, 107], ["cell membrane", "CELLULAR_COMPONENT", 94, 107], ["heptad repeat regions", "PROTEIN", 16, 37], ["coiled-coil structure", "PROTEIN", 48, 69], ["trimer-of-hairpins structure", "PROTEIN", 127, 155], ["two heptad repeat regions", "TREATMENT", 12, 37], ["coiled-coil structure", "PROBLEM", 48, 69], ["viral and target cell membrane fusion", "TREATMENT", 77, 114], ["a trimer-of-hairpins structure", "TREATMENT", 125, 155], ["fusion peptide", "TREATMENT", 197, 211], ["coiled", "OBSERVATION", 48, 54], ["coil structure", "OBSERVATION", 55, 69], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["target cell membrane fusion", "OBSERVATION", 87, 114]]], ["In human SARS, heptad repeat regions are formed by residues 902\u2013952 and 1145\u20131184, which have mean disorder scores of 0.458 \u00b1 0.067 and 0.353 \u00b1 0.062, respectively.", [["SARS", "DISEASE", 9, 13], ["human", "ORGANISM", 3, 8], ["heptad repeat regions", "DNA", 15, 36], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["heptad repeat regions", "TREATMENT", 15, 36], ["mean disorder scores", "TEST", 94, 114]]], ["The analogous situation is observed for S protein of bat CoV, where these heptads repeat regions are positioned at residues 889\u2013939 (0.44 \u00b1 0.11) and 1132\u20131171 (0.353 \u00b1 0.062).", [["bat CoV", "ORGANISM", 53, 60], ["heptads", "GENE_OR_GENE_PRODUCT", 74, 81], ["S protein", "PROTEIN", 40, 49], ["bat CoV", "PROTEIN", 53, 60], ["heptads repeat regions", "PROTEIN", 74, 96], ["bat CoV", "SPECIES", 53, 60], ["The analogous situation", "PROBLEM", 0, 23], ["S protein of bat CoV", "PROBLEM", 40, 60]]], ["Another functional region found in S proteins is the RBD (residues 306\u2013527 and 310\u2013514 in human SARS and bat CoVs, respectively) containing a receptor-binding motif responsible for interaction with human ACE2.", [["human", "ORGANISM", 90, 95], ["CoVs", "GENE_OR_GENE_PRODUCT", 109, 113], ["human", "ORGANISM", 198, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 204, 208], ["S proteins", "PROTEIN", 35, 45], ["RBD", "PROTEIN", 53, 56], ["residues 306\u2013527", "PROTEIN", 58, 74], ["310\u2013514", "PROTEIN", 79, 86], ["human SARS", "PROTEIN", 90, 100], ["bat CoVs", "PROTEIN", 105, 113], ["receptor-binding motif", "PROTEIN", 142, 164], ["human ACE2", "PROTEIN", 198, 208], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 198, 203], ["Another functional region", "PROBLEM", 0, 25], ["human SARS", "TEST", 90, 100], ["bat CoVs", "TEST", 105, 113], ["a receptor-binding motif", "TREATMENT", 140, 164], ["human ACE2", "TREATMENT", 198, 208]]], ["In S protein of human SARS, this motif (residues 424\u2013494) is not only characterized by structural flexibility, possessing a mean disorder score of 0.30 \u00b1 0.16, but also contains a disordered region (residues 461\u2013466).", [["SARS", "DISEASE", 22, 26], ["human", "ORGANISM", 16, 21], ["S protein", "PROTEIN", 3, 12], ["disordered region", "PROTEIN", 180, 197], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21], ["a mean disorder score", "TEST", 122, 143], ["a disordered region", "PROBLEM", 178, 197]]], ["Since S protein is known as spike glycoprotein, it contains numerous glycosylation sites.", [["S protein", "GENE_OR_GENE_PRODUCT", 6, 15], ["S protein", "PROTEIN", 6, 15], ["spike glycoprotein", "PROTEIN", 28, 46], ["glycosylation sites", "PROTEIN", 69, 88], ["spike glycoprotein", "PROBLEM", 28, 46], ["numerous glycosylation sites", "TREATMENT", 60, 88], ["numerous", "OBSERVATION_MODIFIER", 60, 68], ["glycosylation sites", "OBSERVATION", 69, 88]]], ["Due to rather close similarity of disorder profiles of S proteins analysed here, we can assume that all the aforementioned indications of the functional importance of disorder and flexible regions in S proteins from human SARS and bat CoVs are also applicable to SARS-CoV-2 S protein.", [["disorder", "DISEASE", 34, 42], ["disorder", "DISEASE", 167, 175], ["SARS", "DISEASE", 222, 226], ["SARS", "DISEASE", 263, 267], ["S proteins", "GENE_OR_GENE_PRODUCT", 55, 65], ["human", "ORGANISM", 216, 221], ["bat CoVs", "ORGANISM", 231, 239], ["SARS-CoV-2 S protein", "GENE_OR_GENE_PRODUCT", 263, 283], ["S proteins", "PROTEIN", 55, 65], ["S proteins", "PROTEIN", 200, 210], ["SARS-CoV-2 S protein", "PROTEIN", 263, 283], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["SARS-CoV", "SPECIES", 263, 271], ["disorder profiles of S proteins", "PROBLEM", 34, 65], ["disorder", "PROBLEM", 167, 175], ["flexible regions in S proteins", "PROBLEM", 180, 210], ["human SARS and bat CoVs", "PROBLEM", 216, 239], ["SARS", "TEST", 263, 267], ["CoV", "TEST", 268, 271], ["disorder", "OBSERVATION", 34, 42]]], ["Finally, Table 2 shows that S protein from SARS-CoV-2 contains a MoRF region at its C-terminal (residues 1265\u20131272) as predicted by MoRFchibi_web, two MoRF regions ((residues 2\u20136, 819\u2013823) by MoRFPred, and one MoRF region at the N-terminal (residues 1\u201310) by DISOPRED3.", [["C", "CHEMICAL", 84, 85], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 43, 53], ["MoRF", "GENE_OR_GENE_PRODUCT", 65, 69], ["S protein", "PROTEIN", 28, 37], ["MoRF region", "DNA", 65, 76], ["C-terminal", "DNA", 84, 94], ["MoRFchibi_web", "PROTEIN", 132, 145], ["MoRF regions", "PROTEIN", 151, 163], ["MoRFPred", "PROTEIN", 192, 200], ["MoRF region", "PROTEIN", 210, 221], ["N-terminal", "PROTEIN", 229, 239], ["residues 1\u201310", "PROTEIN", 241, 254], ["DISOPRED3", "PROTEIN", 259, 268], ["SARS-CoV", "SPECIES", 43, 51], ["S protein", "TEST", 28, 37], ["SARS", "PROBLEM", 43, 47], ["a MoRF region", "TREATMENT", 63, 76]]], ["These results indicate that intrinsic disorder is important for its interaction with binding partners.", [["intrinsic disorder", "DISEASE", 28, 46], ["intrinsic disorder", "PROBLEM", 28, 46]]], ["Strikingly, the N-terminal region of S protein (residues 1\u201310) from all three viruses are predicted to be a MoRF by two servers (MoRFPred and DISOPRED3).", [["N-terminal region", "PROTEIN", 16, 33], ["S protein", "PROTEIN", 37, 46], ["residues 1\u201310", "PROTEIN", 48, 61], ["MoRF", "PROTEIN", 108, 112], ["MoRFPred", "PROTEIN", 129, 137], ["DISOPRED3", "PROTEIN", 142, 151], ["all three viruses", "PROBLEM", 68, 85], ["viruses", "OBSERVATION", 78, 85]]], ["This displays its role in viral interaction with host receptor, while the C-terminal MoRF is engaged in interaction with M protein for assembly of viral particles [58].", [["MoRF", "GENE_OR_GENE_PRODUCT", 85, 89], ["M protein", "GENE_OR_GENE_PRODUCT", 121, 130], ["host receptor", "PROTEIN", 49, 62], ["C-terminal MoRF", "PROTEIN", 74, 89], ["M protein", "PROTEIN", 121, 130], ["host receptor", "TREATMENT", 49, 62], ["viral particles", "PROBLEM", 147, 162], ["viral", "OBSERVATION", 26, 31]]], ["Moreover, MoRF regions lying in the N- and C-terminal regions suggest their possible role during cleavage as well.", [["N", "CHEMICAL", 36, 37], ["C", "CHEMICAL", 43, 44], ["MoRF", "GENE_OR_GENE_PRODUCT", 10, 14], ["MoRF regions", "DNA", 10, 22], ["N- and C-terminal regions", "DNA", 36, 61], ["MoRF regions", "PROBLEM", 10, 22], ["terminal", "ANATOMY_MODIFIER", 45, 53]]], ["In addition to protein-binding regions, S protein also shows many nucleotide-binding residues.", [["nucleotide", "CHEMICAL", 66, 76], ["nucleotide", "CHEMICAL", 66, 76], ["protein-binding regions", "PROTEIN", 15, 38], ["S protein", "PROTEIN", 40, 49], ["protein-binding regions", "TEST", 15, 38], ["S protein", "TEST", 40, 49], ["many nucleotide-binding residues", "PROBLEM", 61, 93], ["binding residues", "OBSERVATION", 77, 93]]], ["Tables S9\u2013S11 shows numerous RNA-binding residues predicted by PPRInt in all three viruses.", [["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 7, 13], ["S9", "PROTEIN", 7, 9], ["PPRInt", "PROTEIN", 63, 69], ["numerous RNA-binding residues", "PROBLEM", 20, 49], ["numerous", "OBSERVATION_MODIFIER", 20, 28], ["RNA", "OBSERVATION", 29, 32], ["binding residues", "OBSERVATION", 33, 49], ["viruses", "OBSERVATION", 83, 90]]], ["Further, DRNApred and DisoRDPbind predicted the presence of many DNA binding residues in all three S proteins.", [["DNA", "CELLULAR_COMPONENT", 65, 68], ["DRNApred", "PROTEIN", 9, 17], ["DisoRDPbind", "PROTEIN", 22, 33], ["S proteins", "PROTEIN", 99, 109], ["many DNA binding residues", "PROBLEM", 60, 85], ["many", "OBSERVATION_MODIFIER", 60, 64], ["DNA binding residues", "OBSERVATION", 65, 85]]], ["These results signify the molecular recognition (protein\u2013protein interaction, RNA binding, and DNA binding) and interactions with host cell membrane and further viral infection.", [["cell membrane", "ANATOMY", 135, 148], ["viral infection", "DISEASE", 161, 176], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cell membrane", "CELLULAR_COMPONENT", 135, 148], ["the molecular recognition (protein\u2013protein interaction", "PROBLEM", 22, 76], ["RNA binding", "PROBLEM", 78, 89], ["DNA binding", "PROBLEM", 95, 106], ["host cell membrane", "TREATMENT", 130, 148], ["further viral infection", "PROBLEM", 153, 176], ["host cell membrane", "OBSERVATION", 130, 148], ["viral infection", "OBSERVATION", 161, 176]]], ["Therefore, IDPs/IDPRs and residues/regions in S proteins that are crucial for molecular recognition can be targeted for disorder-based drug discovery.Envelope (E) small membrane protein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionEnvelope (E) protein is a small, multifunctional membrane protein that plays an important role in the assembly and morphogenesis of virions in the cell [59\u201361].", [["membrane", "ANATOMY", 333, 341], ["virions", "ANATOMY", 416, 423], ["cell", "ANATOMY", 431, 435], ["disorder", "DISEASE", 120, 128], ["Intrinsic disorder", "DISEASE", 190, 208], ["IDPs", "GENE_OR_GENE_PRODUCT", 11, 15], ["IDPRs", "GENE_OR_GENE_PRODUCT", 16, 21], ["S proteins", "GENE_OR_GENE_PRODUCT", 46, 56], ["Envelope (E)", "GENE_OR_GENE_PRODUCT", 150, 162], ["coronaviruses", "ORGANISM", 244, 257], ["Envelope (E)", "GENE_OR_GENE_PRODUCT", 284, 296], ["membrane", "CELLULAR_COMPONENT", 333, 341], ["cell", "CELL", 431, 435], ["IDPs", "PROTEIN", 11, 15], ["IDPRs", "PROTEIN", 16, 21], ["S proteins", "PROTEIN", 46, 56], ["Envelope (E) small membrane protein", "PROTEIN", 150, 185], ["structural proteins", "PROTEIN", 221, 240], ["Envelope (E) protein", "PROTEIN", 284, 304], ["multifunctional membrane protein", "PROTEIN", 317, 349], ["IDPs/IDPRs", "TREATMENT", 11, 21], ["residues/regions in S proteins", "PROBLEM", 26, 56], ["disorder", "PROBLEM", 120, 128], ["Intrinsic disorder analysis", "PROBLEM", 190, 217], ["a small, multifunctional membrane protein", "PROBLEM", 308, 349], ["disorder", "OBSERVATION", 200, 208], ["coronaviruses", "OBSERVATION", 244, 257], ["small", "OBSERVATION_MODIFIER", 310, 315]]], ["It consists of two ectodomains associated with N- and C-terminal regions, and a middle transmembrane domain.", [["transmembrane", "ANATOMY", 87, 100], ["N", "CHEMICAL", 47, 48], ["C", "CHEMICAL", 54, 55], ["ectodomains", "PROTEIN", 19, 30], ["N- and C-terminal regions", "PROTEIN", 47, 72], ["middle transmembrane domain", "PROTEIN", 80, 107], ["two ectodomains", "PROBLEM", 15, 30], ["N- and C-terminal regions", "PROBLEM", 47, 72], ["a middle transmembrane domain", "PROBLEM", 78, 107], ["two", "OBSERVATION_MODIFIER", 15, 18], ["ectodomains", "OBSERVATION", 19, 30], ["terminal", "ANATOMY_MODIFIER", 56, 64], ["regions", "ANATOMY_MODIFIER", 65, 72], ["middle", "ANATOMY_MODIFIER", 80, 86]]], ["It homo-oligomerizes into a pentameric membrane destabilizing transmembrane hairpins to form a pore necessary for its ion channel activity [62].", [["membrane", "ANATOMY", 39, 47], ["transmembrane", "ANATOMY", 62, 75], ["pore", "ANATOMY", 95, 99], ["membrane", "CELLULAR_COMPONENT", 39, 47], ["transmembrane", "CELLULAR_COMPONENT", 62, 75], ["transmembrane hairpins", "PROTEIN", 62, 84], ["a pentameric membrane destabilizing transmembrane hairpins", "TREATMENT", 26, 84]]], ["Figure 4a shows the NMR-structure (PDB ID: 2MM4) of human SARS envelope glycoprotein of 8\u201365 residues [63].Envelope (E) small membrane protein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionMSA results illustrate (Fig. 4b) that this protein is highly conserved, with only three amino acid substitutions in E protein of SARS-CoV-2 conferring its 96% sequence similarity with human SARS and bat CoV.", [["Intrinsic disorder", "DISEASE", 147, 165], ["amino acid", "CHEMICAL", 329, 339], ["SARS", "DISEASE", 431, 435], ["amino acid", "CHEMICAL", 329, 339], ["human", "ORGANISM", 52, 57], ["Envelope (E)", "GENE_OR_GENE_PRODUCT", 107, 119], ["coronaviruses", "ORGANISM", 201, 214], ["amino acid", "AMINO_ACID", 329, 339], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 370, 380], ["human", "ORGANISM", 425, 430], ["2MM4", "PROTEIN", 43, 47], ["human SARS envelope glycoprotein", "PROTEIN", 52, 84], ["Envelope (E) small membrane protein", "PROTEIN", 107, 142], ["structural proteins", "PROTEIN", 178, 197], ["E protein", "PROTEIN", 357, 366], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 425, 430], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 425, 430], ["Figure 4a", "TEST", 0, 9], ["the NMR", "TEST", 16, 23], ["human SARS envelope glycoprotein", "TREATMENT", 52, 84], ["Intrinsic disorder analysis", "PROBLEM", 147, 174], ["this protein", "TEST", 279, 291], ["three amino acid substitutions", "PROBLEM", 323, 353], ["SARS", "TEST", 370, 374], ["CoV", "TEST", 375, 378], ["human SARS", "PROBLEM", 425, 435], ["disorder", "OBSERVATION", 157, 165], ["coronaviruses", "OBSERVATION", 201, 214], ["acid substitutions", "OBSERVATION", 335, 353]]], ["Also, bat CoV shares 100% sequence identity with human SARS.", [["SARS", "DISEASE", 55, 59], ["bat CoV", "ORGANISM", 6, 13], ["human", "ORGANISM", 49, 54], ["bat CoV", "PROTEIN", 6, 13], ["human", "SPECIES", 49, 54], ["bat CoV", "SPECIES", 6, 13], ["human", "SPECIES", 49, 54]]], ["Mean PPID calculated for SARS-CoV-2, human SARS, and bat CoV E proteins are 5.33%, 6.58%, and 6.58%, respectively (Table 1).", [["SARS", "DISEASE", 25, 29], ["SARS", "DISEASE", 43, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["human", "ORGANISM", 37, 42], ["bat CoV E", "GENE_OR_GENE_PRODUCT", 53, 62], ["PPID", "PROTEIN", 5, 9], ["human SARS, and bat CoV E proteins", "PROTEIN", 37, 71], ["human", "SPECIES", 37, 42], ["SARS-CoV", "SPECIES", 25, 33], ["human", "SPECIES", 37, 42], ["bat CoV", "SPECIES", 53, 60], ["Mean PPID", "TEST", 0, 9], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["human SARS", "TEST", 37, 47], ["bat CoV E proteins", "TEST", 53, 71]]], ["The E protein is found to have a reasonably well-predicted structure; however, residues of N- and C-terminals display a higher tendency for the disorder (disorder profiles in Fig. 4c\u2013e).", [["disorder", "DISEASE", 154, 162], ["N", "CHEMICAL", 91, 92], ["E protein", "GENE_OR_GENE_PRODUCT", 4, 13], ["E protein", "PROTEIN", 4, 13], ["N- and C-terminals", "PROTEIN", 91, 109], ["The E protein", "TEST", 0, 13], ["residues", "TEST", 79, 87], ["N", "TEST", 91, 92], ["a higher tendency", "PROBLEM", 118, 135], ["the disorder (disorder profiles", "PROBLEM", 140, 171], ["well-predicted", "OBSERVATION_MODIFIER", 44, 58], ["higher tendency", "OBSERVATION_MODIFIER", 120, 135]]], ["Evidences show that the last 18 hydrophilic residues (residues 59\u201376) adopt a random-coil conformation with and without the addition of lipid membranes [64].", [["lipid membranes", "ANATOMY", 136, 151], ["lipid membranes", "CELLULAR_COMPONENT", 136, 151], ["the last 18 hydrophilic residues", "PROBLEM", 20, 52], ["a random-coil conformation", "TREATMENT", 76, 102], ["lipid membranes", "TREATMENT", 136, 151], ["lipid membranes", "OBSERVATION", 136, 151]]], ["Further, the last four amino acids of the C-terminal region containing a PZD-binding motif are involved in protein\u2013protein interactions with a tight junction protein PALS1.", [["tight junction", "ANATOMY", 143, 157], ["amino acids", "CHEMICAL", 23, 34], ["amino acids", "CHEMICAL", 23, 34], ["C", "CHEMICAL", 42, 43], ["amino acids", "AMINO_ACID", 23, 34], ["PZD", "GENE_OR_GENE_PRODUCT", 73, 76], ["PALS1", "GENE_OR_GENE_PRODUCT", 166, 171], ["C-terminal region", "PROTEIN", 42, 59], ["PZD-binding motif", "PROTEIN", 73, 90], ["tight junction protein", "PROTEIN", 143, 165], ["PALS1", "PROTEIN", 166, 171], ["four amino acids", "TEST", 18, 34], ["the C-terminal region", "TREATMENT", 38, 59], ["a PZD-binding motif", "TREATMENT", 71, 90], ["a tight junction protein PALS1", "TREATMENT", 141, 171], ["terminal", "ANATOMY_MODIFIER", 44, 52], ["binding motif", "OBSERVATION", 77, 90]]], ["PALS1 is involved in maintaining the polarity of epithelial cells in mammals [65].", [["epithelial cells", "ANATOMY", 49, 65], ["PALS1", "GENE_OR_GENE_PRODUCT", 0, 5], ["epithelial cells", "CELL", 49, 65], ["PALS1", "PROTEIN", 0, 5], ["epithelial cells", "CELL_TYPE", 49, 65], ["epithelial cells", "OBSERVATION", 49, 65]]], ["Our results support the existing literature, as we identified a long N-terminal region of ~ 30 residues as a MoRF region in all three viruses (see Tables 2, S7, S8).", [["N", "CHEMICAL", 69, 70], ["N-terminal region", "PROTEIN", 69, 86], ["MoRF region", "DNA", 109, 120], ["S8", "PROTEIN", 161, 163], ["a long N-terminal region", "PROBLEM", 62, 86], ["a MoRF region", "PROBLEM", 107, 120]]], ["We speculate that the disordered regions may facilitate interactions with other proteins as well.", [["the disordered regions", "PROBLEM", 18, 40]]], ["In agreement with this hypothesis, the C-terminal domain of SARS-CoV-2 E protein serves as a protein-binding region.", [["C", "CHEMICAL", 39, 40], ["SARS-CoV-2 E", "GENE_OR_GENE_PRODUCT", 60, 72], ["C-terminal domain", "PROTEIN", 39, 56], ["SARS-CoV-2 E protein", "PROTEIN", 60, 80], ["protein-binding region", "PROTEIN", 93, 115], ["this hypothesis", "PROBLEM", 18, 33], ["the C-terminal domain of SARS", "PROBLEM", 35, 64], ["CoV", "TEST", 65, 68]]], ["We also found that residues from 45\u201375 is a long MoRF in E proteins of all three viruses as predicted by MoRFchibi_web.", [["MoRF", "GENE_OR_GENE_PRODUCT", 49, 53], ["MoRF", "PROTEIN", 49, 53], ["E proteins", "PROTEIN", 57, 67], ["MoRFchibi_web", "PROTEIN", 105, 118], ["a long MoRF in E proteins", "PROBLEM", 42, 67], ["viruses", "OBSERVATION", 81, 88]]], ["As aforementioned, these randomly coiled binding residues at the C-terminus may gain structure while assisting the protein\u2013protein interaction mediated by E protein.", [["C", "CHEMICAL", 65, 66], ["E protein", "GENE_OR_GENE_PRODUCT", 155, 164], ["C-terminus", "PROTEIN", 65, 75], ["E protein", "PROTEIN", 155, 164], ["these randomly coiled binding residues", "PROBLEM", 19, 57], ["binding residues", "OBSERVATION", 41, 57]]], ["One more MoRF region (residues 26\u201330) in the transmembrane domain was observed by DISOPRED3 in all three E proteins.", [["transmembrane", "ANATOMY", 45, 58], ["MoRF", "GENE_OR_GENE_PRODUCT", 9, 13], ["transmembrane", "CELLULAR_COMPONENT", 45, 58], ["MoRF region", "DNA", 9, 20], ["transmembrane domain", "PROTEIN", 45, 65], ["DISOPRED3", "PROTEIN", 82, 91], ["E proteins", "PROTEIN", 105, 115], ["the transmembrane domain", "TEST", 41, 65]]], ["Since these residues are part of the ion channel, they may be involved in guiding the specific function of ion channel activity.", [["residues", "OBSERVATION", 12, 20], ["ion channel activity", "OBSERVATION", 107, 127]]], ["Few nucleotide-binding residues are predicted for all three E proteins (Tables S9\u2013S11).Membrane (M) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionIt plays an important role in virion assembly by interacting with the nucleocapsid (N) and E proteins [66\u201368].", [["Membrane", "ANATOMY", 87, 95], ["virion", "ANATOMY", 241, 247], ["nucleotide", "CHEMICAL", 4, 14], ["Intrinsic disorder", "DISEASE", 117, 135], ["nucleotide", "CHEMICAL", 4, 14], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 79, 85], ["Membrane", "CELLULAR_COMPONENT", 87, 95], ["coronaviruses", "ORGANISM", 171, 184], ["virion", "CELLULAR_COMPONENT", 241, 247], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 281, 297], ["E proteins", "GENE_OR_GENE_PRODUCT", 302, 312], ["E proteins", "PROTEIN", 60, 70], ["S9", "PROTEIN", 79, 81], ["S11", "PROTEIN", 82, 85], ["Membrane (M) glycoprotein", "PROTEIN", 87, 112], ["structural proteins", "PROTEIN", 148, 167], ["nucleocapsid (N) and E proteins", "PROTEIN", 281, 312], ["Few nucleotide-binding residues", "PROBLEM", 0, 31], ["Intrinsic disorder analysis", "PROBLEM", 117, 144], ["binding residues", "OBSERVATION", 15, 31], ["disorder", "OBSERVATION", 127, 135], ["coronaviruses", "OBSERVATION", 171, 184]]], ["Protein M interacts specifically with coronavirus RNA containing a short viral packaging signal in the absence of N protein, highlighting an important nucleocapsid-independent viral RNA packaging mechanism inside the host cells [69].", [["cells", "ANATOMY", 222, 227], ["coronavirus", "ORGANISM", 38, 49], ["host cells", "CELL", 217, 227], ["coronavirus RNA", "RNA", 38, 53], ["N protein", "PROTEIN", 114, 123], ["host cells", "CELL_TYPE", 217, 227], ["Protein M interacts", "PROBLEM", 0, 19], ["coronavirus RNA", "PROBLEM", 38, 53], ["a short viral packaging signal", "PROBLEM", 65, 95], ["N protein", "PROBLEM", 114, 123], ["an important nucleocapsid", "PROBLEM", 138, 163], ["coronavirus RNA", "OBSERVATION", 38, 53], ["short viral", "OBSERVATION_MODIFIER", 67, 78], ["packaging signal", "OBSERVATION", 79, 95], ["nucleocapsid", "OBSERVATION", 151, 163], ["viral RNA", "OBSERVATION", 176, 185], ["host cells", "OBSERVATION", 217, 227]]], ["Cryo-EM and tomography data reveal its two distinct conformations, a compact structure having high flexibility and low spike density, and an elongated M protein having a rigid structure and narrow range of membrane curvature [70].", [["membrane", "ANATOMY", 206, 214], ["membrane", "CELLULAR_COMPONENT", 206, 214], ["M protein", "PROTEIN", 151, 160], ["tomography data", "TEST", 12, 27], ["its two distinct conformations", "PROBLEM", 35, 65], ["high flexibility", "PROBLEM", 94, 110], ["low spike density", "PROBLEM", 115, 132], ["an elongated M protein", "PROBLEM", 138, 160], ["a rigid structure", "PROBLEM", 168, 185], ["distinct", "OBSERVATION_MODIFIER", 43, 51], ["conformations", "OBSERVATION", 52, 65], ["high flexibility", "OBSERVATION_MODIFIER", 94, 110], ["low spike density", "OBSERVATION_MODIFIER", 115, 132], ["elongated", "OBSERVATION_MODIFIER", 141, 150], ["M protein", "OBSERVATION_MODIFIER", 151, 160], ["rigid structure", "OBSERVATION", 170, 185], ["narrow", "OBSERVATION_MODIFIER", 190, 196], ["range", "OBSERVATION_MODIFIER", 197, 202], ["membrane curvature", "OBSERVATION", 206, 224]]], ["Although no structural information is available for full-length M protein, a short peptide of the membrane glycoprotein (residues 88\u201396) from human SARS is co-crystallized with a complex of A-2 \u03b1 chain of the HLA class I histocompatibility antigen and \u03b22-microglobulin (PDB ID:3I6G) [71].", [["membrane", "ANATOMY", 98, 106], ["residues 88\u201396", "CHEMICAL", 121, 135], ["SARS", "DISEASE", 148, 152], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["human", "ORGANISM", 142, 147], ["A-2", "GENE_OR_GENE_PRODUCT", 190, 193], ["HLA class I histocompatibility antigen", "GENE_OR_GENE_PRODUCT", 209, 247], ["\u03b22-microglobulin", "GENE_OR_GENE_PRODUCT", 252, 268], ["full-length M protein", "PROTEIN", 52, 73], ["membrane glycoprotein", "PROTEIN", 98, 119], ["residues 88\u201396", "PROTEIN", 121, 135], ["A", "PROTEIN", 190, 191], ["\u03b1 chain", "PROTEIN", 194, 201], ["HLA class I histocompatibility antigen", "PROTEIN", 209, 247], ["\u03b22", "PROTEIN", 252, 254], ["3I6G", "PROTEIN", 277, 281], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["the membrane glycoprotein", "TEST", 94, 119], ["human SARS", "PROBLEM", 142, 152], ["histocompatibility antigen", "TEST", 221, 247]]], ["Figure 5a shows the extended conformation of M protein.Membrane (M) glycoprotein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionThe M protein of SARS-CoV-2 has a sequence similarity of 90.1% with bat CoV and 89.6% with human SARS M proteins (Fig. 5b).", [["Membrane", "ANATOMY", 55, 63], ["Intrinsic disorder", "DISEASE", 85, 103], ["M protein", "GENE_OR_GENE_PRODUCT", 45, 54], ["Membrane", "CELLULAR_COMPONENT", 55, 63], ["coronaviruses", "ORGANISM", 139, 152], ["SARS-CoV-2", "ORGANISM", 196, 206], ["bat CoV", "ORGANISM", 247, 254], ["human", "ORGANISM", 270, 275], ["SARS M proteins", "GENE_OR_GENE_PRODUCT", 276, 291], ["M protein", "PROTEIN", 45, 54], ["Membrane (M) glycoprotein", "PROTEIN", 55, 80], ["structural proteins", "PROTEIN", 116, 135], ["M protein", "PROTEIN", 183, 192], ["human SARS M proteins", "PROTEIN", 270, 291], ["Fig. 5b", "PROTEIN", 293, 300], ["human", "SPECIES", 270, 275], ["SARS-CoV", "SPECIES", 196, 204], ["bat CoV", "SPECIES", 247, 254], ["human", "SPECIES", 270, 275], ["Intrinsic disorder analysis", "PROBLEM", 85, 112], ["The M protein", "TEST", 179, 192], ["SARS", "TEST", 196, 200], ["CoV", "TEST", 201, 204], ["a sequence similarity", "TEST", 211, 232], ["bat CoV", "TEST", 247, 254], ["human SARS M proteins", "TEST", 270, 291], ["disorder", "OBSERVATION", 95, 103], ["coronaviruses", "OBSERVATION", 139, 152]]], ["Disorder profiles in Fig. 5c\u2013e show a relatively low level of disorder in M proteins of SARS-COV-2 (2.70%), human SARS CoV (1.36%,), and bat CoV (1.36%).", [["disorder", "DISEASE", 62, 70], ["SARS CoV", "DISEASE", 114, 122], ["SARS-COV-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["human", "ORGANISM", 108, 113], ["SARS CoV", "ORGANISM", 114, 122], ["bat CoV", "ORGANISM", 137, 144], ["M proteins", "PROTEIN", 74, 84], ["human", "SPECIES", 108, 113], ["human SARS CoV", "SPECIES", 108, 122], ["bat CoV", "SPECIES", 137, 144], ["Disorder profiles in Fig", "PROBLEM", 0, 24], ["a relatively low level of disorder", "PROBLEM", 36, 70], ["SARS", "TEST", 88, 92], ["COV", "TEST", 93, 96], ["human SARS CoV", "TEST", 108, 122], ["bat CoV", "TEST", 137, 144], ["Fig", "OBSERVATION_MODIFIER", 21, 24], ["relatively", "OBSERVATION_MODIFIER", 38, 48], ["low level", "OBSERVATION_MODIFIER", 49, 58]]], ["This is consistent with a previous publication by Goh et al. on human SARS HKU4, where they found the mean PPID of 4% using additional predictors such as TopIDP and FoldIndex along with the predictors used in our study [72].", [["human", "ORGANISM", 64, 69], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["human SARS HKU4", "TEST", 64, 79], ["the mean PPID", "TEST", 98, 111], ["TopIDP and FoldIndex", "TREATMENT", 154, 174], ["consistent with", "UNCERTAINTY", 8, 23]]], ["The last 20 residues of MERS-CoV M protein are important for intracellular trafficking and contain a determinant that localizes it into the Golgi network [73].", [["intracellular", "ANATOMY", 61, 74], ["Golgi network", "ANATOMY", 140, 153], ["MERS-CoV M", "GENE_OR_GENE_PRODUCT", 24, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 74], ["Golgi", "CELLULAR_COMPONENT", 140, 145], ["MERS-CoV M protein", "PROTEIN", 24, 42], ["MERS-CoV", "SPECIES", 24, 32], ["MERS", "PROBLEM", 24, 28], ["CoV M protein", "TREATMENT", 29, 42], ["intracellular trafficking", "PROBLEM", 61, 86]]], ["MoRF analysis revealed that the disordered C-tail of M protein contains a MoRF region which can serve as a binding site for its partner required during localization inside the host cell.", [["cell", "ANATOMY", 181, 185], ["M protein", "GENE_OR_GENE_PRODUCT", 53, 62], ["MoRF", "GENE_OR_GENE_PRODUCT", 74, 78], ["cell", "CELL", 181, 185], ["MoRF", "PROTEIN", 0, 4], ["C-tail", "PROTEIN", 43, 49], ["M protein", "PROTEIN", 53, 62], ["MoRF region", "PROTEIN", 74, 85], ["host cell", "CELL_TYPE", 176, 185], ["MoRF analysis", "TEST", 0, 13], ["the disordered C-tail of M protein", "PROBLEM", 28, 62], ["a MoRF region", "TREATMENT", 72, 85], ["a binding site", "PROBLEM", 105, 119], ["host cell", "OBSERVATION", 176, 185]]], ["A long MoRF region (residues 186\u2013220) at the C-terminal of M protein in all three viruses is located by MoRFchibi_web.", [["long MoRF region", "DNA", 2, 18], ["C-terminal of M protein", "PROTEIN", 45, 68], ["MoRFchibi_web", "PROTEIN", 104, 117], ["A long MoRF region (residues", "TREATMENT", 0, 28], ["viruses", "OBSERVATION", 82, 89]]], ["Two MoRF regions [one at N-terminus (residues 1\u201316) and one at the C-terminus (residues 205\u2013221)] are predicted by DISOPRED3 in human SARS and bat CoV.", [["SARS", "DISEASE", 134, 138], ["C", "CHEMICAL", 67, 68], ["MoRF", "GENE_OR_GENE_PRODUCT", 4, 8], ["human", "ORGANISM", 128, 133], ["MoRF regions", "DNA", 4, 16], ["N-terminus", "PROTEIN", 25, 35], ["residues 1\u201316", "PROTEIN", 37, 50], ["C-terminus", "PROTEIN", 67, 77], ["residues 205\u2013221", "PROTEIN", 79, 95], ["DISOPRED3", "PROTEIN", 115, 124], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["Two MoRF regions", "PROBLEM", 0, 16], ["terminus", "ANATOMY_MODIFIER", 69, 77]]], ["However, only a single MoRF (residues 117\u2013132) is observed in SARS-CoV-2 (by DISOPRED3) (Tables 2, S7, S8).", [["SARS", "DISEASE", 62, 66], ["MoRF", "GENE_OR_GENE_PRODUCT", 23, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 62, 72], ["MoRF", "DNA", 23, 27], ["SARS-CoV", "SPECIES", 62, 70], ["SARS", "TEST", 62, 66], ["CoV", "TEST", 67, 70]]], ["Furthermore, the M protein from all three viruses displays strong tendency to bind with RNA (as predicted by PPRInt and DisoRDPbind) and DNA (as predicted by DRNApred and DisoRDPbind) (see Tables S9\u2013S11).", [["PPRInt", "GENE_OR_GENE_PRODUCT", 109, 115], ["DisoRDPbind", "GENE_OR_GENE_PRODUCT", 120, 131], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["M protein", "PROTEIN", 17, 26], ["PPRInt", "PROTEIN", 109, 115], ["DisoRDPbind", "PROTEIN", 120, 131], ["DRNApred", "PROTEIN", 158, 166], ["DisoRDPbind", "PROTEIN", 171, 182], ["S9", "PROTEIN", 196, 198], ["S11", "PROTEIN", 199, 202], ["the M protein", "TEST", 13, 26], ["all three viruses", "PROBLEM", 32, 49], ["strong tendency to bind with RNA", "PROBLEM", 59, 91], ["DNA", "PROBLEM", 137, 140]]], ["Our understanding of M protein of CoVs (IDPs and MoRF at C-terminus) elucidates its critical role in interaction with the N and E proteins for viral assembly.Nucleocapsid (N) protein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionIt is one of the major viral proteins playing an essential role during transcription, and virion assembly of CoVs [74].", [["Intrinsic disorder", "DISEASE", 187, 205], ["M protein", "GENE_OR_GENE_PRODUCT", 21, 30], ["CoVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["IDPs", "GENE_OR_GENE_PRODUCT", 40, 44], ["MoRF", "GENE_OR_GENE_PRODUCT", 49, 53], ["coronaviruses", "ORGANISM", 241, 254], ["CoVs", "GENE_OR_GENE_PRODUCT", 390, 394], ["M protein", "PROTEIN", 21, 30], ["CoVs", "PROTEIN", 34, 38], ["IDPs", "PROTEIN", 40, 44], ["MoRF", "PROTEIN", 49, 53], ["C-terminus", "PROTEIN", 57, 67], ["N and E proteins", "PROTEIN", 122, 138], ["Nucleocapsid (N) protein", "PROTEIN", 158, 182], ["structural proteins", "PROTEIN", 218, 237], ["viral proteins", "PROTEIN", 304, 318], ["CoVs", "PROTEIN", 390, 394], ["CoVs (IDPs", "TREATMENT", 34, 44], ["MoRF at C-terminus", "TREATMENT", 49, 67], ["the N and E proteins", "TREATMENT", 118, 138], ["Intrinsic disorder analysis", "PROBLEM", 187, 214], ["disorder", "OBSERVATION", 197, 205], ["coronaviruses", "OBSERVATION", 241, 254], ["viral proteins", "OBSERVATION", 304, 318]]], ["It binds to viral genomic RNA forming a ribonucleoprotein core required for RNA encapsidation during viral particle assembly [75].", [["viral genomic RNA", "RNA", 12, 29], ["viral genomic RNA", "PROBLEM", 12, 29], ["a ribonucleoprotein core", "TREATMENT", 38, 62], ["RNA encapsidation", "PROBLEM", 76, 93], ["viral genomic RNA", "OBSERVATION", 12, 29]]], ["It consists of two structural domains, the N-terminal RNA-binding domain (NTD: 45\u2013181 residues) and the C-terminal dimerization domain (CTD: 248\u2013365 residues) with a disordered patch between these domains.", [["C", "CHEMICAL", 104, 105], ["structural domains", "PROTEIN", 19, 37], ["N-terminal RNA-binding domain", "PROTEIN", 43, 72], ["NTD: 45\u2013181 residues", "PROTEIN", 74, 94], ["C-terminal dimerization domain", "PROTEIN", 104, 134], ["CTD", "PROTEIN", 136, 139], ["the N-terminal RNA", "TEST", 39, 57], ["the C-terminal dimerization domain", "PROBLEM", 100, 134], ["a disordered patch", "TREATMENT", 164, 182], ["two", "OBSERVATION_MODIFIER", 15, 18], ["structural domains", "OBSERVATION", 19, 37], ["N-terminal RNA", "OBSERVATION", 43, 57], ["terminal", "ANATOMY_MODIFIER", 106, 114]]], ["It is demonstrated to bind with viral RNA using both NTD and CTD [76].", [["viral RNA", "RNA", 32, 41], ["NTD", "PROTEIN", 53, 56], ["CTD", "PROTEIN", 61, 64], ["viral RNA", "TREATMENT", 32, 41], ["viral RNA", "OBSERVATION", 32, 41]]], ["Recently, residues 50\u2013173 of the N protein of SARS-CoV-2 has been crystallized (PDB ID: 6VYO) (Fig. 6a).", [["N protein", "PROTEIN", 33, 42], ["SARS-CoV", "SPECIES", 46, 54], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54]]], ["Figure 6b1 displays the NMR solution structure of NTD (45\u2013181 residues) of human SARS N protein (PDB ID: 1SSK) [77].", [["human", "ORGANISM", 75, 80], ["SARS N protein", "GENE_OR_GENE_PRODUCT", 81, 95], ["NTD", "PROTEIN", 50, 53], ["human SARS N protein", "PROTEIN", 75, 95], ["1SSK", "PROTEIN", 105, 109], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["Figure", "TEST", 0, 6], ["NTD", "TEST", 50, 53], ["human SARS N protein", "TEST", 75, 95]]], ["Figure 6b2 shows an X-ray crystal structure of CTD of human SARS N protein (270\u2013366 residues) (PDB ID: 2GIB) [78].", [["human", "ORGANISM", 54, 59], ["SARS N protein", "GENE_OR_GENE_PRODUCT", 60, 74], ["CTD", "PROTEIN", 47, 50], ["human SARS N protein", "PROTEIN", 54, 74], ["270\u2013366 residues", "PROTEIN", 76, 92], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["Figure", "TEST", 0, 6], ["an X-ray crystal structure", "PROBLEM", 17, 43], ["CTD of human SARS", "PROBLEM", 47, 64]]], ["A model of domain organization of N-protein from SARS-CoV-2 is shown in Fig. 6c.Nucleocapsid (N) protein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionThe 419 amino acid-long N protein of SARS-CoV-2 shows a percentage identity of 88.76% and 89.74% with N proteins of bat and human SARS CoVs (Fig. S2).", [["Intrinsic disorder", "DISEASE", 109, 127], ["amino acid-", "CHEMICAL", 211, 222], ["amino acid-", "CHEMICAL", 211, 222], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 49, 59], ["coronaviruses", "ORGANISM", 163, 176], ["bat", "ORGANISM", 319, 322], ["human", "ORGANISM", 327, 332], ["SARS CoVs", "ORGANISM", 333, 342], ["N-protein", "PROTEIN", 34, 43], ["Nucleocapsid (N) protein", "PROTEIN", 80, 104], ["structural proteins", "PROTEIN", 140, 159], ["419 amino acid-long N protein", "PROTEIN", 207, 236], ["N proteins", "PROTEIN", 305, 315], ["human SARS CoVs", "PROTEIN", 327, 342], ["S2", "PROTEIN", 349, 351], ["human", "SPECIES", 327, 332], ["SARS-CoV", "SPECIES", 240, 248], ["human", "SPECIES", 327, 332], ["N-protein", "TEST", 34, 43], ["SARS", "PROBLEM", 49, 53], ["CoV", "TEST", 54, 57], ["Intrinsic disorder analysis", "PROBLEM", 109, 136], ["amino acid-", "TEST", 211, 222], ["SARS", "TEST", 240, 244], ["CoV", "TEST", 245, 248], ["a percentage identity", "TEST", 257, 278], ["N proteins", "TEST", 305, 315], ["human SARS CoVs", "PROBLEM", 327, 342], ["disorder", "OBSERVATION", 119, 127], ["coronaviruses", "OBSERVATION", 163, 176]]], ["Our analysis revealed the highest levels of intrinsic disorder in N proteins of all three CoVs (graphs in Fig. 6d\u2013f), which is in accordance with the previously evaluated intrinsic disorder predisposition [72].", [["disorder", "DISEASE", 54, 62], ["intrinsic disorder", "DISEASE", 171, 189], ["N proteins", "PROTEIN", 66, 76], ["CoVs", "PROTEIN", 90, 94], ["Our analysis", "TEST", 0, 12], ["intrinsic disorder", "PROBLEM", 44, 62], ["intrinsic disorder predisposition", "PROBLEM", 171, 204], ["intrinsic disorder", "OBSERVATION", 44, 62]]], ["In fact, N proteins from SARS-CoV-2, human SARS, and bat CoVs are characterized by the mean PPIDs of 64.91%, 71.09%, and 65.80%, respectively.", [["SARS-CoV-2", "ORGANISM", 25, 35], ["human", "ORGANISM", 37, 42], ["SARS", "ORGANISM", 43, 47], ["bat", "ORGANISM", 53, 56], ["CoVs", "GENE_OR_GENE_PRODUCT", 57, 61], ["N proteins", "PROTEIN", 9, 19], ["human", "SPECIES", 37, 42], ["SARS-CoV", "SPECIES", 25, 33], ["human", "SPECIES", 37, 42], ["N proteins", "TEST", 9, 19], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["human SARS", "TEST", 37, 47], ["bat CoVs", "TEST", 53, 61], ["the mean PPIDs", "TEST", 83, 97]]], ["This is further supported by Fig. 6g, where PONDR\u00ae VSL2-generated disorder profiles of these three proteins are overlapped to show almost complete coincidence of their major disorder-related features.", [["disorder", "DISEASE", 66, 74], ["disorder", "DISEASE", 174, 182], ["PONDR", "GENE_OR_GENE_PRODUCT", 44, 49], ["PONDR", "PROTEIN", 44, 49], ["VSL2", "PROTEIN", 51, 55], ["PONDR", "TEST", 44, 49], ["generated disorder profiles", "PROBLEM", 56, 83], ["their major disorder", "PROBLEM", 162, 182]]], ["In particular, SARS-CoV-2 N protein residues 1\u201357, 64\u2013102, 145\u2013162, 166\u2013289, and 362\u2013422 are found to be disordered (Fig. 6d).", [["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["protein residues", "TEST", 28, 44]]], ["Many of these residues lie within the NTD and CTD regions, which due to their structural plasticity does not get crystallized in human SARS N protein crystal structure.", [["human", "ORGANISM", 129, 134], ["NTD and CTD regions", "PROTEIN", 38, 57], ["human SARS N protein crystal structure", "PROTEIN", 129, 167], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["these residues lie within the NTD and CTD regions", "PROBLEM", 8, 57], ["residues", "OBSERVATION", 14, 22], ["NTD", "ANATOMY", 38, 41], ["CTD", "OBSERVATION", 46, 49]]], ["Overall, all three N proteins are found to be highly disordered.Nucleocapsid (N) protein ::: Intrinsic disorder analysis of structural proteins of coronaviruses ::: Results and discussionTables 2, S7 and S8 show that the N protein is heavily decorated with MoRFs, suggesting that this protein is a promiscuous binder.", [["Intrinsic disorder", "DISEASE", 93, 111], ["coronaviruses", "ORGANISM", 147, 160], ["S8", "GENE_OR_GENE_PRODUCT", 204, 206], ["MoRFs", "GENE_OR_GENE_PRODUCT", 257, 262], ["N proteins", "PROTEIN", 19, 29], ["Nucleocapsid (N) protein", "PROTEIN", 64, 88], ["structural proteins", "PROTEIN", 124, 143], ["S7", "PROTEIN", 197, 199], ["S8", "PROTEIN", 204, 206], ["N protein", "PROTEIN", 221, 230], ["MoRFs", "PROTEIN", 257, 262], ["Intrinsic disorder analysis", "PROBLEM", 93, 120], ["discussionTables", "TEST", 177, 193], ["the N protein", "TEST", 217, 230], ["a promiscuous binder", "TREATMENT", 296, 316], ["disorder", "OBSERVATION", 103, 111], ["coronaviruses", "OBSERVATION", 147, 160]]], ["Long disorder-based protein bonding regions at the N- and C- terminus of the N protein of all three viruses are observed by all four predictors.", [["disorder", "DISEASE", 5, 13], ["N", "CHEMICAL", 51, 52], ["C", "CHEMICAL", 58, 59], ["protein bonding regions", "PROTEIN", 20, 43], ["N- and C- terminus", "PROTEIN", 51, 69], ["N protein", "PROTEIN", 77, 86], ["Long disorder-based protein bonding regions", "PROBLEM", 0, 43], ["the N", "TEST", 47, 52], ["protein bonding", "OBSERVATION", 20, 35], ["viruses", "OBSERVATION", 100, 107]]], ["The N protein from human SARS has one phosphorylation site (residue S177) and several regions with compositional biases, such as Ser-rich (residues 181\u2013213), Poly-Leu, Poly-Gln, and Poly-Lys (residues 220\u2013225, 240\u2013245, and 370\u2013376), all predicted to be disordered.", [["SARS", "DISEASE", 25, 29], ["Poly-Leu", "CHEMICAL", 158, 166], ["Poly-Gln", "CHEMICAL", 168, 176], ["Poly-Lys", "CHEMICAL", 182, 190], ["Poly-Leu", "CHEMICAL", 158, 166], ["Poly-Gln", "CHEMICAL", 168, 176], ["Poly-Lys", "CHEMICAL", 182, 190], ["human", "ORGANISM", 19, 24], ["S177", "AMINO_ACID", 68, 72], ["Poly-Leu", "GENE_OR_GENE_PRODUCT", 158, 166], ["Poly-Gln", "GENE_OR_GENE_PRODUCT", 168, 176], ["Poly-Lys", "SIMPLE_CHEMICAL", 182, 190], ["N protein", "PROTEIN", 4, 13], ["phosphorylation site", "PROTEIN", 38, 58], ["Ser-rich", "PROTEIN", 129, 137], ["residues 181\u2013213", "PROTEIN", 139, 155], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["The N protein", "TREATMENT", 0, 13], ["compositional biases", "PROBLEM", 99, 119], ["Poly", "TEST", 158, 162], ["Poly", "TEST", 168, 172], ["compositional biases", "OBSERVATION", 99, 119]]], ["Similarly, the N protein of bat CoV, S176 is phosphorylated and has Ser-rich, Poly-Leu, and Poly-Lys regions (residues 176\u2013206, 219\u2013224, and 369\u2013375, respectively), all of which are disordered.", [["Poly-Leu", "CHEMICAL", 78, 86], ["Poly-Lys", "CHEMICAL", 92, 100], ["Poly-Leu", "CHEMICAL", 78, 86], ["Poly-Lys", "CHEMICAL", 92, 100], ["bat CoV", "ORGANISM", 28, 35], ["S176", "GENE_OR_GENE_PRODUCT", 37, 41], ["Ser-rich", "GENE_OR_GENE_PRODUCT", 68, 76], ["Poly-Leu", "GENE_OR_GENE_PRODUCT", 78, 86], ["N protein", "PROTEIN", 15, 24], ["bat CoV", "PROTEIN", 28, 35], ["S176", "PROTEIN", 37, 41], ["Ser-rich, Poly-Leu, and Poly-Lys regions", "PROTEIN", 68, 108], ["bat CoV", "SPECIES", 28, 35], ["the N protein", "TEST", 11, 24], ["bat CoV", "TEST", 28, 35], ["phosphorylated", "TEST", 45, 59], ["Ser-rich", "TEST", 68, 76], ["Poly", "TEST", 78, 82], ["Leu", "TEST", 83, 86], ["Poly", "TEST", 92, 96], ["Leu", "ANATOMY_MODIFIER", 83, 86], ["Poly", "ANATOMY_MODIFIER", 92, 96]]], ["It has been reported to interact using the central disordered region with M protein, hnRNP A1, and self-N\u2013N interaction [79\u201381].", [["hnRNP A1", "GENE_OR_GENE_PRODUCT", 85, 93], ["central disordered region", "PROTEIN", 43, 68], ["M protein", "PROTEIN", 74, 83], ["hnRNP A1", "PROTEIN", 85, 93], ["N\u2013N", "PROTEIN", 104, 107], ["central", "ANATOMY_MODIFIER", 43, 50]]], ["The middle flexible region is also responsible for its RNA-binding activity [82].", [["middle flexible region", "PROTEIN", 4, 26], ["middle", "ANATOMY_MODIFIER", 4, 10]]], ["Deletion of 184\u2013196 residues, 169\u2013308 residues, and 161\u2013210 residues of N abolishes its multimerization, RNA-binding capacity, and hnRNP A1 interactions, respectively.", [["hnRNP A1", "GENE_OR_GENE_PRODUCT", 131, 139], ["hnRNP A1", "PROTEIN", 131, 139], ["Deletion", "TEST", 0, 8], ["residues", "TEST", 38, 46], ["its multimerization", "TEST", 84, 103], ["RNA-binding capacity", "TEST", 105, 125]]], ["The MoRFs present in the aforementioned regions may mediate these interactions of N proteins.", [["MoRFs", "GENE_OR_GENE_PRODUCT", 4, 9], ["MoRFs", "PROTEIN", 4, 9], ["N proteins", "PROTEIN", 82, 92], ["N proteins", "TREATMENT", 82, 92]]], ["Figure 6b2 represents another important disorder-related functional feature of N protein.", [["N protein", "GENE_OR_GENE_PRODUCT", 79, 88], ["6b2", "PROTEIN", 7, 10], ["N protein", "PROTEIN", 79, 88], ["another important disorder", "PROBLEM", 22, 48]]], ["CTD homodimer shown is characterized by highly intertwined morphology, which is typically a result of binding-induced folding [83\u201385], indicating that a very significant part of CTD gains structure during dimerization.", [["CTD", "GENE_OR_GENE_PRODUCT", 178, 181], ["CTD homodimer", "PROTEIN", 0, 13], ["CTD", "PROTEIN", 178, 181], ["CTD homodimer", "TEST", 0, 13], ["CTD gains structure", "PROBLEM", 178, 197], ["highly", "OBSERVATION_MODIFIER", 40, 46], ["intertwined", "OBSERVATION_MODIFIER", 47, 58], ["morphology", "OBSERVATION_MODIFIER", 59, 69], ["CTD", "OBSERVATION", 178, 181]]], ["We identified numerous RNA-binding residues in all three viruses using PPRInt server.", [["PPRInt server", "DNA", 71, 84], ["numerous RNA-binding residues", "PROBLEM", 14, 43], ["numerous", "OBSERVATION_MODIFIER", 14, 22], ["RNA", "OBSERVATION", 23, 26], ["binding residues", "OBSERVATION", 27, 43]]], ["This finding supports the function of N protein as it interacts with genomic RNA for a ribonucleoprotein core formation, which is a crucial step for RNA encapsidation.", [["N protein", "PROTEIN", 38, 47], ["genomic RNA", "RNA", 69, 80], ["N protein", "TREATMENT", 38, 47], ["genomic RNA", "PROBLEM", 69, 80], ["a ribonucleoprotein core formation", "PROBLEM", 85, 119], ["RNA encapsidation", "PROBLEM", 149, 166], ["ribonucleoprotein core", "OBSERVATION_MODIFIER", 87, 109]]], ["Additionally, DRNApred and DisoRDPbind predict multiple DNA-binding residues in N protein of all the studied CoVs.", [["DNA", "CELLULAR_COMPONENT", 56, 59], ["CoVs", "GENE_OR_GENE_PRODUCT", 109, 113], ["DRNApred", "PROTEIN", 14, 22], ["DisoRDPbind", "PROTEIN", 27, 38], ["N protein", "PROTEIN", 80, 89], ["CoVs", "PROTEIN", 109, 113], ["DRNApred", "TEST", 14, 22], ["multiple DNA", "PROBLEM", 47, 59], ["binding residues", "PROBLEM", 60, 76], ["binding residues", "OBSERVATION", 60, 76]]], ["The flexible (IDPRs) regions at the N- and C-terminus of SARS-CoV-2 have long protein-binding as well as nucleotide-binding regions that may play a vital role in its interaction with viral RNA.", [["nucleotide", "CHEMICAL", 105, 115], ["N", "CHEMICAL", 36, 37], ["C", "CHEMICAL", 43, 44], ["nucleotide", "CHEMICAL", 105, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["flexible (IDPRs) regions", "PROTEIN", 4, 28], ["N- and C-terminus", "PROTEIN", 36, 53], ["SARS-CoV-2", "DNA", 57, 67], ["nucleotide-binding regions", "PROTEIN", 105, 131], ["viral RNA", "RNA", 183, 192], ["The flexible (IDPRs) regions", "TREATMENT", 0, 28], ["the N", "TEST", 32, 37], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["long protein-binding", "PROBLEM", 73, 93], ["nucleotide-binding regions", "TREATMENT", 105, 131], ["viral RNA", "PROBLEM", 183, 192], ["viral RNA", "OBSERVATION", 183, 192]]], ["These flexible regions can be targeted to inhibit the interaction of N protein with viral genomic RNA.Proteins ORF3a and ORF3b ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionORF3a is a multifunctional protein (of molecular weight ~ 31 kDa) that performs a major function during virion assembly by co-localizing with E, M, and S viral proteins [87\u201391].", [["virion", "ANATOMY", 328, 334], ["Intrinsic disorder", "DISEASE", 131, 149], ["ORF3a", "GENE_OR_GENE_PRODUCT", 111, 116], ["ORF3b", "GENE_OR_GENE_PRODUCT", 121, 126], ["coronaviruses", "ORGANISM", 184, 197], ["virion", "CELLULAR_COMPONENT", 328, 334], ["E", "GENE_OR_GENE_PRODUCT", 366, 367], ["N protein", "PROTEIN", 69, 78], ["viral genomic RNA", "RNA", 84, 101], ["ORF3a", "PROTEIN", 111, 116], ["ORF3b", "PROTEIN", 121, 126], ["accessory proteins", "PROTEIN", 162, 180], ["discussionORF3a", "PROTEIN", 214, 229], ["multifunctional protein", "PROTEIN", 235, 258], ["E, M, and S viral proteins", "PROTEIN", 366, 392], ["viral genomic RNA", "PROBLEM", 84, 101], ["Intrinsic disorder", "PROBLEM", 131, 149], ["molecular weight", "TEST", 263, 279], ["viral genomic RNA", "OBSERVATION", 84, 101], ["disorder", "OBSERVATION", 141, 149], ["accessory proteins", "OBSERVATION", 162, 180]]], ["The homo-tetrameric complex of ORF3a has been demonstrated to form a potassium-ion channel on the host cell plasma membrane [92].", [["cell plasma membrane", "ANATOMY", 103, 123], ["ORF3a", "CHEMICAL", 31, 36], ["potassium", "CHEMICAL", 69, 78], ["potassium", "CHEMICAL", 69, 78], ["ORF3a", "GENE_OR_GENE_PRODUCT", 31, 36], ["potassium", "SIMPLE_CHEMICAL", 69, 78], ["host cell", "CELLULAR_COMPONENT", 98, 107], ["plasma membrane", "CELLULAR_COMPONENT", 108, 123], ["homo-tetrameric complex", "PROTEIN", 4, 27], ["ORF3a", "PROTEIN", 31, 36], ["potassium-ion channel", "PROTEIN", 69, 90], ["a potassium", "TEST", 67, 78], ["host cell", "OBSERVATION", 98, 107]]], ["ORF3b protein can be found in the cytoplasm, nucleolus, and outer membrane of mitochondria of the host cells [93, 94].", [["cytoplasm", "ANATOMY", 34, 43], ["nucleolus", "ANATOMY", 45, 54], ["outer membrane", "ANATOMY", 60, 74], ["mitochondria", "ANATOMY", 78, 90], ["cells", "ANATOMY", 103, 108], ["ORF3b", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytoplasm", "ORGANISM_SUBSTANCE", 34, 43], ["nucleolus", "CELLULAR_COMPONENT", 45, 54], ["outer membrane", "CELLULAR_COMPONENT", 60, 74], ["mitochondria", "CELLULAR_COMPONENT", 78, 90], ["cells", "CELL", 103, 108], ["ORF3b protein", "PROTEIN", 0, 13], ["host cells", "CELL_TYPE", 98, 108], ["ORF3b protein", "TEST", 0, 13], ["outer membrane", "ANATOMY_MODIFIER", 60, 74], ["host cells", "OBSERVATION", 98, 108]]], ["In Huh 7 cells, its over-expression has been linked with the activation of AP-1 via the ERK and JNK pathways [95].Proteins ORF3a and ORF3b ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionOn performing MSA (Fig. 7d), we found that ORF3a protein of SARS-CoV-2 is almost equally closer to ORF3a proteins of bat (73.36%) and human SARS CoV (72.99%).", [["Huh 7 cells", "ANATOMY", 3, 14], ["Intrinsic disorder", "DISEASE", 143, 161], ["SARS", "DISEASE", 296, 300], ["Huh 7 cells", "CELL", 3, 14], ["AP-1", "GENE_OR_GENE_PRODUCT", 75, 79], ["ERK", "GENE_OR_GENE_PRODUCT", 88, 91], ["JNK", "GENE_OR_GENE_PRODUCT", 96, 99], ["ORF3a", "GENE_OR_GENE_PRODUCT", 123, 128], ["ORF3b", "GENE_OR_GENE_PRODUCT", 133, 138], ["coronaviruses", "ORGANISM", 196, 209], ["ORF3a", "GENE_OR_GENE_PRODUCT", 279, 284], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 296, 306], ["ORF3a", "GENE_OR_GENE_PRODUCT", 335, 340], ["bat", "ORGANISM", 353, 356], ["human", "ORGANISM", 370, 375], ["SARS CoV", "ORGANISM", 376, 384], ["Huh 7 cells", "CELL_LINE", 3, 14], ["AP-1", "PROTEIN", 75, 79], ["ERK", "PROTEIN", 88, 91], ["JNK", "PROTEIN", 96, 99], ["ORF3a", "PROTEIN", 123, 128], ["ORF3b", "PROTEIN", 133, 138], ["accessory proteins", "PROTEIN", 174, 192], ["ORF3a protein", "PROTEIN", 279, 292], ["ORF3a proteins", "PROTEIN", 335, 349], ["human", "SPECIES", 370, 375], ["SARS-CoV", "SPECIES", 296, 304], ["human SARS CoV", "SPECIES", 370, 384], ["the ERK", "TEST", 84, 91], ["JNK pathways", "TEST", 96, 108], ["Intrinsic disorder", "PROBLEM", 143, 161], ["ORF3a protein", "TEST", 279, 292], ["SARS", "TEST", 296, 300], ["CoV", "TEST", 301, 304], ["bat", "TEST", 353, 356], ["human SARS CoV", "TEST", 370, 384], ["disorder", "OBSERVATION", 153, 161], ["accessory proteins", "OBSERVATION", 174, 192]]], ["The graphs in Fig. 7a\u2013c depict the propensity for disorder in ORF3a proteins of novel SARS-CoV-2, human SARS, and bat CoVs, respectively (mean PPIDs are listed in Table 1).", [["disorder", "DISEASE", 50, 58], ["ORF3a", "GENE_OR_GENE_PRODUCT", 62, 67], ["SARS-CoV-2", "ORGANISM", 86, 96], ["human", "ORGANISM", 98, 103], ["bat", "ORGANISM", 114, 117], ["CoVs", "GENE_OR_GENE_PRODUCT", 118, 122], ["ORF3a proteins", "PROTEIN", 62, 76], ["human", "SPECIES", 98, 103], ["SARS-CoV", "SPECIES", 86, 94], ["human", "SPECIES", 98, 103], ["disorder", "PROBLEM", 50, 58], ["novel SARS", "PROBLEM", 80, 90], ["CoV", "TEST", 91, 94], ["human SARS", "TEST", 98, 108], ["bat CoVs", "TEST", 114, 122], ["Fig", "OBSERVATION_MODIFIER", 14, 17]]], ["SARS-CoV-2 ORF3a shows protein-binding regions at its N-terminus (by MoRFchibi_web (residues 1\u20136), MoRFPred [residues 7\u201312), and DISOPRED3 (residues 1\u201319)] and at the C-terminus (by MoRFchibi_web [residues 261\u2013268) and MoRFPred (residues 259\u2013263)] (Table 2).", [["SARS", "DISEASE", 0, 4], ["N", "CHEMICAL", 54, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["ORF3a", "GENE_OR_GENE_PRODUCT", 11, 16], ["DISOPRED3 (residues 1\u201319)", "GENE_OR_GENE_PRODUCT", 129, 154], ["C-terminus", "GENE_OR_GENE_PRODUCT", 167, 177], ["SARS-CoV-2 ORF3a", "DNA", 0, 16], ["protein-binding regions", "PROTEIN", 23, 46], ["N-terminus", "PROTEIN", 54, 64], ["MoRFchibi_web", "PROTEIN", 69, 82], ["residues 1\u20136", "PROTEIN", 84, 96], ["MoRFPred", "PROTEIN", 99, 107], ["residues 7\u201312", "PROTEIN", 109, 122], ["DISOPRED3", "PROTEIN", 129, 138], ["residues 1\u201319", "PROTEIN", 140, 153], ["C-terminus", "PROTEIN", 167, 177], ["MoRFchibi_web", "PROTEIN", 182, 195], ["MoRFPred", "PROTEIN", 219, 227], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["protein-binding regions", "PROBLEM", 23, 46]]], ["Similarly, ORF3a of human SARS and bat CoV also have MoRFs at the N- and C-terminus as predicted by MoRFchibi_web and MoRFPred (Tables S7, S8).", [["SARS", "DISEASE", 26, 30], ["N", "CHEMICAL", 66, 67], ["C", "CHEMICAL", 73, 74], ["ORF3a", "GENE_OR_GENE_PRODUCT", 11, 16], ["human", "ORGANISM", 20, 25], ["SARS", "ORGANISM", 26, 30], ["bat CoV", "ORGANISM", 35, 42], ["MoRFs", "GENE_OR_GENE_PRODUCT", 53, 58], ["ORF3a", "PROTEIN", 11, 16], ["MoRFs", "PROTEIN", 53, 58], ["N- and C-terminus", "PROTEIN", 66, 83], ["MoRFchibi_web", "PROTEIN", 100, 113], ["MoRFPred", "PROTEIN", 118, 126], ["S7", "PROTEIN", 135, 137], ["S8", "PROTEIN", 139, 141], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["bat CoV", "SPECIES", 35, 42], ["human SARS", "PROBLEM", 20, 30], ["bat CoV", "TEST", 35, 42], ["MoRFs", "TEST", 53, 58]]], ["These protein-binding regions in ORF3a may have a role in its co-localization with E, M, and S viral proteins.", [["ORF3a", "GENE_OR_GENE_PRODUCT", 33, 38], ["E", "GENE_OR_GENE_PRODUCT", 83, 84], ["protein-binding regions", "PROTEIN", 6, 29], ["ORF3a", "PROTEIN", 33, 38], ["E, M, and S viral proteins", "PROTEIN", 83, 109], ["These protein-binding regions", "PROBLEM", 0, 29], ["binding regions", "OBSERVATION", 14, 29]]], ["In conjunction with MoRFs, ORF3a proteins have a maximum number of nucleotide-binding residues among all accessory proteins.Proteins ORF3a and ORF3b ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionMean PPID values of ORF3b proteins of SARS-CoV-2, human SARS, and bat CoV are 0%, 7.1%, and 23.1% respectively, as represented in Fig. 8a\u2013c.", [["nucleotide", "CHEMICAL", 67, 77], ["Intrinsic disorder", "DISEASE", 153, 171], ["SARS", "DISEASE", 284, 288], ["nucleotide", "CHEMICAL", 67, 77], ["MoRFs", "GENE_OR_GENE_PRODUCT", 20, 25], ["ORF3a", "GENE_OR_GENE_PRODUCT", 27, 32], ["ORF3a", "GENE_OR_GENE_PRODUCT", 133, 138], ["ORF3b", "GENE_OR_GENE_PRODUCT", 143, 148], ["coronaviruses", "ORGANISM", 206, 219], ["ORF3b", "GENE_OR_GENE_PRODUCT", 266, 271], ["SARS-CoV-2", "ORGANISM", 284, 294], ["human", "ORGANISM", 296, 301], ["SARS", "ORGANISM", 302, 306], ["bat CoV", "ORGANISM", 312, 319], ["MoRFs", "PROTEIN", 20, 25], ["ORF3a proteins", "PROTEIN", 27, 41], ["accessory proteins", "PROTEIN", 105, 123], ["ORF3a", "PROTEIN", 133, 138], ["ORF3b", "PROTEIN", 143, 148], ["accessory proteins", "PROTEIN", 184, 202], ["ORF3b proteins", "PROTEIN", 266, 280], ["human", "SPECIES", 296, 301], ["SARS-CoV", "SPECIES", 284, 292], ["human", "SPECIES", 296, 301], ["bat CoV", "SPECIES", 312, 319], ["nucleotide-binding residues", "TREATMENT", 67, 94], ["Intrinsic disorder", "PROBLEM", 153, 171], ["Mean PPID values", "TEST", 246, 262], ["ORF3b proteins", "TEST", 266, 280], ["SARS", "TEST", 284, 288], ["CoV", "TEST", 289, 292], ["human SARS", "TEST", 296, 306], ["bat CoV", "TEST", 312, 319], ["disorder", "OBSERVATION", 163, 171], ["accessory proteins", "OBSERVATION", 184, 202]]], ["MSA results (Fig. 8d) demonstrate that ORF3b of SARS-CoV-2 is little evolutionarily closer to ORF3b proteins of human SARS and bat CoV, having a sequence similarity of only 54.6% and 59.1%, respectively.", [["SARS", "DISEASE", 48, 52], ["SARS", "DISEASE", 118, 122], ["ORF3b", "GENE_OR_GENE_PRODUCT", 39, 44], ["SARS-CoV-2", "ORGANISM", 48, 58], ["ORF3b", "GENE_OR_GENE_PRODUCT", 94, 99], ["human", "ORGANISM", 112, 117], ["bat CoV", "ORGANISM", 127, 134], ["ORF3b", "PROTEIN", 39, 44], ["ORF3b proteins", "PROTEIN", 94, 108], ["human", "SPECIES", 112, 117], ["SARS-CoV", "SPECIES", 48, 56], ["human", "SPECIES", 112, 117], ["bat CoV", "SPECIES", 127, 134], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["human SARS", "TEST", 112, 122], ["bat CoV", "TEST", 127, 134], ["a sequence similarity", "TEST", 143, 164]]], ["As we can see in Table 2, there is not a single MoRF located in SARS-CoV-2 ORF3b.", [["MoRF", "CANCER", 48, 52], ["SARS-CoV-2 ORF3b", "GENE_OR_GENE_PRODUCT", 64, 80], ["MoRF", "DNA", 48, 52], ["SARS-CoV-2 ORF3b", "DNA", 64, 80], ["SARS", "OBSERVATION", 64, 68]]], ["However, for human SARS, MoRFchibi_web server has identified three MoRFs (residues 32\u201337, 41\u201370, and 125\u2013153), whereas, for bat CoV, a single MoRF at N-terminus is observed (residues 1\u201338).Protein ORF6 ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionAlso known as P6, this membrane-associated protein serves as an interferon (IFN) antagonist [96].", [["membrane", "ANATOMY", 322, 330], ["SARS", "DISEASE", 19, 23], ["Intrinsic disorder", "DISEASE", 206, 224], ["N", "CHEMICAL", 150, 151], ["human", "ORGANISM", 13, 18], ["MoRFs", "GENE_OR_GENE_PRODUCT", 67, 72], ["bat CoV", "ORGANISM", 124, 131], ["MoRF", "GENE_OR_GENE_PRODUCT", 142, 146], ["ORF6", "GENE_OR_GENE_PRODUCT", 197, 201], ["coronaviruses", "ORGANISM", 259, 272], ["P6", "GENE_OR_GENE_PRODUCT", 313, 315], ["membrane", "CELLULAR_COMPONENT", 322, 330], ["IFN", "GENE_OR_GENE_PRODUCT", 375, 378], ["MoRFs", "PROTEIN", 67, 72], ["bat CoV", "PROTEIN", 124, 131], ["MoRF", "PROTEIN", 142, 146], ["N-terminus", "PROTEIN", 150, 160], ["ORF6", "PROTEIN", 197, 201], ["accessory proteins", "PROTEIN", 237, 255], ["membrane-associated protein", "PROTEIN", 322, 349], ["interferon", "PROTEIN", 363, 373], ["IFN", "PROTEIN", 375, 378], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["bat CoV", "SPECIES", 124, 131], ["bat CoV", "PROBLEM", 124, 131], ["a single MoRF at N-terminus", "TREATMENT", 133, 160], ["Intrinsic disorder", "PROBLEM", 206, 224], ["an interferon (IFN) antagonist", "TREATMENT", 360, 390], ["disorder", "OBSERVATION", 216, 224], ["accessory proteins", "OBSERVATION", 237, 255]]], ["Using its C-terminal residues, ORF6 disrupts karyopherin import complex in cytosol and, therefore, hampers the movement of transcription factors like STAT1 into the nucleus resulting in downregulation of the IFN pathway [96, 97].", [["cytosol", "ANATOMY", 75, 82], ["nucleus", "ANATOMY", 165, 172], ["C", "CHEMICAL", 10, 11], ["ORF6", "GENE_OR_GENE_PRODUCT", 31, 35], ["karyopherin", "GENE_OR_GENE_PRODUCT", 45, 56], ["cytosol", "CELLULAR_COMPONENT", 75, 82], ["STAT1", "GENE_OR_GENE_PRODUCT", 150, 155], ["nucleus", "CELLULAR_COMPONENT", 165, 172], ["IFN", "GENE_OR_GENE_PRODUCT", 208, 211], ["C-terminal residues", "PROTEIN", 10, 29], ["ORF6", "PROTEIN", 31, 35], ["karyopherin import complex", "PROTEIN", 45, 71], ["transcription factors", "PROTEIN", 123, 144], ["STAT1", "PROTEIN", 150, 155], ["IFN", "PROTEIN", 208, 211], ["its C-terminal residues", "TREATMENT", 6, 29], ["transcription factors", "PROBLEM", 123, 144], ["the IFN pathway", "TEST", 204, 219], ["terminal residues", "OBSERVATION", 12, 29], ["nucleus", "ANATOMY", 165, 172]]], ["It contains a YSEL motif near its C-terminal region that functions in protein internalization from the plasma membrane into the endosomal vesicles [98].Protein ORF6 ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionMSA results demonstrate that (Fig. 9d), SARS-CoV-2 ORF6 is closer to human SARS ORF6, having a sequence similarity of 68.85% than to bat CoV ORF6 (67.21%).", [["plasma membrane", "ANATOMY", 103, 118], ["endosomal vesicles", "ANATOMY", 128, 146], ["Intrinsic disorder", "DISEASE", 169, 187], ["C", "CHEMICAL", 34, 35], ["plasma membrane", "CELLULAR_COMPONENT", 103, 118], ["endosomal vesicles", "CELLULAR_COMPONENT", 128, 146], ["ORF6", "GENE_OR_GENE_PRODUCT", 160, 164], ["coronaviruses", "ORGANISM", 222, 235], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 302, 312], ["human", "ORGANISM", 331, 336], ["ORF6", "GENE_OR_GENE_PRODUCT", 342, 346], ["bat CoV ORF6", "ORGANISM", 395, 407], ["YSEL motif", "DNA", 14, 24], ["C-terminal region", "PROTEIN", 34, 51], ["ORF6", "PROTEIN", 160, 164], ["accessory proteins", "PROTEIN", 200, 218], ["SARS-CoV-2 ORF6", "DNA", 302, 317], ["human SARS ORF6", "DNA", 331, 346], ["human", "SPECIES", 331, 336], ["SARS-CoV", "SPECIES", 302, 310], ["human SARS ORF6", "SPECIES", 331, 346], ["bat CoV", "SPECIES", 395, 402], ["a YSEL motif", "TREATMENT", 12, 24], ["protein internalization", "TEST", 70, 93], ["the plasma membrane", "TEST", 99, 118], ["Protein ORF6", "TEST", 152, 164], ["Intrinsic disorder", "PROBLEM", 169, 187], ["accessory proteins of coronaviruses", "PROBLEM", 200, 235], ["discussionMSA", "TEST", 252, 265], ["SARS", "TEST", 302, 306], ["CoV", "TEST", 307, 310], ["a sequence similarity", "TEST", 355, 376], ["bat CoV ORF6", "TEST", 395, 407], ["terminal", "ANATOMY_MODIFIER", 36, 44], ["protein internalization", "OBSERVATION", 70, 93], ["plasma membrane", "OBSERVATION", 103, 118], ["endosomal vesicles", "OBSERVATION", 128, 146], ["Intrinsic disorder", "OBSERVATION", 169, 187]]], ["Novel SARS-CoV-2 ORF6 is predicted to be the second most disordered structural protein with a PPID of 22.95%, containing a disordered C-terminal region.Protein ORF6 ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionThe mean PPID of the other two ORF6 proteins are listed in Table 1.", [["Intrinsic disorder", "DISEASE", 169, 187], ["C", "CHEMICAL", 134, 135], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 6, 16], ["ORF6", "GENE_OR_GENE_PRODUCT", 17, 21], ["ORF6", "GENE_OR_GENE_PRODUCT", 160, 164], ["coronaviruses", "ORGANISM", 222, 235], ["ORF6", "GENE_OR_GENE_PRODUCT", 293, 297], ["SARS-CoV-2 ORF6", "DNA", 6, 21], ["PPID", "PROTEIN", 94, 98], ["C-terminal region", "PROTEIN", 134, 151], ["ORF6", "PROTEIN", 160, 164], ["accessory proteins", "PROTEIN", 200, 218], ["ORF6 proteins", "PROTEIN", 293, 306], ["Novel SARS", "TEST", 0, 10], ["a PPID", "TEST", 92, 98], ["a disordered C-terminal region", "PROBLEM", 121, 151], ["Intrinsic disorder", "PROBLEM", 169, 187], ["The mean PPID", "TREATMENT", 262, 275], ["terminal", "ANATOMY_MODIFIER", 136, 144], ["region", "ANATOMY_MODIFIER", 145, 151], ["disorder", "OBSERVATION", 179, 187], ["accessory proteins", "OBSERVATION", 200, 218]]], ["Graphs in Fig. 9a\u2013c illustrate that all three ORF6 proteins are moderately disordered with the presence of high disorder near C-terminal residues.", [["disorder", "DISEASE", 112, 120], ["C", "CHEMICAL", 126, 127], ["ORF6", "GENE_OR_GENE_PRODUCT", 46, 50], ["ORF6 proteins", "PROTEIN", 46, 59], ["C-terminal residues", "PROTEIN", 126, 145], ["moderately disordered", "PROBLEM", 64, 85], ["high disorder near C-terminal residues", "PROBLEM", 107, 145], ["high disorder", "OBSERVATION", 107, 120], ["terminal residues", "OBSERVATION", 128, 145]]], ["As aforementioned, this hydrophilic region contains lysosomal targeting motif (YSEL) and diacidic motif (DDEE) responsible for its binding and recognition during translocation [98], this region is important for the biological activities of ORF6.", [["lysosomal", "ANATOMY", 52, 61], ["ORF6", "GENE_OR_GENE_PRODUCT", 240, 244], ["lysosomal targeting motif", "PROTEIN", 52, 77], ["YSEL", "PROTEIN", 79, 83], ["diacidic motif", "PROTEIN", 89, 103], ["DDEE", "PROTEIN", 105, 109], ["ORF6", "PROTEIN", 240, 244], ["this hydrophilic region", "PROBLEM", 19, 42], ["lysosomal targeting motif (YSEL)", "TREATMENT", 52, 84], ["diacidic motif (DDEE)", "TREATMENT", 89, 110], ["its binding", "PROBLEM", 127, 138], ["hydrophilic", "ANATOMY_MODIFIER", 24, 35], ["lysosomal targeting motif", "OBSERVATION", 52, 77]]], ["Moreover, the N-terminus does not contain any prominent disorder.", [["N", "CHEMICAL", 14, 15], ["N-terminus", "PROTEIN", 14, 24], ["any prominent disorder", "PROBLEM", 42, 64], ["prominent", "OBSERVATION_MODIFIER", 46, 55], ["disorder", "OBSERVATION", 56, 64]]], ["First, 38 amino acids of human SARS ORF6 are described to form an \u03b1-helical structure spanning the membrane [99].", [["membrane", "ANATOMY", 99, 107], ["amino acids", "CHEMICAL", 10, 21], ["amino acids", "CHEMICAL", 10, 21], ["amino acids", "AMINO_ACID", 10, 21], ["human", "ORGANISM", 25, 30], ["ORF6", "GENE_OR_GENE_PRODUCT", 36, 40], ["membrane", "CELLULAR_COMPONENT", 99, 107], ["human SARS ORF6", "PROTEIN", 25, 40], ["\u03b1-helical structure", "PROTEIN", 66, 85], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["human SARS ORF6", "TREATMENT", 25, 40]]], ["A long MoRF region [(residues 26\u201361 in SARS-CoV-2), (residues 31\u201363 in Human SARS), and (residues 30\u201360 in bat Cov)] is also present near the C-terminus.", [["C", "CHEMICAL", 142, 143], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 39, 49], ["Human", "ORGANISM", 71, 76], ["long MoRF region", "DNA", 2, 18], ["C-terminus", "PROTEIN", 142, 152], ["Human", "SPECIES", 71, 76], ["A long MoRF region", "PROBLEM", 0, 18], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["Human SARS", "TEST", 71, 81]]], ["It represents very few RNA- and DNA-binding residues.ORF7a and ORF7b proteins ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionORF7a is a type I transmembrane protein [100, 101].", [["Intrinsic disorder", "DISEASE", 82, 100], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["ORF7a", "GENE_OR_GENE_PRODUCT", 53, 58], ["ORF7b", "GENE_OR_GENE_PRODUCT", 63, 68], ["coronaviruses", "ORGANISM", 135, 148], ["ORF7a", "PROTEIN", 53, 58], ["ORF7b proteins", "PROTEIN", 63, 77], ["accessory proteins", "PROTEIN", 113, 131], ["discussionORF7a", "PROTEIN", 165, 180], ["type I transmembrane protein", "PROTEIN", 186, 214], ["very few RNA", "PROBLEM", 14, 26], ["DNA-binding residues", "PROBLEM", 32, 52], ["Intrinsic disorder", "PROBLEM", 82, 100], ["very", "OBSERVATION_MODIFIER", 14, 18], ["few", "OBSERVATION_MODIFIER", 19, 22], ["RNA", "OBSERVATION", 23, 26], ["binding residues", "OBSERVATION", 36, 52], ["disorder", "OBSERVATION", 92, 100], ["accessory proteins", "OBSERVATION", 113, 131]]], ["It contributes to viral pathogenesis by activating the release of pro-inflammatory cytokines and chemokines, such as IL-8 and RANTES [102, 103].", [["IL-8", "GENE_OR_GENE_PRODUCT", 117, 121], ["RANTES", "GENE_OR_GENE_PRODUCT", 126, 132], ["pro-inflammatory cytokines", "PROTEIN", 66, 92], ["chemokines", "PROTEIN", 97, 107], ["IL-8", "PROTEIN", 117, 121], ["RANTES", "PROTEIN", 126, 132], ["viral pathogenesis", "PROBLEM", 18, 36], ["pro-inflammatory cytokines", "TREATMENT", 66, 92], ["chemokines", "TREATMENT", 97, 107], ["IL", "TEST", 117, 119], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["pro-inflammatory cytokines", "OBSERVATION", 66, 92]]], ["The presence of a KRKTE motif near the C-terminal region is needed for its import from ER to Golgi apparatus [100, 101].", [["ER", "ANATOMY", 87, 89], ["Golgi apparatus", "ANATOMY", 93, 108], ["C", "CHEMICAL", 39, 40], ["KRKTE", "GENE_OR_GENE_PRODUCT", 18, 23], ["ER", "GENE_OR_GENE_PRODUCT", 87, 89], ["Golgi", "CELLULAR_COMPONENT", 93, 98], ["KRKTE motif", "DNA", 18, 29], ["C-terminal region", "DNA", 39, 56], ["ER", "PROTEIN", 87, 89], ["a KRKTE motif near the C-terminal region", "TREATMENT", 16, 56], ["terminal", "ANATOMY_MODIFIER", 41, 49]]], ["On the other hand, ORF7b is an integral membrane protein that has been shown to localize in the Golgi complex [104, 105].", [["membrane", "ANATOMY", 40, 48], ["Golgi complex", "ANATOMY", 96, 109], ["ORF7b", "GENE_OR_GENE_PRODUCT", 19, 24], ["membrane", "CELLULAR_COMPONENT", 40, 48], ["Golgi", "CELLULAR_COMPONENT", 96, 101], ["ORF7b", "PROTEIN", 19, 24], ["integral membrane protein", "PROTEIN", 31, 56], ["Golgi complex", "PROTEIN", 96, 109], ["an integral membrane protein", "PROBLEM", 28, 56]]], ["These reports also confirm the role of ORF7b as an accessory as well as a structural protein in SARS-CoV virion [104, 105].ORF7a and ORF7b proteins ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionFigure 10d represents the 1.8 \u00c5 X-ray crystal structure of the 14\u201396 fragment of the ORF7a from human SARS (PDB ID: 1XAK) and demonstrates the compact seven \u03b2-stranded topology of this protein similar to the Ig-superfamily members [106].", [["Intrinsic disorder", "DISEASE", 152, 170], ["SARS", "DISEASE", 347, 351], ["ORF7b", "GENE_OR_GENE_PRODUCT", 39, 44], ["SARS-CoV virion", "ORGANISM", 96, 111], ["ORF7a", "GENE_OR_GENE_PRODUCT", 123, 128], ["ORF7b", "GENE_OR_GENE_PRODUCT", 133, 138], ["coronaviruses", "ORGANISM", 205, 218], ["ORF7a", "GENE_OR_GENE_PRODUCT", 330, 335], ["human", "ORGANISM", 341, 346], ["PDB ID: 1XAK", "GENE_OR_GENE_PRODUCT", 353, 365], ["Ig", "GENE_OR_GENE_PRODUCT", 453, 455], ["ORF7b", "PROTEIN", 39, 44], ["structural protein", "PROTEIN", 74, 92], ["ORF7a", "PROTEIN", 123, 128], ["ORF7b proteins", "PROTEIN", 133, 147], ["accessory proteins", "PROTEIN", 183, 201], ["14\u201396 fragment", "PROTEIN", 308, 322], ["ORF7a", "PROTEIN", 330, 335], ["1XAK", "PROTEIN", 361, 365], ["Ig", "PROTEIN", 453, 455], ["human", "SPECIES", 341, 346], ["SARS-CoV", "SPECIES", 96, 104], ["human", "SPECIES", 341, 346], ["a structural protein in SARS", "PROBLEM", 72, 100], ["Intrinsic disorder", "PROBLEM", 152, 170], ["disorder", "OBSERVATION", 162, 170], ["accessory proteins", "OBSERVATION", 183, 201]]], ["Importantly, in this crystal structure, residues 82\u201396 constitute the region with missing electron density, indicating the highly dynamic nature of this segment.", [["electron", "SIMPLE_CHEMICAL", 90, 98], ["missing electron density", "PROBLEM", 82, 106], ["electron density", "OBSERVATION", 90, 106], ["highly", "OBSERVATION_MODIFIER", 123, 129], ["dynamic", "OBSERVATION", 130, 137], ["segment", "ANATOMY_MODIFIER", 153, 160]]], ["In line with this hypothesis, NMR solution structure of the 16\u201399 fragment of ORF7a of human SARS (PDB ID: 1YO4) showed that residues 81\u201399 are highly disordered [107].ORF7a and ORF7b proteins ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionWe found that 121 residues-long ORF7a protein of SARS-CoV-2 shares 89.26% and 85.95% sequence identity with ORF7a proteins of bat CoV and human SARS, respectively (Fig. 10e).", [["SARS", "DISEASE", 93, 97], ["Intrinsic disorder", "DISEASE", 197, 215], ["SARS", "DISEASE", 434, 438], ["ORF7a", "GENE_OR_GENE_PRODUCT", 78, 83], ["human", "ORGANISM", 87, 92], ["ORF7a", "GENE_OR_GENE_PRODUCT", 168, 173], ["ORF7b", "GENE_OR_GENE_PRODUCT", 178, 183], ["coronaviruses", "ORGANISM", 250, 263], ["ORF7a", "GENE_OR_GENE_PRODUCT", 322, 327], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 339, 349], ["ORF7a", "GENE_OR_GENE_PRODUCT", 398, 403], ["bat CoV", "ORGANISM", 416, 423], ["human", "ORGANISM", 428, 433], ["16\u201399 fragment", "PROTEIN", 60, 74], ["ORF7a", "PROTEIN", 78, 83], ["1YO4", "PROTEIN", 107, 111], ["ORF7a", "PROTEIN", 168, 173], ["ORF7b proteins", "PROTEIN", 178, 192], ["accessory proteins", "PROTEIN", 228, 246], ["ORF7a protein", "PROTEIN", 322, 335], ["ORF7a proteins", "PROTEIN", 398, 412], ["bat CoV", "PROTEIN", 416, 423], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 428, 433], ["human", "SPECIES", 87, 92], ["SARS-CoV", "SPECIES", 339, 347], ["bat CoV", "SPECIES", 416, 423], ["human", "SPECIES", 428, 433], ["this hypothesis", "PROBLEM", 13, 28], ["NMR solution structure", "TREATMENT", 30, 52], ["human SARS", "PROBLEM", 87, 97], ["Intrinsic disorder", "PROBLEM", 197, 215], ["SARS", "TEST", 339, 343], ["CoV", "TEST", 344, 347], ["sequence identity", "TEST", 375, 392], ["ORF7a proteins", "TEST", 398, 412], ["bat CoV", "TEST", 416, 423], ["human SARS", "TEST", 428, 438], ["disorder", "OBSERVATION", 207, 215], ["accessory proteins", "OBSERVATION", 228, 246]]], ["In contrast, SARS-CoV-2 ORF7b is found to be closer to human SARS ORF7b (81.40%) than bat CoV ORF7b (79.07%) (see Fig. S3D).ORF7a and ORF7b proteins ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionAs observed from Table 1 and Fig. 10a\u2013c, our disorder predisposition analyses resulted in the overall PPID values for ORF7a proteins\u20141.65% (SARS-CoV-2), 0.82% (bat CoV), and 0.82% (Human SARS).", [["SARS", "DISEASE", 61, 65], ["Intrinsic disorder", "DISEASE", 153, 171], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["ORF7b", "GENE_OR_GENE_PRODUCT", 24, 29], ["human", "ORGANISM", 55, 60], ["ORF7b", "GENE_OR_GENE_PRODUCT", 66, 71], ["bat CoV", "ORGANISM", 86, 93], ["ORF7a", "GENE_OR_GENE_PRODUCT", 124, 129], ["ORF7b", "GENE_OR_GENE_PRODUCT", 134, 139], ["coronaviruses", "ORGANISM", 206, 219], ["ORF7a", "GENE_OR_GENE_PRODUCT", 364, 369], ["Human", "ORGANISM", 427, 432], ["SARS-CoV-2 ORF7b", "DNA", 13, 29], ["ORF7a", "PROTEIN", 124, 129], ["ORF7b proteins", "PROTEIN", 134, 148], ["accessory proteins", "PROTEIN", 184, 202], ["ORF7a proteins", "PROTEIN", 364, 378], ["human", "SPECIES", 55, 60], ["Human", "SPECIES", 427, 432], ["SARS-CoV", "SPECIES", 13, 21], ["human", "SPECIES", 55, 60], ["bat CoV", "SPECIES", 86, 93], ["bat CoV", "SPECIES", 406, 413], ["SARS", "TEST", 13, 17], ["human SARS ORF7b", "TEST", 55, 71], ["bat CoV ORF7b", "TEST", 86, 99], ["Intrinsic disorder", "PROBLEM", 153, 171], ["our disorder predisposition analyses", "PROBLEM", 287, 323], ["ORF7a proteins", "TEST", 364, 378], ["SARS", "TEST", 386, 390], ["CoV", "TEST", 391, 394], ["bat CoV", "TEST", 406, 413], ["disorder", "OBSERVATION", 163, 171], ["accessory proteins", "OBSERVATION", 184, 202]]], ["The mean PPIDs estimated for ORF7b proteins are 9.30% for SARS-CoV-2, 4.55% for bat CoV and 4.55% human SARS.", [["SARS", "DISEASE", 58, 62], ["SARS", "DISEASE", 104, 108], ["ORF7b", "GENE_OR_GENE_PRODUCT", 29, 34], ["bat CoV", "ORGANISM", 80, 87], ["human", "ORGANISM", 98, 103], ["PPIDs", "PROTEIN", 9, 14], ["ORF7b proteins", "PROTEIN", 29, 43], ["human", "SPECIES", 98, 103], ["SARS-CoV", "SPECIES", 58, 66], ["bat CoV", "SPECIES", 80, 87], ["human", "SPECIES", 98, 103], ["The mean PPIDs", "TEST", 0, 14], ["ORF7b proteins", "TEST", 29, 43], ["SARS", "TEST", 58, 62], ["CoV", "TEST", 63, 66], ["bat CoV", "TEST", 80, 87]]], ["Table 2 shows the presence of several MoRFs in ORF7a, indicating its potential involvement in disorder-dependent protein\u2013protein interactions.", [["disorder", "DISEASE", 94, 102], ["MoRFs", "GENE_OR_GENE_PRODUCT", 38, 43], ["ORF7a", "GENE_OR_GENE_PRODUCT", 47, 52], ["MoRFs", "PROTEIN", 38, 43], ["ORF7a", "PROTEIN", 47, 52], ["disorder", "PROBLEM", 94, 102], ["dependent protein\u2013protein interactions", "PROBLEM", 103, 141], ["several", "OBSERVATION_MODIFIER", 30, 37], ["MoRFs", "OBSERVATION", 38, 43], ["indicating its potential", "UNCERTAINTY", 54, 78], ["dependent", "OBSERVATION_MODIFIER", 103, 112], ["protein\u2013protein interactions", "OBSERVATION", 113, 141]]], ["At the N-terminus, one MoRF region (residues 1\u201310) is predicted by DISOPRED3 in all three ORF7a proteins.", [["N", "CHEMICAL", 7, 8], ["MoRF", "GENE_OR_GENE_PRODUCT", 23, 27], ["ORF7a", "GENE_OR_GENE_PRODUCT", 90, 95], ["N-terminus", "PROTEIN", 7, 17], ["MoRF region", "PROTEIN", 23, 34], ["residues 1\u201310", "PROTEIN", 36, 49], ["DISOPRED3", "PROTEIN", 67, 76], ["ORF7a proteins", "PROTEIN", 90, 104], ["terminus", "ANATOMY_MODIFIER", 9, 17]]], ["In addition to protein-binding regions, ORF7a also contains several RNA- and DNA-binding residues.", [["ORF7a", "GENE_OR_GENE_PRODUCT", 40, 45], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["protein-binding regions", "PROTEIN", 15, 38], ["ORF7a", "PROTEIN", 40, 45], ["protein-binding regions", "PROBLEM", 15, 38], ["ORF7a", "TEST", 40, 45], ["several RNA", "PROBLEM", 60, 71], ["DNA-binding residues", "PROBLEM", 77, 97], ["binding regions", "OBSERVATION", 23, 38], ["several", "OBSERVATION_MODIFIER", 60, 67], ["RNA", "OBSERVATION", 68, 71], ["binding residues", "OBSERVATION", 81, 97]]], ["Analysis also reveals the low disorder content in all three ORF7b proteins (Fig. S3A\u2013C), and subsequently no MoRFs.", [["disorder", "DISEASE", 30, 38], ["ORF7b", "GENE_OR_GENE_PRODUCT", 60, 65], ["MoRFs", "GENE_OR_GENE_PRODUCT", 109, 114], ["ORF7b proteins", "PROTEIN", 60, 74], ["S3A\u2013C", "PROTEIN", 81, 86], ["MoRFs", "PROTEIN", 109, 114], ["Analysis", "TEST", 0, 8], ["the low disorder content", "PROBLEM", 22, 46], ["low disorder", "OBSERVATION", 26, 38]]], ["Although ORF7b does not contain protein-binding regions, it has many nucleotide (both RNA and DNA)-binding residues.", [["nucleotide", "CHEMICAL", 69, 79], ["nucleotide", "CHEMICAL", 69, 79], ["ORF7b", "GENE_OR_GENE_PRODUCT", 9, 14], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["ORF7b", "PROTEIN", 9, 14], ["protein-binding regions", "PROTEIN", 32, 55], ["protein-binding regions", "PROBLEM", 32, 55], ["many nucleotide (both RNA", "PROBLEM", 64, 89], ["binding residues", "PROBLEM", 99, 115], ["protein", "OBSERVATION", 32, 39], ["binding regions", "OBSERVATION", 40, 55]]], ["Figures S3A, 3B, and 3C depict the residues predisposed for disorder in ORF7b proteins of SARS-CoV-2, human SARS CoV, and bat CoV, respectively.", [["disorder", "DISEASE", 60, 68], ["S3A", "GENE_OR_GENE_PRODUCT", 8, 11], ["ORF7b", "GENE_OR_GENE_PRODUCT", 72, 77], ["SARS-CoV-2", "ORGANISM", 90, 100], ["human", "ORGANISM", 102, 107], ["SARS CoV", "ORGANISM", 108, 116], ["bat CoV", "ORGANISM", 122, 129], ["S3A, 3B, and 3C", "PROTEIN", 8, 23], ["ORF7b proteins", "PROTEIN", 72, 86], ["human SARS CoV", "PROTEIN", 102, 116], ["human", "SPECIES", 102, 107], ["SARS-CoV", "SPECIES", 90, 98], ["human SARS CoV", "SPECIES", 102, 116], ["bat CoV", "SPECIES", 122, 129], ["the residues", "PROBLEM", 31, 43], ["disorder", "PROBLEM", 60, 68], ["SARS", "TEST", 90, 94], ["CoV", "TEST", 95, 98], ["human SARS CoV", "TEST", 102, 116]]], ["In particular, both proteins in all three studied viruses have ordered structures.Proteins ORF8a and ORF8b ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionIn isolates from early human infections, the ORF8 gene codes for a single ORF8 protein.", [["Intrinsic disorder", "DISEASE", 111, 129], ["human infections", "DISEASE", 227, 243], ["ORF8a", "GENE_OR_GENE_PRODUCT", 91, 96], ["ORF8b", "GENE_OR_GENE_PRODUCT", 101, 106], ["coronaviruses", "ORGANISM", 164, 177], ["human", "ORGANISM", 227, 232], ["ORF8", "GENE_OR_GENE_PRODUCT", 249, 253], ["ORF8", "GENE_OR_GENE_PRODUCT", 278, 282], ["ORF8a", "PROTEIN", 91, 96], ["ORF8b", "PROTEIN", 101, 106], ["accessory proteins", "PROTEIN", 142, 160], ["ORF8 gene", "DNA", 249, 258], ["ORF8 protein", "PROTEIN", 278, 290], ["human", "SPECIES", 227, 232], ["human", "SPECIES", 227, 232], ["Proteins", "TEST", 82, 90], ["ORF8b", "TEST", 101, 106], ["Intrinsic disorder", "PROBLEM", 111, 129], ["early human infections", "PROBLEM", 221, 243], ["a single ORF8 protein", "TREATMENT", 269, 290], ["viruses", "OBSERVATION", 50, 57], ["disorder", "OBSERVATION", 121, 129], ["accessory proteins", "OBSERVATION", 142, 160], ["early human", "OBSERVATION_MODIFIER", 221, 232], ["infections", "OBSERVATION", 233, 243]]], ["However, in late infections, more specifically, at middle and late stages, a 29 nucleotide deletion in the ORF8 gene led to the formation of two distinct proteins, ORF8a and ORF8b containing 39 and 84 residues, respectively [108, 109].", [["infections", "DISEASE", 17, 27], ["nucleotide", "CHEMICAL", 80, 90], ["nucleotide", "CHEMICAL", 80, 90], ["ORF8", "GENE_OR_GENE_PRODUCT", 107, 111], ["ORF8a", "GENE_OR_GENE_PRODUCT", 164, 169], ["ORF8b", "GENE_OR_GENE_PRODUCT", 174, 179], ["29 nucleotide deletion", "DNA", 77, 99], ["ORF8 gene", "DNA", 107, 116], ["ORF8a", "PROTEIN", 164, 169], ["ORF8b", "PROTEIN", 174, 179], ["a 29 nucleotide deletion", "PROBLEM", 75, 99], ["ORF8b", "TEST", 174, 179], ["late", "OBSERVATION_MODIFIER", 12, 16], ["infections", "OBSERVATION", 17, 27], ["distinct", "OBSERVATION_MODIFIER", 145, 153], ["proteins", "OBSERVATION", 154, 162]]], ["Both proteins have conformations different from that of the longer ORF8 protein and interacts with different structural proteins [110].", [["ORF8", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF8 protein", "PROTEIN", 67, 79], ["structural proteins", "PROTEIN", 109, 128]]], ["The disorder-based protein-binding regions of this protein identified in this study may have an important role in interaction with other proteins.Proteins ORF8a and ORF8b ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionORF8 protein found in early SARS-CoV-2 isolates having 121 residues shares a 90.05% sequence identity with bat CoV ORF8 (Fig. S4C).", [["disorder", "DISEASE", 4, 12], ["Intrinsic disorder", "DISEASE", 175, 193], ["ORF8a", "GENE_OR_GENE_PRODUCT", 155, 160], ["ORF8b", "GENE_OR_GENE_PRODUCT", 165, 170], ["coronaviruses", "ORGANISM", 228, 241], ["discussionORF8", "GENE_OR_GENE_PRODUCT", 258, 272], ["SARS-CoV-2", "ORGANISM", 296, 306], ["bat CoV", "ORGANISM", 375, 382], ["S4C", "GENE_OR_GENE_PRODUCT", 394, 397], ["protein-binding regions", "PROTEIN", 19, 42], ["ORF8a", "PROTEIN", 155, 160], ["ORF8b", "PROTEIN", 165, 170], ["accessory proteins", "PROTEIN", 206, 224], ["discussionORF8 protein", "PROTEIN", 258, 280], ["bat CoV ORF8", "PROTEIN", 375, 387], ["Fig. S4C", "PROTEIN", 389, 397], ["SARS-CoV", "SPECIES", 296, 304], ["bat CoV", "SPECIES", 375, 382], ["The disorder", "PROBLEM", 0, 12], ["this protein", "PROBLEM", 46, 58], ["this study", "TEST", 73, 83], ["Intrinsic disorder", "PROBLEM", 175, 193], ["discussionORF8 protein", "TEST", 258, 280], ["early SARS", "TEST", 290, 300], ["CoV", "TEST", 301, 304], ["disorder", "OBSERVATION", 4, 12], ["disorder", "OBSERVATION", 185, 193], ["accessory proteins", "OBSERVATION", 206, 224]]], ["S4A and S4B illustrates the absence of intrinsic disorder in both ORF8 proteins.", [["intrinsic disorder", "DISEASE", 39, 57], ["S4A", "GENE_OR_GENE_PRODUCT", 0, 3], ["S4B", "GENE_OR_GENE_PRODUCT", 8, 11], ["ORF8", "GENE_OR_GENE_PRODUCT", 66, 70], ["S4A", "PROTEIN", 0, 3], ["S4B", "PROTEIN", 8, 11], ["ORF8 proteins", "PROTEIN", 66, 79], ["intrinsic disorder", "PROBLEM", 39, 57], ["intrinsic disorder", "OBSERVATION", 39, 57]]], ["Therefore, these two proteins are predicted to be completely structured (mean PPID of 0.00%).", [["mean PPID", "TEST", 73, 82]]], ["In ORF8a and ORF8b proteins of the human SARS, the predicted disorder is estimated to be 2.56% and 2.38%, respectively (Table 1).", [["SARS", "DISEASE", 41, 45], ["ORF8a", "GENE_OR_GENE_PRODUCT", 3, 8], ["ORF8b", "GENE_OR_GENE_PRODUCT", 13, 18], ["human", "ORGANISM", 35, 40], ["ORF8a", "PROTEIN", 3, 8], ["ORF8b proteins", "PROTEIN", 13, 27], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["the human SARS", "PROBLEM", 31, 45], ["the predicted disorder", "PROBLEM", 47, 69]]], ["Graphs in Figs.", [["Figs", "OBSERVATION", 10, 14]]], ["S5A and 5B illustrate the presence of some disorder near the N- and C-terminals of ORF8a and ORF8b proteins.", [["N", "CHEMICAL", 61, 62], ["S5A", "GENE_OR_GENE_PRODUCT", 0, 3], ["ORF8a", "GENE_OR_GENE_PRODUCT", 83, 88], ["ORF8b", "GENE_OR_GENE_PRODUCT", 93, 98], ["S5A", "PROTEIN", 0, 3], ["N- and C-terminals", "PROTEIN", 61, 79], ["ORF8a", "PROTEIN", 83, 88], ["ORF8b proteins", "PROTEIN", 93, 107], ["some disorder", "PROBLEM", 38, 51], ["the N", "TEST", 57, 62], ["ORF8b proteins", "PROBLEM", 93, 107], ["some", "OBSERVATION_MODIFIER", 38, 42], ["disorder", "OBSERVATION", 43, 51]]], ["Table 2 shows three MoRF regions (residues 1\u20135, 26\u201352, and 69\u201391) by MoRFchibi_web and one MoRF region (residues 1\u201310) by DISOPRED3 in SARS-CoV-2 ORF8.", [["MoRF", "GENE_OR_GENE_PRODUCT", 20, 24], ["SARS-CoV-2 ORF8", "GENE_OR_GENE_PRODUCT", 135, 150], ["MoRF regions", "DNA", 20, 32], ["MoRFchibi_web", "PROTEIN", 69, 82], ["MoRF region", "PROTEIN", 91, 102], ["DISOPRED3", "PROTEIN", 122, 131], ["SARS-CoV-2 ORF8", "DNA", 135, 150], ["SARS-CoV", "SPECIES", 135, 143], ["CoV", "TEST", 140, 143]]], ["Bat CoV has four protein-binding regions (residues 26\u201353, 70\u201391, 98\u2013104, and 113\u2013130) identified by MoRFchibi_web server (Table S8).", [["Bat CoV", "ORGANISM", 0, 7], ["Bat CoV", "PROTEIN", 0, 7], ["protein-binding regions", "PROTEIN", 17, 40], ["Bat CoV", "SPECIES", 0, 7], ["Bat CoV", "TEST", 0, 7], ["four protein", "OBSERVATION_MODIFIER", 12, 24]]], ["Furthermore, in human SARS, the N-terminus of both ORF8a (residues 1\u201339) and ORF8b (residues 1\u201383) is predicted to be MoRF by the MoRFchibi_web server (Table S7).", [["SARS", "DISEASE", 22, 26], ["human", "ORGANISM", 16, 21], ["ORF8a", "GENE_OR_GENE_PRODUCT", 51, 56], ["ORF8b", "GENE_OR_GENE_PRODUCT", 77, 82], ["MoRF", "GENE_OR_GENE_PRODUCT", 118, 122], ["ORF8a", "PROTEIN", 51, 56], ["residues 1\u201339", "PROTEIN", 58, 71], ["ORF8b", "PROTEIN", 77, 82], ["residues 1\u201383", "PROTEIN", 84, 97], ["MoRF", "PROTEIN", 118, 122], ["MoRFchibi_web server", "DNA", 130, 150], ["human", "SPECIES", 16, 21], ["human", "SPECIES", 16, 21]]], ["In addition with protein-binding regions, ORF8, ORF8a and ORF8b proteins contain many nucleotide-binding residues (Tables S9\u2013S11).ORF9b protein ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionThis protein is expressed from an alternative ORF within the N gene through a leaky ribosome-binding process [111].", [["nucleotide", "CHEMICAL", 86, 96], ["Intrinsic disorder", "DISEASE", 148, 166], ["nucleotide", "CHEMICAL", 86, 96], ["ORF8", "GENE_OR_GENE_PRODUCT", 42, 46], ["ORF8a", "GENE_OR_GENE_PRODUCT", 48, 53], ["ORF8b", "GENE_OR_GENE_PRODUCT", 58, 63], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 122, 128], ["ORF9b", "GENE_OR_GENE_PRODUCT", 130, 135], ["coronaviruses", "ORGANISM", 201, 214], ["protein-binding regions", "PROTEIN", 17, 40], ["ORF8", "PROTEIN", 42, 46], ["ORF8a", "PROTEIN", 48, 53], ["ORF8b proteins", "PROTEIN", 58, 72], ["S9", "PROTEIN", 122, 124], ["S11", "PROTEIN", 125, 128], ["ORF9b protein", "PROTEIN", 130, 143], ["accessory proteins", "PROTEIN", 179, 197], ["ORF", "DNA", 287, 290], ["N gene", "DNA", 302, 308], ["protein-binding regions", "PROBLEM", 17, 40], ["ORF8", "TEST", 42, 46], ["ORF8a", "TEST", 48, 53], ["ORF8b proteins", "TEST", 58, 72], ["many nucleotide-binding residues", "PROBLEM", 81, 113], ["Intrinsic disorder", "PROBLEM", 148, 166], ["an alternative ORF", "PROBLEM", 272, 290], ["a leaky ribosome-binding process", "PROBLEM", 317, 349], ["binding residues", "OBSERVATION", 97, 113], ["disorder", "OBSERVATION", 158, 166], ["accessory proteins", "OBSERVATION", 179, 197]]], ["This protein is shown to interact with a nuclear export protein receptor Exportin 1 (Crm1), using which it's translocated out of the nucleus [112].", [["nuclear", "ANATOMY", 41, 48], ["nucleus", "ANATOMY", 133, 140], ["Exportin 1", "GENE_OR_GENE_PRODUCT", 73, 83], ["Crm1", "GENE_OR_GENE_PRODUCT", 85, 89], ["nucleus", "CELLULAR_COMPONENT", 133, 140], ["nuclear export protein receptor", "PROTEIN", 41, 72], ["Exportin 1", "PROTEIN", 73, 83], ["Crm1", "PROTEIN", 85, 89], ["nucleus", "ANATOMY", 133, 140]]], ["Our MoRFs analysis shows the presence of disorder-based protein-binding regions in ORF9b protein which may have a role in its interaction with Crm1 for translocation outside the nucleus.", [["nucleus", "ANATOMY", 178, 185], ["disorder", "DISEASE", 41, 49], ["ORF9b", "GENE_OR_GENE_PRODUCT", 83, 88], ["Crm1", "GENE_OR_GENE_PRODUCT", 143, 147], ["nucleus", "CELLULAR_COMPONENT", 178, 185], ["MoRFs", "DNA", 4, 9], ["protein-binding regions", "PROTEIN", 56, 79], ["ORF9b protein", "PROTEIN", 83, 96], ["Crm1", "PROTEIN", 143, 147], ["Our MoRFs analysis", "TEST", 0, 18], ["disorder", "PROBLEM", 41, 49], ["based protein-binding regions in ORF9b protein", "PROBLEM", 50, 96], ["disorder", "OBSERVATION", 41, 49], ["nucleus", "ANATOMY", 178, 185]]], ["A 2.8 \u00c5 resolution crystal structure of ORF9b protein from human SARS CoV (PDB ID: 2CME) shows the presence of a dimeric tent-like \u03b2-structure along with the central hydrophobic amino acids (Fig. 11d) [113].ORF9b protein ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionBased on the sequence availability (accession ID NC_045512.2), translated protein sequence of ORF9b is not reported for SARS-CoV-2.", [["SARS", "DISEASE", 65, 69], ["amino acids", "CHEMICAL", 178, 189], ["Intrinsic disorder", "DISEASE", 225, 243], ["amino acids", "CHEMICAL", 178, 189], ["ORF9b", "GENE_OR_GENE_PRODUCT", 40, 45], ["human", "ORGANISM", 59, 64], ["SARS CoV", "ORGANISM", 65, 73], ["amino acids", "AMINO_ACID", 178, 189], ["ORF9b", "GENE_OR_GENE_PRODUCT", 207, 212], ["coronaviruses", "ORGANISM", 278, 291], ["ORF9b", "GENE_OR_GENE_PRODUCT", 412, 417], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 438, 448], ["ORF9b protein", "PROTEIN", 40, 53], ["human SARS CoV", "PROTEIN", 59, 73], ["2CME", "PROTEIN", 83, 87], ["dimeric tent-like \u03b2-structure", "PROTEIN", 113, 142], ["ORF9b protein", "PROTEIN", 207, 220], ["accessory proteins", "PROTEIN", 256, 274], ["ORF9b", "PROTEIN", 412, 417], ["human", "SPECIES", 59, 64], ["human SARS CoV", "SPECIES", 59, 73], ["SARS-CoV", "SPECIES", 438, 446], ["A 2.8 \u00c5 resolution crystal structure", "PROBLEM", 0, 36], ["ORF9b protein", "TEST", 40, 53], ["a dimeric tent-like \u03b2-structure", "PROBLEM", 111, 142], ["the central hydrophobic amino acids", "TREATMENT", 154, 189], ["Intrinsic disorder", "PROBLEM", 225, 243], ["translated protein sequence", "TEST", 381, 408], ["SARS", "PROBLEM", 438, 442], ["CoV", "TEST", 443, 446], ["2.8 \u00c5", "OBSERVATION_MODIFIER", 2, 7], ["disorder", "OBSERVATION", 235, 243], ["accessory proteins", "OBSERVATION", 256, 274]]], ["However, based on a report by Wu and colleagues [45], corresponding annotated sequence is used for intrinsic disorder analysis.", [["intrinsic disorder", "DISEASE", 99, 117], ["intrinsic disorder analysis", "PROBLEM", 99, 126]]], ["According to the MSA (results shown in Fig. 11e), ORF9b protein from SARS-CoV-2 shares 73.2% identity with human SARS and 74.23% identity with bat CoV.ORF9b protein ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionOur IDP analysis (Table 1) exposed moderate disorder content in ORF9b of human SARS having a mean PPID of 26.53%.", [["SARS", "DISEASE", 113, 117], ["Intrinsic disorder", "DISEASE", 169, 187], ["disorder", "DISEASE", 306, 314], ["SARS", "DISEASE", 341, 345], ["ORF9b", "GENE_OR_GENE_PRODUCT", 50, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["human", "ORGANISM", 107, 112], ["CoV.ORF9b", "GENE_OR_GENE_PRODUCT", 147, 156], ["coronaviruses", "ORGANISM", 222, 235], ["human", "ORGANISM", 335, 340], ["ORF9b protein", "PROTEIN", 50, 63], ["bat CoV.ORF9b protein", "PROTEIN", 143, 164], ["accessory proteins", "PROTEIN", 200, 218], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 335, 340], ["SARS-CoV", "SPECIES", 69, 77], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 335, 340], ["the MSA", "TEST", 13, 20], ["ORF9b protein", "TEST", 50, 63], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["human SARS", "TEST", 107, 117], ["Intrinsic disorder", "PROBLEM", 169, 187], ["discussionOur IDP analysis", "TEST", 252, 278], ["moderate disorder content", "PROBLEM", 297, 322], ["a mean PPID", "TEST", 353, 364], ["disorder", "OBSERVATION", 179, 187], ["accessory proteins", "OBSERVATION", 200, 218], ["moderate", "OBSERVATION_MODIFIER", 297, 305], ["disorder", "OBSERVATION", 306, 314]]], ["As depicted in Fig. 11a\u2013c, disorder in human SARS ORF9b protein mainly lies near the N-terminal end (residues 1\u201310) and near the central region (residues 28\u201340) with a well-ordered inner core.", [["disorder", "DISEASE", 27, 35], ["SARS", "DISEASE", 45, 49], ["N", "CHEMICAL", 85, 86], ["human", "ORGANISM", 39, 44], ["ORF9b", "GENE_OR_GENE_PRODUCT", 50, 55], ["Fig. 11a\u2013c", "PROTEIN", 15, 25], ["human SARS ORF9b protein", "PROTEIN", 39, 63], ["N-terminal end", "PROTEIN", 85, 99], ["residues 1\u201310", "PROTEIN", 101, 114], ["central region", "PROTEIN", 129, 143], ["residues 28\u201340", "PROTEIN", 145, 159], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["disorder", "PROBLEM", 27, 35], ["protein", "TEST", 56, 63], ["terminal", "ANATOMY_MODIFIER", 87, 95], ["central", "ANATOMY_MODIFIER", 129, 136], ["region", "ANATOMY_MODIFIER", 137, 143]]], ["The X-ray crystal structure of ORF9b has a missing electron density of first 8 residues and 26\u201337 residues near the central region.", [["ORF9b", "CHEMICAL", 31, 36], ["ORF9b", "GENE_OR_GENE_PRODUCT", 31, 36], ["electron", "SIMPLE_CHEMICAL", 51, 59], ["ORF9b", "PROTEIN", 31, 36], ["central region", "PROTEIN", 116, 130], ["The X-ray crystal structure", "TEST", 0, 27], ["central", "ANATOMY_MODIFIER", 116, 123], ["region", "ANATOMY_MODIFIER", 124, 130]]], ["This indicates that the corresponding regions are disordered, which are difficult to crystallize due to their highly dynamic structural organization.", [["disordered", "OBSERVATION", 50, 60], ["highly", "OBSERVATION_MODIFIER", 110, 116], ["dynamic", "OBSERVATION_MODIFIER", 117, 124], ["structural organization", "OBSERVATION", 125, 148]]], ["SARS-CoV-2 ORF9b with a mean PPID of 10.31% also has an N-terminal (1\u201310 residues) disordered segment.", [["SARS", "DISEASE", 0, 4], ["N", "CHEMICAL", 56, 57], ["SARS-CoV-2 ORF9b", "ORGANISM", 0, 16], ["SARS-CoV-2 ORF9b", "DNA", 0, 16], ["CoV", "TEST", 5, 8], ["a mean PPID", "TEST", 22, 33], ["an N-terminal (1\u201310 residues) disordered segment", "PROBLEM", 53, 101], ["segment", "ANATOMY_MODIFIER", 94, 101]]], ["ORF9b of bat CoV is shown to have an intrinsic disorder content of 9.28%, comparatively lower than the other two ORF9b proteins.", [["ORF9b", "GENE_OR_GENE_PRODUCT", 0, 5], ["bat CoV", "ORGANISM", 9, 16], ["ORF9b", "GENE_OR_GENE_PRODUCT", 113, 118], ["ORF9b", "PROTEIN", 0, 5], ["bat CoV", "PROTEIN", 9, 16], ["ORF9b proteins", "PROTEIN", 113, 127], ["bat CoV", "SPECIES", 9, 16], ["bat CoV", "TEST", 9, 16], ["an intrinsic disorder content", "PROBLEM", 34, 63], ["bat", "ANATOMY", 9, 12], ["intrinsic", "OBSERVATION_MODIFIER", 37, 46], ["disorder", "OBSERVATION", 47, 55]]], ["MoRFs lies in the N-terminal region of ORF9b proteins of all three viruses (Tables 2, S7, S8).", [["MoRFs", "GENE_OR_GENE_PRODUCT", 0, 5], ["ORF9b", "GENE_OR_GENE_PRODUCT", 39, 44], ["MoRFs", "PROTEIN", 0, 5], ["N-terminal region", "PROTEIN", 18, 35], ["ORF9b proteins", "PROTEIN", 39, 53], ["S7", "PROTEIN", 86, 88], ["S8", "PROTEIN", 90, 92], ["all three", "OBSERVATION_MODIFIER", 57, 66], ["viruses", "OBSERVATION", 67, 74]]], ["In the absence of other viral proteins, its first 41 residues are demonstrated to induce membranous structures similar to DMVs [99].", [["membranous structures", "ANATOMY", 89, 110], ["viral proteins", "PROTEIN", 24, 38], ["other viral proteins", "PROBLEM", 18, 38], ["membranous structures", "PROBLEM", 89, 110], ["DMVs", "TEST", 122, 126], ["membranous", "OBSERVATION", 89, 99]]], ["The available crystal structure also has a missing electron density in the N-terminal region suggesting that these flexible amino acids are likely to interact with host lipids.", [["amino acids", "CHEMICAL", 124, 135], ["N", "CHEMICAL", 75, 76], ["amino acids", "CHEMICAL", 124, 135], ["electron", "SIMPLE_CHEMICAL", 51, 59], ["amino acids", "AMINO_ACID", 124, 135], ["N-terminal region", "PROTEIN", 75, 92], ["a missing electron density", "PROBLEM", 41, 67], ["these flexible amino acids", "TREATMENT", 109, 135], ["host lipids", "TREATMENT", 164, 175], ["electron density", "OBSERVATION", 51, 67], ["terminal", "ANATOMY_MODIFIER", 77, 85], ["region", "ANATOMY_MODIFIER", 86, 92], ["amino acids", "OBSERVATION", 124, 135]]], ["The 3\u201329 amino acid segment of SARS-CoV-2 is identified as disorder-based protein-binding region that may mediate its interaction with host lipids for the formation of DMVs.ORF10 protein ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionThe newly emerged SARS-CoV-2 has an ORF10 protein of 38 amino acids.", [["amino acid", "CHEMICAL", 9, 19], ["SARS", "DISEASE", 31, 35], ["Intrinsic disorder", "DISEASE", 191, 209], ["SARS", "DISEASE", 302, 306], ["amino acids", "CHEMICAL", 340, 351], ["amino acid", "CHEMICAL", 9, 19], ["amino acids", "CHEMICAL", 340, 351], ["amino acid", "AMINO_ACID", 9, 19], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 31, 41], ["DMVs", "SIMPLE_CHEMICAL", 168, 172], ["ORF10", "GENE_OR_GENE_PRODUCT", 173, 178], ["coronaviruses", "ORGANISM", 244, 257], ["SARS-CoV-2", "ORGANISM", 302, 312], ["ORF10", "GENE_OR_GENE_PRODUCT", 320, 325], ["amino acids", "AMINO_ACID", 340, 351], ["3\u201329 amino acid segment", "PROTEIN", 4, 27], ["SARS-CoV-2", "DNA", 31, 41], ["protein-binding region", "PROTEIN", 74, 96], ["DMVs", "PROTEIN", 168, 172], ["ORF10 protein", "PROTEIN", 173, 186], ["accessory proteins", "PROTEIN", 222, 240], ["ORF10 protein", "PROTEIN", 320, 333], ["SARS-CoV", "SPECIES", 31, 39], ["SARS-CoV", "SPECIES", 302, 310], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["disorder", "PROBLEM", 59, 67], ["based protein-binding region", "PROBLEM", 68, 96], ["host lipids", "TREATMENT", 135, 146], ["DMVs", "PROBLEM", 168, 172], ["Intrinsic disorder", "PROBLEM", 191, 209], ["an ORF10 protein", "TEST", 317, 333], ["amino acids", "TREATMENT", 340, 351], ["disorder", "OBSERVATION", 201, 209], ["accessory proteins", "OBSERVATION", 222, 240]]], ["ORF10 of SARS-CoV-2 has a 100% sequence similarity with ORF10 of bat CoV strain bat-SL-CoVZC45 [11].", [["SARS", "DISEASE", 9, 13], ["ORF10", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV-2", "ORGANISM", 9, 19], ["ORF10", "GENE_OR_GENE_PRODUCT", 56, 61], ["bat CoV", "ORGANISM", 65, 72], ["ORF10", "PROTEIN", 0, 5], ["SARS-CoV-2", "DNA", 9, 19], ["ORF10", "DNA", 56, 61], ["SARS-CoV", "SPECIES", 9, 17], ["bat CoV strain bat-SL-CoVZC45", "SPECIES", 65, 94], ["SARS", "PROBLEM", 9, 13], ["CoV", "TEST", 14, 17], ["ORF10", "TEST", 56, 61], ["bat CoV strain bat", "TEST", 65, 83]]], ["However, we did not conduct the disorder analysis for ORF10 from the bat-SL-CoVZC45 strain, since all our studies reported here are related to a different strain of bat CoV (reviewed strain HKU3-1).", [["disorder", "DISEASE", 32, 40], ["ORF10", "GENE_OR_GENE_PRODUCT", 54, 59], ["bat-SL-CoVZC45 strain", "ORGANISM", 69, 90], ["bat CoV", "ORGANISM", 165, 172], ["ORF10", "PROTEIN", 54, 59], ["bat CoV", "SPECIES", 165, 172], ["the disorder analysis", "PROBLEM", 28, 49], ["the bat", "TEST", 65, 72], ["CoVZC45 strain", "PROBLEM", 76, 90], ["all our studies", "TEST", 98, 113], ["a different strain of bat CoV", "PROBLEM", 143, 172]]], ["Therefore, we have only reported the results of disorder analysis for the ORF10 protein from SARS-CoV-2, according to which this protein has a mean PPID of 0.00% (see also Fig. S6 for disorder profile of ORF10).", [["disorder", "DISEASE", 48, 56], ["disorder", "DISEASE", 184, 192], ["ORF10", "GENE_OR_GENE_PRODUCT", 74, 79], ["SARS-CoV-2", "ORGANISM", 93, 103], ["S6", "GENE_OR_GENE_PRODUCT", 177, 179], ["ORF10", "GENE_OR_GENE_PRODUCT", 204, 209], ["ORF10 protein", "PROTEIN", 74, 87], ["S6", "PROTEIN", 177, 179], ["ORF10", "PROTEIN", 204, 209], ["SARS-CoV", "SPECIES", 93, 101], ["disorder analysis", "TEST", 48, 65], ["the ORF10 protein", "TEST", 70, 87], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["a mean PPID", "TEST", 141, 152], ["disorder profile", "PROBLEM", 184, 200]]], ["This protein contains a MoRF from three to seven residues at its N-terminus as predicted by MoRFchibi_web.", [["N", "CHEMICAL", 65, 66], ["MoRF", "GENE_OR_GENE_PRODUCT", 24, 28], ["MoRF", "PROTEIN", 24, 28], ["N-terminus", "PROTEIN", 65, 75], ["MoRFchibi_web", "PROTEIN", 92, 105], ["a MoRF", "TREATMENT", 22, 28]]], ["Further, we predicted its binding tendency to nucleotides and found the presence of few RNA-binding sites; however, it does not contain DNA-binding residues.Protein ORF14 ::: Intrinsic disorder analysis of accessory proteins of coronaviruses ::: Results and discussionThis is a 70 amino acid long uncharacterized protein of unknown function.", [["Intrinsic disorder", "DISEASE", 175, 193], ["amino acid", "CHEMICAL", 281, 291], ["nucleotides", "CHEMICAL", 46, 57], ["amino acid", "CHEMICAL", 281, 291], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["ORF14", "GENE_OR_GENE_PRODUCT", 165, 170], ["coronaviruses", "ORGANISM", 228, 241], ["RNA-binding sites", "DNA", 88, 105], ["ORF14", "PROTEIN", 165, 170], ["accessory proteins", "PROTEIN", 206, 224], ["70 amino acid long uncharacterized protein", "PROTEIN", 278, 320], ["few RNA-binding sites", "PROBLEM", 84, 105], ["Intrinsic disorder", "PROBLEM", 175, 193], ["few", "OBSERVATION_MODIFIER", 84, 87], ["RNA", "OBSERVATION", 88, 91], ["binding sites", "OBSERVATION", 92, 105], ["binding residues", "OBSERVATION", 140, 156], ["disorder", "OBSERVATION", 185, 193], ["accessory proteins", "OBSERVATION", 206, 224], ["unknown function", "OBSERVATION", 324, 340]]], ["According to the MSA, ORF14 of SARS-CoV-2 has 77.1% identity with human-SARS and 72.9% identity with bat CoV as represented in Fig. S7D.", [["SARS", "DISEASE", 31, 35], ["SARS", "DISEASE", 72, 76], ["ORF14", "GENE_OR_GENE_PRODUCT", 22, 27], ["SARS-CoV-2", "ORGANISM", 31, 41], ["human", "ORGANISM", 66, 71], ["bat CoV", "ORGANISM", 101, 108], ["ORF14", "DNA", 22, 27], ["S7D", "PROTEIN", 132, 135], ["human", "SPECIES", 66, 71], ["SARS-CoV", "SPECIES", 31, 39], ["human", "SPECIES", 66, 71], ["bat CoV", "SPECIES", 101, 108], ["the MSA", "TEST", 13, 20], ["SARS", "TEST", 31, 35], ["CoV", "TEST", 36, 39], ["human", "TEST", 66, 71], ["SARS", "PROBLEM", 72, 76], ["bat CoV", "PROBLEM", 101, 108]]], ["Figure S7A\u2013C shows the resulting disorder profiles of all three ORF14 proteins (mean PPIDs are listed in Table 1).", [["disorder", "DISEASE", 33, 41], ["ORF14", "GENE_OR_GENE_PRODUCT", 64, 69], ["ORF14 proteins", "PROTEIN", 64, 78], ["PPIDs", "PROTEIN", 85, 90], ["Figure S7A\u2013C", "TEST", 0, 12], ["the resulting disorder profiles", "PROBLEM", 19, 50]]], ["Further, these proteins have calculated mean PPID values of 0.00%, 2.86%, and 0.00%, respectively.", [["these proteins", "TEST", 9, 23]]], ["These proteins have flexible N- and C-terminal regions.", [["N", "CHEMICAL", 29, 30], ["C", "CHEMICAL", 36, 37], ["N- and C-terminal regions", "PROTEIN", 29, 54], ["These proteins", "TEST", 0, 14], ["flexible N- and C-terminal regions", "PROBLEM", 20, 54], ["terminal", "ANATOMY_MODIFIER", 38, 46], ["regions", "ANATOMY_MODIFIER", 47, 54]]], ["It can use intrinsic disorder or structural flexibility for protein\u2013protein interactions since it possesses MoRFs.", [["disorder", "DISEASE", 21, 29], ["MoRFs", "GENE_OR_GENE_PRODUCT", 108, 113], ["MoRFs", "PROTEIN", 108, 113], ["intrinsic disorder", "PROBLEM", 11, 29], ["protein\u2013protein interactions", "PROBLEM", 60, 88]]], ["It mainly contains MoRFs at the N- and C-terminal regions (Tables 2, S7, S8) and several RNA- and DNA-binding residues (Tables S9\u2013S11).", [["N", "CHEMICAL", 32, 33], ["C", "CHEMICAL", 39, 40], ["MoRFs", "GENE_OR_GENE_PRODUCT", 19, 24], ["S7", "GENE_OR_GENE_PRODUCT", 69, 71], ["S8", "GENE_OR_GENE_PRODUCT", 73, 75], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 127, 133], ["MoRFs", "PROTEIN", 19, 24], ["N- and C-terminal regions", "DNA", 32, 57], ["S7", "PROTEIN", 69, 71], ["S8", "PROTEIN", 73, 75], ["S9", "PROTEIN", 127, 129], ["S11", "PROTEIN", 130, 133], ["MoRFs", "TEST", 19, 24], ["several RNA", "TEST", 81, 92], ["DNA-binding residues", "PROBLEM", 98, 118], ["terminal", "ANATOMY_MODIFIER", 41, 49], ["regions", "ANATOMY_MODIFIER", 50, 57], ["several", "OBSERVATION_MODIFIER", 81, 88], ["RNA", "OBSERVATION_MODIFIER", 89, 92], ["binding residues", "OBSERVATION", 102, 118]]], ["These regions indicate its vital role in protein function related to protein\u2013RNA and protein\u2013DNA interaction.Intrinsic disorder analysis of non-structural proteins of coronaviruses ::: Results and discussionIn coronaviruses, due to ribosomal leakage during translation, two-third of the RNA genome is processed into two polyproteins: (i) replicase polyprotein 1a and (ii) replicase polyprotein 1ab.", [["ribosomal", "ANATOMY", 232, 241], ["Intrinsic disorder", "DISEASE", 109, 127], ["protein\u2013", "GENE_OR_GENE_PRODUCT", 69, 77], ["protein\u2013DNA", "GENE_OR_GENE_PRODUCT", 85, 96], ["coronaviruses", "ORGANISM", 167, 180], ["discussionIn coronaviruses", "ORGANISM", 197, 223], ["ribosomal", "CELLULAR_COMPONENT", 232, 241], ["replicase polyprotein 1a", "GENE_OR_GENE_PRODUCT", 338, 362], ["protein\u2013RNA", "RNA", 69, 80], ["non-structural proteins", "PROTEIN", 140, 163], ["RNA genome", "DNA", 287, 297], ["replicase polyprotein 1a", "PROTEIN", 338, 362], ["replicase polyprotein 1", "PROTEIN", 372, 395], ["protein\u2013RNA and protein\u2013DNA interaction", "PROBLEM", 69, 108], ["Intrinsic disorder analysis", "PROBLEM", 109, 136], ["coronaviruses", "PROBLEM", 210, 223], ["ribosomal leakage", "PROBLEM", 232, 249], ["the RNA genome", "PROBLEM", 283, 297], ["replicase polyprotein 1a and (ii) replicase polyprotein", "TREATMENT", 338, 393], ["protein function", "OBSERVATION", 41, 57], ["protein\u2013RNA", "OBSERVATION", 69, 80], ["disorder", "OBSERVATION", 119, 127], ["non-structural proteins", "OBSERVATION", 140, 163], ["leakage", "OBSERVATION", 242, 249], ["RNA genome", "OBSERVATION", 287, 297]]], ["Both contains non-structural proteins (Nsp1-10) in addition to different proteins required for viral replication and pathogenesis.", [["Nsp1-10", "GENE_OR_GENE_PRODUCT", 39, 46], ["non-structural proteins", "PROTEIN", 14, 37], ["Nsp1", "PROTEIN", 39, 43], ["non-structural proteins", "TEST", 14, 37], ["Nsp1", "TEST", 39, 43], ["different proteins", "PROBLEM", 63, 81], ["viral replication", "TREATMENT", 95, 112], ["pathogenesis", "PROBLEM", 117, 129], ["non-structural proteins", "OBSERVATION", 14, 37], ["viral replication", "OBSERVATION", 95, 112]]], ["Replicase polyprotein 1a contains an additional Nsp11 protein of 13 amino acids, the function of which has not been investigated yet.", [["amino acids", "CHEMICAL", 68, 79], ["amino acids", "CHEMICAL", 68, 79], ["Replicase polyprotein 1a", "GENE_OR_GENE_PRODUCT", 0, 24], ["Nsp11", "GENE_OR_GENE_PRODUCT", 48, 53], ["amino acids", "AMINO_ACID", 68, 79], ["Replicase polyprotein 1a", "PROTEIN", 0, 24], ["Nsp11 protein", "PROTEIN", 48, 61], ["Replicase polyprotein 1a", "TREATMENT", 0, 24], ["an additional Nsp11 protein", "TREATMENT", 34, 61], ["amino acids", "TREATMENT", 68, 79], ["polyprotein 1a", "OBSERVATION", 10, 24]]], ["The longer replicase polyprotein 1ab of 7073 amino acids accommodates five other non-structural proteins (Nsp12-16) [114, 115].Replicase polyprotein 1ab ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionThe longer replicase polyprotein contains 15 Nsps listed in Table 3.", [["amino acids", "CHEMICAL", 45, 56], ["intrinsic disorder", "DISEASE", 176, 194], ["amino acids", "CHEMICAL", 45, 56], ["amino acids", "AMINO_ACID", 45, 56], ["non-structural proteins", "PROTEIN", 81, 104], ["Nsp12", "PROTEIN", 106, 111], ["replicase polyprotein", "PROTEIN", 265, 286], ["Nsps", "PROTEIN", 299, 303], ["The longer replicase polyprotein", "TEST", 0, 32], ["amino acids", "TEST", 45, 56], ["non-structural proteins", "TEST", 81, 104], ["Nsp12", "TEST", 106, 111], ["Global analysis", "TEST", 157, 172], ["intrinsic disorder", "PROBLEM", 176, 194], ["The longer replicase polyprotein", "TREATMENT", 254, 286], ["intrinsic disorder", "OBSERVATION", 176, 194]]], ["Nsp1, Nsp2, and Nsp3 are cleaved using a viral papain-like proteinase (Nsp3/PL-Pro), while the rest of the Nsps are cleaved by another viral 3C-like proteinase, Nsp5/3CL-Pro.We mapped the cleavage sites of the replicase 1ab polyprotein from human SARS CoV to the disorder profile of this polyprotein.", [["Nsp1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Nsp2", "GENE_OR_GENE_PRODUCT", 6, 10], ["Nsp3", "GENE_OR_GENE_PRODUCT", 16, 20], ["papain-like proteinase", "GENE_OR_GENE_PRODUCT", 47, 69], ["Nsp3", "GENE_OR_GENE_PRODUCT", 71, 75], ["PL-Pro", "GENE_OR_GENE_PRODUCT", 76, 82], ["Nsps", "GENE_OR_GENE_PRODUCT", 107, 111], ["Nsp5", "GENE_OR_GENE_PRODUCT", 161, 165], ["3CL-Pro", "GENE_OR_GENE_PRODUCT", 166, 173], ["replicase 1", "GENE_OR_GENE_PRODUCT", 210, 221], ["human", "ORGANISM", 241, 246], ["SARS CoV", "ORGANISM", 247, 255], ["Nsp1", "PROTEIN", 0, 4], ["Nsp2", "PROTEIN", 6, 10], ["Nsp3", "PROTEIN", 16, 20], ["viral papain-like proteinase", "PROTEIN", 41, 69], ["Nsp3", "PROTEIN", 71, 75], ["PL", "PROTEIN", 76, 78], ["Pro", "PROTEIN", 79, 82], ["Nsps", "PROTEIN", 107, 111], ["viral 3C-like proteinase", "PROTEIN", 135, 159], ["Nsp5", "PROTEIN", 161, 165], ["3CL", "PROTEIN", 166, 169], ["Pro", "PROTEIN", 170, 173], ["cleavage sites", "DNA", 188, 202], ["replicase 1ab polyprotein", "DNA", 210, 235], ["human", "SPECIES", 241, 246], ["human SARS CoV", "SPECIES", 241, 255], ["Nsp1", "TEST", 0, 4], ["Nsp2", "PROBLEM", 6, 10], ["Nsp3", "PROBLEM", 16, 20], ["a viral papain", "TREATMENT", 39, 53], ["Nsp3", "TEST", 71, 75], ["proteinase", "TEST", 149, 159], ["the cleavage sites", "PROBLEM", 184, 202], ["the replicase 1ab polyprotein", "TREATMENT", 206, 235], ["the disorder profile", "PROBLEM", 259, 279], ["this polyprotein", "TREATMENT", 283, 299], ["Nsp2", "OBSERVATION", 6, 10]]], ["Figure 13 represents the results of this analysis by showing zoomed-in regions surrounding all the cleavage sites with few residues spanning at both terminals.", [["terminals", "CELLULAR_COMPONENT", 149, 158], ["cleavage sites", "PROTEIN", 99, 113], ["this analysis", "TEST", 36, 49], ["few residues", "PROBLEM", 119, 131], ["cleavage sites", "OBSERVATION", 99, 113], ["few", "OBSERVATION_MODIFIER", 119, 122], ["residues", "OBSERVATION", 123, 131]]], ["Interestingly, we observed that all the cleavage sites are largely disordered, suggesting that intrinsic disorder may have a crucial role in the maturation of individual non-structural proteins.", [["intrinsic disorder", "DISEASE", 95, 113], ["cleavage sites", "PROTEIN", 40, 54], ["non-structural proteins", "PROTEIN", 170, 193], ["all the cleavage sites", "PROBLEM", 32, 54], ["intrinsic disorder", "PROBLEM", 95, 113], ["individual non-structural proteins", "PROBLEM", 159, 193], ["non-structural proteins", "OBSERVATION", 170, 193]]], ["As Nsps of human SARS are evolutionarily closer to Nsps of SARS-CoV-2, we hypothesize that cleavage sites in the SARS-CoV-2 replicase 1ab polyprotein are also intrinsically disordered or flexible.", [["SARS", "DISEASE", 17, 21], ["Nsps", "GENE_OR_GENE_PRODUCT", 3, 7], ["human", "ORGANISM", 11, 16], ["Nsps", "GENE_OR_GENE_PRODUCT", 51, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 59, 69], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 113, 123], ["Nsps", "PROTEIN", 3, 7], ["Nsps", "DNA", 51, 55], ["cleavage sites", "DNA", 91, 105], ["SARS-CoV-2 replicase 1ab polyprotein", "DNA", 113, 149], ["human", "SPECIES", 11, 16], ["CoV-2 replicase", "SPECIES", 118, 133], ["human", "SPECIES", 11, 16], ["SARS-CoV", "SPECIES", 59, 67], ["SARS", "PROBLEM", 59, 63], ["cleavage sites", "PROBLEM", 91, 105], ["the SARS", "PROBLEM", 109, 117], ["CoV-2 replicase 1ab polyprotein", "TREATMENT", 118, 149]]], ["To shed more light on other implications of IDPRs, the structural and functional properties of Nsps and their predicted IDPRs are thoroughly described below.Non-structural protein 1 (Nsp1) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionThis protein acts as a host translation inhibitor as it binds to the 40S subunit of ribosome and blocks the translation of cap-dependent mRNAs as well as mRNAs that uses the internal ribosome entry site (IRES) [116].", [["intrinsic disorder", "DISEASE", 212, 230], ["IDPRs", "GENE_OR_GENE_PRODUCT", 44, 49], ["Nsps", "GENE_OR_GENE_PRODUCT", 95, 99], ["IDPRs", "GENE_OR_GENE_PRODUCT", 120, 125], ["Non-structural protein 1", "GENE_OR_GENE_PRODUCT", 157, 181], ["Nsp1", "GENE_OR_GENE_PRODUCT", 183, 187], ["ribosome", "CELLULAR_COMPONENT", 374, 382], ["IDPRs", "PROTEIN", 44, 49], ["Nsps", "PROTEIN", 95, 99], ["IDPRs", "PROTEIN", 120, 125], ["Non-structural protein 1", "PROTEIN", 157, 181], ["Nsp1", "PROTEIN", 183, 187], ["40S subunit", "PROTEIN", 359, 370], ["cap-dependent mRNAs", "RNA", 413, 432], ["mRNAs", "RNA", 444, 449], ["internal ribosome entry site", "DNA", 464, 492], ["IRES", "DNA", 494, 498], ["IDPRs", "TREATMENT", 44, 49], ["Non-structural protein", "TEST", 157, 179], ["Global analysis", "TEST", 193, 208], ["intrinsic disorder", "PROBLEM", 212, 230], ["This protein acts", "TREATMENT", 290, 307], ["a host translation inhibitor", "TREATMENT", 311, 339], ["ribosome", "TREATMENT", 374, 382], ["cap-dependent mRNAs", "TREATMENT", 413, 432], ["more light", "OBSERVATION_MODIFIER", 8, 18], ["intrinsic disorder", "OBSERVATION", 212, 230], ["cap", "OBSERVATION_MODIFIER", 413, 416], ["dependent mRNAs", "OBSERVATION", 417, 432]]], ["Figure 14a shows the NMR solution structure (PDB ID: 2GDT) of human SARS Nsp1 protein (13\u2013128 residues) [117].Non-structural protein 1 (Nsp1) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionSARS-CoV-2 Nsp1 shares 84.44% and 83.80% sequence identity with Nsp1s of human SARS and bat CoV, respectively (Fig. 14b).", [["intrinsic disorder", "DISEASE", 165, 183], ["SARS", "DISEASE", 322, 326], ["human", "ORGANISM", 62, 67], ["Non-structural protein 1", "GENE_OR_GENE_PRODUCT", 110, 134], ["Nsp1", "GENE_OR_GENE_PRODUCT", 136, 140], ["discussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 233, 253], ["Nsp1", "GENE_OR_GENE_PRODUCT", 254, 258], ["Nsp1s", "GENE_OR_GENE_PRODUCT", 307, 312], ["human", "ORGANISM", 316, 321], ["bat CoV", "ORGANISM", 331, 338], ["2GDT", "PROTEIN", 53, 57], ["human SARS Nsp1 protein", "PROTEIN", 62, 85], ["Non-structural protein 1", "PROTEIN", 110, 134], ["Nsp1", "PROTEIN", 136, 140], ["discussionSARS-CoV-2 Nsp1", "DNA", 233, 258], ["Nsp1s", "PROTEIN", 307, 312], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 316, 321], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 316, 321], ["bat CoV", "SPECIES", 331, 338], ["human SARS Nsp1 protein", "TEST", 62, 85], ["Non-structural protein", "TEST", 110, 132], ["Global analysis", "TEST", 146, 161], ["intrinsic disorder", "PROBLEM", 165, 183], ["discussionSARS", "TEST", 233, 247], ["CoV", "TEST", 248, 251], ["Nsp1 shares", "TEST", 254, 265], ["Nsp1s", "TEST", 307, 312], ["human SARS", "TEST", 316, 326], ["bat CoV", "TEST", 331, 338], ["intrinsic disorder", "OBSERVATION", 165, 183]]], ["The respective mean PPIDs of Nsp1s from SARS-CoV-2, Human SARS, and bat CoV are 12.78%, 14.44%, and 12.85% (disorder profiles in Fig. 14c\u2013e).", [["Nsp1s", "GENE_OR_GENE_PRODUCT", 29, 34], ["SARS-CoV-2", "ORGANISM", 40, 50], ["Human", "ORGANISM", 52, 57], ["bat CoV", "ORGANISM", 68, 75], ["PPIDs", "PROTEIN", 20, 25], ["Nsp1s", "PROTEIN", 29, 34], ["Human", "SPECIES", 52, 57], ["SARS-CoV", "SPECIES", 40, 48], ["Human SARS", "SPECIES", 52, 62], ["bat CoV", "SPECIES", 68, 75], ["Nsp1s", "TEST", 29, 34], ["SARS", "TEST", 40, 44], ["CoV", "TEST", 45, 48], ["Human SARS", "TEST", 52, 62], ["bat CoV", "TEST", 68, 75], ["disorder profiles", "TEST", 108, 125]]], ["In particular, the following regions are predicted to be disordered: SARS-CoV-2 (residues 1\u20137 and 165\u2013180), human SARS (residues 1\u20135 and 165\u2013180), and bat CoV (residues 1\u20135 and 165\u2013179).", [["SARS", "DISEASE", 114, 118], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["human", "ORGANISM", 108, 113], ["bat CoV", "GENE_OR_GENE_PRODUCT", 151, 158], ["bat CoV", "PROTEIN", 151, 158], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["bat CoV", "SPECIES", 151, 158], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["human SARS", "TEST", 108, 118], ["bat CoV", "TEST", 151, 158]]], ["NMR solution structure of Nsp1 from human SARS revealed the presence of two unstructured segments near the N-terminal (1\u201312 residues) and C-terminal (129\u2013179 residues) regions [117].", [["SARS", "DISEASE", 42, 46], ["N", "CHEMICAL", 107, 108], ["C", "CHEMICAL", 138, 139], ["Nsp1", "GENE_OR_GENE_PRODUCT", 26, 30], ["human", "ORGANISM", 36, 41], ["Nsp1", "PROTEIN", 26, 30], ["N-terminal (1\u201312 residues", "PROTEIN", 107, 132], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["Nsp1 from human SARS", "TEST", 26, 46], ["C", "TEST", 138, 139], ["two", "OBSERVATION_MODIFIER", 72, 75], ["unstructured", "OBSERVATION", 76, 88], ["segments", "ANATOMY_MODIFIER", 89, 97], ["terminal", "OBSERVATION_MODIFIER", 109, 117]]], ["The disordered region (128\u2013180 residues) at the C-terminus is already mapped important for its expression [118].", [["C-terminus", "PROTEIN", 48, 58], ["The disordered region", "PROBLEM", 0, 21]]], ["Based on sequence homology with human SARS Nsp1, the predicted disordered C-terminal region of SARS-CoV-2 Nsp1 may play a critical role in its expression.", [["C", "CHEMICAL", 74, 75], ["human", "ORGANISM", 32, 37], ["Nsp1", "GENE_OR_GENE_PRODUCT", 43, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 95, 105], ["Nsp1", "GENE_OR_GENE_PRODUCT", 106, 110], ["human SARS Nsp1", "PROTEIN", 32, 47], ["C-terminal region", "DNA", 74, 91], ["SARS-CoV-2 Nsp1", "DNA", 95, 110], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["human SARS Nsp1", "PROBLEM", 32, 47], ["the predicted disordered C-terminal region of SARS", "PROBLEM", 49, 99]]], ["Alanine mutants at K164 and H165 near the C-terminal region are reported to abolish its binding with the 40S subunit of the host ribosome [119].", [["Alanine", "CHEMICAL", 0, 7], ["Alanine", "CHEMICAL", 0, 7], ["C", "CHEMICAL", 42, 43], ["Alanine", "AMINO_ACID", 0, 7], ["K164", "AMINO_ACID", 19, 23], ["H165", "AMINO_ACID", 28, 32], ["H165", "PROTEIN", 28, 32], ["C-terminal region", "PROTEIN", 42, 59], ["40S subunit", "PROTEIN", 105, 116], ["Alanine mutants", "TEST", 0, 15], ["terminal", "ANATOMY_MODIFIER", 44, 52]]], ["In conjunction with this data, several MoRFs are present in the unstructured segments of Nsp1 proteins.", [["MoRFs", "GENE_OR_GENE_PRODUCT", 39, 44], ["Nsp1", "GENE_OR_GENE_PRODUCT", 89, 93], ["MoRFs", "PROTEIN", 39, 44], ["Nsp1 proteins", "PROTEIN", 89, 102], ["this data", "TEST", 20, 29], ["Nsp1 proteins", "PROBLEM", 89, 102], ["Nsp1 proteins", "OBSERVATION", 89, 102]]], ["These regions are shown in Tables 2, S7 and S8.Non-structural protein 2 (Nsp2) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionThis protein functions by disrupting the host survival pathway via interaction with the host proteins prohibitin-1 and prohibitin-2 [120].", [["intrinsic disorder", "DISEASE", 102, 120], ["S8", "GENE_OR_GENE_PRODUCT", 44, 46], ["Non-structural protein 2", "GENE_OR_GENE_PRODUCT", 47, 71], ["Nsp2", "GENE_OR_GENE_PRODUCT", 73, 77], ["prohibitin-1", "GENE_OR_GENE_PRODUCT", 282, 294], ["prohibitin-2", "GENE_OR_GENE_PRODUCT", 299, 311], ["Non-structural protein 2", "PROTEIN", 47, 71], ["Nsp2", "PROTEIN", 73, 77], ["host proteins", "PROTEIN", 268, 281], ["prohibitin-1", "PROTEIN", 282, 294], ["prohibitin", "PROTEIN", 299, 309], ["Non-structural protein", "TEST", 47, 69], ["Global analysis", "TEST", 83, 98], ["intrinsic disorder", "PROBLEM", 102, 120], ["the host proteins prohibitin", "TREATMENT", 264, 292], ["prohibitin", "TEST", 299, 309], ["intrinsic disorder", "OBSERVATION", 102, 120]]], ["Reverse genetic deletion in the coding sequence of Nsp2 of SARS virus attenuated little viral growth as well as replication and allowed the recovery of mutant virulent viruses [121].Non-structural protein 2 (Nsp2) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionThe sequence identity of Nsp2 protein of SARS-CoV-2 with Nsp2s of human SARS and bat CoV amounts to 68.34% and 68.97%, respectively (Fig. S8).", [["SARS", "DISEASE", 59, 63], ["intrinsic disorder", "DISEASE", 237, 255], ["SARS", "DISEASE", 387, 391], ["Nsp2", "GENE_OR_GENE_PRODUCT", 51, 55], ["SARS virus", "ORGANISM", 59, 69], ["Non-structural protein 2", "GENE_OR_GENE_PRODUCT", 182, 206], ["Nsp2", "GENE_OR_GENE_PRODUCT", 208, 212], ["Nsp2", "GENE_OR_GENE_PRODUCT", 340, 344], ["SARS-CoV-2", "ORGANISM", 356, 366], ["Nsp2s", "GENE_OR_GENE_PRODUCT", 372, 377], ["human", "ORGANISM", 381, 386], ["bat CoV", "ORGANISM", 396, 403], ["S8", "GENE_OR_GENE_PRODUCT", 453, 455], ["Nsp2", "PROTEIN", 51, 55], ["Non-structural protein 2", "PROTEIN", 182, 206], ["Nsp2", "PROTEIN", 208, 212], ["Nsp2 protein", "PROTEIN", 340, 352], ["Nsp2s", "PROTEIN", 372, 377], ["S8", "PROTEIN", 453, 455], ["human", "SPECIES", 381, 386], ["SARS virus", "SPECIES", 59, 69], ["SARS-CoV", "SPECIES", 356, 364], ["human", "SPECIES", 381, 386], ["bat CoV", "SPECIES", 396, 403], ["Reverse genetic deletion", "PROBLEM", 0, 24], ["Nsp2", "PROBLEM", 51, 55], ["SARS virus", "PROBLEM", 59, 69], ["little viral growth", "PROBLEM", 81, 100], ["mutant virulent viruses", "PROBLEM", 152, 175], ["Non-structural protein", "TEST", 182, 204], ["Global analysis", "TEST", 218, 233], ["intrinsic disorder", "PROBLEM", 237, 255], ["Nsp2 protein", "TEST", 340, 352], ["SARS", "TEST", 356, 360], ["CoV", "TEST", 361, 364], ["human SARS", "TEST", 381, 391], ["bat CoV amounts", "TEST", 396, 411], ["genetic deletion", "OBSERVATION", 8, 24], ["virulent viruses", "OBSERVATION", 159, 175], ["intrinsic disorder", "OBSERVATION", 237, 255]]], ["We have estimated the mean PPIDs of Nsp2s of SARS-CoV-2, human SARS, and batbat CoV to be 5.17%, 2.04%, and 2.03% respectively (see Table 3) (per-residue predisposition of intrinsic disorder is depicted in Fig. S9A\u2013C).", [["intrinsic disorder", "DISEASE", 172, 190], ["Nsp2s", "GENE_OR_GENE_PRODUCT", 36, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["human", "ORGANISM", 57, 62], ["SARS", "ORGANISM", 63, 67], ["batbat CoV", "ORGANISM", 73, 83], ["Nsp2s", "PROTEIN", 36, 41], ["S9A\u2013C", "PROTEIN", 211, 216], ["human", "SPECIES", 57, 62], ["SARS-CoV", "SPECIES", 45, 53], ["human", "SPECIES", 57, 62], ["batbat CoV", "SPECIES", 73, 83], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["human SARS", "TEST", 57, 67], ["batbat CoV", "TEST", 73, 83], ["intrinsic disorder", "PROBLEM", 172, 190], ["intrinsic disorder", "OBSERVATION", 172, 190]]], ["According to the results, residues 570\u2013595 (SARS-CoV-2), residues 110\u2013115 (Human SARS), and residues 112\u2013116 (bat CoV) are predicted to be disordered.", [["Human", "ORGANISM", 75, 80], ["bat CoV", "GENE_OR_GENE_PRODUCT", 110, 117], ["Human", "SPECIES", 75, 80], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["residues", "TEST", 57, 65], ["Human SARS", "TEST", 75, 85], ["residues", "TEST", 92, 100]]], ["As listed in Tables 2, S7 and S8, human SARS does not contain MoRF, while SARS-CoV-2 and bat CoV have a N-terminally located MoRF region predicted by MoRFchibi_web.Non-structural protein 3 (Nsp3) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp3 is a viral papain-like protease (PLP) that affects the phosphorylation and activation of IRF3 and, therefore, antagonizes the IFN pathway [122].", [["SARS", "DISEASE", 40, 44], ["intrinsic disorder", "DISEASE", 219, 237], ["N", "CHEMICAL", 104, 105], ["S7", "GENE_OR_GENE_PRODUCT", 23, 25], ["S8", "GENE_OR_GENE_PRODUCT", 30, 32], ["human", "ORGANISM", 34, 39], ["MoRF", "GENE_OR_GENE_PRODUCT", 62, 66], ["SARS-CoV-2", "ORGANISM", 74, 84], ["bat CoV", "ORGANISM", 89, 96], ["MoRF", "GENE_OR_GENE_PRODUCT", 125, 129], ["Non-structural protein 3", "GENE_OR_GENE_PRODUCT", 164, 188], ["Nsp3", "GENE_OR_GENE_PRODUCT", 190, 194], ["Nsp3", "GENE_OR_GENE_PRODUCT", 297, 301], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 313, 333], ["PLP", "GENE_OR_GENE_PRODUCT", 335, 338], ["IRF3", "GENE_OR_GENE_PRODUCT", 391, 395], ["IFN", "GENE_OR_GENE_PRODUCT", 428, 431], ["S7", "PROTEIN", 23, 25], ["S8", "PROTEIN", 30, 32], ["MoRF", "PROTEIN", 62, 66], ["N-terminally located MoRF region", "DNA", 104, 136], ["MoRFchibi_web", "PROTEIN", 150, 163], ["Non-structural protein 3", "PROTEIN", 164, 188], ["Nsp3", "PROTEIN", 190, 194], ["Nsp3", "PROTEIN", 297, 301], ["viral papain-like protease", "PROTEIN", 307, 333], ["PLP", "PROTEIN", 335, 338], ["IRF3", "PROTEIN", 391, 395], ["IFN", "PROTEIN", 428, 431], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["SARS-CoV", "SPECIES", 74, 82], ["bat CoV", "SPECIES", 89, 96], ["MoRF", "TEST", 62, 66], ["SARS", "TEST", 74, 78], ["CoV", "TEST", 79, 82], ["bat CoV", "PROBLEM", 89, 96], ["Non-structural protein", "TEST", 164, 186], ["Global analysis", "TEST", 200, 215], ["intrinsic disorder", "PROBLEM", 219, 237], ["a viral papain", "TREATMENT", 305, 319], ["protease (PLP", "TREATMENT", 325, 338], ["IRF3", "PROBLEM", 391, 395], ["intrinsic disorder", "OBSERVATION", 219, 237]]], ["It's also reported to stabilize NF-\u03ba\u03b2 inhibitor which further blocks the NF-\u03ba\u03b2 pathway [122].", [["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 32, 37], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 73, 78], ["NF-\u03ba\u03b2", "PROTEIN", 32, 37], ["NF-\u03ba\u03b2", "PROTEIN", 73, 78], ["NF-\u03ba\u03b2 inhibitor", "TREATMENT", 32, 47]]], ["Figure 15d represents the 1.85 \u00c5 resolution X-ray crystal structure of the catalytic core of Nsp3 protein from human SARS CoV (PDB ID: 2FE8) [123].", [["Nsp3", "GENE_OR_GENE_PRODUCT", 93, 97], ["human", "ORGANISM", 111, 116], ["SARS CoV", "ORGANISM", 117, 125], ["catalytic core", "PROTEIN", 75, 89], ["Nsp3 protein", "PROTEIN", 93, 105], ["human", "SPECIES", 111, 116], ["human SARS CoV", "SPECIES", 111, 125]]], ["The structure consisting of residues 723\u20131036 revealed folds similar to a deubiquitinating enzyme in vitro, the deubiquitinating activity of which was found to be efficiently high [123].", [["residues 723\u20131036", "CHEMICAL", 28, 45], ["deubiquitinating enzyme", "PROTEIN", 74, 97], ["folds", "PROBLEM", 55, 60], ["a deubiquitinating enzyme", "TEST", 72, 97]]], ["A 1.45 \u00c5 resolution structure (PDB ID: 6W6Y) of SARS-CoV-2 Nsp3 homodimer (chains A and B from 207\u2013374 residues) is recently generated using X-ray diffraction (Fig. 15e) [124].Non-structural protein 3 (Nsp3) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp3 protein of SARS-CoV-2 contains several substituted residues throughout the protein.", [["intrinsic disorder", "DISEASE", 231, 249], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 48, 58], ["Non-structural protein 3", "GENE_OR_GENE_PRODUCT", 176, 200], ["Nsp3", "GENE_OR_GENE_PRODUCT", 202, 206], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 325, 335], ["SARS-CoV-2 Nsp3 homodimer", "PROTEIN", 48, 73], ["chains A", "PROTEIN", 75, 83], ["B", "PROTEIN", 88, 89], ["Non-structural protein 3", "PROTEIN", 176, 200], ["Nsp3", "PROTEIN", 202, 206], ["discussionNsp3 protein", "PROTEIN", 299, 321], ["SARS-CoV", "SPECIES", 325, 333], ["PDB ID", "TEST", 31, 37], ["SARS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["X-ray diffraction", "TEST", 141, 158], ["Non-structural protein", "TEST", 176, 198], ["Global analysis", "TEST", 212, 227], ["intrinsic disorder", "PROBLEM", 231, 249], ["SARS", "TEST", 325, 329], ["CoV", "TEST", 330, 333], ["several substituted residues throughout the protein", "PROBLEM", 345, 396], ["intrinsic disorder", "OBSERVATION", 231, 249], ["substituted residues", "OBSERVATION", 353, 373]]], ["It is equally close to both Nsp3 proteins of human SARS and bat CoV, sharing 76.69% and 76.31% identity respectively (Fig. S10).", [["Nsp3", "GENE_OR_GENE_PRODUCT", 28, 32], ["human", "ORGANISM", 45, 50], ["bat CoV", "ORGANISM", 60, 67], ["Nsp3 proteins", "PROTEIN", 28, 41], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["bat CoV", "SPECIES", 60, 67], ["human SARS", "TEST", 45, 55], ["bat CoV", "TEST", 60, 67]]], ["According to our results, the mean PPIDs of Nsp3 proteins of SARS-CoV-2, human SARS, and bat CoV are 7.40%, 7.91%, and 7.78% respectively (Table 3).", [["Nsp3", "GENE_OR_GENE_PRODUCT", 44, 48], ["SARS-CoV-2", "ORGANISM", 61, 71], ["human", "ORGANISM", 73, 78], ["SARS", "ORGANISM", 79, 83], ["bat CoV", "ORGANISM", 89, 96], ["PPIDs", "PROTEIN", 35, 40], ["Nsp3 proteins", "PROTEIN", 44, 57], ["human", "SPECIES", 73, 78], ["SARS-CoV", "SPECIES", 61, 69], ["human", "SPECIES", 73, 78], ["bat CoV", "SPECIES", 89, 96], ["Nsp3 proteins", "TEST", 44, 57], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["human SARS", "TEST", 73, 83], ["bat CoV", "TEST", 89, 96], ["bat CoV", "ANATOMY", 89, 96]]], ["Disorder profiles in Fig. 15a\u2013c shows that all three Nsp3 proteins are highly structured.", [["Nsp3", "GENE_OR_GENE_PRODUCT", 53, 57], ["Nsp3 proteins", "PROTEIN", 53, 66], ["Disorder profiles", "PROBLEM", 0, 17], ["all three Nsp3 proteins", "PROBLEM", 43, 66], ["Nsp3 proteins", "OBSERVATION", 53, 66]]], ["This is further supported by Fig. 15f, where PONDR\u00ae VSL2-generated disorder profiles of these three proteins are overlapped to show almost complete coincidence of their major disorder-related features.", [["disorder", "DISEASE", 67, 75], ["disorder", "DISEASE", 175, 183], ["PONDR", "GENE_OR_GENE_PRODUCT", 45, 50], ["PONDR", "PROTEIN", 45, 50], ["VSL2", "PROTEIN", 52, 56], ["PONDR", "TEST", 45, 50], ["generated disorder profiles", "PROBLEM", 57, 84], ["their major disorder", "PROBLEM", 163, 183]]], ["According to the mean disorder analysis (see Fig. 15a\u2013c), Nsp3 proteins are predicted to have the following IDPRs: SARS-CoV-2 (1\u20135, 105\u2013199, 1221\u20131238), human SARS (102\u2013189, 355\u2013384, 1195\u20131223) and bat CoV (107\u2013182, 352\u2013376, 1191\u20131217).", [["SARS", "DISEASE", 159, 163], ["Nsp3", "GENE_OR_GENE_PRODUCT", 58, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 115, 125], ["human", "ORGANISM", 153, 158], ["Nsp3 proteins", "PROTEIN", 58, 71], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 153, 158], ["the mean disorder analysis", "TEST", 13, 39], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123], ["human SARS", "TEST", 153, 163], ["bat CoV", "TEST", 198, 205]]], ["The first 112 residues represent a ubiquitin-like globular fold, while 113\u2013183 residues form the flexible acidic domain rich in glutamic acid.", [["glutamic acid", "CHEMICAL", 128, 141], ["glutamic acid", "CHEMICAL", 128, 141], ["glutamic acid", "SIMPLE_CHEMICAL", 128, 141], ["ubiquitin-like globular fold", "PROTEIN", 35, 63], ["flexible acidic domain", "PROTEIN", 97, 119], ["a ubiquitin-like globular fold", "PROBLEM", 33, 63], ["glutamic acid", "TREATMENT", 128, 141], ["globular fold", "OBSERVATION_MODIFIER", 50, 63], ["glutamic acid", "OBSERVATION", 128, 141]]], ["It is thought to bind and ubiquitinate viral E protein using the N-terminal acidic domain [125, 126].", [["N", "CHEMICAL", 65, 66], ["viral E protein", "PROTEIN", 39, 54], ["N-terminal acidic domain", "PROTEIN", 65, 89], ["viral E protein", "TEST", 39, 54], ["thought to", "UNCERTAINTY", 6, 16]]], ["This unstructured segment has many MoRFs predicted by ANCHOR and MoRFPred servers which may facilitate the protein\u2013protein interaction (Table 2).", [["MoRFs", "GENE_OR_GENE_PRODUCT", 35, 40], ["MoRFs", "DNA", 35, 40], ["ANCHOR and MoRFPred servers", "DNA", 54, 81]]], ["Interestingly, Nsp3 of all three viruses is found to have the highest number of RNA-binding residues (Tables S9\u2013S11).Non-structural protein 4 (Nsp4) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp4 is reported to induce the formation of DMVs for optimal replication inside host cells [127\u2013129].", [["cells", "ANATOMY", 335, 340], ["intrinsic disorder", "DISEASE", 172, 190], ["Nsp4", "CHEMICAL", 250, 254], ["Nsp3", "GENE_OR_GENE_PRODUCT", 15, 19], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 109, 115], ["Non-structural protein 4", "GENE_OR_GENE_PRODUCT", 117, 141], ["Nsp4", "GENE_OR_GENE_PRODUCT", 143, 147], ["Nsp4", "GENE_OR_GENE_PRODUCT", 250, 254], ["DMVs", "GENE_OR_GENE_PRODUCT", 294, 298], ["host cells", "CELL", 330, 340], ["Nsp3", "PROTEIN", 15, 19], ["RNA-binding residues", "PROTEIN", 80, 100], ["S9", "PROTEIN", 109, 111], ["S11", "PROTEIN", 112, 115], ["Non-structural protein 4", "PROTEIN", 117, 141], ["Nsp4", "PROTEIN", 143, 147], ["Nsp4", "PROTEIN", 250, 254], ["DMVs", "PROTEIN", 294, 298], ["host cells", "CELL_TYPE", 330, 340], ["all three viruses", "PROBLEM", 23, 40], ["RNA-binding residues", "PROBLEM", 80, 100], ["Non-structural protein", "TEST", 117, 139], ["Global analysis", "TEST", 153, 168], ["intrinsic disorder", "PROBLEM", 172, 190], ["DMVs", "TREATMENT", 294, 298], ["viruses", "OBSERVATION", 33, 40], ["highest", "OBSERVATION_MODIFIER", 62, 69], ["number", "OBSERVATION_MODIFIER", 70, 76], ["RNA", "OBSERVATION", 80, 83], ["binding residues", "OBSERVATION", 84, 100], ["intrinsic disorder", "OBSERVATION", 172, 190]]], ["Although no crystal or NMR solution structure is reported, Nsp4 is demonstrated to contain a tetra-spanning transmembrane region with its N- and C-terminals present in cytosol [130].Non-structural protein 4 (Nsp4) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp4 protein of SARS-CoV-2 has multiple substitutions near the N-terminal region and has a quite conserved C-terminus (Fig. S11).", [["transmembrane", "ANATOMY", 108, 121], ["cytosol", "ANATOMY", 168, 175], ["intrinsic disorder", "DISEASE", 237, 255], ["N", "CHEMICAL", 138, 139], ["C", "CHEMICAL", 145, 146], ["N", "CHEMICAL", 378, 379], ["Nsp4", "GENE_OR_GENE_PRODUCT", 59, 63], ["cytosol", "ORGANISM_SUBSTANCE", 168, 175], ["Non-structural protein 4", "GENE_OR_GENE_PRODUCT", 182, 206], ["Nsp4", "GENE_OR_GENE_PRODUCT", 208, 212], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 331, 341], ["C-terminus", "GENE_OR_GENE_PRODUCT", 422, 432], ["Fig. S11", "GENE_OR_GENE_PRODUCT", 434, 442], ["Nsp4", "PROTEIN", 59, 63], ["tetra-spanning transmembrane region", "PROTEIN", 93, 128], ["N- and C-terminals", "PROTEIN", 138, 156], ["Non-structural protein 4", "PROTEIN", 182, 206], ["Nsp4", "PROTEIN", 208, 212], ["discussionNsp4 protein", "PROTEIN", 305, 327], ["N-terminal region", "PROTEIN", 378, 395], ["C-terminus", "PROTEIN", 422, 432], ["Fig. S11", "PROTEIN", 434, 442], ["SARS-CoV", "SPECIES", 331, 339], ["crystal or NMR solution structure", "PROBLEM", 12, 45], ["Nsp4", "PROBLEM", 59, 63], ["a tetra-spanning transmembrane region", "PROBLEM", 91, 128], ["its N", "TEST", 134, 139], ["Non-structural protein", "TEST", 182, 204], ["Global analysis", "TEST", 218, 233], ["intrinsic disorder", "PROBLEM", 237, 255], ["SARS", "TEST", 331, 335], ["CoV", "TEST", 336, 339], ["multiple substitutions", "PROBLEM", 346, 368], ["no", "UNCERTAINTY", 9, 11], ["crystal", "OBSERVATION_MODIFIER", 12, 19], ["intrinsic disorder", "OBSERVATION", 237, 255], ["multiple", "OBSERVATION_MODIFIER", 346, 354], ["substitutions", "OBSERVATION", 355, 368], ["terminal", "ANATOMY_MODIFIER", 380, 388], ["region", "ANATOMY_MODIFIER", 389, 395]]], ["It is found to be closer to Nsp4 of bat CoV (81.40% identity) than to human SARS Nsp4 (80%).", [["SARS", "DISEASE", 76, 80], ["Nsp4", "GENE_OR_GENE_PRODUCT", 28, 32], ["bat CoV", "ORGANISM", 36, 43], ["human", "ORGANISM", 70, 75], ["Nsp4", "PROTEIN", 28, 32], ["bat CoV", "PROTEIN", 36, 43], ["human", "SPECIES", 70, 75], ["bat CoV", "SPECIES", 36, 43], ["human SARS Nsp4", "SPECIES", 70, 85], ["bat CoV", "TEST", 36, 43], ["human SARS Nsp4", "TEST", 70, 85]]], ["The low level of intrinsic disorder illustrated in Fig. S12A\u2013C and mean PPIDs of Nsp4 proteins (Table 3) classify it as a highly structured protein which, however, contains some flexible regions.", [["disorder", "DISEASE", 27, 35], ["Nsp4 proteins (Table 3", "GENE_OR_GENE_PRODUCT", 81, 103], ["S12A\u2013C", "PROTEIN", 56, 62], ["PPIDs", "PROTEIN", 72, 77], ["Nsp4 proteins", "PROTEIN", 81, 94], ["Table 3", "PROTEIN", 96, 103], ["flexible regions", "PROTEIN", 178, 194], ["intrinsic disorder", "PROBLEM", 17, 35], ["S12A\u2013C", "TEST", 56, 62], ["Nsp4 proteins", "PROBLEM", 81, 94], ["a highly structured protein", "PROBLEM", 120, 147], ["low level", "OBSERVATION_MODIFIER", 4, 13], ["intrinsic disorder", "OBSERVATION", 17, 35], ["Fig", "OBSERVATION_MODIFIER", 51, 54], ["protein", "OBSERVATION", 140, 147], ["some", "OBSERVATION_MODIFIER", 173, 177], ["flexible", "OBSERVATION_MODIFIER", 178, 186]]], ["Likewise, only N- and C-terminal MoRFs which possibly assist in its cleavage from long polyproteins 1a and 1ab are shown in Table 2.Non-structural protein 5 (Nsp5) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionAlso referred to as 3CL-pro, it works as a protease and cleaves the replicase polyproteins (1a and 1ab) at 11 major sites [131, 132].", [["intrinsic disorder", "DISEASE", 187, 205], ["N", "CHEMICAL", 15, 16], ["C", "CHEMICAL", 22, 23], ["MoRFs", "GENE_OR_GENE_PRODUCT", 33, 38], ["Non-structural protein 5", "GENE_OR_GENE_PRODUCT", 132, 156], ["Nsp5", "GENE_OR_GENE_PRODUCT", 158, 162], ["1a", "GENE_OR_GENE_PRODUCT", 357, 359], ["1ab", "GENE_OR_GENE_PRODUCT", 364, 367], ["N- and C-terminal MoRFs", "PROTEIN", 15, 38], ["Non-structural protein 5", "PROTEIN", 132, 156], ["Nsp5", "PROTEIN", 158, 162], ["3CL", "PROTEIN", 285, 288], ["protease", "PROTEIN", 308, 316], ["replicase polyproteins", "PROTEIN", 333, 355], ["1ab", "PROTEIN", 364, 367], ["N", "TEST", 15, 16], ["C-terminal MoRFs", "TREATMENT", 22, 38], ["its cleavage", "PROBLEM", 64, 76], ["Non-structural protein", "TEST", 132, 154], ["Global analysis", "TEST", 168, 183], ["intrinsic disorder", "PROBLEM", 187, 205], ["a protease", "TREATMENT", 306, 316], ["the replicase polyproteins", "TREATMENT", 329, 355], ["intrinsic disorder", "OBSERVATION", 187, 205]]], ["Recently, the X-ray diffraction-based crystal structure of SARS-CoV-2 Nsp5 in complex with an inhibitor N3 has been solved (PDB ID:6LU7) (Fig. 16d) [133].", [["N3", "CHEMICAL", 104, 106], ["SARS-CoV-2 Nsp5", "GENE_OR_GENE_PRODUCT", 59, 74], ["SARS-CoV-2 Nsp5", "PROTEIN", 59, 74], ["the X-ray diffraction", "TEST", 10, 31], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["an inhibitor N3", "TREATMENT", 91, 106]]], ["An X-ray crystal structure (PDB ID: 5C5O) obtained for human SARS CoV Nsp5 is shown in Fig. 16e.", [["human", "ORGANISM", 55, 60], ["SARS CoV", "ORGANISM", 61, 69], ["human SARS CoV Nsp5", "PROTEIN", 55, 74], ["human", "SPECIES", 55, 60], ["human SARS CoV", "SPECIES", 55, 69], ["An X-ray crystal structure", "TEST", 0, 26], ["human SARS CoV Nsp5", "TEST", 55, 74]]], ["Here, 3CL-protease is bound to a phenyl-beta-alanyl (S, R)-N-decalin type inhibitor [134].Non-structural protein 5 (Nsp5) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp5 protein is found to be highly conserved in all three studied CoVs.", [["phenyl-beta-alanyl", "CHEMICAL", 33, 51], ["intrinsic disorder", "DISEASE", 145, 163], ["phenyl-beta-alanyl (S, R)-N-decalin", "CHEMICAL", 33, 68], ["3CL-protease", "GENE_OR_GENE_PRODUCT", 6, 18], ["phenyl-beta-alanyl (S, R)-N-decalin type", "SIMPLE_CHEMICAL", 33, 73], ["[134]", "SIMPLE_CHEMICAL", 84, 89], ["Non-structural protein 5", "GENE_OR_GENE_PRODUCT", 90, 114], ["Nsp5", "GENE_OR_GENE_PRODUCT", 116, 120], ["discussionNsp5", "GENE_OR_GENE_PRODUCT", 213, 227], ["CoVs", "CANCER", 289, 293], ["3CL", "PROTEIN", 6, 9], ["protease", "PROTEIN", 10, 18], ["Non-structural protein 5", "PROTEIN", 90, 114], ["Nsp5", "PROTEIN", 116, 120], ["discussionNsp5 protein", "PROTEIN", 213, 235], ["CoVs", "DNA", 289, 293], ["protease", "TREATMENT", 10, 18], ["a phenyl-beta", "TREATMENT", 31, 44], ["decalin type inhibitor", "TREATMENT", 61, 83], ["Non-structural protein", "TEST", 90, 112], ["Global analysis", "TEST", 126, 141], ["intrinsic disorder", "PROBLEM", 145, 163], ["discussionNsp5 protein", "TEST", 213, 235], ["intrinsic disorder", "OBSERVATION", 145, 163]]], ["SARS-CoV-2 Nsp5 shares a 96.08% sequence identity with human SARS Nsp5 and 95.42% with bat CoV Nsp5 (Fig. S13).", [["SARS", "DISEASE", 61, 65], ["SARS-CoV-2", "ORGANISM", 0, 10], ["Nsp5", "GENE_OR_GENE_PRODUCT", 11, 15], ["human", "ORGANISM", 55, 60], ["Fig. S13", "GENE_OR_GENE_PRODUCT", 101, 109], ["SARS-CoV-2 Nsp5", "DNA", 0, 15], ["bat CoV Nsp5", "PROTEIN", 87, 99], ["human", "SPECIES", 55, 60], ["human SARS Nsp5", "SPECIES", 55, 70], ["bat CoV", "SPECIES", 87, 94], ["human SARS Nsp5", "TEST", 55, 70], ["bat CoV Nsp5", "TEST", 87, 99]]], ["Therefore, it is not surprising that our analysis demonstrated the identical mean PPID values of 1.96% for all three Nsp5s (Table 3).", [["Nsp5s", "PROTEIN", 117, 122], ["our analysis", "TEST", 37, 49]]], ["As the graphs (Fig. 16a\u2013c) depict, Nsp5s have several flexible regions and N-terminally IDPR of six residues.", [["N", "CHEMICAL", 75, 76], ["Nsp5s", "GENE_OR_GENE_PRODUCT", 35, 40], ["Nsp5s", "PROTEIN", 35, 40], ["N-terminally IDPR", "PROTEIN", 75, 92], ["the graphs", "TEST", 3, 13], ["several flexible regions", "PROBLEM", 46, 70], ["several", "OBSERVATION_MODIFIER", 46, 53], ["flexible", "OBSERVATION", 54, 62]]], ["Due to the low flexibility of this protein, a single MoRF predicted by MoRFchibi_web is present in the N-terminal region (residues 3\u20138) in all Nsp5s (Tables 2, S7, S8).", [["N", "CHEMICAL", 103, 104], ["MoRF", "GENE_OR_GENE_PRODUCT", 53, 57], ["MoRFchibi_web", "GENE_OR_GENE_PRODUCT", 71, 84], ["MoRF", "PROTEIN", 53, 57], ["MoRFchibi_web", "PROTEIN", 71, 84], ["N-terminal region", "PROTEIN", 103, 120], ["residues 3\u20138", "PROTEIN", 122, 134], ["Nsp5s", "PROTEIN", 143, 148], ["S7", "PROTEIN", 160, 162], ["S8", "PROTEIN", 164, 166], ["the low flexibility of this protein", "PROBLEM", 7, 42], ["low flexibility", "OBSERVATION_MODIFIER", 11, 26], ["terminal", "ANATOMY_MODIFIER", 105, 113], ["region", "ANATOMY_MODIFIER", 114, 120]]], ["Further, the identified nucleotide-binding residues in Nsp5 proteins are tabulated in Tables S9\u2013S11.Non-structural protein 6 (Nsp6) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp6 protein is involved in blocking ER-induced autophagosome/autolysosome vesicle formation that functions in restricting viral production inside host cells.", [["autophagosome", "ANATOMY", 281, 294], ["autolysosome vesicle", "ANATOMY", 295, 315], ["cells", "ANATOMY", 385, 390], ["nucleotide", "CHEMICAL", 24, 34], ["intrinsic disorder", "DISEASE", 155, 173], ["nucleotide", "CHEMICAL", 24, 34], ["Nsp5", "GENE_OR_GENE_PRODUCT", 55, 59], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 93, 99], ["Non-structural protein 6", "GENE_OR_GENE_PRODUCT", 100, 124], ["Nsp6", "GENE_OR_GENE_PRODUCT", 126, 130], ["Nsp6", "GENE_OR_GENE_PRODUCT", 233, 237], ["ER", "GENE_OR_GENE_PRODUCT", 270, 272], ["autophagosome", "CELLULAR_COMPONENT", 281, 294], ["autolysosome vesicle", "CELLULAR_COMPONENT", 295, 315], ["host cells", "CELL", 380, 390], ["Nsp5 proteins", "PROTEIN", 55, 68], ["S9", "PROTEIN", 93, 95], ["S11", "PROTEIN", 96, 99], ["Non-structural protein 6", "PROTEIN", 100, 124], ["Nsp6", "PROTEIN", 126, 130], ["Nsp6 protein", "PROTEIN", 233, 245], ["ER", "PROTEIN", 270, 272], ["host cells", "CELL_TYPE", 380, 390], ["nucleotide-binding residues in Nsp5 proteins", "PROBLEM", 24, 68], ["Non-structural protein", "TEST", 100, 122], ["Global analysis", "TEST", 136, 151], ["intrinsic disorder", "PROBLEM", 155, 173], ["autolysosome vesicle formation", "PROBLEM", 295, 325], ["intrinsic disorder", "OBSERVATION", 155, 173], ["host cells", "OBSERVATION", 380, 390]]], ["It induces autophagy by activating the omegasome pathway, which is normally utilized by cells in response to starvation [135].Non-structural protein 6 (Nsp6) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp6 of SARS-CoV-2 is equally close to Nsp6s from both human SARS and bat CoV, having a sequence identity of 87.24% (Fig. S14D).", [["cells", "ANATOMY", 88, 93], ["intrinsic disorder", "DISEASE", 181, 199], ["SARS", "DISEASE", 267, 271], ["omegasome", "GENE_OR_GENE_PRODUCT", 39, 48], ["cells", "CELL", 88, 93], ["Non-structural protein 6", "GENE_OR_GENE_PRODUCT", 126, 150], ["Nsp6", "GENE_OR_GENE_PRODUCT", 152, 156], ["SARS-CoV-2", "ORGANISM", 267, 277], ["Nsp6s", "GENE_OR_GENE_PRODUCT", 298, 303], ["human", "ORGANISM", 314, 319], ["bat CoV", "ORGANISM", 329, 336], ["Non-structural protein 6", "PROTEIN", 126, 150], ["Nsp6", "PROTEIN", 152, 156], ["Nsp6s", "DNA", 298, 303], ["human", "SPECIES", 314, 319], ["SARS-CoV", "SPECIES", 267, 275], ["human", "SPECIES", 314, 319], ["bat CoV", "SPECIES", 329, 336], ["Non-structural protein", "TEST", 126, 148], ["Global analysis", "TEST", 162, 177], ["intrinsic disorder", "PROBLEM", 181, 199], ["SARS", "PROBLEM", 267, 271], ["CoV", "TEST", 272, 275], ["bat CoV", "TEST", 329, 336], ["a sequence identity", "TEST", 345, 364], ["intrinsic disorder", "OBSERVATION", 181, 199]]], ["Similarly, mean PPIDs for all three Nsp6 proteins is calculated to be 1.03%.", [["Nsp6", "GENE_OR_GENE_PRODUCT", 36, 40], ["PPIDs", "PROTEIN", 16, 21], ["Nsp6 proteins", "PROTEIN", 36, 49], ["mean PPIDs", "TREATMENT", 11, 21], ["all three Nsp6 proteins", "TEST", 26, 49]]], ["The graphs in Fig. S14A\u2013C further illustrates its highly structured nature.", [["S14A\u2013C", "SIMPLE_CHEMICAL", 19, 25], ["S14A\u2013C", "PROTEIN", 19, 25], ["Fig", "OBSERVATION_MODIFIER", 14, 17], ["highly", "OBSERVATION_MODIFIER", 50, 56], ["structured", "OBSERVATION_MODIFIER", 57, 67]]], ["As Nsp6 is a membrane protein, all three proteins are predicted to have a single MoRF near the N-terminal region (residues 1\u201319 in SARS-CoV-2, residues 1\u201322 in human SARS, and residues 1\u201321 in bat CoV) by the DISOPRED3 server.", [["membrane", "ANATOMY", 13, 21], ["N", "CHEMICAL", 95, 96], ["Nsp6", "GENE_OR_GENE_PRODUCT", 3, 7], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["MoRF", "GENE_OR_GENE_PRODUCT", 81, 85], ["human", "ORGANISM", 160, 165], ["Nsp6", "PROTEIN", 3, 7], ["membrane protein", "PROTEIN", 13, 29], ["MoRF", "PROTEIN", 81, 85], ["N-terminal region", "PROTEIN", 95, 112], ["residues 1\u201319", "PROTEIN", 114, 127], ["residues 1\u201322", "PROTEIN", 143, 156], ["human SARS", "PROTEIN", 160, 170], ["residues 1\u201321", "PROTEIN", 176, 189], ["bat CoV", "PROTEIN", 193, 200], ["DISOPRED3", "PROTEIN", 209, 218], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["a membrane protein", "TEST", 11, 29], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["terminal", "ANATOMY_MODIFIER", 97, 105], ["region", "ANATOMY_MODIFIER", 106, 112]]], ["The role of this protein-binding region for the induction of autophagy needs to be elucidated.Non-structural proteins 7 and 8 (Nsp7 and 8) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionThe ~ 10 kDa Nsp7 helps in primase-independent de novo initiation of viral RNA replication by forming a hexadecameric ring-like structure with Nsp8 protein [136, 137].", [["intrinsic disorder", "DISEASE", 162, 180], ["Non-structural proteins 7", "GENE_OR_GENE_PRODUCT", 94, 119], ["8", "GENE_OR_GENE_PRODUCT", 124, 125], ["Nsp7", "GENE_OR_GENE_PRODUCT", 127, 131], ["Nsp7", "GENE_OR_GENE_PRODUCT", 253, 257], ["Nsp8", "GENE_OR_GENE_PRODUCT", 383, 387], ["protein-binding region", "PROTEIN", 17, 39], ["Non-structural proteins 7 and 8", "PROTEIN", 94, 125], ["Nsp7 and 8", "PROTEIN", 127, 137], ["Nsp7", "PROTEIN", 253, 257], ["hexadecameric ring", "PROTEIN", 344, 362], ["Nsp8 protein", "PROTEIN", 383, 395], ["this protein-binding region", "TREATMENT", 12, 39], ["the induction of autophagy", "TREATMENT", 44, 70], ["Non-structural proteins", "TEST", 94, 117], ["Global analysis", "TEST", 143, 158], ["intrinsic disorder", "PROBLEM", 162, 180], ["The ~ 10 kDa Nsp7", "TREATMENT", 240, 257], ["viral RNA replication", "TREATMENT", 309, 330], ["a hexadecameric ring", "TREATMENT", 342, 362], ["Nsp8 protein", "TEST", 383, 395], ["intrinsic disorder", "OBSERVATION", 162, 180], ["viral RNA replication", "OBSERVATION", 309, 330]]], ["Both Nsp 7 and 8 contribute 8 molecules to the ring-structured multimeric viral RNA polymerase (Nsp12) [136].", [["Nsp 7", "GENE_OR_GENE_PRODUCT", 5, 10], ["8", "GENE_OR_GENE_PRODUCT", 15, 16], ["Nsp 7 and 8", "PROTEIN", 5, 16], ["multimeric viral RNA polymerase", "PROTEIN", 63, 94], ["Nsp12", "PROTEIN", 96, 101], ["Nsp", "TEST", 5, 8], ["viral RNA", "OBSERVATION", 74, 83]]], ["Figure 17d depicts the 2.90 \u00c5 resolution structure (PDB ID: 6M71) of SARS-CoV-2 Nsp12 with its cofactors Nsp7 and Nsp8 [138].", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["Nsp7", "GENE_OR_GENE_PRODUCT", 105, 109], ["CoV", "PROTEIN", 74, 77], ["Nsp12", "PROTEIN", 80, 85], ["Nsp7", "PROTEIN", 105, 109], ["Nsp8", "PROTEIN", 114, 118], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["its cofactors", "TEST", 91, 104], ["Nsp8", "TEST", 114, 118]]], ["Another 3.1 \u00c5 resolution electron microscopy-based structure (PDB ID: 6NUR) of human SARS Nsp12\u2013Nsp8\u2013Nsp7 complex is shown in Fig. 17e [139].Non-structural proteins 7 and 8 (Nsp7 and 8) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionIn this study, we found that Nsp7 of SARS-CoV-2 shares 100% sequence identity with the other two Nsp7 proteins (Fig. 17f), while SARS-CoV-2 Nsp8 is slightly closer to Nsp8 of human SARS (97.47%) than to other Nsp8 protein (96.46%) (Fig. 18d).Non-structural proteins 7 and 8 (Nsp7 and 8) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionDue to the similar sequence identities, mean PPIDs of all Nsp7s proteins are 9.64%, indicating their ordered structure (disorder profiles in Fig. 17a\u2013c).", [["intrinsic disorder", "DISEASE", 209, 227], ["SARS", "DISEASE", 324, 328], ["SARS", "DISEASE", 468, 472], ["intrinsic disorder", "DISEASE", 597, 615], ["human", "ORGANISM", 79, 84], ["Nsp12", "GENE_OR_GENE_PRODUCT", 90, 95], ["Nsp8", "GENE_OR_GENE_PRODUCT", 96, 100], ["Nsp7", "GENE_OR_GENE_PRODUCT", 101, 105], ["Non-structural proteins 7", "GENE_OR_GENE_PRODUCT", 141, 166], ["8", "GENE_OR_GENE_PRODUCT", 171, 172], ["Nsp7", "GENE_OR_GENE_PRODUCT", 174, 178], ["Nsp7", "GENE_OR_GENE_PRODUCT", 316, 320], ["SARS-CoV-2", "ORGANISM", 324, 334], ["Nsp7", "GENE_OR_GENE_PRODUCT", 384, 388], ["SARS-CoV-2", "ORGANISM", 416, 426], ["Nsp8", "GENE_OR_GENE_PRODUCT", 427, 431], ["Nsp8", "GENE_OR_GENE_PRODUCT", 454, 458], ["human", "ORGANISM", 462, 467], ["Nsp8", "GENE_OR_GENE_PRODUCT", 496, 500], ["Non-structural proteins 7", "GENE_OR_GENE_PRODUCT", 529, 554], ["8", "GENE_OR_GENE_PRODUCT", 559, 560], ["Nsp7", "GENE_OR_GENE_PRODUCT", 562, 566], ["Nsp7s", "GENE_OR_GENE_PRODUCT", 733, 738], ["NUR", "PROTEIN", 71, 74], ["human SARS Nsp12", "PROTEIN", 79, 95], ["Nsp8", "PROTEIN", 96, 100], ["Nsp7 complex", "PROTEIN", 101, 113], ["Non-structural proteins 7 and 8", "PROTEIN", 141, 172], ["Nsp7 and 8", "PROTEIN", 174, 184], ["Nsp7", "PROTEIN", 316, 320], ["Nsp7 proteins", "PROTEIN", 384, 397], ["Fig. 17f", "PROTEIN", 399, 407], ["SARS-CoV-2 Nsp8", "DNA", 416, 431], ["Nsp8", "PROTEIN", 454, 458], ["Nsp8 protein", "PROTEIN", 496, 508], ["Non-structural proteins 7 and 8", "PROTEIN", 529, 560], ["Nsp7 and 8", "PROTEIN", 562, 572], ["Nsp7s proteins", "PROTEIN", 733, 747], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 462, 467], ["human", "SPECIES", 79, 84], ["SARS-CoV", "SPECIES", 324, 332], ["SARS-CoV", "SPECIES", 416, 424], ["human", "SPECIES", 462, 467], ["electron microscopy", "TEST", 25, 44], ["human SARS", "TEST", 79, 89], ["Non-structural proteins", "TEST", 141, 164], ["Global analysis", "TEST", 190, 205], ["intrinsic disorder", "PROBLEM", 209, 227], ["this study", "TEST", 290, 300], ["SARS", "TEST", 324, 328], ["CoV", "TEST", 329, 332], ["SARS", "TEST", 416, 420], ["CoV", "TEST", 421, 424], ["human SARS", "TEST", 462, 472], ["other Nsp8 protein", "TEST", 490, 508], ["Non-structural proteins", "TEST", 529, 552], ["Global analysis", "TEST", 578, 593], ["intrinsic disorder", "PROBLEM", 597, 615], ["all Nsp7s proteins", "TEST", 729, 747], ["their ordered structure (disorder profiles", "PROBLEM", 770, 812], ["intrinsic disorder", "OBSERVATION", 209, 227], ["intrinsic disorder", "OBSERVATION", 597, 615]]], ["Both SARS-CoV-2 and human SARS Nsp8 proteins have a mean PPID of 23.74%, while Nsp8 of bat CoV has a PPID of 22.22% (disorder profiles in Fig. 18a\u2013c).", [["SARS-CoV-2", "ORGANISM", 5, 15], ["human", "ORGANISM", 20, 25], ["Nsp8", "GENE_OR_GENE_PRODUCT", 31, 35], ["bat CoV", "ORGANISM", 87, 94], ["SARS-CoV-2 and human SARS Nsp8 proteins", "PROTEIN", 5, 44], ["Nsp8", "PROTEIN", 79, 83], ["human", "SPECIES", 20, 25], ["SARS-CoV", "SPECIES", 5, 13], ["human", "SPECIES", 20, 25], ["bat CoV", "SPECIES", 87, 94], ["Both SARS", "TEST", 0, 9], ["CoV", "TEST", 10, 13], ["human SARS Nsp8 proteins", "TEST", 20, 44], ["a mean PPID", "TEST", 50, 61], ["bat CoV", "TEST", 87, 94], ["a PPID", "TEST", 99, 105]]], ["As moderately disordered proteins, Nsp8s are predicted to have a long IDPR (residues 44\u201384) in both SARS-CoV-2 and human SARS, and a bit shorter IDPR in bat CoV (residues 48\u201384).", [["SARS", "DISEASE", 121, 125], ["Nsp8s", "GENE_OR_GENE_PRODUCT", 35, 40], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 100, 110], ["human", "ORGANISM", 115, 120], ["bat CoV", "ORGANISM", 153, 160], ["Nsp8s", "PROTEIN", 35, 40], ["IDPR", "PROTEIN", 70, 74], ["residues 44\u201384", "PROTEIN", 76, 90], ["IDPR", "PROTEIN", 145, 149], ["bat CoV", "PROTEIN", 153, 160], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["bat CoV", "SPECIES", 153, 160], ["moderately disordered proteins", "PROBLEM", 3, 33], ["a long IDPR (residues", "PROBLEM", 63, 84], ["CoV", "TEST", 105, 108], ["human SARS", "PROBLEM", 115, 125], ["a bit shorter IDPR", "TREATMENT", 131, 149], ["moderately", "OBSERVATION_MODIFIER", 3, 13], ["disordered", "OBSERVATION", 14, 24]]], ["Furthermore, SARS-CoV Nsp7 using its N-terminus residues (V11, C13, V17, and V21) forms a hydrophobic core with Nsp8 residues (M92, M95, L96, M99, and L103).", [["N", "CHEMICAL", 37, 38], ["SARS-CoV Nsp7", "GENE_OR_GENE_PRODUCT", 13, 26], ["Nsp8", "GENE_OR_GENE_PRODUCT", 112, 116], ["SARS-CoV Nsp7", "PROTEIN", 13, 26], ["N-terminus residues", "PROTEIN", 37, 56], ["V11", "PROTEIN", 58, 61], ["C13", "PROTEIN", 63, 66], ["V17", "PROTEIN", 68, 71], ["V21", "PROTEIN", 77, 80], ["Nsp8 residues", "PROTEIN", 112, 125], ["L96", "PROTEIN", 137, 140], ["M99", "PROTEIN", 142, 145], ["L103", "PROTEIN", 151, 155], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "TEST", 13, 17], ["CoV Nsp7", "TEST", 18, 26], ["Nsp8 residues", "PROBLEM", 112, 125], ["M92", "TEST", 127, 130], ["M95", "TEST", 132, 135], ["L96", "TEST", 137, 140], ["M99", "TEST", 142, 145], ["Nsp8 residues", "OBSERVATION", 112, 125]]], ["Additionally, H-bonding takes place between Nsp7 Q24 and Nsp8 T89 residues [137].", [["Nsp7", "CHEMICAL", 44, 48], ["Nsp8", "CHEMICAL", 57, 61], ["Nsp7 Q24", "GENE_OR_GENE_PRODUCT", 44, 52], ["Nsp7 Q24", "PROTEIN", 44, 52]]], ["These amino acids are the part of MoRFs predicted in these proteins.", [["amino acids", "CHEMICAL", 6, 17], ["amino acids", "CHEMICAL", 6, 17], ["amino acids", "AMINO_ACID", 6, 17], ["MoRFs", "GENE_OR_GENE_PRODUCT", 34, 39], ["MoRFs", "PROTEIN", 34, 39], ["These amino acids", "TREATMENT", 0, 17]]], ["Three protein-binding regions in Nsp7 of SARS-CoV-2 (residues 1\u201330, 39\u201358, and 65\u201383), human SARS (residues 1\u201330, 44\u201358, and 64\u201383), and bat CoV (residues 1\u201330, 39\u201358, and 65\u201383) are identified by MoRFchibi_web server.", [["SARS", "DISEASE", 93, 97], ["Nsp7", "GENE_OR_GENE_PRODUCT", 33, 37], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["1\u201330", "GENE_OR_GENE_PRODUCT", 62, 66], ["39\u201358", "GENE_OR_GENE_PRODUCT", 68, 73], ["\u2013", "GENE_OR_GENE_PRODUCT", 81, 82], ["human", "ORGANISM", 87, 92], ["SARS", "GENE_OR_GENE_PRODUCT", 93, 97], ["44\u201358", "GENE_OR_GENE_PRODUCT", 114, 119], ["bat CoV", "GENE_OR_GENE_PRODUCT", 137, 144], ["protein-binding regions", "PROTEIN", 6, 29], ["Nsp7", "PROTEIN", 33, 37], ["SARS-CoV-2", "DNA", 41, 51], ["bat CoV", "PROTEIN", 137, 144], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["bat CoV", "SPECIES", 137, 144], ["Three protein", "TEST", 0, 13], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["human SARS", "TEST", 87, 97], ["residues", "TEST", 99, 107], ["bat CoV (residues", "TEST", 137, 154], ["binding regions", "OBSERVATION", 14, 29]]], ["Nsp7 shows the presence of very few nucleotide-binding regions while Nsp8 contains several DNA- as well as RNA-binding residues (see Tables S9\u2013S11).Non-structural protein 9 (Nsp9) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp9 protein is a single-stranded RNA-binding protein [140].", [["nucleotide", "CHEMICAL", 36, 46], ["intrinsic disorder", "DISEASE", 203, 221], ["nucleotide", "CHEMICAL", 36, 46], ["Nsp7", "GENE_OR_GENE_PRODUCT", 0, 4], ["Nsp8", "GENE_OR_GENE_PRODUCT", 69, 73], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["Non-structural protein 9", "GENE_OR_GENE_PRODUCT", 148, 172], ["Nsp9", "GENE_OR_GENE_PRODUCT", 174, 178], ["Nsp9", "GENE_OR_GENE_PRODUCT", 281, 285], ["Nsp7", "PROTEIN", 0, 4], ["nucleotide-binding regions", "DNA", 36, 62], ["Nsp8", "PROTEIN", 69, 73], ["S9", "PROTEIN", 140, 142], ["S11", "PROTEIN", 143, 146], ["Non-structural protein 9", "PROTEIN", 148, 172], ["Nsp9", "PROTEIN", 174, 178], ["Nsp9 protein", "PROTEIN", 281, 293], ["single-stranded RNA-binding protein", "PROTEIN", 299, 334], ["very few nucleotide-binding regions", "PROBLEM", 27, 62], ["several DNA", "PROBLEM", 83, 94], ["RNA-binding residues", "PROBLEM", 107, 127], ["Non-structural protein", "TEST", 148, 170], ["Global analysis", "TEST", 184, 199], ["intrinsic disorder", "PROBLEM", 203, 221], ["very", "OBSERVATION_MODIFIER", 27, 31], ["few", "OBSERVATION_MODIFIER", 32, 35], ["binding regions", "OBSERVATION", 47, 62], ["several", "OBSERVATION_MODIFIER", 83, 90], ["DNA", "OBSERVATION", 91, 94], ["intrinsic disorder", "OBSERVATION", 203, 221]]], ["It might protect RNA from nucleases by binding and stabilizing viral nucleic acids during replication or transcription [140].", [["nucleic acids", "CHEMICAL", 69, 82], ["viral nucleic acids", "TREATMENT", 63, 82]]], ["Our results on nucleotide-binding tendency of Nsp9 shows the presence of several RNA-binding and few DNA-binding residues in Nsp9 of SARS-CoV-2, Human SARS, and bat CoV (Tables S9\u2013S11).", [["nucleotide", "CHEMICAL", 15, 25], ["nucleotide", "CHEMICAL", 15, 25], ["Nsp9", "GENE_OR_GENE_PRODUCT", 46, 50], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["Nsp9", "GENE_OR_GENE_PRODUCT", 125, 129], ["SARS-CoV-2", "ORGANISM", 133, 143], ["Human", "ORGANISM", 145, 150], ["bat CoV", "ORGANISM", 161, 168], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 177, 183], ["Nsp9", "PROTEIN", 46, 50], ["Nsp9", "PROTEIN", 125, 129], ["S9", "PROTEIN", 177, 179], ["Human", "SPECIES", 145, 150], ["SARS-CoV", "SPECIES", 133, 141], ["bat CoV", "SPECIES", 161, 168], ["nucleotide-binding tendency", "TEST", 15, 42], ["Nsp9", "PROBLEM", 46, 50], ["several RNA-binding", "PROBLEM", 73, 92], ["few DNA-binding residues", "PROBLEM", 97, 121], ["SARS", "PROBLEM", 133, 137], ["CoV", "TEST", 138, 141], ["Human SARS", "TEST", 145, 155], ["bat CoV", "TREATMENT", 161, 168]]], ["Presumed to evolve from a protease, Nsp9 forms a dimer using its GXXXG motif [141, 142].", [["Nsp9", "GENE_OR_GENE_PRODUCT", 36, 40], ["protease", "PROTEIN", 26, 34], ["Nsp9", "PROTEIN", 36, 40], ["dimer", "PROTEIN", 49, 54], ["a protease", "TREATMENT", 24, 34]]], ["Figure 19d shows a 2.7 \u00c5 crystal structure of human SARS Nsp9 homodimer (PDB ID: 1QZ8) that identified a unique and previously unreported oligosaccharide/oligonucleotide fold-like fold [140].", [["human", "ORGANISM", 46, 51], ["human SARS Nsp9 homodimer", "PROTEIN", 46, 71], ["PDB ID: 1QZ8", "PROTEIN", 73, 85], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["Figure", "TEST", 0, 6], ["a unique and previously unreported oligosaccharide/oligonucleotide fold", "PROBLEM", 103, 174], ["oligonucleotide fold", "OBSERVATION", 154, 174]]], ["Here, each monomer contains a cone-shaped \u03b2-barrel and a C-terminal \u03b1-helix arranged into a compact domain [140].Non-structural protein 9 (Nsp9) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp9 of SARS-CoV-2 is equally similar to other two Nsp9 proteins (with a percentage identity of 97.35%).", [["intrinsic disorder", "DISEASE", 168, 186], ["SARS", "DISEASE", 254, 258], ["C", "CHEMICAL", 57, 58], ["Non-structural protein 9", "GENE_OR_GENE_PRODUCT", 113, 137], ["Nsp9", "GENE_OR_GENE_PRODUCT", 139, 143], ["SARS-CoV-2", "ORGANISM", 254, 264], ["Nsp9", "GENE_OR_GENE_PRODUCT", 297, 301], ["cone-shaped \u03b2-barrel", "PROTEIN", 30, 50], ["C-terminal \u03b1-helix", "PROTEIN", 57, 75], ["Non-structural protein 9", "PROTEIN", 113, 137], ["Nsp9", "PROTEIN", 139, 143], ["Nsp9 proteins", "PROTEIN", 297, 310], ["SARS-CoV", "SPECIES", 254, 262], ["a C-terminal \u03b1-helix", "TREATMENT", 55, 75], ["Non-structural protein", "TEST", 113, 135], ["Global analysis", "TEST", 149, 164], ["intrinsic disorder", "PROBLEM", 168, 186], ["SARS", "TEST", 254, 258], ["CoV", "TEST", 259, 262], ["a percentage identity", "TEST", 317, 338], ["intrinsic disorder", "OBSERVATION", 168, 186]]], ["The difference in the three amino acids at 34, 35 and 48 positions accounts for its similarity (Fig. 19e).", [["amino acids", "CHEMICAL", 28, 39], ["amino acids", "CHEMICAL", 28, 39], ["amino acids", "AMINO_ACID", 28, 39], ["the three amino acids", "TEST", 18, 39], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["Mean PPIDs of all Nsp9s are listed in Table 3.", [["Nsp9s", "PROTEIN", 18, 23], ["all", "OBSERVATION_MODIFIER", 14, 17], ["Nsp9s", "OBSERVATION", 18, 23]]], ["Graphs in Fig. 19a\u2013c show that all three Nsp9s are rather structured, but contain flexible regions.", [["Nsp9s", "GENE_OR_GENE_PRODUCT", 41, 46], ["Nsp9s", "PROTEIN", 41, 46], ["Graphs in Fig. 19a\u2013c", "TEST", 0, 20], ["flexible", "OBSERVATION", 82, 90]]], ["It contains conserved residues (R10, K52, Y53, R55, R74, F75, K86, Y87, F90, K92, R99, and R111) of positively charged side chains suitable for binding with the negatively charged phosphate backbone of RNA and aromatic side-chain amino acids providing stacking interactions [140].", [["phosphate", "CHEMICAL", 180, 189], ["amino acids", "CHEMICAL", 230, 241], ["phosphate", "CHEMICAL", 180, 189], ["amino acids", "CHEMICAL", 230, 241], ["amino acids", "AMINO_ACID", 230, 241], ["R111", "PROTEIN", 91, 95], ["R10", "TEST", 32, 35], ["K52", "TEST", 37, 40], ["Y53", "TEST", 42, 45], ["R55", "TEST", 47, 50], ["F75", "TEST", 57, 60], ["K86", "TEST", 62, 65], ["Y87", "TEST", 67, 70], ["F90", "TEST", 72, 75], ["K92", "TEST", 77, 80], ["positively charged side chains", "PROBLEM", 100, 130], ["the negatively charged phosphate backbone of RNA", "TREATMENT", 157, 205], ["aromatic side-chain amino acids", "TREATMENT", 210, 241], ["conserved residues", "OBSERVATION", 12, 30]]], ["These residues are a part of multiple disorder-based binding sites predicted by MoRFchibi_webserver (Tables 2, S7, S8).Non-structural protein 10 (Nsp10) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp10 forms a complex with Nsp14 for hydrolysing dsRNA in 3\u2032\u20135\u2032 direction [143].", [["disorder", "DISEASE", 38, 46], ["intrinsic disorder", "DISEASE", 176, 194], ["Non-structural protein 10", "GENE_OR_GENE_PRODUCT", 119, 144], ["Nsp10", "GENE_OR_GENE_PRODUCT", 146, 151], ["Nsp10", "GENE_OR_GENE_PRODUCT", 254, 259], ["Nsp14", "GENE_OR_GENE_PRODUCT", 281, 286], ["MoRFchibi_webserver", "PROTEIN", 80, 99], ["S7", "PROTEIN", 111, 113], ["S8", "PROTEIN", 115, 117], ["Non-structural protein 10", "PROTEIN", 119, 144], ["Nsp10", "PROTEIN", 146, 151], ["Nsp10", "PROTEIN", 254, 259], ["Nsp14", "PROTEIN", 281, 286], ["These residues", "PROBLEM", 0, 14], ["multiple disorder-based binding sites", "PROBLEM", 29, 66], ["Non-structural protein", "TEST", 119, 141], ["Global analysis", "TEST", 157, 172], ["intrinsic disorder", "PROBLEM", 176, 194], ["hydrolysing dsRNA", "TREATMENT", 291, 308], ["multiple", "OBSERVATION_MODIFIER", 29, 37], ["disorder", "OBSERVATION", 38, 46], ["binding sites", "OBSERVATION", 53, 66], ["intrinsic disorder", "OBSERVATION", 176, 194]]], ["In addition to activating the exonuclease activity of Nsp14, it also stimulates its methyltransferase (MTase) activity required during RNA-cap formation after replication [144].", [["Nsp14", "GENE_OR_GENE_PRODUCT", 54, 59], ["MTase", "GENE_OR_GENE_PRODUCT", 103, 108], ["exonuclease", "PROTEIN", 30, 41], ["Nsp14", "PROTEIN", 54, 59], ["methyltransferase", "PROTEIN", 84, 101], ["MTase", "PROTEIN", 103, 108], ["activating the exonuclease activity of Nsp14", "TREATMENT", 15, 59], ["its methyltransferase (MTase) activity", "TREATMENT", 80, 118], ["RNA-cap formation", "TREATMENT", 135, 152]]], ["Figure 20d represents the X-ray crystal structure of the Nsp10/Nsp14 complex (PDB ID: 5C8T) [145].", [["Nsp10", "GENE_OR_GENE_PRODUCT", 57, 62], ["Nsp10", "PROTEIN", 57, 62], ["Nsp14 complex", "PROTEIN", 63, 76], ["5C8T", "PROTEIN", 86, 90], ["the X-ray crystal structure", "TEST", 22, 49]]], ["In agreement with the results of previous biochemical experimental studies, the structure identified important interactions with the ExoN (exonuclease domain) of Nsp14 without affecting its N7-MTase activity [143, 144].Non-structural protein 10 (Nsp10) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionSARS-CoV-2 Nsp10 protein is quite conserved having a 97.12% sequence identity with Nsp10 of human SARS and 97.84% with Nsp10 of bat CoV (Fig. 20e).", [["intrinsic disorder", "DISEASE", 276, 294], ["SARS", "DISEASE", 452, 456], ["ExoN", "GENE_OR_GENE_PRODUCT", 133, 137], ["Nsp14", "GENE_OR_GENE_PRODUCT", 162, 167], ["Non-structural protein 10", "GENE_OR_GENE_PRODUCT", 219, 244], ["Nsp10", "GENE_OR_GENE_PRODUCT", 246, 251], ["discussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 344, 364], ["Nsp10", "GENE_OR_GENE_PRODUCT", 365, 370], ["Nsp10", "GENE_OR_GENE_PRODUCT", 437, 442], ["human", "ORGANISM", 446, 451], ["bat CoV", "ORGANISM", 482, 489], ["ExoN", "PROTEIN", 133, 137], ["exonuclease domain", "PROTEIN", 139, 157], ["Nsp14", "PROTEIN", 162, 167], ["MTase", "PROTEIN", 193, 198], ["Non-structural protein 10", "PROTEIN", 219, 244], ["Nsp10", "PROTEIN", 246, 251], ["discussionSARS-CoV-2 Nsp10 protein", "PROTEIN", 344, 378], ["Nsp10", "PROTEIN", 437, 442], ["Nsp10", "PROTEIN", 473, 478], ["human", "SPECIES", 446, 451], ["human", "SPECIES", 446, 451], ["bat CoV", "SPECIES", 482, 489], ["previous biochemical experimental studies", "TEST", 33, 74], ["the ExoN (exonuclease domain", "TREATMENT", 129, 157], ["Nsp14", "TREATMENT", 162, 167], ["Non-structural protein", "TEST", 219, 241], ["Global analysis", "TEST", 257, 272], ["intrinsic disorder", "PROBLEM", 276, 294], ["discussionSARS", "TEST", 344, 358], ["CoV", "TEST", 359, 362], ["human SARS", "TEST", 446, 456], ["Nsp10", "TEST", 473, 478], ["bat CoV", "TEST", 482, 489], ["intrinsic disorder", "OBSERVATION", 276, 294]]], ["Mean PPIDs of all three studied Nsp10 proteins are found to be 5.04%.", [["Nsp10", "GENE_OR_GENE_PRODUCT", 32, 37], ["Nsp10 proteins", "PROTEIN", 32, 46], ["Mean PPIDs", "TEST", 0, 10], ["Nsp10 proteins", "TEST", 32, 46]]], ["Figure 20a\u2013c represents the disorder profiles of Nsp10s and signifies the lack of long IDPRs.", [["disorder", "DISEASE", 28, 36], ["Nsp10s", "GENE_OR_GENE_PRODUCT", 49, 55], ["IDPRs", "GENE_OR_GENE_PRODUCT", 87, 92], ["Nsp10s", "PROTEIN", 49, 55], ["IDPRs", "PROTEIN", 87, 92], ["the disorder profiles of Nsp10s", "PROBLEM", 24, 55], ["long IDPRs", "PROBLEM", 82, 92]]], ["Furthermore, Tables 2, S7 and S8 shows that all three Nps10 proteins have multiple MoRFs.", [["Tables 2", "GENE_OR_GENE_PRODUCT", 13, 21], ["S7", "GENE_OR_GENE_PRODUCT", 23, 25], ["S8", "GENE_OR_GENE_PRODUCT", 30, 32], ["Nps10", "GENE_OR_GENE_PRODUCT", 54, 59], ["MoRFs", "GENE_OR_GENE_PRODUCT", 83, 88], ["S7", "PROTEIN", 23, 25], ["S8", "PROTEIN", 30, 32], ["Nps10 proteins", "PROTEIN", 54, 68], ["MoRFs", "PROTEIN", 83, 88], ["multiple MoRFs", "TREATMENT", 74, 88]]], ["For SARS-CoV-2, three MoRFs (residues 25\u201332, 91\u201399, and 133\u2013138) were identified by MoRFchibi_web server and one MoRF (residues 11\u201318) was predicted by MoRFPred server.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["MoRFs", "GENE_OR_GENE_PRODUCT", 22, 27], ["MoRFs", "DNA", 22, 27], ["MoRFchibi_web server", "DNA", 84, 104], ["MoRF", "PROTEIN", 113, 117], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "TEST", 4, 8], ["CoV", "TEST", 9, 12]]], ["Interestingly, the SARS-CoV Nsp10 residues F16, F19, and V21 form van der Waals interactions with many of the Nsp14 amino acids [145] out of which one residue (F16) is located in the MoRF region identified in this study.", [["SARS", "DISEASE", 19, 23], ["amino acids", "CHEMICAL", 116, 127], ["amino acids", "CHEMICAL", 116, 127], ["V21", "AMINO_ACID", 57, 60], ["Nsp14", "SIMPLE_CHEMICAL", 110, 115], ["amino acids", "AMINO_ACID", 116, 127], ["F19", "PROTEIN", 48, 51], ["V21", "PROTEIN", 57, 60], ["Nsp14 amino acids", "PROTEIN", 110, 127], ["MoRF region", "PROTEIN", 183, 194], ["SARS-CoV", "SPECIES", 19, 27], ["the SARS", "TEST", 15, 23], ["CoV Nsp10 residues", "TEST", 24, 42], ["the Nsp14 amino acids", "TEST", 106, 127], ["this study", "TEST", 209, 219], ["MoRF", "ANATOMY", 183, 187], ["region", "ANATOMY_MODIFIER", 188, 194]]], ["Furthermore, many nucleotide-binding residues which are found in all three Nsp10s are listed in Tables S9\u2013S11.Non-structural protein 12 (Nsp12) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionIn coronaviruses, Nsp12 acts an RNA-dependent RNA polymerase (RDRP).", [["nucleotide", "CHEMICAL", 18, 28], ["intrinsic disorder", "DISEASE", 167, 185], ["nucleotide", "CHEMICAL", 18, 28], ["Nsp10s", "GENE_OR_GENE_PRODUCT", 75, 81], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 103, 109], ["Non-structural protein 12", "GENE_OR_GENE_PRODUCT", 110, 135], ["Nsp12", "GENE_OR_GENE_PRODUCT", 137, 142], ["Nsp12", "GENE_OR_GENE_PRODUCT", 263, 268], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 277, 305], ["Nsp10s", "PROTEIN", 75, 81], ["S9", "PROTEIN", 103, 105], ["S11", "PROTEIN", 106, 109], ["Non-structural protein 12", "PROTEIN", 110, 135], ["Nsp12", "PROTEIN", 137, 142], ["Nsp12", "PROTEIN", 263, 268], ["RNA-dependent RNA polymerase", "PROTEIN", 277, 305], ["RDRP", "PROTEIN", 307, 311], ["many nucleotide-binding residues", "PROBLEM", 13, 45], ["Non-structural protein", "TEST", 110, 132], ["Global analysis", "TEST", 148, 163], ["intrinsic disorder", "PROBLEM", 167, 185], ["an RNA", "TEST", 274, 280], ["binding residues", "OBSERVATION", 29, 45], ["intrinsic disorder", "OBSERVATION", 167, 185]]], ["It accomplishes both primer-independent and primer-dependent synthesis of viral RNA with Mn2+ as its metallic co-factor and viral Nsp7 and 8 as protein co-factors [146].", [["Mn2", "CHEMICAL", 89, 92], ["Mn2+", "CHEMICAL", 89, 93], ["Mn2+", "SIMPLE_CHEMICAL", 89, 93], ["Nsp7", "GENE_OR_GENE_PRODUCT", 130, 134], ["viral RNA", "RNA", 74, 83], ["Mn2", "PROTEIN", 89, 92], ["metallic co-factor", "PROTEIN", 101, 119], ["viral Nsp7 and 8", "PROTEIN", 124, 140], ["protein co-factors", "PROTEIN", 144, 162], ["viral RNA", "PROBLEM", 74, 83], ["its metallic co-factor", "TEST", 97, 119], ["viral Nsp7", "TEST", 124, 134], ["protein co-factors", "TEST", 144, 162], ["viral RNA", "OBSERVATION", 74, 83]]], ["As aforementioned, a 3.1 \u00c5 resolution structure of human SARS Nsp12 in association with Nsp7 and Nsp8 proteins (PDB ID: 6NUR) has been reported using electron microscopy (Fig. 17e).", [["SARS", "DISEASE", 57, 61], ["human", "ORGANISM", 51, 56], ["Nsp12", "GENE_OR_GENE_PRODUCT", 62, 67], ["Nsp7", "GENE_OR_GENE_PRODUCT", 88, 92], ["Nsp8", "GENE_OR_GENE_PRODUCT", 97, 101], ["PDB ID: 6NUR", "GENE_OR_GENE_PRODUCT", 112, 124], ["human SARS Nsp12", "PROTEIN", 51, 67], ["Nsp7", "PROTEIN", 88, 92], ["Nsp8 proteins", "PROTEIN", 97, 110], ["PDB ID", "PROTEIN", 112, 118], ["NUR", "PROTEIN", 121, 124], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["Nsp7", "TEST", 88, 92], ["Nsp8 proteins", "PROBLEM", 97, 110], ["electron microscopy", "TEST", 150, 169]]], ["Nsp12 has a polymerase domain similar to \u201cright hand\u201d containing finger subdomain (398\u2013581, 628\u2013687 residues), palm subdomain (582\u2013627, 688\u2013815 residues) and a thumb subdomain (816\u2013919) [139].Non-structural protein 12 (Nsp12) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionSARS-CoV-2 Nsp12 protein has a highly conserved C-terminal region (Fig. S16).", [["right hand", "ANATOMY", 42, 52], ["Nsp12", "CHEMICAL", 0, 5], ["intrinsic disorder", "DISEASE", 249, 267], ["C", "CHEMICAL", 375, 376], ["Nsp12", "GENE_OR_GENE_PRODUCT", 0, 5], ["Non-structural protein 12", "GENE_OR_GENE_PRODUCT", 192, 217], ["Nsp12", "GENE_OR_GENE_PRODUCT", 219, 224], ["discussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 317, 337], ["Nsp12", "GENE_OR_GENE_PRODUCT", 338, 343], ["Nsp12", "PROTEIN", 0, 5], ["polymerase domain", "PROTEIN", 12, 29], ["\u201cright hand\u201d", "PROTEIN", 41, 53], ["finger subdomain", "PROTEIN", 65, 81], ["398\u2013581", "PROTEIN", 83, 90], ["palm subdomain", "PROTEIN", 111, 125], ["582\u2013627", "PROTEIN", 127, 134], ["thumb subdomain", "PROTEIN", 160, 175], ["816\u2013919", "PROTEIN", 177, 184], ["Non-structural protein 12", "PROTEIN", 192, 217], ["Nsp12", "PROTEIN", 219, 224], ["discussionSARS-CoV-2 Nsp12 protein", "PROTEIN", 317, 351], ["C-terminal region", "DNA", 375, 392], ["a polymerase domain", "PROBLEM", 10, 29], ["palm subdomain", "TEST", 111, 125], ["a thumb subdomain", "TEST", 158, 175], ["Non-structural protein", "TEST", 192, 214], ["Global analysis", "TEST", 230, 245], ["intrinsic disorder", "PROBLEM", 249, 267], ["discussionSARS", "TEST", 317, 331], ["CoV", "TEST", 332, 335], ["Nsp12 protein", "TEST", 338, 351], ["right", "ANATOMY_MODIFIER", 42, 47], ["finger subdomain", "ANATOMY", 65, 81], ["thumb", "ANATOMY", 160, 165], ["intrinsic disorder", "OBSERVATION", 249, 267], ["terminal", "ANATOMY_MODIFIER", 377, 385], ["region", "ANATOMY_MODIFIER", 386, 392]]], ["It is found to share a 96.35% sequence identity with human SARS Nsp12 and 95.60% with bat CoV Nsp12.", [["SARS", "DISEASE", 59, 63], ["human", "ORGANISM", 53, 58], ["human SARS Nsp12", "PROTEIN", 53, 69], ["bat CoV Nsp12", "PROTEIN", 86, 99], ["human", "SPECIES", 53, 58], ["human SARS Nsp12", "SPECIES", 53, 69], ["bat CoV", "SPECIES", 86, 93], ["human SARS Nsp12", "TEST", 53, 69], ["bat CoV Nsp", "TEST", 86, 97]]], ["Mean PPID values for all three Nsp12s are estimated to be 0.43% (Table 3).", [["PPID", "PROTEIN", 5, 9], ["Nsp12s", "PROTEIN", 31, 37], ["Mean PPID values", "TEST", 0, 16]]], ["Graphs in Fig. S15A\u2013C show that although Nsp12s are mostly ordered, they have multiple flexible regions.", [["Nsp12s", "GENE_OR_GENE_PRODUCT", 41, 47], ["S15A\u2013C", "PROTEIN", 15, 21], ["Nsp12s", "PROTEIN", 41, 47], ["Graphs in Fig", "TEST", 0, 13], ["Nsp12s", "TEST", 41, 47], ["multiple", "OBSERVATION_MODIFIER", 78, 86], ["flexible", "OBSERVATION", 87, 95]]], ["As RDRP protein is observed to be mostly structured, significant MoRFs in disordered regions are not found (Tables 2, S7, S8).Non-structural protein 13 (Nsp13) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp13 functions as a viral helicase and unwinds dsDNA/dsRNA in 5\u2032\u20133\u2032 direction [147].", [["intrinsic disorder", "DISEASE", 183, 201], ["RDRP", "GENE_OR_GENE_PRODUCT", 3, 7], ["MoRFs", "GENE_OR_GENE_PRODUCT", 65, 70], ["Non-structural protein 13", "GENE_OR_GENE_PRODUCT", 126, 151], ["Nsp13", "GENE_OR_GENE_PRODUCT", 153, 158], ["Nsp13", "GENE_OR_GENE_PRODUCT", 261, 266], ["RDRP protein", "PROTEIN", 3, 15], ["MoRFs", "PROTEIN", 65, 70], ["Non-structural protein 13", "PROTEIN", 126, 151], ["Nsp13", "PROTEIN", 153, 158], ["Nsp13", "PROTEIN", 261, 266], ["viral helicase", "PROTEIN", 282, 296], ["RDRP protein", "TEST", 3, 15], ["significant MoRFs in disordered regions", "PROBLEM", 53, 92], ["Non-structural protein", "TEST", 126, 148], ["Global analysis", "TEST", 164, 179], ["intrinsic disorder", "PROBLEM", 183, 201], ["a viral helicase", "TREATMENT", 280, 296], ["dsRNA", "PROBLEM", 315, 320], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["MoRFs", "OBSERVATION", 65, 70], ["intrinsic disorder", "OBSERVATION", 183, 201]]], ["Recombinant viral helicase expressed in E.coli Rosetta 2 strain was reported to unwind ~ 280 bp per second [147].", [["E.coli Rosetta 2", "ORGANISM", 40, 56], ["Recombinant viral helicase", "PROTEIN", 0, 26], ["E.coli Rosetta 2 strain", "SPECIES", 40, 63], ["Recombinant viral helicase", "PROBLEM", 0, 26], ["E.coli Rosetta", "OBSERVATION", 40, 54]]], ["Figure 21d represents 2.8 \u00c5 crystal structure of human SARS Nsp13 (PDB ID: 6JYT) [148].", [["SARS", "DISEASE", 55, 59], ["human", "ORGANISM", 49, 54], ["human SARS Nsp13", "PROTEIN", 49, 65], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["Figure", "TEST", 0, 6]]], ["This helicase contains a \u03b219\u2013\u03b220 loop on 1A domain, which is primarily responsible for its unwinding activity.", [["\u03b219\u2013\u03b220 loop", "PROTEIN", 25, 37], ["1A domain", "PROTEIN", 41, 50], ["primarily responsible for", "UNCERTAINTY", 61, 86], ["unwinding activity", "OBSERVATION", 91, 109]]], ["Furthermore, the study revealed an important interaction of Nsp12 with Nsp13 which further enhances its helicase activity [148].Non-structural protein 13 (Nsp13) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp13 of SARS-CoV-2 is found to be almost conserved as it shares 99.83% with Nsp13 of human SARS and 98.84% with Nsp13 of bat CoV (Fig. S17).", [["intrinsic disorder", "DISEASE", 185, 203], ["SARS", "DISEASE", 272, 276], ["SARS", "DISEASE", 355, 359], ["Nsp12", "GENE_OR_GENE_PRODUCT", 60, 65], ["Nsp13", "GENE_OR_GENE_PRODUCT", 71, 76], ["Non-structural protein 13", "GENE_OR_GENE_PRODUCT", 128, 153], ["Nsp13", "GENE_OR_GENE_PRODUCT", 155, 160], ["SARS-CoV-2", "ORGANISM", 272, 282], ["Nsp13", "GENE_OR_GENE_PRODUCT", 340, 345], ["human", "ORGANISM", 349, 354], ["Nsp13", "GENE_OR_GENE_PRODUCT", 376, 381], ["bat CoV", "ORGANISM", 385, 392], ["Nsp12", "PROTEIN", 60, 65], ["Nsp13", "PROTEIN", 71, 76], ["Non-structural protein 13", "PROTEIN", 128, 153], ["Nsp13", "PROTEIN", 155, 160], ["Nsp13", "PROTEIN", 340, 345], ["Nsp13", "PROTEIN", 376, 381], ["bat CoV", "PROTEIN", 385, 392], ["human", "SPECIES", 349, 354], ["SARS-CoV", "SPECIES", 272, 280], ["human", "SPECIES", 349, 354], ["bat CoV", "SPECIES", 385, 392], ["the study", "TEST", 13, 22], ["Nsp12", "TREATMENT", 60, 65], ["Nsp13", "TREATMENT", 71, 76], ["Non-structural protein", "TEST", 128, 150], ["Global analysis", "TEST", 166, 181], ["intrinsic disorder", "PROBLEM", 185, 203], ["SARS", "TEST", 272, 276], ["CoV", "TEST", 277, 280], ["human SARS", "TEST", 349, 359], ["Nsp13", "TEST", 376, 381], ["bat CoV", "TEST", 385, 392], ["intrinsic disorder", "OBSERVATION", 185, 203]]], ["Accordingly, mean PPIDs of all three Nsp13 proteins are estimated to be 0.67%.", [["Nsp13", "GENE_OR_GENE_PRODUCT", 37, 42], ["Nsp13 proteins", "PROTEIN", 37, 51], ["mean PPIDs", "TEST", 13, 23]]], ["Graphs in Fig. 21a\u2013c show that Nsp13s contain multiple flexible regions but does not possess significant disorder.", [["Nsp13s", "GENE_OR_GENE_PRODUCT", 31, 37], ["Nsp13s", "PROTEIN", 31, 37], ["Graphs in Fig. 21a\u2013c", "TEST", 0, 20], ["multiple flexible regions", "PROBLEM", 46, 71], ["significant disorder", "PROBLEM", 93, 113], ["multiple", "OBSERVATION_MODIFIER", 46, 54], ["flexible", "OBSERVATION", 55, 63], ["does not possess", "UNCERTAINTY", 76, 92], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["disorder", "OBSERVATION", 105, 113]]], ["As expected, being ordered proteins, Nsp13s does not contain any MoRF (Tables 2, S7, S8), but has several nucleotide-binding residues (Tables S9\u2013S11).Non-structural protein 14 (Nsp14) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp14 is a multifunctional viral protein that acts as an exoribonuclease (ExoN) and methyltransferase (N7-MTase) in SARS coronaviruses.", [["nucleotide", "CHEMICAL", 106, 116], ["intrinsic disorder", "DISEASE", 207, 225], ["SARS coronaviruses", "DISEASE", 401, 419], ["nucleotide", "CHEMICAL", 106, 116], ["Nsp13s", "GENE_OR_GENE_PRODUCT", 37, 43], ["MoRF", "GENE_OR_GENE_PRODUCT", 65, 69], ["Tables 2", "GENE_OR_GENE_PRODUCT", 71, 79], ["S7", "GENE_OR_GENE_PRODUCT", 81, 83], ["S8", "GENE_OR_GENE_PRODUCT", 85, 87], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 142, 148], ["Nsp14", "GENE_OR_GENE_PRODUCT", 285, 290], ["exoribonuclease", "GENE_OR_GENE_PRODUCT", 342, 357], ["ExoN", "GENE_OR_GENE_PRODUCT", 359, 363], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 388, 396], ["SARS coronaviruses", "ORGANISM", 401, 419], ["Nsp13s", "PROTEIN", 37, 43], ["MoRF", "PROTEIN", 65, 69], ["S7", "PROTEIN", 81, 83], ["S8", "PROTEIN", 85, 87], ["S9", "PROTEIN", 142, 144], ["S11", "PROTEIN", 145, 148], ["Non-structural protein 14", "PROTEIN", 150, 175], ["Nsp14", "PROTEIN", 177, 182], ["Nsp14", "PROTEIN", 285, 290], ["multifunctional viral protein", "PROTEIN", 296, 325], ["exoribonuclease", "PROTEIN", 342, 357], ["ExoN", "PROTEIN", 359, 363], ["methyltransferase", "PROTEIN", 369, 386], ["N7", "PROTEIN", 388, 390], ["MTase", "PROTEIN", 391, 396], ["SARS coronaviruses", "SPECIES", 401, 419], ["Nsp13s", "TREATMENT", 37, 43], ["several nucleotide-binding residues", "PROBLEM", 98, 133], ["Non-structural protein", "TEST", 150, 172], ["Global analysis", "TEST", 188, 203], ["intrinsic disorder", "PROBLEM", 207, 225], ["a multifunctional viral protein", "TREATMENT", 294, 325], ["an exoribonuclease (ExoN)", "TREATMENT", 339, 364], ["methyltransferase (N7-MTase)", "TREATMENT", 369, 397], ["SARS coronaviruses", "PROBLEM", 401, 419], ["binding residues", "OBSERVATION", 117, 133], ["intrinsic disorder", "OBSERVATION", 207, 225]]], ["Its 3\u2032\u20135\u2032 exonuclease activity lies in conserved DEDD residues related to the exonuclease superfamily [149].", [["3\u2032", "GENE_OR_GENE_PRODUCT", 4, 6], ["3\u2032\u20135\u2032 exonuclease", "PROTEIN", 4, 21], ["DEDD residues", "PROTEIN", 49, 62], ["exonuclease superfamily", "PROTEIN", 78, 101], ["exonuclease activity", "TREATMENT", 10, 30]]], ["Its guanine-N7 methyltransferase activity depends upon the S-adenosyl-l-methionine (AdoMet) as a cofactor [144].", [["guanine", "CHEMICAL", 4, 11], ["S-adenosyl-l-methionine", "CHEMICAL", 59, 82], ["AdoMet", "CHEMICAL", 84, 90], ["guanine", "CHEMICAL", 4, 11], ["S-adenosyl-l-methionine", "CHEMICAL", 59, 82], ["AdoMet", "CHEMICAL", 84, 90], ["guanine-N7 methyltransferase", "GENE_OR_GENE_PRODUCT", 4, 32], ["S-adenosyl-l-methionine", "SIMPLE_CHEMICAL", 59, 82], ["AdoMet", "SIMPLE_CHEMICAL", 84, 90], ["Its guanine", "TREATMENT", 0, 11], ["N7 methyltransferase activity", "TREATMENT", 12, 41], ["the S-adenosyl-l-methionine (AdoMet)", "TREATMENT", 55, 91]]], ["As mentioned previously, Nsp14 requires Nsp10 for activating its ExoN and N7-MTase activity inside host cells.", [["cells", "ANATOMY", 104, 109], ["Nsp14", "GENE_OR_GENE_PRODUCT", 25, 30], ["Nsp10", "GENE_OR_GENE_PRODUCT", 40, 45], ["ExoN", "GENE_OR_GENE_PRODUCT", 65, 69], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 74, 82], ["host cells", "CELL", 99, 109], ["Nsp14", "PROTEIN", 25, 30], ["Nsp10", "PROTEIN", 40, 45], ["MTase", "PROTEIN", 77, 82], ["host cells", "CELL_TYPE", 99, 109], ["Nsp10", "TREATMENT", 40, 45], ["activating its ExoN", "PROBLEM", 50, 69], ["host cells", "OBSERVATION", 99, 109]]], ["Figure 20d depicts the 3.2 \u00c5 crystal structure of human SARS nsp10/nsp14 complex (PDB ID: 5C8T), where amino acids 1\u2013287 form the ExoN domain and 288\u2013527 residues form the N7-MTase domain of nsp14.", [["amino acids", "CHEMICAL", 103, 114], ["amino acids", "CHEMICAL", 103, 114], ["human", "ORGANISM", 50, 55], ["amino acids", "AMINO_ACID", 103, 114], ["1\u2013287", "AMINO_ACID", 115, 120], ["nsp14", "GENE_OR_GENE_PRODUCT", 191, 196], ["human SARS nsp10/nsp14 complex", "PROTEIN", 50, 80], ["5C8T", "PROTEIN", 90, 94], ["amino acids 1\u2013287", "PROTEIN", 103, 120], ["ExoN domain", "PROTEIN", 130, 141], ["N7-MTase domain", "PROTEIN", 172, 187], ["nsp14", "PROTEIN", 191, 196], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["Figure", "TEST", 0, 6], ["human SARS", "TEST", 50, 60], ["amino acids", "TEST", 103, 114], ["the ExoN domain", "TEST", 126, 141], ["the N7-MTase domain of nsp14", "TREATMENT", 168, 196]]], ["A loop (residues 288\u2013301) is essential for its N7-MTase activity [145].Non-structural protein 14 (Nsp14) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionSARS-CoV-2 Nsp14 protein shares a 95.07% identity with human SARS Nsp14 and 94.69% with bat CoV Nsp14 (Fig. S18).", [["intrinsic disorder", "DISEASE", 128, 146], ["SARS", "DISEASE", 267, 271], ["N7-MTase", "GENE_OR_GENE_PRODUCT", 47, 55], ["Non-structural protein 14", "GENE_OR_GENE_PRODUCT", 71, 96], ["Nsp14", "GENE_OR_GENE_PRODUCT", 98, 103], ["discussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 196, 216], ["Nsp14", "GENE_OR_GENE_PRODUCT", 217, 222], ["human", "ORGANISM", 261, 266], ["Fig. S18", "GENE_OR_GENE_PRODUCT", 309, 317], ["MTase", "PROTEIN", 50, 55], ["Non-structural protein 14", "PROTEIN", 71, 96], ["Nsp14", "PROTEIN", 98, 103], ["discussionSARS-CoV-2 Nsp14 protein", "PROTEIN", 196, 230], ["human SARS Nsp14", "PROTEIN", 261, 277], ["bat CoV Nsp14", "PROTEIN", 294, 307], ["human", "SPECIES", 261, 266], ["human SARS Nsp14", "SPECIES", 261, 277], ["bat CoV", "SPECIES", 294, 301], ["A loop (residues", "TREATMENT", 0, 16], ["Non-structural protein", "TEST", 71, 93], ["intrinsic disorder", "PROBLEM", 128, 146], ["discussionSARS", "TEST", 196, 210], ["CoV", "TEST", 211, 214], ["human SARS Nsp14", "TEST", 261, 277], ["bat CoV Nsp14", "TEST", 294, 307], ["loop", "OBSERVATION", 2, 6], ["intrinsic disorder", "OBSERVATION", 128, 146]]], ["Low mean PPID values for all three Nsp14s (Table 3) and disorder profiles depicted in Fig. S19A\u2013C shows its highly structured nature.", [["disorder", "DISEASE", 56, 64], ["S19A\u2013C", "CHEMICAL", 91, 97], ["S19A\u2013C", "SIMPLE_CHEMICAL", 91, 97], ["PPID", "PROTEIN", 9, 13], ["Nsp14s", "PROTEIN", 35, 41], ["S19A\u2013C", "PROTEIN", 91, 97], ["Low mean PPID values", "PROBLEM", 0, 20], ["disorder profiles", "PROBLEM", 56, 73], ["Fig", "OBSERVATION_MODIFIER", 86, 89], ["highly", "OBSERVATION_MODIFIER", 108, 114], ["structured", "OBSERVATION", 115, 125]]], ["Likewise, all three Nsp14 proteins contains two protein binding regions (residues 8\u201313 and 441\u2013445) predicted by the MoRFPred.Non-structural protein 15 (Nsp15) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp15 is a uridylate-specific RNA endonuclease (NendoU) which creates a 2\u2032\u20133\u2032 cyclic phosphates after cleavage.", [["intrinsic disorder", "DISEASE", 183, 201], ["2\u2032\u20133\u2032 cyclic phosphates", "CHEMICAL", 333, 356], ["uridylate", "CHEMICAL", 272, 281], ["2\u2032\u20133\u2032 cyclic phosphates", "CHEMICAL", 333, 356], ["Nsp14", "GENE_OR_GENE_PRODUCT", 20, 25], ["Non-structural protein 15", "GENE_OR_GENE_PRODUCT", 126, 151], ["Nsp15", "GENE_OR_GENE_PRODUCT", 153, 158], ["Nsp15", "GENE_OR_GENE_PRODUCT", 261, 266], ["uridylate", "SIMPLE_CHEMICAL", 272, 281], ["NendoU", "GENE_OR_GENE_PRODUCT", 309, 315], ["2\u2032\u20133\u2032 cyclic phosphates", "SIMPLE_CHEMICAL", 333, 356], ["Nsp14 proteins", "PROTEIN", 20, 34], ["protein binding regions", "PROTEIN", 48, 71], ["MoRFPred", "PROTEIN", 117, 125], ["Non-structural protein 15", "PROTEIN", 126, 151], ["Nsp15", "PROTEIN", 153, 158], ["Nsp15", "PROTEIN", 261, 266], ["uridylate-specific RNA endonuclease", "PROTEIN", 272, 307], ["NendoU", "PROTEIN", 309, 315], ["Non-structural protein", "TEST", 126, 148], ["Global analysis", "TEST", 164, 179], ["intrinsic disorder", "PROBLEM", 183, 201], ["a 2\u2032\u20133\u2032 cyclic phosphates", "TREATMENT", 331, 356], ["protein binding", "OBSERVATION", 48, 63], ["intrinsic disorder", "OBSERVATION", 183, 201]]], ["Its endonuclease activity depends upon Mn2+ ions as co-factors.", [["Mn2", "CHEMICAL", 39, 42], ["Mn2+", "CHEMICAL", 39, 43], ["Mn2+ ions", "SIMPLE_CHEMICAL", 39, 48], ["endonuclease", "PROTEIN", 4, 16], ["Mn2", "PROTEIN", 39, 42]]], ["Conserved in Nidoviruses, it acts as an important genetic marker due to its absence in other RNA viruses [150].", [["Nidoviruses", "GENE_OR_GENE_PRODUCT", 13, 24], ["Nidoviruses", "TREATMENT", 13, 24], ["other RNA viruses", "PROBLEM", 87, 104]]], ["A crystal structure of SARS-CoV-2 Nsp15 (207\u2013374 residues) has been resolved using X-ray diffraction [151] (depicted in Fig. 22d).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["A crystal structure of SARS", "PROBLEM", 0, 27], ["CoV", "TEST", 28, 31], ["crystal", "OBSERVATION_MODIFIER", 2, 9], ["SARS", "OBSERVATION", 23, 27]]], ["Figure 22e represents a 2.6 \u00c5 crystal structure of human SARS Nsp15 (PDB ID: 2H85) deduced by Bruno and colleagues [152].Non-structural protein 15 (Nsp15) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionSARS-CoV-2 Nsp15 shares 88.73% sequence identity with human SARS and 88.15% with bat CoV (Fig. S20).", [["SARS", "DISEASE", 57, 61], ["intrinsic disorder", "DISEASE", 178, 196], ["SARS", "DISEASE", 316, 320], ["human", "ORGANISM", 51, 56], ["Non-structural protein 15", "GENE_OR_GENE_PRODUCT", 121, 146], ["Nsp15", "GENE_OR_GENE_PRODUCT", 148, 153], ["Nsp15", "GENE_OR_GENE_PRODUCT", 267, 272], ["human", "ORGANISM", 310, 315], ["bat CoV", "ORGANISM", 337, 344], ["human SARS Nsp15", "PROTEIN", 51, 67], ["Non-structural protein 15", "PROTEIN", 121, 146], ["Nsp15", "PROTEIN", 148, 153], ["discussionSARS-CoV-2 Nsp15", "DNA", 246, 272], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 310, 315], ["bat CoV", "SPECIES", 337, 344], ["Non-structural protein", "TEST", 121, 143], ["Global analysis", "TEST", 159, 174], ["intrinsic disorder", "PROBLEM", 178, 196], ["discussionSARS", "TEST", 246, 260], ["CoV", "TEST", 261, 264], ["human SARS", "TEST", 310, 320], ["intrinsic disorder", "OBSERVATION", 178, 196]]], ["The calculated mean PPIDs of Nsp15s from SARS-CoV-2, human SARS, and bat CoV are 1.73%, 2.60%, and 2.60%, respectively.", [["Nsp15s", "GENE_OR_GENE_PRODUCT", 29, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["human", "ORGANISM", 53, 58], ["bat CoV", "ORGANISM", 69, 76], ["PPIDs", "PROTEIN", 20, 25], ["Nsp15s", "PROTEIN", 29, 35], ["human", "SPECIES", 53, 58], ["SARS-CoV", "SPECIES", 41, 49], ["human", "SPECIES", 53, 58], ["bat CoV", "SPECIES", 69, 76], ["The calculated mean PPIDs", "TEST", 0, 25], ["Nsp15s", "TEST", 29, 35], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["human SARS", "TEST", 53, 63], ["bat CoV", "TEST", 69, 76], ["mean", "OBSERVATION_MODIFIER", 15, 19], ["bat CoV", "ANATOMY", 69, 76]]], ["Similar to many other Nsps, all three Nsp15 proteins are predicted to possess multiple flexible regions but contain virtually no IDPRs (see Fig. 22a\u2013c).", [["Nsps", "GENE_OR_GENE_PRODUCT", 22, 26], ["Nsp15", "GENE_OR_GENE_PRODUCT", 38, 43], ["Nsps", "PROTEIN", 22, 26], ["Nsp15 proteins", "PROTEIN", 38, 52], ["IDPRs", "PROTEIN", 129, 134], ["Fig. 22a\u2013c", "PROTEIN", 140, 150], ["Nsps", "OBSERVATION_MODIFIER", 22, 26], ["multiple", "OBSERVATION_MODIFIER", 78, 86], ["flexible", "OBSERVATION", 87, 95]]], ["Also, no significant disorder-binding regions are predicted in Nsp15 proteins (Table 2).", [["Nsp15 proteins", "GENE_OR_GENE_PRODUCT", 63, 77], ["Nsp15 proteins", "PROTEIN", 63, 77], ["significant disorder-binding regions", "PROBLEM", 9, 45], ["no", "UNCERTAINTY", 6, 8], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["disorder", "OBSERVATION", 21, 29], ["binding regions", "OBSERVATION", 30, 45]]], ["SARS-CoV-2 and bat CoV Nsp15s possesses very short binding regions, while human SARS Nsp15 does not contain any MoRF (Tables S7, S8).", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["bat CoV", "ORGANISM", 15, 22], ["Nsp15s", "GENE_OR_GENE_PRODUCT", 23, 29], ["human", "ORGANISM", 74, 79], ["SARS-CoV-2 and bat CoV Nsp15s", "DNA", 0, 29], ["human SARS Nsp15", "PROTEIN", 74, 90], ["MoRF", "PROTEIN", 112, 116], ["S7", "PROTEIN", 125, 127], ["S8", "PROTEIN", 129, 131], ["human", "SPECIES", 74, 79], ["bat CoV", "SPECIES", 15, 22], ["human", "SPECIES", 74, 79], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["bat CoV Nsp15s", "TREATMENT", 15, 29], ["very short binding regions", "PROBLEM", 40, 66], ["very", "OBSERVATION_MODIFIER", 40, 44], ["short binding", "OBSERVATION_MODIFIER", 45, 58]]], ["Tables S9\u2013S11 depict the presence of many RNA-binding residues and few DNA-binding residues in Nsp15 of all three viruses.Non-structural protein 16 (Nsp16) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp16 protein is another MTase domain-containing protein.", [["intrinsic disorder", "DISEASE", 179, 197], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 7, 13], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["Nsp15", "GENE_OR_GENE_PRODUCT", 95, 100], ["Non-structural protein 16", "GENE_OR_GENE_PRODUCT", 122, 147], ["Nsp16", "GENE_OR_GENE_PRODUCT", 257, 262], ["S9", "PROTEIN", 7, 9], ["DNA-binding residues", "PROTEIN", 71, 91], ["Nsp15", "PROTEIN", 95, 100], ["Non-structural protein 16", "PROTEIN", 122, 147], ["Nsp16", "PROTEIN", 149, 154], ["Nsp16 protein", "PROTEIN", 257, 270], ["MTase domain-containing protein", "PROTEIN", 282, 313], ["many RNA-binding residues", "PROBLEM", 37, 62], ["few DNA-binding residues", "PROBLEM", 67, 91], ["Non-structural protein", "TEST", 122, 144], ["Nsp", "TEST", 149, 152], ["intrinsic disorder", "PROBLEM", 179, 197], ["another MTase domain", "TREATMENT", 274, 294], ["many", "OBSERVATION_MODIFIER", 37, 41], ["RNA", "OBSERVATION", 42, 45], ["binding residues", "OBSERVATION", 46, 62], ["few", "OBSERVATION_MODIFIER", 67, 70], ["binding residues", "OBSERVATION", 75, 91], ["viruses", "OBSERVATION", 114, 121], ["intrinsic disorder", "OBSERVATION", 179, 197]]], ["As methylation of CoV mRNAs occurs in steps, three proteins Nsp10, Nsp14, and Nsp16 act one after another.", [["CoV", "GENE_OR_GENE_PRODUCT", 18, 21], ["Nsp10", "GENE_OR_GENE_PRODUCT", 60, 65], ["Nsp14", "GENE_OR_GENE_PRODUCT", 67, 72], ["Nsp16", "GENE_OR_GENE_PRODUCT", 78, 83], ["CoV mRNAs", "RNA", 18, 27], ["Nsp10", "PROTEIN", 60, 65], ["Nsp14", "PROTEIN", 67, 72], ["Nsp16", "PROTEIN", 78, 83], ["methylation of CoV mRNAs", "TREATMENT", 3, 27], ["Nsp14", "TREATMENT", 67, 72], ["CoV mRNAs", "OBSERVATION", 18, 27]]], ["First event requires the initiation trigger from Nsp10 protein, after which Nsp14 methylates capped mRNAs forming cap-0 (7Me) GpppA-RNAs.", [["Nsp10", "GENE_OR_GENE_PRODUCT", 49, 54], ["Nsp14", "GENE_OR_GENE_PRODUCT", 76, 81], ["cap-0", "GENE_OR_GENE_PRODUCT", 114, 119], ["Nsp10 protein", "PROTEIN", 49, 62], ["Nsp14", "PROTEIN", 76, 81], ["mRNAs", "RNA", 100, 105], ["cap-0 (7Me) GpppA-RNAs", "RNA", 114, 136], ["Nsp10 protein", "TREATMENT", 49, 62], ["cap", "TEST", 114, 117]]], ["Nsp16 protein, along with its co-activator protein Nsp10, acts on cap-0 (7Me) GpppA-RNAs to give rise to final cap-1 (7Me)GpppA(2\u2032OMe)-RNAs [144, 153].", [["Nsp16", "GENE_OR_GENE_PRODUCT", 0, 5], ["Nsp10", "GENE_OR_GENE_PRODUCT", 51, 56], ["cap-0", "GENE_OR_GENE_PRODUCT", 66, 71], ["cap-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["Nsp16 protein", "PROTEIN", 0, 13], ["co-activator protein", "PROTEIN", 30, 50], ["Nsp10", "PROTEIN", 51, 56], ["cap-0 (7Me) GpppA-RNAs", "RNA", 66, 88], ["cap-1 (7Me)GpppA(2\u2032OMe)", "DNA", 111, 134], ["Nsp16 protein", "TEST", 0, 13], ["its co-activator protein Nsp10", "TEST", 26, 56], ["cap", "TEST", 66, 69], ["GpppA", "TEST", 78, 83], ["final cap", "TEST", 105, 114], ["GpppA", "TEST", 122, 127], ["RNAs", "TEST", 135, 139]]], ["The crystal structure (PDB ID: 6W75) of Nsp10\u2013Nsp16 complex of SARS-CoV-2 is generated using X-ray diffraction (Fig. 23d).", [["Nsp10", "GENE_OR_GENE_PRODUCT", 40, 45], ["Nsp10", "PROTEIN", 40, 45], ["Nsp16 complex", "PROTEIN", 46, 59], ["Nsp10", "TEST", 40, 45], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["X-ray diffraction", "TEST", 93, 110]]], ["A 2 \u00c5 X-ray crystal structure of human SARS Nsp10\u2013Nsp16 complex is depicted in Fig. 23e (PDB ID: 3R24) [154].", [["human", "ORGANISM", 33, 38], ["Nsp10", "GENE_OR_GENE_PRODUCT", 44, 49], ["Nsp16", "GENE_OR_GENE_PRODUCT", 50, 55], ["human SARS Nsp10\u2013Nsp16 complex", "PROTEIN", 33, 63], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["A 2 \u00c5 X-ray crystal structure", "TEST", 0, 29], ["human SARS", "TEST", 33, 43]]], ["The structure consists of a characteristic fold present in class I MTase family comprising \u03b1-helices and loops surrounding a seven-stranded \u03b2-sheet [154].Non-structural protein 16 (Nsp16) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp16 of SARS-CoV-2 is found to be identical with other two Nsp16 proteins (93.29%) (Fig. S21).", [["intrinsic disorder", "DISEASE", 211, 229], ["SARS", "DISEASE", 298, 302], ["class I MTase", "GENE_OR_GENE_PRODUCT", 59, 72], ["\u03b1-helices", "GENE_OR_GENE_PRODUCT", 91, 100], ["Non-structural protein 16", "GENE_OR_GENE_PRODUCT", 154, 179], ["Nsp16", "GENE_OR_GENE_PRODUCT", 181, 186], ["Nsp16", "GENE_OR_GENE_PRODUCT", 289, 294], ["SARS-CoV-2", "ORGANISM", 298, 308], ["Nsp16", "GENE_OR_GENE_PRODUCT", 349, 354], ["class I MTase family", "PROTEIN", 59, 79], ["\u03b1-helices", "PROTEIN", 91, 100], ["Non-structural protein 16", "PROTEIN", 154, 179], ["Nsp16", "PROTEIN", 181, 186], ["Nsp16", "PROTEIN", 289, 294], ["Nsp16 proteins", "PROTEIN", 349, 363], ["SARS-CoV", "SPECIES", 298, 306], ["a characteristic fold", "PROBLEM", 26, 47], ["Non-structural protein", "TEST", 154, 176], ["intrinsic disorder", "PROBLEM", 211, 229], ["SARS", "TEST", 298, 302], ["CoV", "TEST", 303, 306], ["two Nsp16 proteins", "TEST", 345, 363], ["characteristic", "OBSERVATION_MODIFIER", 28, 42], ["fold", "OBSERVATION", 43, 47], ["loops", "ANATOMY_MODIFIER", 105, 110], ["intrinsic disorder", "OBSERVATION", 211, 229]]], ["Mean PPIDs for Nsp16s from SARS-CoV-2, human SARS, and bat CoV are 5.37%, 3.02%, and 3.02%, respectively.", [["Nsp16s", "GENE_OR_GENE_PRODUCT", 15, 21], ["SARS-CoV-2", "ORGANISM", 27, 37], ["human", "ORGANISM", 39, 44], ["SARS", "ORGANISM", 45, 49], ["bat CoV", "ORGANISM", 55, 62], ["PPIDs", "PROTEIN", 5, 10], ["Nsp16s", "PROTEIN", 15, 21], ["human", "SPECIES", 39, 44], ["SARS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 39, 44], ["bat CoV", "SPECIES", 55, 62], ["Mean PPIDs", "TEST", 0, 10], ["Nsp16s", "TEST", 15, 21], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["human SARS", "TEST", 39, 49], ["bat CoV", "TEST", 55, 62], ["bat CoV", "ANATOMY", 55, 62]]], ["In line with these PPID values, graphs in Fig. 23a\u2013c show that these proteins are mostly ordered having several flexible regions.", [["PPID", "DNA", 19, 23], ["these PPID values", "TEST", 13, 30], ["graphs in Fig.", "TEST", 32, 46], ["these proteins", "TEST", 63, 77], ["flexible", "OBSERVATION_MODIFIER", 112, 120]]], ["Correspondingly, only a single MoRF (residues 151\u2013156) is present in all three Nsp16s.", [["MoRF", "GENE_OR_GENE_PRODUCT", 31, 35], ["Nsp16s", "GENE_OR_GENE_PRODUCT", 79, 85], ["MoRF", "DNA", 31, 35], ["Nsp16s", "DNA", 79, 85]]], ["Further, several RNA-binding and few DNA-binding residues are also identified (Tables S9\u2013S11).Replicase polyprotein 1a ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionSince replicase polyprotein 1a contains non-structural proteins 1\u201310 identical to those found in replicase polyprotein 1ab, we did not perform their disorder analysis separately.", [["intrinsic disorder", "DISEASE", 142, 160], ["DNA", "CELLULAR_COMPONENT", 37, 40], ["S9\u2013S11", "GENE_OR_GENE_PRODUCT", 86, 92], ["S9", "PROTEIN", 86, 88], ["S11", "PROTEIN", 89, 92], ["discussionSince replicase polyprotein 1a", "PROTEIN", 210, 250], ["non-structural proteins", "PROTEIN", 260, 283], ["1\u201310", "PROTEIN", 284, 288], ["several RNA-binding", "PROBLEM", 9, 28], ["few DNA-binding residues", "PROBLEM", 33, 57], ["Global analysis", "TEST", 123, 138], ["intrinsic disorder", "PROBLEM", 142, 160], ["discussionSince replicase polyprotein 1a", "TREATMENT", 210, 250], ["non-structural proteins", "TREATMENT", 260, 283], ["their disorder analysis", "TEST", 363, 386], ["several", "OBSERVATION_MODIFIER", 9, 16], ["RNA", "OBSERVATION", 17, 20], ["few", "OBSERVATION_MODIFIER", 33, 36], ["DNA", "OBSERVATION", 37, 40], ["binding residues", "OBSERVATION", 41, 57], ["intrinsic disorder", "OBSERVATION", 142, 160]]], ["However, replicase polyprotein 1a has one additional non-structural protein designated as Nsp11.Non-structural protein 11 (Nsp11) ::: Global analysis of intrinsic disorder in the replicase polyprotein 1ab ::: Results and discussionNsp11 is a small uncharacterized protein with unknown function and requires extensive experimental insights to reveal its structural indentity.", [["intrinsic disorder", "DISEASE", 153, 171], ["replicase polyprotein 1a", "GENE_OR_GENE_PRODUCT", 9, 33], ["Nsp11", "GENE_OR_GENE_PRODUCT", 90, 95], ["Non-structural protein 11", "GENE_OR_GENE_PRODUCT", 96, 121], ["Nsp11", "GENE_OR_GENE_PRODUCT", 123, 128], ["Nsp11", "GENE_OR_GENE_PRODUCT", 231, 236], ["replicase polyprotein 1a", "PROTEIN", 9, 33], ["non-structural protein", "PROTEIN", 53, 75], ["Nsp11", "PROTEIN", 90, 95], ["Non-structural protein 11", "PROTEIN", 96, 121], ["Nsp11", "PROTEIN", 123, 128], ["Nsp11", "PROTEIN", 231, 236], ["replicase polyprotein 1a", "TREATMENT", 9, 33], ["Non-structural protein", "TEST", 96, 118], ["Global analysis", "TEST", 134, 149], ["intrinsic disorder", "PROBLEM", 153, 171], ["a small uncharacterized protein", "PROBLEM", 240, 271], ["its structural indentity", "PROBLEM", 349, 373], ["intrinsic disorder", "OBSERVATION", 153, 171]]], ["The intrinsic disorder-predicting software used in this study requires amino acid sequences which are at least 30-residue long.", [["disorder", "DISEASE", 14, 22], ["amino acid", "CHEMICAL", 71, 81], ["amino acid", "CHEMICAL", 71, 81], ["amino acid", "AMINO_ACID", 71, 81], ["The intrinsic disorder", "PROBLEM", 0, 22], ["this study", "TEST", 51, 61], ["amino acid sequences", "TEST", 71, 91], ["intrinsic disorder", "OBSERVATION", 4, 22]]], ["Therefore, because of their short sequences (just 13 residues), Nsp11s from all three studied coronaviruses are not checked for the intrinsic disorder, disorder-based protein-binding regions, and nucleotide-binding residues.", [["disorder", "DISEASE", 142, 150], ["disorder", "DISEASE", 152, 160], ["nucleotide", "CHEMICAL", 196, 206], ["nucleotide", "CHEMICAL", 196, 206], ["Nsp11s", "GENE_OR_GENE_PRODUCT", 64, 70], ["coronaviruses", "ORGANISM", 94, 107], ["Nsp11s", "PROTEIN", 64, 70], ["protein-binding regions", "PROTEIN", 167, 190], ["their short sequences", "PROBLEM", 22, 43], ["Nsp11s", "TEST", 64, 70], ["all three studied coronaviruses", "PROBLEM", 76, 107], ["the intrinsic disorder", "PROBLEM", 128, 150], ["disorder", "PROBLEM", 152, 160], ["based protein-binding regions", "PROBLEM", 161, 190], ["nucleotide-binding residues", "TREATMENT", 196, 223]]], ["Based on the MSA outputs, Nsp11 from SARS-CoV-2 is found to have a sequence identity of 84.62% with Nsp11s from human SARS and bat CoV (Fig. S22).Concluding remarksEmergence of new viruses and associated deaths around the globe represent one of the major concerns of modern times.", [["SARS", "DISEASE", 118, 122], ["deaths", "DISEASE", 204, 210], ["Nsp11", "GENE_OR_GENE_PRODUCT", 26, 31], ["SARS-CoV-2", "ORGANISM", 37, 47], ["Nsp11s", "GENE_OR_GENE_PRODUCT", 100, 106], ["human", "ORGANISM", 112, 117], ["bat CoV", "ORGANISM", 127, 134], ["Nsp11", "PROTEIN", 26, 31], ["Nsp11s", "PROTEIN", 100, 106], ["human", "SPECIES", 112, 117], ["SARS-CoV", "SPECIES", 37, 45], ["human", "SPECIES", 112, 117], ["bat CoV", "SPECIES", 127, 134], ["the MSA outputs", "TEST", 9, 24], ["Nsp11", "TEST", 26, 31], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["a sequence identity", "TEST", 65, 84], ["Nsp11s", "TEST", 100, 106], ["human SARS", "TEST", 112, 122], ["bat CoV", "TEST", 127, 134], ["new viruses", "PROBLEM", 177, 188], ["associated deaths around the globe", "PROBLEM", 193, 227], ["new", "OBSERVATION_MODIFIER", 177, 180], ["viruses", "OBSERVATION", 181, 188], ["globe", "ANATOMY", 222, 227]]], ["Despite its pandemic nature, there is very little information available in the public domain regarding the structures and functions of SARS-CoV-2 proteins.", [["SARS", "DISEASE", 135, 139], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["SARS-CoV-2 proteins", "PROTEIN", 135, 154], ["SARS", "TEST", 135, 139], ["CoV", "TEST", 140, 143], ["pandemic", "OBSERVATION_MODIFIER", 12, 20]]], ["Based on its similarity with human SARS CoV and bat CoV, the published reports have suggested the functions of SARS-CoV-2 proteins.", [["human", "ORGANISM", 29, 34], ["SARS CoV", "ORGANISM", 35, 43], ["bat CoV", "ORGANISM", 48, 55], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 111, 121], ["SARS-CoV-2 proteins", "PROTEIN", 111, 130], ["human", "SPECIES", 29, 34], ["human SARS CoV", "SPECIES", 29, 43], ["bat CoV", "SPECIES", 48, 55], ["human SARS CoV", "TEST", 29, 43], ["bat CoV", "TEST", 48, 55], ["SARS", "PROBLEM", 111, 115], ["CoV", "TEST", 116, 119]]], ["In this study, we utilized information available on SARS-CoV-2 genome as well as translated proteome from GenBank, and carried out a comprehensive computational analysis of the prevalence of intrinsic disorder in SARS-CoV-2 proteins.", [["intrinsic disorder", "DISEASE", 191, 209], ["SARS", "DISEASE", 213, 217], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 213, 223], ["SARS-CoV-2 genome", "DNA", 52, 69], ["SARS-CoV-2 proteins", "PROTEIN", 213, 232], ["SARS-CoV", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 213, 221], ["this study", "TEST", 3, 13], ["intrinsic disorder", "PROBLEM", 191, 209], ["SARS", "PROBLEM", 213, 217], ["CoV", "TEST", 218, 221]]], ["Additionally, a comparison is also made with proteins from close relatives of SARS-CoV-2 from the same group of beta coronaviruses, human SARS CoV and bat CoV.", [["SARS", "DISEASE", 78, 82], ["SARS-CoV-2", "ORGANISM", 78, 88], ["beta coronaviruses", "ORGANISM", 112, 130], ["human", "ORGANISM", 132, 137], ["SARS CoV", "ORGANISM", 138, 146], ["bat CoV.", "ORGANISM", 151, 159], ["human", "SPECIES", 132, 137], ["SARS-CoV", "SPECIES", 78, 86], ["beta coronaviruses", "SPECIES", 112, 130], ["human SARS CoV", "SPECIES", 132, 146], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["beta coronaviruses", "PROBLEM", 112, 130], ["human SARS CoV", "TEST", 132, 146]]], ["Our analysis revealed that in these three CoVs, the N proteins are highly disordered, possessing the PPID values of more than 60%.", [["CoVs", "GENE_OR_GENE_PRODUCT", 42, 46], ["CoVs", "PROTEIN", 42, 46], ["N proteins", "PROTEIN", 52, 62], ["PPID", "PROTEIN", 101, 105], ["Our analysis", "TEST", 0, 12], ["the N proteins", "TEST", 48, 62], ["the PPID values", "TEST", 97, 112]]], ["These viruses also have several moderately disordered proteins, such as Nsp8, ORF6, and ORF9b.", [["Nsp8", "GENE_OR_GENE_PRODUCT", 72, 76], ["ORF6", "GENE_OR_GENE_PRODUCT", 78, 82], ["ORF9b", "GENE_OR_GENE_PRODUCT", 88, 93], ["Nsp8", "PROTEIN", 72, 76], ["ORF6", "PROTEIN", 78, 82], ["ORF9b", "PROTEIN", 88, 93], ["These viruses", "PROBLEM", 0, 13], ["several moderately disordered proteins", "PROBLEM", 24, 62], ["ORF6", "TEST", 78, 82], ["viruses", "OBSERVATION", 6, 13], ["several", "OBSERVATION_MODIFIER", 24, 31], ["moderately", "OBSERVATION_MODIFIER", 32, 42], ["disordered", "OBSERVATION_MODIFIER", 43, 53], ["proteins", "OBSERVATION", 54, 62]]], ["Although other proteins have shown lower disorder content, almost all of them contain at least one IDPR.", [["disorder", "DISEASE", 41, 49], ["IDPR", "GENE_OR_GENE_PRODUCT", 99, 103], ["IDPR", "PROTEIN", 99, 103], ["lower disorder content", "PROBLEM", 35, 57], ["lower", "OBSERVATION_MODIFIER", 35, 40], ["disorder", "OBSERVATION", 41, 49]]], ["Importantly, our study provides novel information on the presence of intrinsic disorder at the cleavage sites of replicase polyprotein 1ab of SARS CoVs.", [["intrinsic disorder", "DISEASE", 69, 87], ["SARS", "DISEASE", 142, 146], ["replicase polyprotein 1", "GENE_OR_GENE_PRODUCT", 113, 136], ["cleavage sites", "DNA", 95, 109], ["replicase polyprotein 1", "PROTEIN", 113, 136], ["SARS CoVs", "PROTEIN", 142, 151], ["our study", "TEST", 13, 22], ["intrinsic disorder", "PROBLEM", 69, 87], ["replicase polyprotein", "TREATMENT", 113, 134], ["SARS CoVs", "PROBLEM", 142, 151]]], ["This observation confirms the crucial role of IDPRs in maturation of individual proteins.", [["IDPRs", "GENE_OR_GENE_PRODUCT", 46, 51], ["IDPRs", "PROTEIN", 46, 51], ["This observation", "TEST", 0, 16], ["individual proteins", "PROBLEM", 69, 88]]], ["We also established that many of these proteins contain disorder-based binding motifs.", [["disorder", "DISEASE", 56, 64], ["these proteins contain disorder", "PROBLEM", 33, 64]]], ["Since IDPs/IDPRs might undergo structural transition upon association with their physiological partners, our study generates important grounds for better understanding of the functionality of these proteins, their interactions with other viral proteins, as well as interaction with host proteins in different physiological conditions.Future perspectiveThe periodical outbreaks of pathogens worldwide always pinpoint the lack of suitable drugs or vaccines for proper cure or treatment.", [["IDPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["IDPRs", "GENE_OR_GENE_PRODUCT", 11, 16], ["IDPs", "PROTEIN", 6, 10], ["IDPRs", "PROTEIN", 11, 16], ["viral proteins", "PROTEIN", 238, 252], ["host proteins", "PROTEIN", 282, 295], ["our study", "TEST", 105, 114], ["other viral proteins", "PROBLEM", 232, 252], ["pathogens", "PROBLEM", 380, 389], ["suitable drugs", "TREATMENT", 428, 442], ["vaccines", "TREATMENT", 446, 454], ["treatment", "TREATMENT", 474, 483]]], ["In 2003, nearly 750 deaths were reported due to the SARS outbreak in more than 24 countries.", [["deaths", "DISEASE", 20, 26], ["SARS", "DISEASE", 52, 56], ["the SARS outbreak", "PROBLEM", 48, 65]]], ["But this time, the outbreak of Wuhan\u2019s novel coronavirus (SARS-CoV-2) has quickly surpassed this number, indicating more casualities soon.", [["coronavirus", "DISEASE", 45, 56], ["SARS", "DISEASE", 58, 62], ["Wuhan\u2019s novel coronavirus", "ORGANISM", 31, 56], ["SARS-CoV-2", "ORGANISM", 58, 68], ["Wuhan\u2019s novel coronavirus", "SPECIES", 31, 56]]], ["The lack of accurate information and ignorance of primary symptoms are major reasons, which cause many infection cases.", [["infection", "DISEASE", 103, 112], ["primary symptoms", "PROBLEM", 50, 66], ["many infection cases", "PROBLEM", 98, 118], ["infection", "OBSERVATION", 103, 112]]], ["Although efficient transmission from human to human has been confirmed, the actual reasons for fast SARS-CoV-2 spread are still unknown, but some assumptions are made by researchers and the Chinese authorities.", [["SARS", "DISEASE", 100, 104], ["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["fast SARS-CoV-2 spread", "PROBLEM", 95, 117]]], ["The fast spread of SARS-CoV-2, COVID-19 pandemic, and associated introduction of quarantine also have made major impacts on economy and education worldwide due to several restrictions, such as limited transportation, restrained or frozen travel, halted attendance of mass events and the introduction of distant teaching and learning.", [["SARS", "DISEASE", 19, 23], ["SARS-CoV-2", "ORGANISM", 19, 29], ["COVID-19", "ORGANISM", 31, 39], ["SARS-CoV", "SPECIES", 19, 27], ["CoV", "TEST", 24, 27], ["COVID", "TEST", 31, 36], ["mass events", "PROBLEM", 267, 278], ["distant teaching", "TREATMENT", 303, 319], ["fast", "OBSERVATION_MODIFIER", 4, 8], ["spread", "OBSERVATION_MODIFIER", 9, 15], ["mass", "OBSERVATION", 267, 271]]], ["Due to advancements in sequencing techniques, the full genomic sequence of SARS-CoV-2 was made available in a few days of the first infection report from Wuhan, China.", [["SARS", "DISEASE", 75, 79], ["infection", "DISEASE", 132, 141], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 75, 83], ["sequencing techniques", "TEST", 23, 44]]], ["However, massive subsequent research needs to be done to identify the actual cause of SARS-CoV-2 infectivity and to design suitable treatment in the future.", [["SARS", "DISEASE", 86, 90], ["CoV-2", "ORGANISM", 91, 96], ["SARS-CoV", "SPECIES", 86, 94], ["SARS", "PROBLEM", 86, 90], ["CoV-2 infectivity", "PROBLEM", 91, 108], ["suitable treatment", "TREATMENT", 123, 141], ["massive", "OBSERVATION_MODIFIER", 9, 16], ["SARS", "OBSERVATION", 86, 90]]], ["The mutational pressure study on this virus will be very interesting to see if this virus transforms from bat SARS to human SARS to SARS-CoV-2.", [["SARS", "DISEASE", 110, 114], ["SARS", "DISEASE", 124, 128], ["SARS", "DISEASE", 132, 136], ["bat SARS", "ORGANISM", 106, 114], ["human", "ORGANISM", 118, 123], ["SARS-CoV-2", "ORGANISM", 132, 142], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 118, 123], ["SARS-CoV", "SPECIES", 132, 140], ["The mutational pressure study", "TEST", 0, 29], ["this virus", "PROBLEM", 33, 43], ["this virus transforms", "TREATMENT", 79, 100], ["CoV", "TEST", 137, 140]]], ["More in-depth experimental studies using molecular and cell biology techniques to establish structure\u2013function relationships are required for a better understanding of the functioning of SARS-CoV-2 proteins.", [["cell", "ANATOMY", 55, 59], ["SARS", "DISEASE", 187, 191], ["cell", "CELL", 55, 59], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 187, 197], ["SARS-CoV-2 proteins", "PROTEIN", 187, 206], ["SARS", "PROBLEM", 187, 191], ["CoV", "TEST", 192, 195]]], ["Additionally, based on the sequence homology and information on protein\u2013protein interactions, the associated viral and host proteins should be explored, for finding means suitable for limiting replication, maturation, and ultimately pathogenesis of this virus.", [["associated viral and host proteins", "PROTEIN", 98, 132], ["protein\u2013protein interactions", "TREATMENT", 64, 92], ["the associated viral and host proteins", "PROBLEM", 94, 132], ["this virus", "PROBLEM", 249, 259]]], ["Although structural biology techniques (so-called rational drug design) can be used in drug development utilizing high-throughput screening of compounds virtually or experimentally, the applicability of these techniques is limited by the presence of intrinsic disorder in target proteins.", [["disorder", "DISEASE", 260, 268], ["target proteins", "PROTEIN", 272, 287], ["these techniques", "TEST", 203, 219], ["intrinsic disorder in target proteins", "PROBLEM", 250, 287]]], ["Therefore, the thorough disorder analysis of three coronaviruses conducted in this study will help structural biologists to rationally design experiments keeping this information in mind.", [["the thorough disorder analysis", "TEST", 11, 41], ["three coronaviruses", "PROBLEM", 45, 64], ["this study", "TEST", 78, 88]]]], "3c76b36d2ccb1855ff28c0e06b6f97316d67348a": [["BackgroundSince the emergence of the novel coronavirus disease 2019 (COVID-19), policy makers and governments have had to make important decisions around what mitigation and control measures to implement.", [["coronavirus disease", "DISEASE", 43, 62], ["coronavirus", "ORGANISM", 43, 54], ["coronavirus", "SPECIES", 43, 54], ["the novel coronavirus disease", "PROBLEM", 33, 62], ["COVID", "TEST", 69, 74], ["coronavirus disease", "OBSERVATION", 43, 62]]], ["Given initial uncertainties about the nature of the disease, responses were varied country to country.", [["the disease", "PROBLEM", 48, 59], ["disease", "OBSERVATION", 52, 59]]], ["Over time, three strategies have become recognized as the \"backbone\" of the response to COVID-19: testing, isolation and contact tracing [1] .", [["COVID-19", "CHEMICAL", 88, 96], ["COVID-19", "CHEMICAL", 88, 96], ["COVID", "TEST", 88, 93], ["testing", "TEST", 98, 105]]], ["In certain countries, these measures appear to have contributed to reductions in the incidence of COVID-19 [2] .", [["COVID-19", "CHEMICAL", 98, 106], ["COVID", "TEST", 98, 103], ["reductions", "OBSERVATION_MODIFIER", 67, 77]]], ["Many low-and middle-income countries (LMICs), however, do not have the resources nor the infrastructure to emulate such initiatives to the same extent, and yet may feel pressured to do so.", [["low", "OBSERVATION_MODIFIER", 5, 8], ["middle", "ANATOMY_MODIFIER", 13, 19]]], ["There is a need to consider the inequalities that exist, both between countries and within countries, and ensure that response strategies are appropriate to the capacity of each jurisdiction.Between-country inequalitiesThese, perhaps unrealistic, pressures have been visible in the Philippines.", [["pressures", "TEST", 247, 256], ["unrealistic", "OBSERVATION_MODIFIER", 234, 245], ["pressures", "OBSERVATION_MODIFIER", 247, 256], ["visible", "OBSERVATION_MODIFIER", 267, 274]]], ["Initially, the government responded by enforcing strict home quarantines and a lockdown on business and transportation in regions with significant COVID-19 cases.", [["significant COVID", "TEST", 135, 152]]], ["More recently, the focus has turned towards scaling-up national capacities for mass testing, with the expectation that the Philippines should follow in the example of other Asian countries.", [["mass testing", "TEST", 79, 91]]], ["Researchers in the Philippines have commended Singapore and South Korea's successful suppression of the reductive number by increased testing and contact tracing [3] .", [["increased testing", "TEST", 124, 141]]], ["In another report by the University of Philippines, authors made recommendations to expand nationwide testing capabilities to a capacity similar to that of South Korea [4] but it is difficult to see how this would be feasible in the Philippines.", [["a capacity", "PROBLEM", 126, 136]]], ["Beyond the procurement of COVID-19 test kits, mass testing would require substantial investment in equipment, lab facilities, and manpower.", [["COVID", "TEST", 26, 31], ["test kits", "TEST", 35, 44], ["mass testing", "TEST", 46, 58]]], ["Although the Philippines has been able to gradually expand testing capacity, with only 10 tests conducted per 100,000 population on June 16, 2020, compared to 27 tests per 100,000 population in South Korea on the same day (Fig. 1a) , it is evident that the two countries are on different playing fields.", [["testing capacity", "TEST", 59, 75]]], ["Local government units (LGUs) have been expected to enforce measures that are consistent with those in the National Capital Region (NCR), but the geographical, social and economic landscape from which these directives originate often differ from the rural communities in which they are meant to be implemented.", [["consistent with", "UNCERTAINTY", 78, 93], ["Capital", "ANATOMY_MODIFIER", 116, 123]]], ["While 12% of the nation's population lives within NCR, the region accounts for 36% of the total GDP [8] .", [["GDP", "CHEMICAL", 96, 99], ["GDP", "CHEMICAL", 96, 99], ["GDP", "SIMPLE_CHEMICAL", 96, 99], ["NCR", "DNA", 50, 53], ["the total GDP", "TEST", 86, 99]]], ["Just as the Philippines lacks the resources and infrastructure to match South Korea's COVID-19 response, regions outside of NCR likewise do not have the resources to replicate the proposed ambition of mass testing in the capital region.", [["NCR", "DNA", 124, 127], ["South Korea's COVID", "TEST", 72, 91], ["mass testing", "TEST", 201, 213], ["mass", "OBSERVATION", 201, 205], ["capital", "ANATOMY_MODIFIER", 221, 228], ["region", "ANATOMY_MODIFIER", 229, 235]]], ["Between April 3 and June 16, 2020, 75.5% of all COVID-19 tests were conducted in NCR, and Fig. 1b compares the daily number of tests per 100,000 population that were conducted by location.", [["all COVID-19 tests", "TEST", 44, 62], ["tests", "TEST", 127, 132]]], ["We note that before regions were assigned COVID-19 labs within a 'zoning area' on April 23 [9] , all specimens were tested in NCR, even if they originated from individuals elsewhere.", [["specimens", "ANATOMY", 101, 110], ["specimens", "CANCER", 101, 110], ["COVID", "TEST", 42, 47], ["labs", "TEST", 51, 55], ["all specimens", "TEST", 97, 110]]], ["However, the gap in testing capacity has since continued to widen, and the difference in number of tests conducted daily per 100,000 population is now almost tenfold.Within-country inequalitiesAnother pressing challenge in light of these inequalities are the other health issues that will persist, if not be exacerbated by this public health emergency [10] .", [["the gap in testing capacity", "TEST", 9, 36], ["tests", "TEST", 99, 104], ["Another pressing challenge", "TREATMENT", 193, 219]]], ["The expansion in testing capacity achieved within NCR has been resource intensive, facilitated by public and private sector investment.", [["The expansion in testing capacity", "TEST", 0, 33], ["expansion", "OBSERVATION_MODIFIER", 4, 13]]], ["However, given persisting resource limitations, many tuberculosis (TB) testing facilities have been reconfigured for COVID-19 testing in order to meet demands [11] .", [["tuberculosis", "DISEASE", 53, 65], ["TB", "DISEASE", 67, 69], ["many tuberculosis", "PROBLEM", 48, 65], ["COVID", "TEST", 117, 122], ["many", "OBSERVATION_MODIFIER", 48, 52], ["tuberculosis", "OBSERVATION", 53, 65]]], ["These facilities were already limited in regions outside of NCR, but due to resource disparities and the pressure to keep up with the capital region,Within-country inequalitiesLGUs have implemented COVID-19 control strategies at the expense of other disease control initiatives.", [["resource disparities", "PROBLEM", 76, 96], ["the pressure", "TEST", 101, 113], ["COVID", "TEST", 198, 203], ["other disease control initiatives", "TREATMENT", 244, 277], ["capital", "ANATOMY_MODIFIER", 134, 141]]], ["If the repercussions of ineffective responses could be compounded by unintended harms, it is imperative that due consideration is given to whatWithin-country inequalitiesLGUs are capable of doing given local resource constraints.ConclusionsIn an analysis of the challenges the Philippines has faced raising testing capacity [12] , we agree with the authors' appeals for the integrity of testing to be upheld despite pressures to rapidly scale up.", [["ineffective responses", "PROBLEM", 24, 45], ["testing", "TEST", 387, 394], ["pressures", "TREATMENT", 416, 425]]], ["Increasing testing capacity without compromising quality, however, requires technical capacity and significant resources.", [["Increasing testing capacity", "PROBLEM", 0, 27]]], ["While there has been increasing recognition that COVID-19 response strategies need to be contextspecific, discussions have primarily been focused on the national level, while differences within the country have tended to be overlooked.", [["COVID", "TEST", 49, 54], ["increasing", "OBSERVATION_MODIFIER", 21, 31]]], ["The global health community must be sensitive to both between and within-country inequalities as formal guidance for low-resource contexts are developed.ConclusionsNational and local governments have been under immense pressure to act and contain the virus, but inappropriately copying approaches could create more unintended harm than good.", [["the virus", "PROBLEM", 247, 256], ["global", "OBSERVATION_MODIFIER", 4, 10]]], ["We have highlighted the observed and anticipated disparities in COVID-19 testing, but other aspects of COVID-19 responses also warrant further exploration.", [["COVID", "TEST", 64, 69], ["COVID", "TEST", 103, 108], ["further exploration", "TEST", 135, 154]]], ["While the fight against COVID-19 is far from over, we need to appreciate between-and withincountry inequalities to formulate appropriate, rather than reactionary, pandemic management strategies.", [["COVID", "TEST", 24, 29], ["pandemic management strategies", "TREATMENT", 163, 193]]]], "59f12f57fb6dee2b0514b51f9ec7582b07bafbae": [["cross-reaction of IBV RT-LAMP was found when tested with other viruses including Newcastle disease virus (NDV), avian reovirus (ARV), and infectious laryngotrachietis virus (ILTV) due to their mismatch with IBV RT-LAMP primers.", [["Newcastle disease", "DISEASE", 81, 98], ["infectious laryngotrachietis virus", "DISEASE", 138, 172], ["IBV", "ORGANISM", 18, 21], ["Newcastle disease virus", "ORGANISM", 81, 104], ["NDV", "ORGANISM", 106, 109], ["avian reovirus", "ORGANISM", 112, 126], ["infectious laryngotrachietis virus", "ORGANISM", 138, 172], ["ILTV", "CANCER", 174, 178], ["IBV", "ORGANISM", 207, 210], ["IBV RT-LAMP primers", "DNA", 207, 226], ["Newcastle disease virus", "SPECIES", 81, 104], ["NDV", "SPECIES", 106, 109], ["avian reovirus", "SPECIES", 112, 126], ["infectious laryngotrachietis virus", "SPECIES", 138, 172], ["IBV", "SPECIES", 18, 21], ["Newcastle disease virus", "SPECIES", 81, 104], ["NDV", "SPECIES", 106, 109], ["ARV", "SPECIES", 128, 131], ["infectious laryngotrachietis virus", "SPECIES", 138, 172], ["ILTV", "SPECIES", 174, 178], ["IBV", "SPECIES", 207, 210], ["IBV RT", "TREATMENT", 18, 24], ["LAMP", "PROBLEM", 25, 29], ["other viruses", "PROBLEM", 57, 70], ["Newcastle disease virus", "PROBLEM", 81, 104], ["NDV", "PROBLEM", 106, 109], ["avian reovirus (ARV)", "PROBLEM", 112, 132], ["infectious laryngotrachietis virus", "PROBLEM", 138, 172], ["their mismatch", "PROBLEM", 187, 201], ["IBV RT", "TREATMENT", 207, 213], ["LAMP primers", "TREATMENT", 214, 226], ["IBV", "OBSERVATION", 18, 21], ["infectious", "OBSERVATION_MODIFIER", 138, 148]]], ["A total of 187 clinical tissues samples (88 blood, 62 kidney and 37 lung) were evaluated and compared to conventional RT-PCR.", [["tissues samples", "ANATOMY", 24, 39], ["blood", "ANATOMY", 44, 49], ["kidney", "ANATOMY", 54, 60], ["lung", "ANATOMY", 68, 72], ["tissues samples", "CANCER", 24, 39], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["kidney", "ORGAN", 54, 60], ["lung", "ORGAN", 68, 72], ["clinical tissues samples", "TEST", 15, 39], ["blood", "TEST", 44, 49], ["kidney", "TEST", 54, 60], ["conventional RT-PCR", "TEST", 105, 124], ["kidney", "ANATOMY", 54, 60], ["lung", "ANATOMY", 68, 72]]], ["The sensitivity of RT-LAMP and RT-PCR assays for detecting IBV RNA in clinical specimens was 99.5% and 98.4%, respectively.", [["specimens", "ANATOMY", 79, 88], ["IBV", "ORGANISM", 59, 62], ["IBV RNA", "RNA", 59, 66], ["IBV", "SPECIES", 59, 62], ["RT-LAMP", "TEST", 19, 26], ["RT-PCR assays", "TEST", 31, 44], ["IBV RNA", "TEST", 59, 66], ["clinical specimens", "TEST", 70, 88]]], ["These findings showed that the RT-LAMP assay has potential usefulness for rapid and sensitive diagnosis in outbreak of IBV.", [["IBV", "ORGANISM", 119, 122], ["IBV", "SPECIES", 119, 122], ["the RT-LAMP assay", "TEST", 27, 44], ["IBV", "PROBLEM", 119, 122]]]], "02dd647a66cfcd271b399c04b3d8f99cd8360d81": [["IntroductionWith the rising popularity of information access through devices with small screens, e.g., smartphones, and voice-only interfaces, e.g., Amazon's Alexa and Google Home, there is a growing need to develop retrieval models that satisfy user information needs with sentence-level and passage-level answers.", [["small screens", "TEST", 82, 95], ["smartphones", "TEST", 103, 114], ["retrieval models", "TREATMENT", 216, 232]]], ["This has motivated researchers to study answer sentence and passage retrieval, in particular in response to non-factoid questions [1, 18] .", [["passage retrieval", "TREATMENT", 60, 77]]], ["Some existing collections, e.g., [8, 13] , consist of few queries, which are not sufficient to train sophisticated machine learning models for the task.", [["Some existing collections", "PROBLEM", 0, 25], ["collections", "OBSERVATION", 14, 25]]], ["Most recently, Cohen et al. [3] developed a publicly available collection for non-factoid question answering with a few thousands questions, which is called WikiPassageQA.", [["a publicly available collection", "PROBLEM", 42, 73]]], ["Although WikiPassageQA is an invaluable contribution to the community, it does not cover all aspects of the non-factoid question answering task and has the following limitations: (i) it only contains an average of 1.7 relevant passages per question and does not cover many questions with multiple correct answers; (ii) it was created from the Wikipedia website, containing only formal text; (iii) more importantly, the questions in the WikiPassageQA dataset were generated by crowdworkers, which is different from the questions that users ask in real-world systems; (iv) the relevant passages in WikiPassageQA contain the answer to the question in addition to some surrounding text.", [["WikiPassageQA", "CHEMICAL", 9, 22], ["WikiPassageQA dataset", "DNA", 436, 457]]], ["Non-factoid CQA data without relevance annotation has been previously used in [1] , however, as mentioned by the authors, it significantly suffers from incomplete judgments (see Sect.", [["CQA", "DNA", 12, 15], ["Non-factoid CQA data", "TEST", 0, 20]]], ["2 for more information on existing collections).", [["collections", "OBSERVATION", 35, 46]]], ["We collected four-level relevance labels through a careful crowdsourcing procedure involving multiple iterations and several automatic and manual quality checks.", [["a careful crowdsourcing procedure", "TREATMENT", 49, 82], ["multiple iterations", "TREATMENT", 93, 112], ["manual quality checks", "TEST", 139, 160]]], ["Note that we paid extra attention to collect reliable and comprehensive relevance judgments for the test set.", [["the test set", "TEST", 96, 108]]], ["Therefore, we annotated the answers after conducting result pooling among several term-matching and neural retrieval models.", [["neural", "ANATOMY", 100, 106], ["several term-matching and neural retrieval models", "TREATMENT", 74, 123]]], ["In summary, ANTIQUE provides annotations for 34,011 question-answer pairs, which is significantly larger than many comparable datasets.IntroductionWe further provide brief analysis to uncover the characteristics of ANTIQUE.", [["ANTIQUE", "DNA", 12, 19], ["ANTIQUE", "DNA", 215, 222], ["brief analysis", "TEST", 166, 180]]], ["Moreover, we conduct extensive experiments with ANTIQUE to present benchmark results of various methods, including classical and neural IR models on the created dataset, demonstrating the unique challenges ANTIQUE introduces to the community.", [["neural", "ANATOMY", 129, 135], ["various methods", "TREATMENT", 88, 103]]], ["1Existing Related CollectionsFactoid QA Datasets.", [["CollectionsFactoid", "OBSERVATION_MODIFIER", 18, 36], ["QA Datasets", "OBSERVATION", 37, 48]]], ["TREC QA [14] and WikiQA [17] are examples of factoid QA datasets whose answers are typically brief and concise facts, such as named entities and numbers.", [["factoid QA datasets", "PROBLEM", 45, 64]]], ["The answers to these questions are often passage level, which is contrary to the factoid QA datasets.Existing Related CollectionsNon-factoid QA Datasets.", [["Existing Related Collections", "PROBLEM", 101, 129], ["Collections", "OBSERVATION_MODIFIER", 118, 129], ["Non-factoid", "OBSERVATION_MODIFIER", 129, 140], ["QA Datasets", "OBSERVATION", 141, 152]]], ["Keikha et al. [8] introduced the WebAP dataset, which is a non-factoid QA dataset with 82 queries.", [["WebAP dataset", "DNA", 33, 46]]], ["Webscope L6, Qatar Living [9] , and StackExchange.", [["L6", "ANATOMY", 9, 11]]], ["Webscope L6.", [["L6", "ANATOMY", 9, 11]]], ["Its main drawback is the absence of complete relevance annotation.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["WikiPassageQA is another non-factoid QA dataset that has been recently created by Cohen et al. [3] .", [["WikiPassageQA", "CHEMICAL", 0, 13]]], ["1, despite its great potentials, it has a number of limitations.", [["great potentials", "OBSERVATION_MODIFIER", 15, 31]]], ["More recently, Microsoft has released the MS MARCO V2.1 passage re-ranking dataset [10] , containing a large number of queries sampled from the Bing search engine.", [["large", "OBSERVATION_MODIFIER", 103, 108]]], ["In contrast, ANTIQUE provides a reliable collection with complete relevance annotations for evaluating non-factoid QA models.Data CollectionFollowing Cohen et al. [1] , we used the publicly available dataset of non-factoid questions collected from the Yahoo!", [["ANTIQUE", "PROTEIN", 13, 20]]], ["Webscope L6, called nfL6.", [["nfL6", "GENE_OR_GENE_PRODUCT", 20, 24], ["nfL6", "DNA", 20, 24], ["L6", "ANATOMY", 9, 11]]], ["Products\" and \"Computers & Internet\" since they are beyond the expertise of most workers; (v) From the remaining data, we randomly sampled 2,626 questions (out of 66,634).Data CollectionEach question q in nfL6 corresponds to a list of answers named 'nbest answers', which we denote with A = {a 1 , . . . , a n }.", [["nfL6", "DNA", 205, 209]]], ["For every question, one answer is marked by the question author on the community web site as the best answer, denoted by\u00e2.", [["marked", "OBSERVATION_MODIFIER", 34, 40]]], ["It is important to note that as different people have different information needs, this answer is not necessarily the best answer to the question.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48]]], ["Therefore, we do not collect relevance assessments for those answers.Relevance AssessmentWe created a Human Intelligence Task (HIT) on Amazon Mechanical Turk, in which we presented workers with a question-answer pair, and instructed them to annotate the answer with a label between 1 to 4.", [["HIT", "DISEASE", 127, 130], ["Human", "ORGANISM", 102, 107], ["Human", "SPECIES", 102, 107], ["relevance assessments", "TEST", 29, 50], ["Amazon Mechanical Turk", "TREATMENT", 135, 157]]], ["To facilitate the labeling procedure, we described labels in the form of a flowchart to users.", [["the labeling procedure", "TREATMENT", 14, 36]]], ["Our aim was to preserve the notion of relevance in QA systems as we discriminate it with the typical topical relevance definition in ad-hoc retrieval tasks.", [["QA systems", "TEST", 51, 61]]], ["In cases where the workers could agree on a label (i.e., majority vote), we considered the label as the ground truth.", [["ground truth", "OBSERVATION", 104, 116]]], ["To allow further analysis, we have added a flag in the dataset identifying the answers annotated by the expert annotator.", [["further analysis", "TEST", 9, 25]]], ["In total, the annotation task costed 2,400 USD.Quality Check.To ensure the quality of the data, we limited the HIT to the workers with over 98% approval rate, who have completed at least 5,000 assignments.", [["HIT", "DISEASE", 111, 114], ["Quality Check", "TEST", 47, 60]]], ["Moreover, we recorded the click log of the workers to detect any abnormal behavior (e.g., employing automatic labeling scripts) that would affect the quality of the data.", [["any abnormal behavior", "PROBLEM", 61, 82]]], ["Finally, we constantly performed manual quality checks by reading the QA pairs and their respective labels.", [["QA pairs", "DNA", 70, 78], ["manual quality checks", "TEST", 33, 54]]], ["The manual inspection was done on the 20% of each worker's submission as well as the QA pairs with no agreement.Quality Check.Training Set.", [["The manual inspection", "TEST", 0, 21], ["Quality Check", "TEST", 112, 125]]], ["To test this assumption, we sampled 100 questions from the filtered version of nfL6 and annotated the top 10 results retrieved by BM25 using the same crowdsourcing procedure.", [["nfL6", "DNA", 79, 83], ["nfL6", "TREATMENT", 79, 83], ["the same crowdsourcing procedure", "TREATMENT", 141, 173]]], ["This error rate can be tolerated in the training process as it enables us to collect significantly larger amount of training labels.", [["the training process", "TREATMENT", 36, 56], ["larger", "OBSERVATION_MODIFIER", 99, 105], ["amount", "OBSERVATION_MODIFIER", 106, 112]]], ["On the other hand, for the test set we performed pooling to label all possibly relevant answers.", [["the test set", "TEST", 23, 35]]], ["In total, the ANTIQUE's training set contains 27,422 answer annotations as it shown in Table 1 , that is 11.3 annotated candidate answers per training question, which is significantly larger than its similar datasets, e.g., WikiPassageQA [3] .Quality Check.Test Set.", [["ANTIQUE", "DNA", 14, 21], ["the ANTIQUE's training", "TREATMENT", 10, 32], ["Quality Check", "TEST", 243, 256], ["significantly", "OBSERVATION_MODIFIER", 170, 183], ["larger", "OBSERVATION_MODIFIER", 184, 190]]], ["The test set in ANTIQUE consists of 200 questions which were randomly sampled from nfL6 after pre-processing and filtering.", [["ANTIQUE", "DNA", 16, 23], ["nfL6", "DNA", 83, 87], ["The test", "TEST", 0, 8]]], ["Statistics of the test set can be found in Table 1 .", [["the test set", "TEST", 14, 26]]], ["The set of candidate questions for annotation was selected by performing depth-k (k = 10) pooling.", [["k", "TEST", 82, 83]]], ["To do so, we considered the union of the top k results of various retrieval models, including term-matching and neural models (listed in Table 2 ).", [["neural", "ANATOMY", 112, 118], ["various retrieval models", "TREATMENT", 58, 82]]], ["Here, we present a brief analysis of ANTIQUE to highlight its characteristics.", [["ANTIQUE", "DNA", 37, 44], ["a brief analysis", "TEST", 17, 33]]], ["As we see, ANTIQUE consists of 2,426 non-factoid questions that can be used for training, followed by 200 questions as a test set.", [["a test set", "TEST", 119, 129]]], ["Furthermore, ANTIQUE contains 27.4k and 6.5k annotations (judged answers) for the train and test sets, respectively.", [["ANTIQUE", "DNA", 13, 20], ["ANTIQUE", "TEST", 13, 20], ["k", "TEST", 34, 35], ["k annotations", "TEST", 43, 56], ["the train and test sets", "TEST", 78, 101]]], ["We also report the total number of answers with specific labels.Statistics of ANTIQUE.Workers Performance.", [["ANTIQUE", "DNA", 78, 85]]], ["Overall, we launched 7 crowdsourcing batches to collect ANTIQUE.", [["ANTIQUE", "PROTEIN", 56, 63]]], ["As reported in Table 1 , a total number of 577 workers made over 148k annotations (257 per worker), out of which we rejected 12% because they failed to satisfy the quality criteria.Statistics of ANTIQUE.Questions Distribution.", [["ANTIQUE", "DNA", 195, 202]]], ["It is notable that, according to Fig. 1 , a considerable number of questions start with \"how do you,\" \"how can you,\" \"what do you,\" and \"why do you,\" suggesting that their corresponding answers would be highly subjective and opinion based.", [["notable", "OBSERVATION_MODIFIER", 6, 13]]], ["The distribution, however, has a long tail which is not shown in the figure.Benchmark ResultsIn this section, we provide benchmark results on the ANTIQUE dataset.", [["ANTIQUE dataset", "DNA", 146, 161], ["a long tail", "PROBLEM", 31, 42], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["long tail", "OBSERVATION_MODIFIER", 33, 42], ["not shown", "UNCERTAINTY", 52, 61]]], ["We report the results for a wide range of retrieval models in Table 2 .", [["a wide range of retrieval models", "TREATMENT", 26, 58]]], ["Note that for the metrics that require binary labels (i.e., MAP, MRR, and P@k), we assume that the labels 3 and 4 are relevant, while 1 and 2 are non-relevant.", [["MAP", "PROTEIN", 60, 63], ["MAP", "TEST", 60, 63], ["MRR", "TEST", 65, 68]]], ["As shown in the table, the neural models significantly outperform BM25, an effective term-matching retrieval model.", [["neural", "ANATOMY", 27, 33], ["BM25", "CELL_LINE", 66, 70], ["an effective term-matching retrieval model", "TREATMENT", 72, 114]]], ["Recent work on passage retrieval also made similar observations [11, 12] .", [["passage retrieval", "TREATMENT", 15, 32]]], ["Since MAP is a recall-oriented metric, the results suggest that all the models still fail at retrieving all relevant answers.", [["MAP", "GENE_OR_GENE_PRODUCT", 6, 9], ["MAP", "TEST", 6, 9]]], ["There is still a large room for improvement, in terms of both precision-and recall-oriented metrics.ConclusionsThis paper introduced ANTIQUE; a non-factoid question answering dataset.", [["ANTIQUE", "DNA", 133, 140], ["large", "OBSERVATION_MODIFIER", 17, 22]]], ["We collected four-level relevance annotations through a multi-stage crowdsourcing as well as expert annotation.", [["a multi-stage crowdsourcing", "TREATMENT", 54, 81]]], ["In summary, ANTIQUE consists of 34,011 QA-pair relevance annotations for 2,426 and 200 questions in the training and test sets, respectively.", [["ANTIQUE", "DNA", 12, 19]]], ["Additionally, we reported the benchmark results for a set of retrieval models, ranging from term-matching to recent neural ranking models, on ANTIQUE.", [["neural", "ANATOMY", 116, 122], ["retrieval models", "TEST", 61, 77], ["neural ranking models", "OBSERVATION", 116, 137]]], ["Our data analysis and retrieval experiments demonstrated that ANTIQUE introduces unique challenges while fostering research for non-factoid question answering.", [["Our data analysis", "TEST", 0, 17], ["retrieval experiments", "TEST", 22, 43]]]], "PMC7459973": [["IntroductionMore than 100 years past the catastrophic 1918 Spanish influenza pandemic, influenza viruses remain a constant global health threat.", [["influenza pandemic", "DISEASE", 67, 85], ["influenza viruses", "DISEASE", 87, 104], ["influenza viruses", "ORGANISM", 87, 104], ["influenza viruses", "PROBLEM", 87, 104]]], ["Three types of influenza viruses infect humans: type A (influenza A virus, IAV), type B (IBV) and type C (ICV).", [["influenza viruses", "DISEASE", 15, 32], ["influenza A virus, IAV), type B (IBV) and type C", "DISEASE", 56, 104], ["influenza viruses", "ORGANISM", 15, 32], ["humans", "ORGANISM", 40, 46], ["type A (", "ORGANISM", 48, 56], ["influenza A virus", "ORGANISM", 56, 73], ["IAV", "ORGANISM", 75, 78], ["type B (IBV", "ORGANISM", 81, 92], ["type C", "ORGANISM", 98, 104], ["humans", "SPECIES", 40, 46], ["influenza A virus", "SPECIES", 56, 73], ["humans", "SPECIES", 40, 46], ["type A (influenza A virus", "SPECIES", 48, 73], ["IAV", "SPECIES", 75, 78], ["IBV", "SPECIES", 89, 92], ["influenza viruses infect", "PROBLEM", 15, 39], ["type A (influenza A virus", "PROBLEM", 48, 73], ["type B (IBV", "TREATMENT", 81, 92], ["type C (ICV)", "PROBLEM", 98, 110], ["influenza viruses", "OBSERVATION", 15, 32]]], ["Two IAV subtypes (H3N2 and H1N1pdm09) and two IBV lineages (Yamagata and Victoria) co-circulate annually, causing seasonal epidemics and up to 650,000 respiratory deaths globally, while ICV is detected less frequently and usually causes mild infections (Krammer et al.2018; WHO 2018).", [["respiratory deaths", "DISEASE", 151, 169], ["ICV", "CHEMICAL", 186, 189], ["infections", "DISEASE", 242, 252], ["H3N2", "ORGANISM", 18, 22], ["H1N1pdm09", "CANCER", 27, 36], ["IBV", "ORGANISM", 46, 49], ["IBV", "SPECIES", 46, 49], ["Two IAV subtypes", "PROBLEM", 0, 16], ["H3N2 and H1N1pdm09", "TREATMENT", 18, 36], ["two IBV lineages", "PROBLEM", 42, 58], ["seasonal epidemics", "PROBLEM", 114, 132], ["mild infections", "PROBLEM", 237, 252], ["IAV", "OBSERVATION", 4, 7], ["seasonal epidemics", "OBSERVATION", 114, 132], ["mild", "OBSERVATION_MODIFIER", 237, 241], ["infections", "OBSERVATION", 242, 252]]], ["In addition, antigenically novel IAVs generated by reassortment of the segmented genome can occasionally infect humans with high rates of morbidity and mortality, as well as potential pandemic risk (Krammer et al.2018; WHO 2018).IntroductionVaccines provide cost-effective protection against influenza.", [["pandemic", "DISEASE", 184, 192], ["influenza", "DISEASE", 292, 301], ["IAVs", "GENE_OR_GENE_PRODUCT", 33, 37], ["humans", "ORGANISM", 112, 118], ["IAVs", "PROTEIN", 33, 37], ["humans", "SPECIES", 112, 118], ["humans", "SPECIES", 112, 118], ["antigenically novel IAVs", "PROBLEM", 13, 37], ["IntroductionVaccines", "TREATMENT", 229, 249], ["cost-effective protection", "TREATMENT", 258, 283], ["influenza", "PROBLEM", 292, 301], ["IAVs", "OBSERVATION", 33, 37]]], ["Currently, seasonal influenza virus vaccines predominantly induce antibody responses against the hemagglutinin (HA), one of the two major surface glycoproteins of the virus (Krammer 2019).", [["surface", "ANATOMY", 138, 145], ["seasonal influenza virus", "ORGANISM", 11, 35], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 97, 110], ["HA", "GENE_OR_GENE_PRODUCT", 112, 114], ["hemagglutinin", "PROTEIN", 97, 110], ["HA", "PROTEIN", 112, 114], ["major surface glycoproteins", "PROTEIN", 132, 159], ["seasonal influenza virus", "SPECIES", 11, 35], ["seasonal influenza virus", "SPECIES", 11, 35], ["seasonal influenza virus vaccines", "TREATMENT", 11, 44], ["antibody responses", "TEST", 66, 84], ["the hemagglutinin (HA)", "PROBLEM", 93, 115], ["influenza virus", "OBSERVATION", 20, 35]]], ["However, the majority of vaccine-induced antibodies are directed against the highly plastic head region of HA and are strain-specific (Caton et al.1982; Heaton et al.2013).", [["head region", "ANATOMY", 92, 103], ["head", "ORGAN", 92, 96], ["HA", "GENE_OR_GENE_PRODUCT", 107, 109], ["vaccine-induced antibodies", "PROTEIN", 25, 51], ["vaccine-induced antibodies", "TREATMENT", 25, 51], ["HA", "PROBLEM", 107, 109], ["strain", "PROBLEM", 118, 124], ["highly", "OBSERVATION_MODIFIER", 77, 83], ["plastic", "OBSERVATION", 84, 91], ["head", "ANATOMY", 92, 96]]], ["Amino acid residues on the surface of this immunodominant head region vary substantially among different strains and change continuously (referred to as antigenic drift), leading to new circulating virus strains (Wang and Palese 2011).", [["surface", "ANATOMY", 27, 34], ["head region", "ANATOMY", 58, 69], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["surface", "CELLULAR_COMPONENT", 27, 34], ["Amino acid residues", "PROBLEM", 0, 19], ["this immunodominant head region", "PROBLEM", 38, 69], ["different strains", "PROBLEM", 95, 112], ["new circulating virus strains", "PROBLEM", 182, 211], ["acid residues", "OBSERVATION", 6, 19], ["immunodominant", "ANATOMY_MODIFIER", 43, 57], ["head", "ANATOMY", 58, 62], ["region", "ANATOMY_MODIFIER", 63, 69], ["different strains", "OBSERVATION", 95, 112]]], ["Therefore, current influenza vaccines have to be reformulated each year based on surveillance and prediction, which is cumbersome, and their effectiveness is highly variable depending on the accurate forecasts of the circulating strains in each year (de Jong et al.2000; Gerdil 2003).", [["current influenza vaccines", "TREATMENT", 11, 37], ["surveillance", "TEST", 81, 93]]], ["Moreover, the protection conferred by seasonal influenza vaccines does not cover emerging pandemic influenza virus strains.IntroductionThese limitations of current vaccines emphasize the need to develop novel \u201cuniversal\u201d or \u201cbroadly protective\u201d influenza vaccines.", [["influenza", "DISEASE", 99, 108], ["influenza virus", "ORGANISM", 99, 114], ["pandemic influenza virus", "SPECIES", 90, 114], ["the protection", "TREATMENT", 10, 24], ["seasonal influenza vaccines", "TREATMENT", 38, 65], ["emerging pandemic influenza virus strains", "PROBLEM", 81, 122], ["current vaccines", "TREATMENT", 156, 172], ["influenza vaccines", "TREATMENT", 245, 263]]], ["An ideal universal vaccine should cover all influenza A and influenza B viruses independent of antigenic drift or HA/neuraminidase (NA) subtype.", [["influenza B", "DISEASE", 60, 71], ["NA", "CHEMICAL", 132, 134], ["influenza A", "ORGANISM", 44, 55], ["influenza B viruses", "ORGANISM", 60, 79], ["neuraminidase (NA) subtype", "PROTEIN", 117, 143], ["influenza A", "SPECIES", 44, 55], ["An ideal universal vaccine", "TREATMENT", 0, 26], ["all influenza A", "PROBLEM", 40, 55], ["influenza B viruses", "PROBLEM", 60, 79], ["antigenic drift", "PROBLEM", 95, 110], ["HA", "PROBLEM", 114, 116], ["neuraminidase (NA) subtype", "PROBLEM", 117, 143]]], ["In contrast, a broadly protective vaccine would cover a large subset of influenza viruses, for example, all human seasonal influenza virus strains.", [["influenza viruses", "DISEASE", 72, 89], ["influenza virus", "DISEASE", 123, 138], ["influenza viruses", "ORGANISM", 72, 89], ["human", "ORGANISM", 108, 113], ["seasonal influenza virus", "ORGANISM", 114, 138], ["human", "SPECIES", 108, 113], ["seasonal influenza virus", "SPECIES", 114, 138], ["human seasonal influenza virus", "SPECIES", 108, 138], ["a broadly protective vaccine", "TREATMENT", 13, 41], ["influenza viruses", "PROBLEM", 72, 89], ["all human seasonal influenza virus strains", "PROBLEM", 104, 146], ["large", "OBSERVATION_MODIFIER", 56, 61], ["influenza viruses", "OBSERVATION", 72, 89]]], ["These two types of vaccines are generally referred to as \u201cuniversal vaccines\u201d (Memoli et al.2019).IntroductionMost universal vaccines in development aim at inducing broadly protective antibody responses, while some others focus on inducing T cell responses alternatively (Nachbagauer and Krammer 2017).", [["T cell", "ANATOMY", 240, 246], ["T cell", "CELL", 240, 246], ["vaccines", "TREATMENT", 19, 27], ["universal vaccines", "TREATMENT", 58, 76], ["IntroductionMost universal vaccines", "TREATMENT", 98, 133]]], ["In either case, the conserved immunogens of the virus need to be targeted, and the mechanism of protection mainly depends on the immunogens of choice (Nachbagauer and Krammer 2017; Asthagiri Arunkumar et al.2019).", [["the virus", "PROBLEM", 44, 53]]], ["This review will discuss the conserved antigenic regions/epitopes of influenza viruses that can facilitate immunogen design and contribute to the development of universal influenza vaccines.Hemagglutinin ::: Surface Proteins and Antibody ResponsesHA is assembled as homotrimers consisting of two domains, the membrane-distal globular head domain and the membrane-proximal helix-rich stalk domain (Fig. 1B).", [["membrane", "ANATOMY", 309, 317], ["membrane", "ANATOMY", 354, 362], ["influenza viruses", "DISEASE", 69, 86], ["Hemagglutinin", "CHEMICAL", 190, 203], ["influenza viruses", "ORGANISM", 69, 86], ["Hemagglutinin", "SIMPLE_CHEMICAL", 190, 203], ["Antibody ResponsesHA", "GENE_OR_GENE_PRODUCT", 229, 249], ["membrane", "CELLULAR_COMPONENT", 309, 317], ["membrane", "CELLULAR_COMPONENT", 354, 362], ["epitopes", "PROTEIN", 57, 65], ["Antibody ResponsesHA", "PROTEIN", 229, 249], ["homotrimers", "PROTEIN", 266, 277], ["membrane-distal globular head domain", "PROTEIN", 309, 345], ["membrane-proximal helix-rich stalk domain", "PROTEIN", 354, 395], ["Fig. 1B", "PROTEIN", 397, 404], ["influenza viruses", "PROBLEM", 69, 86], ["immunogen design", "TREATMENT", 107, 123], ["universal influenza vaccines", "TREATMENT", 161, 189], ["Hemagglutinin", "TREATMENT", 190, 203], ["Surface Proteins", "TEST", 208, 224], ["Antibody", "TEST", 229, 237], ["homotrimers", "TEST", 266, 277], ["the membrane", "TEST", 305, 317], ["influenza viruses", "OBSERVATION", 69, 86], ["Antibody ResponsesHA", "OBSERVATION", 229, 249], ["distal", "ANATOMY_MODIFIER", 318, 324], ["globular", "ANATOMY_MODIFIER", 325, 333], ["head", "ANATOMY", 334, 338], ["proximal", "ANATOMY_MODIFIER", 363, 371], ["helix", "ANATOMY_MODIFIER", 372, 377]]], ["Based on the antigenicity, HA can be divided into 18 subtypes, which fall into 2 groups, including group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, H18) and group 2 (H3, H4, H7, H10, H14, H15) (Du et al.2019).", [["HA", "GENE_OR_GENE_PRODUCT", 27, 29], ["H2, H5, H6, H8", "ORGANISM", 112, 126], ["H9", "ORGANISM", 128, 130], ["H11, H12, H13, H16, H17, H18", "ORGANISM", 132, 160], ["H4", "GENE_OR_GENE_PRODUCT", 179, 181], ["H7", "ORGANISM", 183, 185], ["H14", "ORGANISM", 192, 195], ["H3", "PROTEIN", 175, 177], ["H4", "PROTEIN", 179, 181], ["HA", "PROBLEM", 27, 29], ["H12", "TEST", 137, 140], ["H13", "TEST", 142, 145], ["H16", "TEST", 147, 150], ["H17", "TEST", 152, 155], ["group", "TEST", 166, 171], ["H3", "TEST", 175, 177], ["H4", "TEST", 179, 181], ["H7", "TEST", 183, 185], ["H10", "TEST", 187, 190], ["H14", "TEST", 192, 195], ["H15", "TEST", 197, 200], ["Du et al", "TEST", 203, 211], ["H10", "ANATOMY", 187, 190]]], ["As mentioned above, HA head domain is the major target of the antibody response following vaccination with seasonal influenza vaccines, however its high plasticity makes it easy for the virus to escape immune pressure (Heaton et al.2013).", [["HA head domain", "PROTEIN", 20, 34], ["HA head domain", "PROBLEM", 20, 34], ["vaccination", "TREATMENT", 90, 101], ["seasonal influenza vaccines", "TREATMENT", 107, 134], ["the virus", "PROBLEM", 182, 191]]], ["Despite of this, monoclonal antibodies (mAbs) that cross-react between the head domains of different HA subtypes have been reported (Ekiert et al.2012; Krause et al.2012; Lee et al.2012; Boonsathorn et al.2014; Lee et al.2014).", [["head", "ANATOMY", 75, 79], ["head", "ORGANISM_SUBDIVISION", 75, 79], ["monoclonal antibodies", "PROTEIN", 17, 38], ["mAbs", "PROTEIN", 40, 44], ["head domains", "PROTEIN", 75, 87], ["monoclonal antibodies (mAbs", "TREATMENT", 17, 44], ["different HA subtypes", "PROBLEM", 91, 112], ["head", "ANATOMY", 75, 79]]], ["These cross-reactive head antibodies seem rare, but they are interesting since they suggest the existence of cross-reactive epitopes in the head domains.Hemagglutinin ::: Surface Proteins and Antibody ResponsesIn contrast, HA stalk is the least variable region of HA, and great efforts have been focused on the development of universal influenza vaccines that depend on protective epitopes in this domain (Krammer and Palese 2015; Wu and Wilson 2018).", [["head", "ANATOMY", 21, 25], ["head", "ANATOMY", 140, 144], ["Hemagglutinin", "CHEMICAL", 153, 166], ["cross-reactive head antibodies", "GENE_OR_GENE_PRODUCT", 6, 36], ["head", "ORGANISM_SUBDIVISION", 140, 144], ["Hemagglutinin", "SIMPLE_CHEMICAL", 153, 166], ["HA", "GENE_OR_GENE_PRODUCT", 264, 266], ["cross-reactive head antibodies", "PROTEIN", 6, 36], ["cross-reactive epitopes", "PROTEIN", 109, 132], ["head domains", "PROTEIN", 140, 152], ["These cross-reactive head antibodies", "TEST", 0, 36], ["cross-reactive epitopes in the head domains", "PROBLEM", 109, 152], ["Hemagglutinin", "TREATMENT", 153, 166], ["Surface Proteins", "TEST", 171, 187], ["Antibody Responses", "TEST", 192, 210], ["HA stalk", "PROBLEM", 223, 231], ["HA", "PROBLEM", 264, 266], ["universal influenza vaccines", "TREATMENT", 326, 354], ["protective epitopes", "TREATMENT", 370, 389], ["head", "ANATOMY", 21, 25], ["antibodies", "OBSERVATION", 26, 36], ["cross-reactive", "OBSERVATION_MODIFIER", 109, 123], ["epitopes", "OBSERVATION", 124, 132], ["head", "ANATOMY", 140, 144], ["Antibody Responses", "OBSERVATION", 192, 210], ["least", "OBSERVATION_MODIFIER", 239, 244], ["variable", "OBSERVATION_MODIFIER", 245, 253], ["region", "OBSERVATION_MODIFIER", 254, 260], ["HA", "OBSERVATION", 264, 266]]], ["Monoclonal antibodies against this domain can broadly neutralize different subtypes of group 1 (Okuno et al.1993; Ekiert et al.2009; Sui et al.2009) or group 2 viruses (Ekiert et al.2011) or even both (Corti et al.2011).", [["Monoclonal antibodies", "PROTEIN", 0, 21], ["Monoclonal antibodies", "TREATMENT", 0, 21]]], ["Interestingly, although some stalk-antibodies show lower or even none neutralizing potency in vitro, they can render robust protection against challenges with divergent influenza viruses in vivo (Dreyfus et al.2012; DiLillo et al.2014; He et al.2015), most likely by Fc-mediated mechanisms like antibody dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (Terajima et al.2011; Jegaskanda et al.2013a, b; Miller et al.2013; DiLillo et al.2014; Florek et al.2014; Jegaskanda et al.2014).Hemagglutinin ::: Surface Proteins and Antibody ResponsesGlycosylation and conformational mobility (shape-shifting) of surface glycoproteins can help viruses to mask sensitive epitopes and evade the immune system.", [["cell", "ANATOMY", 314, 318], ["surface", "ANATOMY", 641, 648], ["immune system", "ANATOMY", 721, 734], ["influenza viruses", "DISEASE", 169, 186], ["Hemagglutinin", "CHEMICAL", 522, 535], ["influenza viruses", "ORGANISM", 169, 186], ["Fc", "GENE_OR_GENE_PRODUCT", 267, 269], ["cell", "CELL", 314, 318], ["Hemagglutinin", "SIMPLE_CHEMICAL", 522, 535], ["stalk-antibodies", "PROTEIN", 29, 45], ["Fc", "PROTEIN", 267, 269], ["surface glycoproteins", "PROTEIN", 641, 662], ["epitopes", "PROTEIN", 698, 706], ["some stalk-antibodies", "TEST", 24, 45], ["divergent influenza viruses", "PROBLEM", 159, 186], ["antibody dependent cell", "PROBLEM", 295, 318], ["mediated cytotoxicity", "PROBLEM", 319, 340], ["ADCC", "TEST", 342, 346], ["complement-dependent cytotoxicity", "PROBLEM", 352, 385], ["Surface Proteins", "TEST", 540, 556], ["Antibody", "TEST", 561, 569], ["Glycosylation", "TEST", 579, 592], ["surface glycoproteins", "TREATMENT", 641, 662], ["mask sensitive epitopes", "TREATMENT", 683, 706], ["influenza viruses", "OBSERVATION", 169, 186], ["most likely", "UNCERTAINTY", 252, 263], ["dependent cytotoxicity", "OBSERVATION_MODIFIER", 363, 385]]], ["Interestingly, two latest studies revealed that glycan repositioning within either head or stem domains of HA can facilitate the elicitation of protective cross-reactive antibody responses.", [["head", "ANATOMY", 83, 87], ["stem domains", "ANATOMY", 91, 103], ["head", "ORGANISM_SUBDIVISION", 83, 87], ["HA", "GENE_OR_GENE_PRODUCT", 107, 109], ["head or stem domains", "PROTEIN", 83, 103], ["two latest studies", "TEST", 15, 33], ["glycan repositioning", "TREATMENT", 48, 68], ["HA", "PROBLEM", 107, 109], ["glycan repositioning", "OBSERVATION", 48, 68], ["head", "ANATOMY", 83, 87]]], ["Huang et al. reported that removing glycosylation at residue 144 and deletion of lysine at position 147 can synergize to elicit broadly-reactive H1N1 influenza antibodies (Huang et al.2019).", [["lysine", "CHEMICAL", 81, 87], ["influenza", "DISEASE", 150, 159], ["lysine", "CHEMICAL", 81, 87], ["residue 144", "AMINO_ACID", 53, 64], ["lysine", "AMINO_ACID", 81, 87], ["position 147", "AMINO_ACID", 91, 103], ["H1N1", "ORGANISM", 145, 149], ["H1N1 influenza antibodies", "PROTEIN", 145, 170], ["glycosylation at residue", "TREATMENT", 36, 60], ["deletion of lysine at position", "TREATMENT", 69, 99], ["reactive H1N1 influenza antibodies", "PROBLEM", 136, 170], ["reactive", "OBSERVATION_MODIFIER", 136, 144], ["H1N1", "OBSERVATION", 145, 149]]], ["A study by Boyoglu-Barnum et al. showed that introduction of the group 2 glycan at Asn38HA1 to a group 1 stem-nanoparticle can broaden antibody responses to cross-react with group 2 HAs (Boyoglu-Barnum et al.2020).", [["Asn38HA1", "CHEMICAL", 83, 91], ["Asn38HA1", "SIMPLE_CHEMICAL", 83, 91], ["Asn38HA1", "PROTEIN", 83, 91], ["A study", "TEST", 0, 7], ["the group 2 glycan", "TREATMENT", 61, 79], ["a group 1 stem", "TREATMENT", 95, 109]]], ["Although the precise sites that are vulnerable by glycan repositioning are not identified yet, they may provide novel target epitopes to achieve universal protection.Hemagglutinin ::: Surface Proteins and Antibody ResponsesMore recently, a novel conserved epitope at the HA head domain trimer interface was reported (Bajic et al.2019; Bangaru et al.2019; Watanabe et al.2019).", [["Hemagglutinin", "CHEMICAL", 166, 179], ["Hemagglutinin", "SIMPLE_CHEMICAL", 166, 179], ["HA head domain", "PROTEIN", 271, 285], ["glycan repositioning", "TREATMENT", 50, 70], ["novel target epitopes", "TREATMENT", 112, 133], ["universal protection", "TREATMENT", 145, 165], ["Hemagglutinin", "TREATMENT", 166, 179], ["Surface Proteins", "TEST", 184, 200], ["Antibody", "TEST", 205, 213], ["a novel conserved epitope at the HA head domain trimer interface", "PROBLEM", 238, 302], ["glycan repositioning", "OBSERVATION", 50, 70]]], ["Primarily, the epitope is occluded at the contact surface between HA head domains, while the reversible HA \u201cbreathing\u201d conformational dynamics can cause exposure of the interface.", [["contact surface", "ANATOMY", 42, 57], ["contact surface", "CELLULAR_COMPONENT", 42, 57], ["HA head domains", "PROTEIN", 66, 81], ["HA head domains", "PROBLEM", 66, 81], ["the reversible HA \u201cbreathing", "PROBLEM", 89, 117], ["occluded", "OBSERVATION", 26, 34], ["surface", "OBSERVATION_MODIFIER", 50, 57], ["reversible", "OBSERVATION_MODIFIER", 93, 103]]], ["Antibodies targeting this cryptic epitope were shown to be protective against broad-spectrum subtypes of IAVs, suggesting the HA head interface is a new potential immunogen component for influenza universal vaccine design (Bajic et al.2019; Bangaru et al.2019; Watanabe et al.2019; Wu and Gao 2019).Neuraminidase ::: Surface Proteins and Antibody ResponsesNA is the second most abundant glycoprotein on the surface of influenza A and B viruses, and plays an essential role during virus replication by facilitating release of progeny virions (Fig. 1B) (Du et al.2019).", [["IAVs", "ANATOMY", 105, 109], ["head", "ANATOMY", 129, 133], ["surface", "ANATOMY", 407, 414], ["IAVs", "DISEASE", 105, 109], ["IAVs", "CANCER", 105, 109], ["Antibody ResponsesNA", "GENE_OR_GENE_PRODUCT", 338, 358], ["surface", "CELLULAR_COMPONENT", 407, 414], ["influenza A and B viruses", "ORGANISM", 418, 443], ["Antibody ResponsesNA", "PROTEIN", 338, 358], ["glycoprotein", "PROTEIN", 387, 399], ["influenza A", "SPECIES", 418, 429], ["B viruses", "SPECIES", 434, 443], ["Antibodies", "TREATMENT", 0, 10], ["this cryptic epitope", "PROBLEM", 21, 41], ["IAVs", "PROBLEM", 105, 109], ["the HA head interface", "PROBLEM", 122, 143], ["a new potential immunogen component", "PROBLEM", 147, 182], ["influenza", "PROBLEM", 187, 196], ["Neuraminidase", "TREATMENT", 299, 312], ["Surface Proteins", "TEST", 317, 333], ["Antibody", "TEST", 338, 346], ["influenza A and B viruses", "PROBLEM", 418, 443], ["virus replication", "TREATMENT", 480, 497], ["IAVs", "OBSERVATION", 105, 109], ["Antibody ResponsesNA", "OBSERVATION", 338, 358], ["abundant", "OBSERVATION_MODIFIER", 378, 386], ["glycoprotein", "OBSERVATION", 387, 399]]], ["It is well known that NA antibodies can protect against infection of influenza viruses (Schulman et al.1968; Murphy et al.1972; Monto and Kendal 1973; Doyle et al.2013; Wan et al.2013; Wilson et al.2016; Wohlbold et al.2017), by preventing virus budding and egress from infected cells, as well as ADCC and CDC (Wan et al.2013; Krammer and Palese 2015; Wohlbold et al.2017).", [["cells", "ANATOMY", 279, 284], ["NA", "CHEMICAL", 22, 24], ["infection", "DISEASE", 56, 65], ["influenza viruses", "DISEASE", 69, 86], ["NA antibodies", "GENE_OR_GENE_PRODUCT", 22, 35], ["influenza viruses", "ORGANISM", 69, 86], ["cells", "CELL", 279, 284], ["NA antibodies", "PROTEIN", 22, 35], ["infected cells", "CELL_TYPE", 270, 284], ["NA antibodies", "TREATMENT", 22, 35], ["infection", "PROBLEM", 56, 65], ["influenza viruses", "PROBLEM", 69, 86], ["virus budding", "PROBLEM", 240, 253], ["infected cells", "PROBLEM", 270, 284], ["infected cells", "OBSERVATION", 270, 284]]], ["NA consists of 11 subtypes (N1 to N11), and a series of \u201cbroadly\u201d cross-reactive mAbs of NA have been isolated (Wan et al.2013; Wilson et al.2016; Wohlbold et al.2017; Chen et al.2018).", [["NA", "CHEMICAL", 0, 2], ["NA", "CHEMICAL", 89, 91], ["NA", "SIMPLE_CHEMICAL", 89, 91], ["cross-reactive mAbs", "PROTEIN", 66, 85], ["NA", "TEST", 0, 2], ["a series", "TEST", 44, 52], ["cross-reactive mAbs of NA", "PROBLEM", 66, 91], ["11 subtypes", "OBSERVATION_MODIFIER", 15, 26]]], ["Of note, most of these cross-reactive NA mAbs are limited to recognize heterologous virus strains of the same NA subtype, suggesting existence of conserved subtype-specific NA epitopes (Wan et al.2013; Wilson et al.2016; Wohlbold et al.2017; Chen et al.2018).Neuraminidase ::: Surface Proteins and Antibody ResponsesInterestingly, Doyle et al. reported a unique universally conserved sequence (amino acids 222\u2013230, located in the vicinity of enzymatic active site) amongst all IAV NA subtypes, and a mAb targeting this specific epitope was demonstrated to inhibit all NA subtypes and protect mice from lethal doses of mouse-adapted H1N1 and H3N2 (Doyle et al.2013).", [["NA", "CHEMICAL", 38, 40], ["amino acids 222\u2013230", "CHEMICAL", 394, 413], ["amino acids", "CHEMICAL", 394, 405], ["NA mAbs", "GENE_OR_GENE_PRODUCT", 38, 45], ["heterologous virus strains", "ORGANISM", 71, 97], ["Neuraminidase", "SIMPLE_CHEMICAL", 259, 272], ["amino acids", "AMINO_ACID", 394, 405], ["222\u2013230", "AMINO_ACID", 406, 413], ["mAb", "GENE_OR_GENE_PRODUCT", 500, 503], ["mice", "ORGANISM", 592, 596], ["mouse", "ORGANISM", 618, 623], ["H1N1", "ORGANISM", 632, 636], ["H3N2", "ORGANISM", 641, 645], ["cross-reactive NA mAbs", "PROTEIN", 23, 45], ["NA epitopes", "PROTEIN", 173, 184], ["amino acids 222\u2013230", "PROTEIN", 394, 413], ["enzymatic active site", "PROTEIN", 442, 463], ["mAb", "PROTEIN", 500, 503], ["mice", "SPECIES", 592, 596], ["mouse", "SPECIES", 618, 623], ["mice", "SPECIES", 592, 596], ["mouse", "SPECIES", 618, 623], ["these cross-reactive NA mAbs", "TREATMENT", 17, 45], ["heterologous virus strains", "PROBLEM", 71, 97], ["conserved subtype-specific NA epitopes", "PROBLEM", 146, 184], ["Surface Proteins", "TEST", 277, 293], ["Antibody", "TEST", 298, 306], ["amino acids", "TEST", 394, 405], ["all IAV NA subtypes", "PROBLEM", 473, 492], ["a mAb", "TREATMENT", 498, 503], ["H3N2 (Doyle et al", "TREATMENT", 641, 658]]], ["More recently, Stadlbauer et al. identified three broadly-protective mAbs targeting the NA active site that is highly conserved among all NA subtypes (Stadlbauer et al.2019).", [["mAbs", "PROTEIN", 69, 73], ["NA active site", "DNA", 88, 102], ["protective mAbs", "TREATMENT", 58, 73], ["the NA active site", "PROBLEM", 84, 102], ["broadly", "OBSERVATION_MODIFIER", 50, 57], ["protective", "OBSERVATION_MODIFIER", 58, 68], ["mAbs", "OBSERVATION", 69, 73], ["NA active", "OBSERVATION_MODIFIER", 88, 97], ["NA subtypes", "OBSERVATION_MODIFIER", 138, 149]]], ["These conserved NA epitopes, either subtype specific or universal, may be attractive immunological target for universal influenza vaccine design.Matrix Protein 2 ::: Surface Proteins and Antibody ResponsesM2 of IAV (AM2) is a type III integral membrane protein, consisting of an N-terminal extracellular region (M2e), transmembrane region, and C-terminal cytoplasmic tail region (Fig. 1B) (Tobler et al.1999).", [["membrane", "ANATOMY", 244, 252], ["extracellular", "ANATOMY", 290, 303], ["transmembrane region", "ANATOMY", 318, 338], ["cytoplasmic", "ANATOMY", 355, 366], ["N", "CHEMICAL", 279, 280], ["C", "CHEMICAL", 344, 345], ["NA epitopes", "GENE_OR_GENE_PRODUCT", 16, 27], ["IAV", "ORGANISM", 211, 214], ["AM2", "GENE_OR_GENE_PRODUCT", 216, 219], ["type III integral", "GENE_OR_GENE_PRODUCT", 226, 243], ["membrane", "CELLULAR_COMPONENT", 244, 252], ["transmembrane", "CELLULAR_COMPONENT", 318, 331], ["NA epitopes", "PROTEIN", 16, 27], ["Antibody ResponsesM2", "PROTEIN", 187, 207], ["AM2", "PROTEIN", 216, 219], ["type III integral membrane protein", "PROTEIN", 226, 260], ["N-terminal extracellular region", "PROTEIN", 279, 310], ["M2e", "PROTEIN", 312, 315], ["transmembrane region", "PROTEIN", 318, 338], ["C-terminal cytoplasmic tail region", "PROTEIN", 344, 378], ["1B", "PROTEIN", 385, 387], ["These conserved NA epitopes", "PROBLEM", 0, 27], ["universal influenza vaccine design", "TREATMENT", 110, 144], ["Matrix Protein", "TEST", 145, 159], ["Surface Proteins", "TEST", 166, 182], ["Antibody", "TEST", 187, 195], ["IAV", "TEST", 211, 214], ["a type III integral membrane protein", "PROBLEM", 224, 260], ["an N-terminal extracellular region", "PROBLEM", 276, 310], ["transmembrane region", "TEST", 318, 338], ["C-terminal cytoplasmic tail region", "PROBLEM", 344, 378], ["NA epitopes", "OBSERVATION", 16, 27], ["Antibody ResponsesM2", "OBSERVATION", 187, 207], ["IAV", "OBSERVATION_MODIFIER", 211, 214], ["membrane protein", "OBSERVATION", 244, 260], ["terminal", "ANATOMY_MODIFIER", 281, 289], ["extracellular", "ANATOMY_MODIFIER", 290, 303], ["region", "ANATOMY_MODIFIER", 304, 310], ["terminal", "ANATOMY_MODIFIER", 346, 354], ["cytoplasmic tail", "ANATOMY", 355, 371]]], ["The M2e is a 24-residue peptide and is highly conserved among different IAV subtypes (Deng et al.2015).", [["M2e", "PROTEIN", 4, 7], ["IAV subtypes", "OBSERVATION", 72, 84]]], ["Although the natural M2e has low immunogenicity and abundance, a M2e-specific and protective monoclonal antibody 14C2 has been isolated early (Zebedee and Lamb 1989; Treanor et al.1990).", [["M2e", "PROTEIN", 65, 68], ["protective monoclonal antibody 14C2", "PROTEIN", 82, 117], ["low immunogenicity", "PROBLEM", 29, 47], ["a M2e", "TEST", 63, 68], ["protective monoclonal antibody", "TEST", 82, 112], ["low immunogenicity", "OBSERVATION_MODIFIER", 29, 47]]], ["Therefore this region has since been extensively evaluated as a promising immunogen for universal influenza vaccines (Farahmand et al.2019; Yao et al.2019).Matrix Protein 2 ::: Surface Proteins and Antibody ResponsesBM2 of IBV is a functional homolog of AM2 but shares little sequence identity (Wanitchang et al.2016; Mandala et al.2019), and most mAbs targeting M2e are IAV-wide.", [["IBV", "ORGANISM", 223, 226], ["AM2", "GENE_OR_GENE_PRODUCT", 254, 257], ["M2e", "GENE_OR_GENE_PRODUCT", 363, 366], ["Antibody ResponsesBM2", "PROTEIN", 198, 219], ["AM2", "PROTEIN", 254, 257], ["mAbs", "PROTEIN", 348, 352], ["M2e", "PROTEIN", 363, 366], ["IBV", "SPECIES", 223, 226], ["a promising immunogen", "TREATMENT", 62, 83], ["universal influenza vaccines", "TREATMENT", 88, 116], ["Matrix Protein", "TEST", 156, 170], ["Surface Proteins", "TEST", 177, 193], ["Antibody", "TEST", 198, 206], ["IBV", "PROBLEM", 223, 226], ["wide", "OBSERVATION_MODIFIER", 375, 379]]], ["Despite a mAb AS2 that recognizes the conservative N-terminus of M2 (amino acids 2\u201310) has been identified to possess neutralizing activity against both IAV and IBV in vitro (Liu et al.2003), no evidence showed that immunity with current universal influenza vaccine candidates based on M2e of IAV can suppress IBV replication (Mezhenskaya et al.2019).Internal Proteins and T-cell ResponsesCD8+ T cells can detect and kill virus-infected cells by recognizing viral protein-derived peptides (epitopes) presented by major histocompatibility complex class I (MHC-I) on the cell surface (Fig. 2A).", [["T-cell ResponsesCD8+ T cells", "ANATOMY", 373, 401], ["cells", "ANATOMY", 437, 442], ["cell surface", "ANATOMY", 569, 581], ["amino acids 2\u201310", "CHEMICAL", 69, 85], ["N", "CHEMICAL", 51, 52], ["amino acids", "CHEMICAL", 69, 80], ["mAb AS2", "GENE_OR_GENE_PRODUCT", 10, 17], ["M2", "GENE_OR_GENE_PRODUCT", 65, 67], ["amino acids", "AMINO_ACID", 69, 80], ["2\u201310", "AMINO_ACID", 81, 85], ["IAV", "ORGANISM", 153, 156], ["IBV", "ORGANISM", 161, 164], ["IAV", "ORGANISM", 293, 296], ["IBV", "ORGANISM", 310, 313], ["T-cell", "CELL", 373, 379], ["cells", "CELL", 437, 442], ["major histocompatibility complex class I", "GENE_OR_GENE_PRODUCT", 513, 553], ["MHC-I", "GENE_OR_GENE_PRODUCT", 555, 560], ["cell surface", "CELLULAR_COMPONENT", 569, 581], ["mAb AS2", "PROTEIN", 10, 17], ["N-terminus", "PROTEIN", 51, 61], ["M2", "PROTEIN", 65, 67], ["amino acids 2\u201310", "PROTEIN", 69, 85], ["T-cell ResponsesCD8+ T cells", "CELL_TYPE", 373, 401], ["viral protein", "PROTEIN", 458, 471], ["epitopes", "PROTEIN", 490, 498], ["major histocompatibility complex class I", "PROTEIN", 513, 553], ["MHC", "PROTEIN", 555, 558], ["I", "PROTEIN", 559, 560], ["IAV", "SPECIES", 153, 156], ["IBV", "SPECIES", 161, 164], ["IAV", "SPECIES", 293, 296], ["IBV", "SPECIES", 310, 313], ["a mAb AS2", "TREATMENT", 8, 17], ["the conservative N-terminus of M2 (amino acids", "TREATMENT", 34, 80], ["current universal influenza vaccine", "TREATMENT", 230, 265], ["IAV", "TREATMENT", 293, 296], ["IBV replication", "TREATMENT", 310, 325], ["Internal Proteins", "TEST", 351, 368], ["T cells", "PROBLEM", 394, 401], ["kill virus", "PROBLEM", 417, 427], ["infected cells", "PROBLEM", 428, 442], ["viral protein", "TEST", 458, 471], ["neutralizing activity", "OBSERVATION", 118, 139], ["no evidence showed", "UNCERTAINTY", 192, 210], ["infected cells", "OBSERVATION", 428, 442]]], ["While CD8+ T cell-based immunity does not prevent infection, it can facilitate viral clearance and reduce the severity of disease (McMichael et al.1983; Sridhar et al.2013).Internal Proteins and T-cell ResponsesThe current inactivated influenza vaccine formulation does not boost T cell response (Koutsakos et al.2018).", [["CD8+ T cell", "ANATOMY", 6, 17], ["T-cell", "ANATOMY", 195, 201], ["T cell", "ANATOMY", 280, 286], ["infection", "DISEASE", 50, 59], ["CD8", "GENE_OR_GENE_PRODUCT", 6, 9], ["T-cell", "CELL", 195, 201], ["T cell", "CELL", 280, 286], ["CD8", "PROTEIN", 6, 9], ["CD8", "TEST", 6, 9], ["T cell", "PROBLEM", 11, 17], ["infection", "PROBLEM", 50, 59], ["viral clearance", "TEST", 79, 94], ["the severity of disease", "PROBLEM", 106, 129], ["Internal Proteins", "TEST", 173, 190], ["The current inactivated influenza vaccine formulation", "TREATMENT", 211, 264], ["infection", "OBSERVATION", 50, 59]]], ["Nevertheless cytotoxic CD8+ T cells specific to the conserved viral epitopes have been evidenced to provide cross-protection across IAV, IBV and ICV (McMichael et al.1983; Greenbaum et al.2009; Gras et al.2010; Sridhar et al.2013; Quinones-Parra et al.2014; Hayward et al.2015; Wang et al.2015, 2018; Koutsakos et al.2019).", [["CD8+ T cells", "ANATOMY", 23, 35], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["IAV", "ORGANISM", 132, 135], ["IBV", "ORGANISM", 137, 140], ["cytotoxic CD8+ T cells", "CELL_TYPE", 13, 35], ["conserved viral epitopes", "PROTEIN", 52, 76], ["IAV", "SPECIES", 132, 135], ["IBV", "SPECIES", 137, 140], ["cytotoxic CD8", "TEST", 13, 26], ["T cells", "PROBLEM", 28, 35], ["the conserved viral epitopes", "PROBLEM", 48, 76], ["cross-protection across IAV", "TREATMENT", 108, 135], ["IBV", "TREATMENT", 137, 140], ["ICV (McMichael et al", "TREATMENT", 145, 165]]], ["Moreover, pre-existing T cell responses have been demonstrated to correlate with protection from influenza disease in humans by epidemiological studies (Epstein 2006; Hayward et al.2015).", [["T cell", "ANATOMY", 23, 29], ["influenza disease", "DISEASE", 97, 114], ["T cell", "CELL", 23, 29], ["humans", "ORGANISM", 118, 124], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 118, 124], ["pre-existing T cell responses", "PROBLEM", 10, 39], ["influenza disease", "PROBLEM", 97, 114], ["epidemiological studies", "TEST", 128, 151], ["influenza", "OBSERVATION", 97, 106]]], ["The antigenic origin of these broadly cross-reactive epitopes is therefore of great interest in the development of CD8+ T cell-based universal influenza vaccines.", [["CD8+ T cell", "ANATOMY", 115, 126], ["CD8", "GENE_OR_GENE_PRODUCT", 115, 118], ["CD8", "PROTEIN", 115, 118], ["CD8+ T cell", "PROBLEM", 115, 126], ["universal influenza vaccines", "TREATMENT", 133, 161], ["antigenic", "OBSERVATION_MODIFIER", 4, 13], ["origin", "OBSERVATION_MODIFIER", 14, 20], ["broadly", "OBSERVATION_MODIFIER", 30, 37], ["cross-reactive epitopes", "OBSERVATION", 38, 61]]], ["It is believed that CD8+ T cell cross-reactivity is provided by the peptides derived from internal influenza proteins, mainly but not limited to nucleoprotein (NP) and matrix protein 1 (M1) (Fig. 2B) (Koutsakos et al.2019).Internal Proteins and T-cell ResponsesIn contrast to HA and NA, the internal influenza virus proteins are relatively well conserved and display limited antigenic diversity (Bui et al.2007).", [["CD8+ T cell", "ANATOMY", 20, 31], ["T-cell", "ANATOMY", 245, 251], ["CD8", "GENE_OR_GENE_PRODUCT", 20, 23], ["nucleoprotein (NP) and matrix protein 1", "GENE_OR_GENE_PRODUCT", 145, 184], ["T-cell", "CELL", 245, 251], ["HA", "GENE_OR_GENE_PRODUCT", 276, 278], ["internal influenza virus", "ORGANISM", 291, 315], ["CD8", "PROTEIN", 20, 23], ["internal influenza proteins", "PROTEIN", 90, 117], ["nucleoprotein", "PROTEIN", 145, 158], ["NP", "PROTEIN", 160, 162], ["matrix protein 1", "PROTEIN", 168, 184], ["M1", "PROTEIN", 186, 188], ["internal influenza virus proteins", "PROTEIN", 291, 324], ["influenza virus", "SPECIES", 300, 315], ["CD8", "TEST", 20, 23], ["T cell cross-reactivity", "PROBLEM", 25, 48], ["the peptides", "PROBLEM", 64, 76], ["internal influenza proteins", "PROBLEM", 90, 117], ["matrix protein", "TEST", 168, 182], ["Internal Proteins", "TEST", 223, 240], ["HA", "PROBLEM", 276, 278], ["NA", "TEST", 283, 285], ["the internal influenza virus proteins", "PROBLEM", 287, 324], ["cell cross-reactivity", "OBSERVATION", 27, 48], ["influenza", "OBSERVATION", 99, 108], ["internal", "ANATOMY", 291, 299], ["influenza virus", "OBSERVATION", 300, 315]]], ["A number of vaccine candidates have been developed to induce T cell responses, by intracellularly expressing NP and M1 using replication deficient viral vectors like Chimpanzee Adenovirus Oxford 1 (ChAdOx1) or Modified Vaccinia Ankara (MVA) (Berthoud et al.2011; Lillie et al.2012; Lambe et al.2013; Antrobus et al.2014a, b).Internal Proteins and T-cell ResponsesInterestingly, a recent study identified a universal PB1 epitope (PB1413), which is derived from a core motif (residues 406\u2013422 of IAV-PB1 protein) present in the viral RNA-dependent polymerases (Koutsakos et al.2019).", [["T cell", "ANATOMY", 61, 67], ["T-cell", "ANATOMY", 347, 353], ["T cell", "CELL", 61, 67], ["NP", "GENE_OR_GENE_PRODUCT", 109, 111], ["M1", "GENE_OR_GENE_PRODUCT", 116, 118], ["Chimpanzee Adenovirus Oxford 1", "ORGANISM", 166, 196], ["ChAdOx1", "ORGANISM", 198, 205], ["Vaccinia Ankara", "ORGANISM", 219, 234], ["T-cell", "CELL", 347, 353], ["PB1413", "GENE_OR_GENE_PRODUCT", 429, 435], ["IAV-PB1", "GENE_OR_GENE_PRODUCT", 494, 501], ["M1", "PROTEIN", 116, 118], ["PB1 epitope", "PROTEIN", 416, 427], ["PB1413", "PROTEIN", 429, 435], ["residues 406\u2013422 of IAV-PB1 protein", "PROTEIN", 474, 509], ["viral RNA-dependent polymerases", "PROTEIN", 526, 557], ["Chimpanzee Adenovirus Oxford 1", "SPECIES", 166, 196], ["vaccine candidates", "TREATMENT", 12, 30], ["replication deficient viral vectors", "TREATMENT", 125, 160], ["Chimpanzee Adenovirus Oxford", "TREATMENT", 166, 194], ["Modified Vaccinia Ankara (MVA) (Berthoud et al", "TREATMENT", 210, 256], ["Internal Proteins", "TEST", 325, 342], ["a recent study", "TEST", 378, 392], ["a universal PB1 epitope", "TREATMENT", 404, 427], ["a core motif (residues", "TREATMENT", 460, 482], ["IAV-PB1 protein", "TREATMENT", 494, 509], ["the viral RNA", "TEST", 522, 535], ["dependent polymerases", "PROBLEM", 536, 557], ["viral RNA", "OBSERVATION", 526, 535], ["dependent", "OBSERVATION_MODIFIER", 536, 545], ["polymerases", "OBSERVATION_MODIFIER", 546, 557]]], ["PB1 is the most conserved protein across IAV and IBV, with about 60% amino acid identity.", [["amino acid", "CHEMICAL", 69, 79], ["amino acid", "CHEMICAL", 69, 79], ["PB1", "GENE_OR_GENE_PRODUCT", 0, 3], ["IBV", "ORGANISM", 49, 52], ["amino acid", "AMINO_ACID", 69, 79], ["PB1", "DNA", 0, 3], ["IBV", "SPECIES", 49, 52], ["PB1", "TEST", 0, 3], ["IBV", "TREATMENT", 49, 52]]], ["Vaccinating against the T cell epitope PB1413 might provide universal protection in humans.", [["T cell", "ANATOMY", 24, 30], ["PB1413", "CHEMICAL", 39, 45], ["T cell", "CELL", 24, 30], ["humans", "ORGANISM", 84, 90], ["humans", "SPECIES", 84, 90], ["humans", "SPECIES", 84, 90], ["the T cell epitope PB1413", "TREATMENT", 20, 45]]], ["Besides, CD8+ T cell targets from IBV HA and NS1 proteins also have been identified and shown IBV-specific protection in mice, suggesting them as ideal targets for IBV-wide influenza vaccines (Koutsakos et al.2019).Internal Proteins and T-cell ResponsesCD4+ T cell responses to influenza virus and their role for host protection against influenza infection have received increasing attention (Wilkinson et al.2012).", [["CD8+ T cell", "ANATOMY", 9, 20], ["T-cell ResponsesCD4+ T cell", "ANATOMY", 237, 264], ["influenza", "DISEASE", 173, 182], ["influenza infection", "DISEASE", 337, 356], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["IBV HA", "ORGANISM", 34, 40], ["NS1", "GENE_OR_GENE_PRODUCT", 45, 48], ["IBV", "ORGANISM", 94, 97], ["mice", "ORGANISM", 121, 125], ["IBV", "ORGANISM", 164, 167], ["T-cell", "CELL", 237, 243], ["influenza virus", "ORGANISM", 278, 293], ["CD8", "PROTEIN", 9, 12], ["IBV HA and NS1 proteins", "PROTEIN", 34, 57], ["mice", "SPECIES", 121, 125], ["influenza virus", "SPECIES", 278, 293], ["IBV", "SPECIES", 34, 37], ["IBV", "SPECIES", 94, 97], ["mice", "SPECIES", 121, 125], ["IBV", "SPECIES", 164, 167], ["CD8", "TEST", 9, 12], ["T cell targets", "PROBLEM", 14, 28], ["IBV HA", "PROBLEM", 34, 40], ["NS1 proteins", "TEST", 45, 57], ["IBV", "PROBLEM", 94, 97], ["IBV", "PROBLEM", 164, 167], ["wide influenza vaccines", "TREATMENT", 168, 191], ["Internal Proteins", "TEST", 215, 232], ["T cell responses", "PROBLEM", 258, 274], ["influenza virus", "PROBLEM", 278, 293], ["host protection", "TREATMENT", 313, 328], ["influenza infection", "PROBLEM", 337, 356], ["T cell targets", "OBSERVATION", 14, 28], ["NS1 proteins", "OBSERVATION", 45, 57], ["T-cell", "OBSERVATION", 237, 243], ["T cell", "OBSERVATION", 258, 264]]], ["It has been well demonstrated that CD4+ memory T cells can help in directing a faster antibody response via cytokine secretion in response to mutated or immunologically novel viral antigens, leading to limited virus shedding and disease severity, possibly due to the direct lysis of infected epithelial cells (Poon et al.2009; Wilkinson et al.2012; Valkenburg et al.2018).", [["CD4+ memory T cells", "ANATOMY", 35, 54], ["epithelial cells", "ANATOMY", 292, 308], ["CD4", "GENE_OR_GENE_PRODUCT", 35, 38], ["epithelial cells", "CELL", 292, 308], ["CD4", "PROTEIN", 35, 38], ["memory T cells", "CELL_TYPE", 40, 54], ["cytokine", "PROTEIN", 108, 116], ["immunologically novel viral antigens", "PROTEIN", 153, 189], ["infected epithelial cells", "CELL_TYPE", 283, 308], ["memory T cells", "PROBLEM", 40, 54], ["a faster antibody response", "PROBLEM", 77, 103], ["cytokine secretion", "PROBLEM", 108, 126], ["mutated or immunologically novel viral antigens", "PROBLEM", 142, 189], ["limited virus shedding", "PROBLEM", 202, 224], ["disease severity", "PROBLEM", 229, 245], ["infected epithelial cells", "PROBLEM", 283, 308], ["possibly due to", "UNCERTAINTY", 247, 262], ["infected epithelial cells", "OBSERVATION", 283, 308]]], ["A vaccine that can induce CD8+ or CD4+ T responses against highly conserved regions of the influenza proteins may overcome the limitations of current season influenza vaccines (Sheikh et al.2016).", [["CD8+ or CD4+", "ANATOMY", 26, 38], ["influenza", "DISEASE", 157, 166], ["CD8", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD8", "PROTEIN", 26, 29], ["CD4", "PROTEIN", 34, 37], ["influenza proteins", "PROTEIN", 91, 109], ["A vaccine", "TREATMENT", 0, 9], ["CD8", "TEST", 26, 29], ["CD4", "PROBLEM", 34, 37], ["the influenza proteins", "PROBLEM", 87, 109], ["current season influenza vaccines", "TREATMENT", 142, 175], ["influenza", "OBSERVATION", 91, 100]]], ["More importantly, universal T cell-inducing vaccines in combination with universal antibodies can confer increased protection against influenza (Asthagiri Arunkumar et al.2019).Low Immunogenicity and Immunofocusing ::: Obstacles and StrategiesSpecific induction of broadly neutralizing antibodies can be achieved by targeting B cell recognition to conserved epitopes.", [["T cell", "ANATOMY", 28, 34], ["B cell", "ANATOMY", 326, 332], ["influenza", "DISEASE", 134, 143], ["T cell", "CELL", 28, 34], ["B cell", "CELL", 326, 332], ["universal antibodies", "PROTEIN", 73, 93], ["broadly neutralizing antibodies", "PROTEIN", 265, 296], ["universal T cell-inducing vaccines", "TREATMENT", 18, 52], ["universal antibodies", "TREATMENT", 73, 93], ["increased protection", "TREATMENT", 105, 125], ["influenza", "PROBLEM", 134, 143], ["broadly neutralizing antibodies", "TREATMENT", 265, 296]]], ["However, the low immunogenicity of the conserved HA stalk and M2e makes antibody responses targeting these antigens constitute only a small fraction of the total anti-virus antibodies in nature infections (Sui et al.2011).", [["infections", "DISEASE", 194, 204], ["HA stalk", "ORGANISM", 49, 57], ["M2e", "PROTEIN", 62, 65], ["antigens", "PROTEIN", 107, 115], ["anti-virus antibodies", "PROTEIN", 162, 183], ["the low immunogenicity of the conserved HA stalk", "PROBLEM", 9, 57], ["antibody responses", "TEST", 72, 90], ["the total anti-virus antibodies in nature infections", "PROBLEM", 152, 204], ["low immunogenicity", "OBSERVATION_MODIFIER", 13, 31], ["small", "OBSERVATION_MODIFIER", 134, 139]]], ["Various immunofocusing approaches have been therefore developed to overcome this problem.Low Immunogenicity and Immunofocusing ::: Obstacles and StrategiesThe M2e is small in size and has low abundance in its native state, but its immunogenicity can be improved using tandem repeats and fusing them to highly immunogenic carriers (Neirynck et al.1999; De Filette et al.2008; Eliasson et al.2008; Turley et al.2011; Kim et al.2013).", [["Various immunofocusing approaches", "TREATMENT", 0, 33], ["small in size", "PROBLEM", 166, 179], ["low abundance in its native state", "PROBLEM", 188, 221], ["tandem repeats", "TREATMENT", 268, 282], ["M2e", "OBSERVATION", 159, 162], ["small", "OBSERVATION_MODIFIER", 166, 171], ["size", "OBSERVATION_MODIFIER", 175, 179], ["low abundance", "OBSERVATION_MODIFIER", 188, 201], ["native state", "OBSERVATION_MODIFIER", 209, 221]]], ["Strategies directing the antibody response to HA stalk were also evaluated, such as shielding of the HA head epitopes by hyperglycosylation (Fig. 3A) (Lin et al.2012; Eggink et al.2014), and constructing headless mini-HA as protective immunogen by removing the head domain completely (Fig. 3B) (Steel et al.2010).", [["head", "ANATOMY", 261, 265], ["head", "ORGANISM_SUBDIVISION", 261, 265], ["HA head epitopes", "PROTEIN", 101, 117], ["head domain", "PROTEIN", 261, 272], ["HA stalk", "PROBLEM", 46, 54], ["the HA head epitopes", "PROBLEM", 97, 117], ["protective immunogen", "TREATMENT", 224, 244], ["head", "ANATOMY", 261, 265]]], ["Notably, the latter strategy requires maintaining the conformation of the stalk domain in absence of the head domain, which is challenging.", [["head", "ANATOMY", 105, 109], ["head", "ORGANISM_SUBDIVISION", 105, 109], ["stalk domain", "PROTEIN", 74, 86], ["head domain", "PROTEIN", 105, 116], ["the stalk domain", "PROBLEM", 70, 86], ["head", "ANATOMY", 105, 109]]], ["Nevertheless promise progress has been made to achieve the stable native structure of trimeric HA stalk, either in soluble form or presented on nanoparticles (Lu et al.2014; Mallajosyula et al.2014; Impagliazzo et al.2015; Yassine et al.2015).Low Immunogenicity and Immunofocusing ::: Obstacles and StrategiesMore recently, Weidenbacher and Kim developed a novel method, called protect, modify, deprotect (PMD), for creating immunogens aimed to elicit antibodies targeting a specific epitope (Weidenbacher and Kim 2019).", [["PMD", "DISEASE", 406, 409], ["antibodies", "PROTEIN", 452, 462], ["trimeric HA stalk", "PROBLEM", 86, 103], ["Impagliazzo et al", "TREATMENT", 199, 216], ["creating immunogens", "TREATMENT", 416, 435], ["stable", "OBSERVATION_MODIFIER", 59, 65]]], ["A monoclonal antibody that recognizes the specific epitope is used to protect the target epitope on the protein, followed by modifications of the remaining exposed surfaces of the protein to render them nonimmunogenic.", [["monoclonal antibody", "PROTEIN", 2, 21], ["A monoclonal antibody", "TEST", 0, 21], ["the remaining exposed surfaces of the protein", "TREATMENT", 142, 187], ["monoclonal antibody", "OBSERVATION", 2, 21]]], ["After removal of the monoclonal antibody, the epitope is deprotected and the resultant protein is modified at the surface other than the target epitope (Fig. 3C).", [["surface", "ANATOMY", 114, 121], ["surface", "CELLULAR_COMPONENT", 114, 121], ["monoclonal antibody", "PROTEIN", 21, 40], ["epitope", "PROTEIN", 46, 53], ["target epitope", "PROTEIN", 137, 151], ["removal", "TREATMENT", 6, 13], ["the monoclonal antibody", "TREATMENT", 17, 40], ["the epitope", "TREATMENT", 42, 53], ["the resultant protein", "PROBLEM", 73, 94], ["monoclonal antibody", "OBSERVATION", 21, 40], ["resultant", "OBSERVATION_MODIFIER", 77, 86], ["protein", "OBSERVATION", 87, 94]]], ["The increasing numbers of broadly-neutralizing mAbs and corresponding conserved epitopes may provide attractive targets for the application of PMD in universal influenza vaccine design.Immunodominance and Immunosubversion ::: Obstacles and StrategiesThe success of mini-HA in inducing robust stalk-specific antibodies strongly implies that the HA stalk is not intrinsically poorly immunogenic, but is the victim of immunodominance, where the immune system tends to respond to complex antigens in a reproducibly hierarchical manner, that is, higher-ranking antigens sometimes suppress responses to lower ranking antigens (Angeletti and Yewdell 2018).", [["immune system", "ANATOMY", 442, 455], ["PMD", "DISEASE", 143, 146], ["mini-HA", "CHEMICAL", 265, 272], ["mini-HA", "SIMPLE_CHEMICAL", 265, 272], ["mAbs", "PROTEIN", 47, 51], ["antibodies", "PROTEIN", 307, 317], ["complex antigens", "PROTEIN", 476, 492], ["antigens", "PROTEIN", 556, 564], ["broadly-neutralizing mAbs", "TREATMENT", 26, 51], ["universal influenza vaccine", "TREATMENT", 150, 177], ["mini-HA", "PROBLEM", 265, 272], ["specific antibodies", "TEST", 298, 317], ["the HA stalk", "PROBLEM", 340, 352], ["the immune system", "PROBLEM", 438, 455], ["complex antigens", "PROBLEM", 476, 492], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["numbers", "OBSERVATION_MODIFIER", 15, 22], ["neutralizing mAbs", "OBSERVATION", 34, 51], ["not intrinsically", "UNCERTAINTY", 356, 373], ["poorly immunogenic", "OBSERVATION_MODIFIER", 374, 392]]], ["In the case of IAV HA, there is clear head immunodomination over stalk.Immunodominance and Immunosubversion ::: Obstacles and StrategiesHowever, immunodominance can be subverted by various strategies.", [["head", "ANATOMY", 38, 42], ["IAV", "ORGANISM", 15, 18], ["head", "ORGANISM_SUBDIVISION", 38, 42], ["IAV", "SPECIES", 15, 18], ["IAV HA", "PROBLEM", 15, 21], ["clear head immunodomination over stalk", "PROBLEM", 32, 70], ["IAV", "OBSERVATION", 15, 18], ["clear", "OBSERVATION_MODIFIER", 32, 37], ["head", "ANATOMY", 38, 42], ["immunodomination", "OBSERVATION", 43, 59]]], ["For example, an \u201cantigen imprinting\u201d strategy was inspired by the phenomenon that natural infection and vaccination with pandemic H1N1 in 2009 preferentially boosted broadly binding antibodies in humans including antibodies targeting the stalk domain (Wrammert et al.2011; Li et al.2012; Pica et al.2012).", [["infection", "DISEASE", 90, 99], ["H1N1", "DISEASE", 130, 134], ["humans", "ORGANISM", 196, 202], ["binding antibodies", "PROTEIN", 174, 192], ["antibodies", "PROTEIN", 213, 223], ["stalk domain", "PROTEIN", 238, 250], ["humans", "SPECIES", 196, 202], ["humans", "SPECIES", 196, 202], ["an \u201cantigen", "PROBLEM", 13, 24], ["the phenomenon", "PROBLEM", 62, 76], ["natural infection", "PROBLEM", 82, 99], ["vaccination", "TREATMENT", 104, 115], ["pandemic H1N1", "PROBLEM", 121, 134], ["broadly binding antibodies in humans", "PROBLEM", 166, 202], ["antibodies", "TREATMENT", 213, 223], ["natural", "OBSERVATION_MODIFIER", 82, 89], ["infection", "OBSERVATION", 90, 99]]], ["Generally, immune response against newly emerging strains of influenza virus would be affected by immune memory acquired by past influenza exposure; memory B cells that are cross-reactive with newly emerging strains is activated, while induction of strain-specific antibodies is prevented (Henry et al.2018).", [["memory B cells", "ANATOMY", 149, 163], ["influenza virus", "DISEASE", 61, 76], ["influenza virus", "ORGANISM", 61, 76], ["memory B cells", "CELL", 149, 163], ["memory B cells", "CELL_TYPE", 149, 163], ["antibodies", "PROTEIN", 265, 275], ["influenza virus", "SPECIES", 61, 76], ["influenza virus", "PROBLEM", 61, 76], ["past influenza exposure", "PROBLEM", 124, 147], ["memory B cells", "PROBLEM", 149, 163], ["newly emerging strains", "PROBLEM", 193, 215], ["strain", "PROBLEM", 249, 255]]], ["In this strategy, chimeric HAs that share the same stalk domain but express different head domains were constructed and used for vaccination sequentially, allowing repeated exposure of the same stalk in the context of an irrelevant globular head domain (Fig. 4A) (Hai et al.2012; Krammer et al.2013; Margine et al.2013; Ermler et al.2017).", [["head", "ANATOMY", 86, 90], ["head", "ANATOMY", 241, 245], ["HAs", "GENE_OR_GENE_PRODUCT", 27, 30], ["head", "ORGANISM_SUBDIVISION", 241, 245], ["chimeric HAs", "PROTEIN", 18, 30], ["stalk domain", "PROTEIN", 51, 63], ["head domains", "PROTEIN", 86, 98], ["globular head domain", "PROTEIN", 232, 252], ["vaccination", "TREATMENT", 129, 140], ["an irrelevant globular head domain", "PROBLEM", 218, 252]]], ["The first immunization with a chimeric HA construct leads to a primary response against the globular head domain and, though much less efficiently, against the stalk domain.", [["head", "ANATOMY", 101, 105], ["chimeric HA construct", "DNA", 30, 51], ["globular head domain", "PROTEIN", 92, 112], ["stalk domain", "PROTEIN", 160, 172], ["The first immunization", "TREATMENT", 0, 22], ["a chimeric HA construct", "TREATMENT", 28, 51]]], ["Upon subsequent booster vaccinations, a recall response against the stalk is anticipated, but immune response against the immunodominant head domain is restricted.Immunodominance and Immunosubversion ::: Obstacles and StrategiesTo further include head-specific cross-reactive epitopes into consideration for universal vaccine design, Krammer and Palese proposed a novel concept of mosaic HAs, which were constructed by replacing the immunodominant antigenic sites in the head with sequences from exotic, avian HA subtypes, instead of changing the whole head domain (Fig. 4B) (Broecker et al.2018; Liu et al.2018; Krammer and Palese 2019).", [["head", "ANATOMY", 137, 141], ["head", "ANATOMY", 247, 251], ["head", "ANATOMY", 471, 475], ["head", "ANATOMY", 553, 557], ["head", "ORGAN", 137, 141], ["head", "ORGANISM_SUBDIVISION", 247, 251], ["head", "ORGANISM_SUBDIVISION", 471, 475], ["head", "ORGANISM_SUBDIVISION", 553, 557], ["immunodominant head domain", "PROTEIN", 122, 148], ["cross-reactive epitopes", "PROTEIN", 261, 284], ["immunodominant antigenic sites", "DNA", 433, 463], ["whole head domain", "PROTEIN", 547, 564], ["subsequent booster vaccinations", "TREATMENT", 5, 36], ["the immunodominant head domain", "PROBLEM", 118, 148], ["head", "TEST", 247, 251], ["universal vaccine design", "TREATMENT", 308, 332], ["Krammer", "TREATMENT", 334, 341], ["Palese", "TREATMENT", 346, 352], ["mosaic HAs", "PROBLEM", 381, 391], ["head", "ANATOMY", 247, 251], ["antigenic sites", "OBSERVATION", 448, 463], ["head", "ANATOMY", 471, 475]]], ["Such a vaccination regimen can induce antibodies targeting both conserved HA stalk and conserved epitopes in the head domain, possessing improved potential as universal vaccines (Sun et al.2019).Immunodominance and Immunosubversion ::: Obstacles and StrategiesRecently, Kanekiyo et al. developed a novel immunosubversion strategy by enhancing the avidity of immunogens to cross-reactive B cells (Fig. 4C) (Kanekiyo et al.2019).", [["head domain", "ANATOMY", 113, 124], ["B cells", "ANATOMY", 387, 394], ["head", "ORGAN", 113, 117], ["B cells", "CELL", 387, 394], ["antibodies", "PROTEIN", 38, 48], ["HA stalk", "PROTEIN", 74, 82], ["conserved epitopes", "PROTEIN", 87, 105], ["head domain", "PROTEIN", 113, 124], ["cross-reactive B cells", "CELL_TYPE", 372, 394], ["a vaccination regimen", "TREATMENT", 5, 26], ["antibodies", "PROBLEM", 38, 48], ["conserved epitopes in the head domain", "PROBLEM", 87, 124], ["universal vaccines", "TREATMENT", 159, 177], ["a novel immunosubversion strategy", "TREATMENT", 296, 329], ["immunogens", "TREATMENT", 358, 368], ["cross-reactive B cells", "TREATMENT", 372, 394], ["head", "ANATOMY", 113, 117]]], ["Heterotypic influenza hemagglutinin antigens were co-localized on a single nanoparticle, generating a mosaic array.", [["Heterotypic influenza hemagglutinin antigens", "PROTEIN", 0, 44], ["Heterotypic influenza hemagglutinin antigens", "PROBLEM", 0, 44], ["a single nanoparticle", "TREATMENT", 66, 87], ["influenza", "OBSERVATION", 12, 21]]], ["After vaccination, the avidity advantage of conserved epitopes to B cells can be achieved over strain-specific B cells, i.e., the B cell responses can adaptively target conserved antigenic surfaces, promoting cross-reactive antibody secretion.", [["B cells", "ANATOMY", 66, 73], ["B cells", "ANATOMY", 111, 118], ["B cell", "ANATOMY", 130, 136], ["B cells", "CELL", 66, 73], ["B cells", "CELL", 111, 118], ["B cell", "CELL", 130, 136], ["B cells", "CELL_TYPE", 66, 73], ["B cells", "CELL_TYPE", 111, 118], ["vaccination", "TREATMENT", 6, 17], ["conserved epitopes to B cells", "PROBLEM", 44, 73], ["cross-reactive antibody secretion", "PROBLEM", 209, 242], ["cross-reactive", "OBSERVATION_MODIFIER", 209, 223], ["antibody secretion", "OBSERVATION", 224, 242]]], ["This heterotypic mosaic nanoparticle immunogen provides a new tool to combat viral genetic plasticity and antigenic variation.Immunodominance and Immunosubversion ::: Obstacles and StrategiesOf note, a latest study using an African green monkey IAV model revealed that although mismatched prime-boost generated a pool of stem-specific memory B cells, head-specific B cells and serum Abs still substantially dominated the immune response (Jegaskanda et al.2019).", [["stem", "ANATOMY", 321, 325], ["memory B cells", "ANATOMY", 335, 349], ["head", "ANATOMY", 351, 355], ["B cells", "ANATOMY", 365, 372], ["serum", "ANATOMY", 377, 382], ["green monkey", "ORGANISM", 232, 244], ["IAV", "ORGANISM", 245, 248], ["stem", "CELL", 321, 325], ["memory B cells", "CELL", 335, 349], ["head-specific B cells", "CELL", 351, 372], ["serum", "ORGANISM_SUBSTANCE", 377, 382], ["Abs", "GENE_OR_GENE_PRODUCT", 383, 386], ["stem-specific memory B cells", "CELL_TYPE", 321, 349], ["head-specific B cells", "CELL_TYPE", 351, 372], ["serum Abs", "PROTEIN", 377, 386], ["green monkey IAV", "SPECIES", 232, 248], ["African green monkey IAV", "SPECIES", 224, 248], ["This heterotypic mosaic nanoparticle immunogen", "TREATMENT", 0, 46], ["viral genetic plasticity", "PROBLEM", 77, 101], ["a latest study", "TEST", 200, 214], ["head-specific B cells", "TEST", 351, 372], ["serum Abs", "TEST", 377, 386], ["antigenic variation", "OBSERVATION", 106, 125], ["head", "ANATOMY", 351, 355]]], ["Moreover, it\u2019s theoretically proven that, at least in prime-boost model of mice, memory B cell (MBC) clones seldom reenter secondary germinal centers upon boosting (Mesin et al.2020).", [["memory B cell", "ANATOMY", 81, 94], ["MBC) clones", "ANATOMY", 96, 107], ["germinal centers", "ANATOMY", 133, 149], ["mice", "ORGANISM", 75, 79], ["memory B cell", "CELL", 81, 94], ["MBC) clones", "CELL", 96, 107], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 133, 149], ["memory B cell (MBC) clones", "CELL_LINE", 81, 107], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["memory B cell (MBC) clones seldom", "PROBLEM", 81, 114], ["germinal centers", "OBSERVATION", 133, 149]]], ["The rearrangement of MBC clones were therefore blocked, and the diversity and specificity were limited, restricting the breadth and effectiveness of the ensuing antibody response (Mesin et al.2020).", [["MBC clones", "ANATOMY", 21, 31], ["MBC", "CHEMICAL", 21, 24], ["MBC clones", "CELL", 21, 31], ["MBC clones", "CELL_LINE", 21, 31], ["MBC clones", "PROBLEM", 21, 31], ["MBC clones", "OBSERVATION", 21, 31]]], ["If this clonality bottleneck is also the case of humans, our ability to elicit antibodies to non-immunodominant epitopes may be further improved once the bottleneck is solved in future.Original Antigenic Sin Versus Additive Approach ::: Obstacles and Strategies\u201cOriginal Antigenic Sin (OAS)\u201d refers to the phenomenon that the antibody response to the first influenza virus variant one encounters dominates the anti-influenza virus antibody response lifelong (reviewed in (Henry et al.2018)).", [["humans", "ORGANISM", 49, 55], ["influenza virus", "ORGANISM", 357, 372], ["antibodies", "PROTEIN", 79, 89], ["non-immunodominant epitopes", "PROTEIN", 93, 120], ["humans", "SPECIES", 49, 55], ["humans", "SPECIES", 49, 55], ["anti-influenza virus", "SPECIES", 410, 430], ["antibodies to non-immunodominant epitopes", "PROBLEM", 79, 120], ["the antibody response", "TEST", 322, 343], ["the first influenza virus variant", "PROBLEM", 347, 380]]], ["To date, the knowledge of how past influenza exposure shapes the response to subsequent antigenically distinct influenza strains remains obscure.", [["influenza", "DISEASE", 35, 44], ["influenza", "DISEASE", 111, 120], ["past influenza exposure", "PROBLEM", 30, 53], ["subsequent antigenically distinct influenza strains", "PROBLEM", 77, 128], ["distinct", "OBSERVATION_MODIFIER", 102, 110], ["influenza strains", "OBSERVATION", 111, 128]]], ["Although \u201cantigen imprinting\u201d strategy has shown positive impact in the context of the development of a \u201cstalk-based\u201d universal influenza virus vaccine, the complex immune response underlying OAS more or less stymies the development of universal influenza vaccines (Cohen 2018).Original Antigenic Sin Versus Additive Approach ::: Obstacles and StrategiesAdditive approach by either serial vaccination or combined vaccination with multiple antigenic types has been successfully employed to produce pneumococcal conjugate vaccines (13 different antigens) and human papillomavirus vaccines (up to nine different antigens), which can elicit accumulated responses with non-overlapping specificities.", [["influenza", "DISEASE", 246, 255], ["antigen", "GENE_OR_GENE_PRODUCT", 10, 17], ["influenza virus", "ORGANISM", 128, 143], ["human", "ORGANISM", 557, 562], ["papillomavirus", "ORGANISM", 563, 577], ["influenza virus vaccine", "SPECIES", 128, 151], ["human", "SPECIES", 557, 562], ["pneumococcal", "SPECIES", 497, 509], ["human papillomavirus", "SPECIES", 557, 577], ["positive impact", "PROBLEM", 49, 64], ["a \u201cstalk", "PROBLEM", 102, 110], ["universal influenza virus vaccine", "TREATMENT", 118, 151], ["the complex immune response underlying OAS", "PROBLEM", 153, 195], ["universal influenza vaccines", "TREATMENT", 236, 264], ["Additive approach", "TREATMENT", 354, 371], ["serial vaccination", "TREATMENT", 382, 400], ["combined vaccination", "TREATMENT", 404, 424], ["pneumococcal conjugate vaccines", "TREATMENT", 497, 528], ["human papillomavirus vaccines", "TREATMENT", 557, 586], ["positive", "OBSERVATION_MODIFIER", 49, 57], ["impact", "OBSERVATION_MODIFIER", 58, 64]]], ["For influenza vaccines, admixture of multivalent influenza vaccines may result in antigenic competition and eventually lead to loss of efficacy for one or more components (Kanekiyo et al.2019).", [["influenza", "DISEASE", 4, 13], ["influenza", "DISEASE", 49, 58], ["influenza vaccines", "TREATMENT", 4, 22], ["multivalent influenza vaccines", "TREATMENT", 37, 67], ["loss of efficacy", "PROBLEM", 127, 143]]], ["Moreover, broad immunity has not been achieved by serial immunization with conventional flu vaccines (Belongia et al.2017).Original Antigenic Sin Versus Additive Approach ::: Obstacles and StrategiesIt is argued by Worobey et al. that the propensity of initial influenza virus exposure to establish a lifelong immunological imprint also presents a remarkable opportunity: immunization of infants prior to their initial, natural virus exposure with multiple versions of common human subtypes simultaneously may promise extended immunological imprinting across all currently circulating strains and against potential pandemic strains of IAV.", [["IAV", "DISEASE", 635, 638], ["influenza virus", "ORGANISM", 261, 276], ["infants", "ORGANISM", 388, 395], ["human", "ORGANISM", 476, 481], ["IAV", "ORGANISM", 635, 638], ["infants", "SPECIES", 388, 395], ["human", "SPECIES", 476, 481], ["human", "SPECIES", 476, 481], ["IAV", "SPECIES", 635, 638], ["serial immunization", "TREATMENT", 50, 69], ["conventional flu vaccines", "TREATMENT", 75, 100], ["initial influenza virus exposure", "PROBLEM", 253, 285], ["immunization", "TREATMENT", 372, 384], ["natural virus exposure", "TREATMENT", 420, 442], ["common human subtypes", "PROBLEM", 469, 490], ["circulating strains", "PROBLEM", 573, 592], ["potential pandemic strains of IAV", "PROBLEM", 605, 638]]], ["This approach might be a possible step toward a universal vaccine (Cohen 2018; Worobey et al.2020).Synthetic Epitope Mimetics ::: Future ProspectsThe huge growth in high-resolution 3D structures of proteins promotes the emergence of a novel paradigm in the study of biomolecular recognition, the design and synthesis of protein epitope mimetics.", [["The huge growth", "PROBLEM", 146, 161], ["the study", "TEST", 253, 262], ["biomolecular recognition", "TEST", 266, 290], ["synthesis of protein epitope mimetics", "TREATMENT", 307, 344], ["huge", "OBSERVATION_MODIFIER", 150, 154], ["growth", "OBSERVATION_MODIFIER", 155, 161], ["high", "OBSERVATION_MODIFIER", 165, 169], ["-resolution", "OBSERVATION_MODIFIER", 169, 180]]], ["Based on the natural structure of interested epitope, the mimetics (synthetic peptides) can be designed and synthesized, with diverse chemistries and cross-links (e.g., helix-stabilizing staples) harnessed to achieve desired folding (Zerbe et al.2017).Synthetic Epitope Mimetics ::: Future ProspectsRecent technological advances have suggested the promising potential of synthetic peptides as antigens to generate focused immune responses.", [["the mimetics (synthetic peptides", "TREATMENT", 54, 86], ["diverse chemistries", "TEST", 126, 145], ["cross-links", "TREATMENT", 150, 161], ["helix-stabilizing staples", "TREATMENT", 169, 194], ["synthetic peptides", "TREATMENT", 371, 389]]], ["By coupling a mimetic of the V3 loop from HIV-1 GP120 to synthetic virus-like nanoparticles, Riedel et al. successfully designed a candidate HIV-1 vaccine which can elicit antibodies in rabbits that recognized recombinant gp120 (Riedel et al.2011).", [["HIV-1", "ORGANISM", 42, 47], ["GP120", "GENE_OR_GENE_PRODUCT", 48, 53], ["HIV-1", "ORGANISM", 141, 146], ["rabbits", "ORGANISM", 186, 193], ["gp120", "GENE_OR_GENE_PRODUCT", 222, 227], ["V3 loop", "PROTEIN", 29, 36], ["antibodies", "PROTEIN", 172, 182], ["recombinant gp120", "PROTEIN", 210, 227], ["HIV-1", "SPECIES", 42, 47], ["HIV-1", "SPECIES", 141, 146], ["rabbits", "SPECIES", 186, 193], ["HIV-1", "SPECIES", 42, 47], ["HIV-1", "SPECIES", 141, 146], ["rabbits", "SPECIES", 186, 193], ["the V3 loop", "PROBLEM", 25, 36], ["HIV", "PROBLEM", 42, 45], ["synthetic virus", "PROBLEM", 57, 72], ["a candidate HIV-1 vaccine", "TREATMENT", 129, 154]]], ["Moreover, both folded B- and linear T- epitopes can be displayed on the engineered nanoparticles, inducing antibody response and T-cell response respectively (Zerbe et al.2017).De Novo Immunogen Design ::: Future ProspectsThe computational design of new proteins sparks hopes in the field of rational vaccinology, particularly to elicit targeted neutralizing antibody responses (Correia et al.2014; Sesterhenn et al.2019).", [["T-cell", "ANATOMY", 129, 135], ["B", "GENE_OR_GENE_PRODUCT", 22, 23], ["T-cell", "CELL", 129, 135], ["folded B- and linear T- epitopes", "PROTEIN", 15, 47], ["the engineered nanoparticles", "TREATMENT", 68, 96], ["antibody response", "TEST", 107, 124], ["T-cell response", "TEST", 129, 144], ["new proteins sparks", "PROBLEM", 250, 269], ["rational vaccinology", "TREATMENT", 292, 312], ["targeted neutralizing antibody responses", "PROBLEM", 337, 377], ["new", "OBSERVATION_MODIFIER", 250, 253], ["proteins sparks", "OBSERVATION", 254, 269]]], ["Interestingly, a great progress has been made recently by Sesterhenn et al., who developed a novel computational design strategy to build de novo proteins presenting complex structural motifs (Sesterhenn et al.2020).", [["complex structural motifs", "PROTEIN", 166, 191], ["a novel computational design strategy", "TREATMENT", 91, 128]]], ["By using this strategy, the authors further engineered epitope-focused immunogens mimicking irregular and discontinuous RSV neutralization epitopes.", [["RSV", "ORGANISM", 120, 123], ["RSV neutralization epitopes", "PROTEIN", 120, 147], ["RSV", "SPECIES", 120, 123], ["this strategy", "TREATMENT", 9, 22], ["focused immunogens", "TREATMENT", 63, 81], ["discontinuous RSV neutralization epitopes", "TREATMENT", 106, 147], ["RSV neutralization", "OBSERVATION", 120, 138]]], ["And excitingly, the de novo\u2013designed immunogens can induce robust neutralizing responses against the respiratory syncytial virus in both mice and nonhuman primates (Sesterhenn et al.2020).ConclusionsThe ever-changing influenza surface proteins, HA and NA, arouse the desire of a universal flu vaccine.", [["surface", "ANATOMY", 227, 234], ["respiratory syncytial virus", "DISEASE", 101, 128], ["NA", "CHEMICAL", 252, 254], ["respiratory syncytial virus", "ORGANISM", 101, 128], ["mice", "ORGANISM", 137, 141], ["nonhuman primates", "ORGANISM", 146, 163], ["influenza surface proteins", "PROTEIN", 217, 243], ["mice", "SPECIES", 137, 141], ["respiratory syncytial virus", "SPECIES", 101, 128], ["mice", "SPECIES", 137, 141], ["the de novo\u2013designed immunogens", "TREATMENT", 16, 47], ["robust neutralizing responses", "PROBLEM", 59, 88], ["the respiratory syncytial virus", "PROBLEM", 97, 128], ["changing influenza surface proteins", "PROBLEM", 208, 243], ["HA", "PROBLEM", 245, 247], ["a universal flu vaccine", "TREATMENT", 277, 300], ["respiratory syncytial virus", "OBSERVATION", 101, 128]]], ["By offering life-long protection against all influenza strains, an universal vaccine can greatly reduce the need for yearly vaccine reformulations and vaccination.", [["influenza", "DISEASE", 45, 54], ["life-long protection", "TREATMENT", 12, 32], ["all influenza strains", "PROBLEM", 41, 62], ["an universal vaccine", "TREATMENT", 64, 84], ["yearly vaccine reformulations", "TREATMENT", 117, 146], ["vaccination", "TREATMENT", 151, 162]]], ["So far, many universal influenza vaccine candidates that are in clinical trials focus on targeting conserved epitopes of influenza, including either surface proteins or highly conserved internal proteins.", [["surface", "ANATOMY", 149, 156], ["influenza", "DISEASE", 121, 130], ["surface proteins", "PROTEIN", 149, 165], ["highly conserved internal proteins", "PROTEIN", 169, 203], ["many universal influenza vaccine candidates", "TREATMENT", 8, 51], ["influenza", "PROBLEM", 121, 130], ["surface proteins", "PROBLEM", 149, 165], ["internal proteins", "OBSERVATION", 186, 203]]], ["Moreover, the new identified highly conserved epitopes and advanced techniques will lead to the fast development of next-generation universal flu vaccines.", [["advanced techniques", "TREATMENT", 59, 78], ["next-generation universal flu vaccines", "TREATMENT", 116, 154]]]], "PMC7197384": [["Praxisbeispiel ::: Transformationale F\u00fchrungIch arbeite in Einzelcoachings gerne mit Pers\u00f6nlichkeits-/Motivstrukturanalysen (vgl.", [["Transformationale", "TEST", 19, 36], ["Einzelcoachings", "TEST", 59, 74], ["Pers\u00f6nlichkeits", "TEST", 85, 100], ["Motivstrukturanalysen", "PROBLEM", 102, 123]]], ["Abschn.", [["Abschn", "PROTEIN", 0, 6]]], ["Dies deshalb, um schneller einen Zugang zu den M\u00f6glichkeiten und Entwicklungsfeldern von F\u00fchrungskr\u00e4ften zu erhalten.", [["Dies deshalb, um schneller einen Zugang zu den M\u00f6glichkeiten und Entwicklungsfeldern von F\u00fchrungskr\u00e4ften zu erhalten", "SPECIES", 0, 116]]], ["Man sp\u00fcrt regelrecht das Unbehagen, wenn sich das Gespr\u00e4ch in diese Richtung neigt.", [["Man", "SPECIES", 0, 3]]], ["Die F\u00fchrungskr\u00e4fte versuchen dann auszuweichen, zu bagatellisieren oder zu theoretisieren.", [["Die F\u00fchrungskr\u00e4fte versuchen dann auszuweichen, zu bagatellisieren oder zu theoretisieren", "SPECIES", 0, 89]]], ["Teilweise suchen sie Gespr\u00e4chsanleitungen und Tools, wie sie emotionalen Situationen mit Ihren Mitarbeiterinnen \u00fcber ihr Engagement und/oder ihre hohe Expertise im Fachlichen und Methodischen.", [["Teilweise suchen sie Gespr\u00e4chsanleitungen und Tools, wie sie emotionalen Situationen mit Ihren Mitarbeiterinnen \u00fcber ihr Engagement und/oder ihre hohe Expertise im Fachlichen und Methodischen", "SPECIES", 0, 191]]], ["Bei der Selbstreflexion fehlen ihnen wichtige innere Zugangswege, um sich selbst und das Miteinander mit anderen besser einordnen zu k\u00f6nnen.", [["Bei der Selbstreflexion fehlen ihnen wichtige innere Zugangswege, um sich selbst und das Miteinander mit anderen besser einordnen zu k\u00f6nnen", "SPECIES", 0, 139]]], ["Sie sp\u00fcren, dass es ihnen schwerer f\u00e4llt, in Konfliktsituationen an das Kernthema des Mitarbeiters/der Mitarbeiterin heranzukommen.", [["Konfliktsituationen an das Kernthema des Mitarbeiters/der Mitarbeiterin heranzukommen", "SPECIES", 45, 130]]], ["Es gelingt ihnen nicht, sich auf deren Bed\u00fcrfnisebene einzulassen, erst recht, wenn es um die Verletzung emotionaler Bed\u00fcrfnisse geht.Praxisbeispiel ::: Transformationale F\u00fchrungNun erleben sie in zunehmendem Ma\u00dfe, dass man ihnen durch neue F\u00fchrungsstile, wie dem transformationalen, vorh\u00e4lt, sich ihren Schw\u00e4chen stellen zu m\u00fcssen.", [["man", "SPECIES", 220, 223]]], ["Mehr Charisma, mehr Emotionalit\u00e4t, mehr Psychologie und Soziologie statt Betriebswirtschaft, Jura, Mathematik oder IT.", [["Jura", "ANATOMY", 93, 97]]], ["Wie so h\u00e4ufig f\u00fchrt es eher zu Verunsicherung und Ablehnung, wenn bei allen F\u00fchrungskr\u00e4ften versucht wird, im Zuge einer \u201eDas-machen-wir-jetzt-k\u00fcnftig-alle-gleich-Forderung\u201c mit der Heckenschere Konformismus zu erzeugen.", [["h\u00e4ufig f\u00fchrt es eher zu Verunsicherung und Ablehnung, wenn bei allen F\u00fchrungskr\u00e4ften versucht wird, im Zuge einer \u201eDas-machen-wir-jetzt-k\u00fcnftig-alle-gleich-Forderung\u201c mit der Heckenschere Konformismus zu erzeugen", "SPECIES", 7, 219], ["machen", "TEST", 126, 132], ["jetzt", "TREATMENT", 137, 142]]], ["10.1007/978-3-658-29031-3_5 wird dies deutlicher thematisieren.Praxisbeispiel ::: Transformationale F\u00fchrungDennoch soll dies kein Alibi sein, sich bei der Reflexion \u00fcber die eigenen F\u00fchrungsaufgaben und Grundhaltungen mit den daf\u00fcr erforderlichen Sachverhalten nicht auseinandersetzen zu m\u00fcssen.Fazit aus diesem AbschnittDie Merkmale des bereits \u00fcber 40 Jahre alten transformationalen F\u00fchrungsstils r\u00fccken aktuell in den Fokus der F\u00fchrungspraxis.", [["10.1007/978-3-658-29031-3_5 wird", "CHEMICAL", 0, 32], ["F\u00fchrungDennoch soll dies kein Alibi sein, sich bei der Reflexion \u00fcber die eigenen F\u00fchrungsaufgaben und Grundhaltungen mit den daf\u00fcr erforderlichen Sachverhalten nicht auseinandersetzen zu m\u00fcssen", "SPECIES", 100, 294], ["Fazit aus diesem", "PROBLEM", 295, 311], ["Merkmale des bereits", "TREATMENT", 325, 345]]], ["F\u00fchrung zeichnet sich in diesem Kontext durch Charisma und das Einbringen einer emotionalen Komponente (im Sinne der Selbstreflexion, aber vor allem der Auseinandersetzung mit den Emotionen und Gef\u00fchlen von Mitarbeiterinnen gegen\u00fcber kommunizieren d\u00fcrfen, dass sie nicht g\u00e4nzlich hinter der Entscheidung des oberen Managements stehen.Praxisbeispiel ::: Authentische, vertrauensbasierte F\u00fchrungSie erleben einen intrapsychischen Konflikt, d. h. in ihnen entstehen unvereinbare, einander entgegengerichtete Handlungstendenzen (stehe ich kommentarlos zur Entscheidung des Managements und mache mich selbst unglaubw\u00fcrdig oder vertrete ich meine Meinung und verhalte mich dadurch dem Management gegen\u00fcber illoyal).", [["diesem Kontext durch Charisma und das Einbringen einer emotionalen Komponente (im Sinne der Selbstreflexion, aber vor allem der Auseinandersetzung mit den Emotionen und Gef\u00fchlen von Mitarbeiterinnen gegen\u00fcber kommunizieren d\u00fcrfen, dass sie nicht g\u00e4nzlich hinter der Entscheidung des oberen Managements stehen", "SPECIES", 25, 333], ["stehe ich kommentarlos zur Entscheidung des Managements und mache mich selbst unglaubw\u00fcrdig oder vertrete ich meine Meinung und verhalte mich dadurch dem Management gegen\u00fcber illoyal", "SPECIES", 525, 707], ["F\u00fchrung zeichnet sich", "PROBLEM", 0, 21], ["emotionalen Komponente (im Sinne der Selbstreflexion", "TREATMENT", 80, 132], ["Authentische", "TREATMENT", 353, 365], ["stehe ich kommentarlos zur Entscheidung des Managements", "TREATMENT", 525, 580], ["ich", "PROBLEM", 631, 634]]], ["Dieses Erleben f\u00fchrt h\u00e4ufig zu emotionalen Spannungen.Praxisbeispiel ::: Authentische, vertrauensbasierte F\u00fchrungWenn F\u00fchrung wirksam sein soll, m\u00fcssen alle F\u00fchrungsebenen eines Hauses an einem Strang und in dieselbe Richtung ziehen.", [["Authentische", "TEST", 73, 85]]], ["Die Frage stellt sich somit nicht, ob die Filial-, Team- oder Abteilungsleitung die Entscheidung des Vorstandes oder der Bereichsleitung mittr\u00e4gt.", [["Die Frage stellt sich somit nicht, ob die Filial-, Team- oder Abteilungsleitung die Entscheidung des Vorstandes oder der Bereichsleitung mittr\u00e4gt", "SPECIES", 0, 145]]], ["Vielmehr ist zu kl\u00e4ren, welche Widerspr\u00fcche und Fragen offen sind, die eine vollumf\u00e4ngliche Identifikation aktuell noch nicht m\u00f6glich machen und wie diese ausger\u00e4umt werden k\u00f6nnen.Praxisbeispiel ::: Authentische, vertrauensbasierte F\u00fchrungAber selbst wenn dieser Diskurs auf allen F\u00fchrungsebenen gef\u00fchrt wurde, kann der innere Widerspruch bei der jeweiligen F\u00fchrungskraft aufgrund differenzierter Wertvorstellungen nach wie vor bestehen bleiben.", [["Authentische", "TREATMENT", 199, 211]]], ["Der Hauptansatz des Coaching liegt dann darin, eine vertretbare innere Grundhaltung zu entwickeln, die ein leichteres Handling des Widerspruchs m\u00f6glich macht.", [["Der Hauptansatz des Coaching liegt dann darin, eine vertretbare innere Grundhaltung zu entwickeln, die ein leichteres Handling des Widerspruchs m\u00f6glich macht", "SPECIES", 0, 157], ["Der Hauptansatz des", "TREATMENT", 0, 19]]], ["Zus\u00e4tzlich k\u00f6nnen gesichtswahrende Kommunikationsans\u00e4tze in Richtung Mitarbeiterinnen.", [["Zus\u00e4tzlich", "TREATMENT", 0, 10]]], ["Kommt dies h\u00e4ufiger vor, sollte sich die betroffene Person im Extremfall zum eigenen Selbstschutz mit der Entscheidung auseinandersetzen, die Bank/Sparkasse zu verlassen oder ihre Rolle als F\u00fchrungskraft aufzugeben.Fazit aus diesem AbschnittEine auf Vertrauen ausgerichtete Unternehmens- und F\u00fchrungskultur f\u00fchrt zu einem signifikant h\u00f6heren Commitment der Mitarbeiterinnen und Kolleginnen aufs Spiel.Praxisbeispiel ::: Digital LeadershipTeilweise ist f\u00fcr einzelne F\u00fchrungskr\u00e4fte nicht unmittelbar nachvollziehbar, worum es genau geht, wenn von einem Aufbau von digitalen Kompetenzen gesprochen wird.", [["Praxisbeispiel", "CHEMICAL", 401, 415], ["sollte sich die betroffene Person im Extremfall zum eigenen Selbstschutz mit der Entscheidung auseinandersetzen, die Bank/Sparkasse zu verlassen oder ihre Rolle als F\u00fchrungskraft aufzugeben", "SPECIES", 25, 214], ["Fazit aus diesem AbschnittEine auf Vertrauen ausgerichtete Unternehmens- und F\u00fchrungskultur f\u00fchrt zu einem signifikant h\u00f6heren Commitment der Mitarbeiterinnen und Kolleginnen aufs", "SPECIES", 215, 394], ["Fazit aus diesem", "PROBLEM", 215, 231]]], ["Dadurch lenken sie ihr Verhalten st\u00e4rker in die gew\u00fcnschte Richtung und zahlen damit mittelbar oder unmittelbar auf diese Ziele ein.", [["Dadurch lenken sie ihr Verhalten st\u00e4rker in die gew\u00fcnschte Richtung und zahlen damit mittelbar oder unmittelbar auf diese Ziele ein", "SPECIES", 0, 131]]], ["Erst nach dieser Erkenntnis gab er die erforderlichen Projektschritte zur Entwicklung einer Kompetenzsystematik frei.Praxisbeispiel ::: Digital LeadershipAuch in den Fachbereichen reicht es oft nicht aus, digitale Kompetenzen und Verhaltensanker zu definieren (siehe Abschn.", [["Praxisbeispiel", "CHEMICAL", 117, 131], ["Digital LeadershipAuch", "TREATMENT", 136, 158]]], ["H\u00e4ufig nimmt dies f\u00fcr die Anwendung eine zu hohe Abstraktionsebene ein.", [["H\u00e4ufig nimmt dies f\u00fcr die Anwendung eine zu hohe Abstraktionsebene ein", "SPECIES", 0, 70]]], ["Beispielsweise wirkt sich dies folgenderma\u00dfen aus:Aufbau und Nutzung einer CRM (Customer-Relationship-Management) -Systematik.Einsatz eines Ticket-Systems/der Vorgangssteuerung zur Schaffung von Transparenz zu Arbeitsabl\u00e4ufen.Einbindung von Recherche-Ergebnissen im Internet in die eigene Arbeit.Nutzung von Foren, Suchmaschinen, Netzwerken und weiteren Plattformen zur Erweiterung des eigenen Wissens, des Wissens des Teams/der Bank/Sparkasse.Ber\u00fccksichtigung von Vorgaben bei fallabschlie\u00dfenden Vorg\u00e4ngen.Bedachte und zielorientierte Nutzung der digitalen Anwendungen und Ger\u00e4te in der Bank/Filiale/am Arbeitsplatz.Einbindung von Spezialisten in den Beratungsprozess \u00fcber Videokan\u00e4le.Unterst\u00fctzung von Kolleginnen stellt dies jedoch nach wie vor ein gro\u00dfes Lernfeld dar, das uns zum nachfolgenden F\u00fchrungsstil bringt.Fazit aus diesem AbschnittF\u00fchrungskr\u00e4fte m\u00fcssen sich selbst fit machen, um die Herausforderungen der digitalen Arbeit bew\u00e4ltigen zu k\u00f6nnen.", [["Einsatz eines Ticket-Systems/der Vorgangssteuerung zur Schaffung von Transparenz zu Arbeitsabl\u00e4ufen", "SPECIES", 126, 225], ["Netzwerken und weiteren Plattformen zur Erweiterung des eigenen Wissens, des Wissens des Teams/der Bank/Sparkasse", "SPECIES", 330, 443], ["Bedachte und zielorientierte Nutzung der digitalen Anwendungen und Ger\u00e4te in der Bank/Filiale/am Arbeitsplatz", "SPECIES", 507, 616], ["Fazit aus diesem AbschnittF\u00fchrungskr\u00e4fte m\u00fcssen sich selbst fit machen, um die Herausforderungen der digitalen Arbeit bew\u00e4ltigen zu k\u00f6nnen", "SPECIES", 819, 957], ["Suchmaschinen", "TREATMENT", 315, 328], ["Bedachte", "TREATMENT", 507, 515], ["Arbeitsplatz", "TREATMENT", 604, 616], ["Fazit aus diesem", "PROBLEM", 819, 835]]], ["Den fachlichen, regelm\u00e4\u00dfigen Austausch versucht sie neben dem g\u00e4ngigen Mailverkehr einmal pro Woche zum Wochenstart \u00fcber kurze, halbst\u00fcndige Video- oder Telefonkonferenzen mit allen, die gerade Zeit und die M\u00f6glichkeit hierzu haben, sicherzustellen.", [["Den fachlichen, regelm\u00e4\u00dfigen Austausch versucht sie neben dem g\u00e4ngigen Mailverkehr einmal pro Woche zum Wochenstart \u00fcber kurze, halbst\u00fcndige Video- oder Telefonkonferenzen mit allen, die gerade Zeit und die M\u00f6glichkeit hierzu haben", "SPECIES", 0, 231]]], ["Am Ende der Woche ruft sie bei jedem Mitarbeiter/jeder Mitarbeiterin pers\u00f6nlich an, um das pers\u00f6nliche Befinden zu erkunden und kurz die Woche Revue passieren zu lassen.", [["Am Ende der Woche ruft sie bei jedem Mitarbeiter/jeder Mitarbeiterin pers\u00f6nlich an, um das pers\u00f6nliche Befinden zu erkunden und kurz die Woche Revue passieren zu lassen", "SPECIES", 0, 168], ["sie bei jedem Mitarbeiter", "TREATMENT", 23, 48], ["jeder Mitarbeiterin", "TREATMENT", 49, 68]]], ["Vertrauen braucht eben eine gewisse N\u00e4he, auch oder vor allem in der virtuellen Welt.Fazit aus diesem AbschnittDie Aufgaben von F\u00fchren in virtuellen Teams/bei der F\u00fchrung auf Distanz unterscheiden sich augenscheinlich nicht von denen bei der F\u00fchrung von Pr\u00e4senzteams.", [["Fazit aus diesem AbschnittDie Aufgaben von F\u00fchren in virtuellen Teams/bei der F\u00fchrung auf Distanz unterscheiden sich augenscheinlich nicht von denen bei der F\u00fchrung von Pr\u00e4senzteams", "SPECIES", 85, 266], ["Fazit aus diesem", "PROBLEM", 85, 101]]], ["Um N\u00e4he \u00fcber Distanz zu gew\u00e4hrleisten und Vertrauen auf Distanz aufzubauen bzw. aufrecht zu erhalten, bedarf es einer Kombination aus einer effizienten Nutzung technischer M\u00f6glichkeiten und einem regelm\u00e4\u00dfigen Austausch auch auf der pers\u00f6nlichen Ebene in Pr\u00e4senztreffen.", [["N\u00e4he \u00fcber Distanz zu gew\u00e4hrleisten und Vertrauen auf Distanz aufzubauen bzw", "SPECIES", 3, 78]]], ["F\u00fchrung sollte den pers\u00f6nlichen Kontakt zu Beginn der Arbeit auf Distanz intensiver gestalten und dann im weiteren Verlauf je nach Komplexit\u00e4t des dahinterliegenden Sachverhaltes angemessen ausrichten.Praxisbeispiel ::: Agile F\u00fchrung/Agiles CoachingBanken und Sparkassen gehen verst\u00e4rkt dazu \u00fcber, Schl\u00fcsselfunktionen f\u00fcr die Entwicklung und Einf\u00fchrung von Innovationen im Sinne eines CDO (Chief Digital Officers) einzurichten.", [["Praxisbeispiel", "CHEMICAL", 201, 215], ["F\u00fchrung sollte den pers\u00f6nlichen Kontakt zu Beginn der Arbeit auf Distanz intensiver gestalten und dann im weiteren Verlauf je nach Komplexit\u00e4t des dahinterliegenden Sachverhaltes angemessen ausrichten", "SPECIES", 0, 200], ["Agile F\u00fchrung/Agiles CoachingBanken und Sparkassen gehen verst\u00e4rkt dazu \u00fcber, Schl\u00fcsselfunktionen f\u00fcr die Entwicklung und Einf\u00fchrung von Innovationen im Sinne eines CDO (Chief Digital Officers) einzurichten", "SPECIES", 220, 426], ["einzurichten", "TREATMENT", 414, 426]]], ["Dies ist grunds\u00e4tzlich sinnvoll, r\u00fcckt die Thematik damit n\u00e4her an die Vorstandsebene.", [["Vorstandsebene", "CHEMICAL", 71, 85]]], ["Da diese Funktionen aber oft als Querschnittsfunktionen daran gemessen werden, wie schnell sie Neuerungen umsetzen, sto\u00dfen sie h\u00e4ufig auf Widerst\u00e4nde in den klassischen Linienfunktionen.Praxisbeispiel ::: Agile F\u00fchrung/Agiles CoachingDie Fachabteilungen und Bereiche verteidigen h\u00e4ufig ihre, nicht selten in Eigenentwicklung, aufgebauten Systeme und Vorgehensweisen als einzig funktionierende L\u00f6sung.", [["Praxisbeispiel", "CHEMICAL", 186, 200]]], ["Hilfreich sind daher eine hohe Transparenz zur Sinnhaftigkeit m\u00f6glicher Neuerungen f\u00fcr die betroffene Abteilung/den betroffenen Bereich sowie eine fr\u00fchzeitige Einbindung der Betroffenen in den Ver\u00e4nderungsprozess.Praxisbeispiel ::: Agile F\u00fchrung/Agiles CoachingAlberts und Hayes (2009) schlagen vor, ein abgewandeltes Verst\u00e4ndnis von agil zu verfolgen, das einer eher hybriden Vorgehensweise entspricht und sowohl ein inkrementell-adaptives Vorgehen als auch ein stark planbestimmtes und auf strikt einzuhaltende Prozesse abgest\u00fctztes Vorgehen erm\u00f6glicht.Praxisbeispiel ::: Agile F\u00fchrung/Agiles CoachingNach ihren Vorstellungen ist eine Organisation dann \u201eagil\u201c, wenn die sie bildenden Menschen die folgenden F\u00e4higkeiten und Eigenschaften mitbringen:Robustheit: die F\u00e4higkeit, aufgaben-, situations- und bedingungs\u00fcbergreifend effektiv zu bleibenBelastbarkeit: die F\u00e4higkeit, sich von Ungl\u00fccksf\u00e4llen, Sch\u00e4den oder einer destabilisierenden St\u00f6rung der Umgebung zu erholen oder sich darauf einzustellenReaktionsf\u00e4higkeit: die F\u00e4higkeit, auf eine Ver\u00e4nderung der Umgebung rechtzeitig zu reagierenFlexibilit\u00e4t: die F\u00e4higkeit, mehrere L\u00f6sungsm\u00f6glichkeiten einzusetzen und nahtlos von einer zur anderen \u00fcberzugehenInnovationsf\u00e4higkeit: die F\u00e4higkeit, neue Dinge zu tun und alte Dinge auf eine neue Art und Weise zu tunAnpassungsf\u00e4higkeit: die F\u00e4higkeit, Arbeitsprozesse zu \u00e4ndern und die Organisation zu \u00e4ndern.Praxisbeispiel ::: Agile F\u00fchrung/Agiles CoachingNur mal rein theoretisch: Wenn die Mitarbeiterinnen unterst\u00fctzt und wenn ihr Ausma\u00df und ihre Art zur jeweiligen Situation passt.Praxisbeispiel ::: Agile F\u00fchrung/Agiles CoachingUm sich Klarheit dar\u00fcber zu verschaffen, welche Arten von F\u00fchrung geeignet sind, mit Unsicherheit und Unplanbarkeit umzugehen, formuliert er folgende Fragen:Praxisbeispiel ::: Agile F\u00fchrung/Agiles Coaching", [["Praxisbeispiel", "CHEMICAL", 555, 569], ["Praxisbeispiel", "CHEMICAL", 1405, 1419], ["Praxisbeispiel", "CHEMICAL", 1581, 1595], ["Hilfreich sind daher eine hohe Transparenz zur Sinnhaftigkeit m\u00f6glicher Neuerungen f\u00fcr die betroffene Abteilung/den betroffenen Bereich sowie eine fr\u00fchzeitige Einbindung der Betroffenen in den Ver\u00e4nderungsprozess", "SPECIES", 0, 212], ["Agile F\u00fchrung/Agiles CoachingAlberts und Hayes (2009) schlagen vor, ein abgewandeltes Verst\u00e4ndnis von agil zu verfolgen, das einer eher hybriden Vorgehensweise entspricht und sowohl ein inkrementell-adaptives Vorgehen als auch ein stark planbestimmtes und auf strikt einzuhaltende Prozesse abgest\u00fctztes Vorgehen erm\u00f6glicht", "SPECIES", 232, 554], ["Agile F\u00fchrung/Agiles CoachingNach ihren Vorstellungen ist eine Organisation dann \u201eagil\u201c, wenn die sie bildenden Menschen die folgenden F\u00e4higkeiten und Eigenschaften mitbringen:Robustheit: die F\u00e4higkeit, aufgaben-, situations- und bedingungs\u00fcbergreifend effektiv zu bleibenBelastbarkeit: die F\u00e4higkeit, sich von Ungl\u00fccksf\u00e4llen, Sch\u00e4den oder einer destabilisierenden St\u00f6rung der Umgebung zu erholen oder sich darauf einzustellen", "SPECIES", 574, 1000], ["auf eine Ver\u00e4nderung der Umgebung rechtzeitig zu reagierenFlexibilit\u00e4t: die F\u00e4higkeit, mehrere L\u00f6sungsm\u00f6glichkeiten einzusetzen und nahtlos von einer zur anderen \u00fcberzugehenInnovationsf\u00e4higkeit: die F\u00e4higkeit, neue Dinge zu tun und alte Dinge auf eine neue Art und Weise zu tunAnpassungsf\u00e4higkeit: die F\u00e4higkeit, Arbeitsprozesse zu \u00e4ndern und die Organisation zu \u00e4ndern", "SPECIES", 1035, 1404], ["Nur mal rein theoretisch: Wenn die Mitarbeiterinnen unterst\u00fctzt und wenn ihr Ausma\u00df und ihre Art zur jeweiligen Situation passt", "SPECIES", 1453, 1580], ["Agile F\u00fchrung/Agiles CoachingUm sich Klarheit dar\u00fcber zu verschaffen, welche Arten von F\u00fchrung geeignet sind, mit Unsicherheit und Unplanbarkeit umzugehen, formuliert er folgende", "SPECIES", 1600, 1778], ["Hilfreich", "TREATMENT", 0, 9], ["CoachingNach", "TREATMENT", 595, 607]]]], "2fb2cdde36df0ff916a4271b6dcfaaaa70f3a1f7": [["IntroductionCOVID-19 represents a serious threat to patients on maintenance dialysis.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["IntroductionCOVID", "TEST", 0, 17], ["maintenance dialysis", "TREATMENT", 64, 84]]], ["The clinical setting, mortality rate and prognostic factors in these patients have not been well established.MethodsWe included all dialyzed patients with COVID-19 referred to our dialysis center between March 11 and April 11, 2020.", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 141, 149], ["mortality rate", "PROBLEM", 22, 36], ["prognostic factors", "PROBLEM", 41, 59]]], ["Data were obtained through the review of the medical records and were censored at the time of data cutoff, on May 11, 2020.ResultsForty-four patients on maintenance dialysis with COVID-19 were referred to our dialysis unit during the COVID-19 epidemic.", [["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["maintenance dialysis", "TREATMENT", 153, 173], ["COVID", "TREATMENT", 179, 184], ["the COVID", "TEST", 230, 239]]], ["65.9% were men.ResultsComorbidities included hypertension (97.7%), diabetes mellitus (50%), chronic cardiac (38.6%) and respiratory (27.3%) diseases.", [["cardiac", "ANATOMY", 100, 107], ["respiratory", "ANATOMY", 120, 131], ["hypertension", "DISEASE", 45, 57], ["diabetes mellitus", "DISEASE", 67, 84], ["men", "ORGANISM", 11, 14], ["cardiac", "ORGAN", 100, 107], ["men", "SPECIES", 11, 14], ["ResultsComorbidities", "TEST", 15, 35], ["hypertension", "PROBLEM", 45, 57], ["diabetes mellitus", "PROBLEM", 67, 84], ["chronic cardiac", "PROBLEM", 92, 107], ["respiratory (27.3%) diseases", "PROBLEM", 120, 148], ["hypertension", "OBSERVATION", 45, 57], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["cardiac", "ANATOMY", 100, 107], ["respiratory", "ANATOMY", 120, 131]]], ["Initial symptoms were fever (79.5%), shortness of breath (29.5%), cough (43.2%), and diarrhea (13.6%).", [["fever", "DISEASE", 22, 27], ["shortness of breath", "DISEASE", 37, 56], ["cough", "DISEASE", 66, 71], ["diarrhea", "DISEASE", 85, 93], ["Initial symptoms", "PROBLEM", 0, 16], ["fever", "PROBLEM", 22, 27], ["shortness of breath", "PROBLEM", 37, 56], ["cough", "PROBLEM", 66, 71], ["diarrhea", "PROBLEM", 85, 93]]], ["Three profiles of severity were distinguished based on the WHO progression scale.", [["severity", "PROBLEM", 18, 26]]], ["Forty-one (93.2%) were hospitalized and only three were maintained on outpatient hemodialysis.", [["outpatient hemodialysis", "TREATMENT", 70, 93]]], ["Thirty-three (75%) patients required oxygen therapy, including 15 (45.5%) who were referred to the intensive care unit.ResultsOverall, 27.3% of patients died, and 58.5% were discharged from hospital, including only two (13.3%) of those admitted to the intensive care unit.", [["oxygen", "CHEMICAL", 37, 43], ["oxygen", "CHEMICAL", 37, 43], ["patients", "ORGANISM", 19, 27], ["oxygen", "SIMPLE_CHEMICAL", 37, 43], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 144, 152], ["oxygen therapy", "TREATMENT", 37, 51], ["oxygen therapy", "OBSERVATION", 37, 51]]], ["By multivariate analysis, cough, thrombopenia < 120 G/L, LDH level greater than 2 times the upper limit of normal, and blood CRP > 175 mg/L were significantly associated with death.ConclusionA major outbreak of COVID-19 occurred in the Paris Region, and spread among dialyzed patients.", [["blood", "ANATOMY", 119, 124], ["cough", "DISEASE", 26, 31], ["thrombopenia", "DISEASE", 33, 45], ["death", "DISEASE", 175, 180], ["COVID-19", "CHEMICAL", 211, 219], ["LDH", "GENE_OR_GENE_PRODUCT", 57, 60], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["CRP", "GENE_OR_GENE_PRODUCT", 125, 128], ["patients", "ORGANISM", 276, 284], ["LDH", "PROTEIN", 57, 60], ["CRP", "PROTEIN", 125, 128], ["patients", "SPECIES", 276, 284], ["multivariate analysis", "TEST", 3, 24], ["cough", "PROBLEM", 26, 31], ["thrombopenia", "PROBLEM", 33, 45], ["G/L", "TEST", 52, 55], ["LDH level", "TEST", 57, 66], ["blood CRP", "TEST", 119, 128], ["death", "PROBLEM", 175, 180], ["COVID", "TEST", 211, 216], ["thrombopenia", "OBSERVATION", 33, 45], ["upper limit", "OBSERVATION_MODIFIER", 92, 103], ["normal", "OBSERVATION", 107, 113], ["Paris", "ANATOMY", 236, 241], ["Region", "ANATOMY_MODIFIER", 242, 248], ["spread", "OBSERVATION_MODIFIER", 254, 260]]], ["Our study underscores the severity of COVID-19 in these patients and identified prognostic markers.INTRODUCTIONIn December 2019, a novel coronavirus disease 2019 disease, caused by SARS-CoV-2 virus, occurred in Wuhan, Hubei Province, China, and rapidly spread worldwide.", [["coronavirus disease 2019 disease", "DISEASE", 137, 169], ["SARS-CoV-2 virus", "DISEASE", 181, 197], ["COVID-19", "GENE_OR_GENE_PRODUCT", 38, 46], ["patients", "ORGANISM", 56, 64], ["SARS-CoV-2 virus", "ORGANISM", 181, 197], ["patients", "SPECIES", 56, 64], ["CoV-2 virus", "SPECIES", 186, 197], ["SARS-CoV-2 virus", "SPECIES", 181, 197], ["Our study", "TEST", 0, 9], ["COVID", "TEST", 38, 43], ["prognostic markers", "TEST", 80, 98], ["a novel coronavirus disease 2019 disease", "PROBLEM", 129, 169], ["SARS", "PROBLEM", 181, 185], ["CoV-2 virus", "PROBLEM", 186, 197], ["coronavirus disease", "OBSERVATION", 137, 156], ["China", "ANATOMY", 234, 239]]], ["1,2 COVID-19 is transmitted via droplets during the incubation period and throughout the course of illness.", [["illness", "DISEASE", 99, 106], ["illness", "PROBLEM", 99, 106]]], ["3 Up to 20% of infected patients develop moderate-tosevere forms and require hospitalization, and 5-10% are admitted to intensive care unit (ICU) for ventilation support.", [["infected", "DISEASE", 15, 23], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["moderate-tosevere forms", "PROBLEM", 41, 64], ["ventilation support", "TREATMENT", 150, 169], ["moderate", "OBSERVATION_MODIFIER", 41, 49]]], ["[4] [5] [6] [7] [8] The elderly, patients with comorbidities, and pregnant women are particularly at-risk for severe forms.", [["[4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 19], ["patients", "ORGANISM", 33, 41], ["women", "ORGANISM", 75, 80], ["patients", "SPECIES", 33, 41], ["women", "SPECIES", 75, 80], ["comorbidities", "PROBLEM", 47, 60]]], ["COVID-19 thus represents a special threat to patients on maintenance dialysis, who frequently display multiple comorbidities, and are particularly vulnerable to infection.", [["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 161, 170], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["COVID", "TEST", 0, 5], ["maintenance dialysis", "TREATMENT", 57, 77], ["multiple comorbidities", "PROBLEM", 102, 124], ["infection", "PROBLEM", 161, 170], ["multiple", "OBSERVATION_MODIFIER", 102, 110], ["comorbidities", "OBSERVATION", 111, 124], ["infection", "OBSERVATION", 161, 170]]], ["10 Strategies have been established to mitigate the risk of infection among patients and staff.", [["infection", "DISEASE", 60, 69], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["10 Unfortunately, a major outbreak of COVID-19 recently occurred in the Paris Region, and rapidly spread among patients on dialysis.", [["COVID-19", "CHEMICAL", 38, 46], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["COVID", "TEST", 38, 43], ["dialysis", "TREATMENT", 123, 131], ["rapidly", "OBSERVATION_MODIFIER", 90, 97], ["spread", "OBSERVATION_MODIFIER", 98, 104]]], ["So far, the clinical setting and disease course of COVID-19 in dialyzed patients has not been well established.", [["COVID-19", "CHEMICAL", 51, 59], ["COVID-19", "CHEMICAL", 51, 59], ["COVID-19", "GENE_OR_GENE_PRODUCT", 51, 59], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["COVID", "TEST", 51, 56]]], ["Our study aimed at describing the clinical presentation, management, and outcome of patients referred to our dialysis center between March 11 and April 11, 2020.Study PopulationWe included all consecutive patients with COVID-19 on maintenance dialysis (hemodialysis or peritoneal dialysis) who were referred to the in-patient dialysis center of Bic\u00eatre University Hospital (Assistance Publique-H\u00f4pitaux de Paris, Le Kremlin-Bic\u00eatre, Paris Region, France) between March 11 and April 11, 2020.", [["peritoneal", "ANATOMY", 269, 279], ["patients", "ORGANISM", 84, 92], ["patients", "ORGANISM", 205, 213], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 269, 279], ["patient", "ORGANISM", 318, 325], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 205, 213], ["patient", "SPECIES", 318, 325], ["Our study", "TEST", 0, 9], ["management", "TREATMENT", 57, 67], ["COVID", "TEST", 219, 224], ["maintenance dialysis", "TREATMENT", 231, 251], ["hemodialysis", "TREATMENT", 253, 265], ["peritoneal dialysis", "TREATMENT", 269, 288], ["Le Kremlin-Bic\u00eatre, Paris Region", "TREATMENT", 413, 445], ["peritoneal", "ANATOMY", 269, 279]]], ["At this time, the national and local policies were to screen only symptomatic patients for SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 91, 111], ["patients", "ORGANISM", 78, 86], ["SARS-CoV-2", "ORGANISM", 91, 101], ["patients", "SPECIES", 78, 86], ["SARS-CoV", "SPECIES", 91, 99], ["SARS", "PROBLEM", 91, 95], ["CoV-2 infection", "PROBLEM", 96, 111], ["infection", "OBSERVATION", 102, 111]]], ["A case of COVID-19 was defined by a positive result on a reverse-transcriptase polymerase chain reaction (RT-PCR) assay based on the World Health Organization (WHO) standard and targeting the SARS-CoV-2 E gene and RdRp gene of a specimen collected on a nasopharyngeal swab.", [["specimen", "ANATOMY", 229, 237], ["nasopharyngeal swab", "ANATOMY", 253, 272], ["SARS-CoV-2 E", "GENE_OR_GENE_PRODUCT", 192, 204], ["nasopharyngeal swab", "CANCER", 253, 272], ["COVID-19", "DNA", 10, 18], ["SARS-CoV-2 E gene", "DNA", 192, 209], ["RdRp gene", "DNA", 214, 223], ["SARS-CoV", "SPECIES", 192, 200], ["COVID", "TEST", 10, 15], ["a reverse-transcriptase polymerase chain reaction", "PROBLEM", 55, 104], ["RT-PCR", "TEST", 106, 112], ["the SARS", "TEST", 188, 196], ["CoV", "TEST", 197, 200], ["a specimen", "TEST", 227, 237], ["a nasopharyngeal swab", "TEST", 251, 272], ["nasopharyngeal", "ANATOMY", 253, 267]]], ["In case of negative RT-PCR, a second RT-PCR could be performed.", [["PCR", "TEST", 23, 26], ["a second RT-PCR", "TEST", 28, 43]]], ["Alternatively, the diagnosis could also be established on the results of a chest CT-scan, showing ground glass opacities with or without consolidative abnormalities highly suggestive of COVID-19 infection.", [["infection", "DISEASE", 195, 204], ["COVID-19", "GENE_OR_GENE_PRODUCT", 186, 194], ["a chest CT-scan", "TEST", 73, 88], ["ground glass opacities", "PROBLEM", 98, 120], ["consolidative abnormalities", "PROBLEM", 137, 164], ["COVID-19 infection", "PROBLEM", 186, 204], ["chest", "ANATOMY", 75, 80], ["ground glass opacities", "OBSERVATION", 98, 120], ["without", "UNCERTAINTY", 129, 136], ["highly suggestive of", "UNCERTAINTY", 165, 185], ["infection", "OBSERVATION", 195, 204]]], ["The study was approved by the local institutional review board.Data CollectionPatients' data were obtained through the retrospective review of the medical electronic records.", [["The study", "TEST", 0, 9]]], ["Demographic data and comorbidities included age, sex, hypertension, diabetes mellitus, body mass index, cause of chronic kidney disease, duration on dialysis prior to admission, cardiovascular diseases, and other notable past medical history.", [["body", "ANATOMY", 87, 91], ["kidney", "ANATOMY", 121, 127], ["cardiovascular", "ANATOMY", 178, 192], ["hypertension", "DISEASE", 54, 66], ["diabetes mellitus", "DISEASE", 68, 85], ["chronic kidney disease", "DISEASE", 113, 135], ["cardiovascular diseases", "DISEASE", 178, 201], ["body", "ORGANISM_SUBDIVISION", 87, 91], ["kidney", "ORGAN", 121, 127], ["hypertension", "PROBLEM", 54, 66], ["diabetes mellitus", "PROBLEM", 68, 85], ["body mass index", "PROBLEM", 87, 102], ["chronic kidney disease", "PROBLEM", 113, 135], ["dialysis", "TREATMENT", 149, 157], ["cardiovascular diseases", "PROBLEM", 178, 201], ["hypertension", "OBSERVATION", 54, 66], ["mass", "OBSERVATION", 92, 96], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["kidney", "ANATOMY", 121, 127], ["disease", "OBSERVATION", 128, 135], ["cardiovascular", "ANATOMY", 178, 192], ["diseases", "OBSERVATION", 193, 201], ["notable", "OBSERVATION_MODIFIER", 213, 220]]], ["The use of angiotensin receptor blockers or angiotensin-converting enzyme inhibitors was also recorded.", [["angiotensin", "CHEMICAL", 11, 22], ["angiotensin", "CHEMICAL", 44, 55], ["angiotensin receptor blockers", "GENE_OR_GENE_PRODUCT", 11, 40], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 44, 73], ["angiotensin receptor blockers", "TREATMENT", 11, 40], ["angiotensin", "TREATMENT", 44, 55], ["converting enzyme inhibitors", "TREATMENT", 56, 84]]], ["Date and nature of presenting signs, and oxygen saturation and oxygen level to reach an oxygen saturation \u2265 94% were collected.", [["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 63, 69], ["oxygen", "CHEMICAL", 88, 94], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 63, 69], ["oxygen", "CHEMICAL", 88, 94], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["oxygen", "SIMPLE_CHEMICAL", 63, 69], ["oxygen", "SIMPLE_CHEMICAL", 88, 94], ["presenting signs", "TEST", 19, 35], ["oxygen saturation", "TEST", 41, 58], ["oxygen level", "TEST", 63, 75], ["an oxygen saturation", "TEST", 85, 105]]], ["The WHO progression scale (Supplementary Table S1 ) was used to establish three groups of severity on admission and during follow-up including: (1) ambulatory or hospitalized patients who did not require oxygen therapy (WHO score = [2] [3] [4] ); (2) hospitalized patients who needed oxygen therapy up to 6 L/min by mask or nasal prongs (WHO score = 5); and (3) hospitalized patients who required higher amounts of oxygen therapy by non-invasive ventilation or intubation and mechanical ventilation (WHO score \u2265 6).", [["nasal", "ANATOMY", 324, 329], ["oxygen", "CHEMICAL", 204, 210], ["oxygen", "CHEMICAL", 284, 290], ["oxygen", "CHEMICAL", 415, 421], ["oxygen", "CHEMICAL", 204, 210], ["oxygen", "CHEMICAL", 284, 290], ["oxygen", "CHEMICAL", 415, 421], ["patients", "ORGANISM", 175, 183], ["oxygen", "SIMPLE_CHEMICAL", 204, 210], ["patients", "ORGANISM", 264, 272], ["oxygen", "SIMPLE_CHEMICAL", 284, 290], ["patients", "ORGANISM", 375, 383], ["oxygen", "SIMPLE_CHEMICAL", 415, 421], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 264, 272], ["patients", "SPECIES", 375, 383], ["The WHO progression scale (Supplementary Table S1 )", "TREATMENT", 0, 51], ["oxygen therapy", "TREATMENT", 204, 218], ["oxygen therapy", "TREATMENT", 284, 298], ["nasal prongs", "TREATMENT", 324, 336], ["oxygen therapy", "TREATMENT", 415, 429], ["non-invasive ventilation", "TREATMENT", 433, 457], ["intubation", "TREATMENT", 461, 471], ["mechanical ventilation", "TREATMENT", 476, 498]]], ["The maximum level of oxygen before ICU transfer, use of non-invasive and mechanical ventilation, severe events during hospitalization, including acute respiratory distress syndrome, thrombosis, bleeding, cardiac arrhythmia, and death were also recorded.", [["respiratory", "ANATOMY", 151, 162], ["cardiac", "ANATOMY", 204, 211], ["oxygen", "CHEMICAL", 21, 27], ["acute respiratory distress syndrome", "DISEASE", 145, 180], ["thrombosis", "DISEASE", 182, 192], ["bleeding", "DISEASE", 194, 202], ["cardiac arrhythmia", "DISEASE", 204, 222], ["death", "DISEASE", 228, 233], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["cardiac", "ORGAN", 204, 211], ["non-invasive and mechanical ventilation", "TREATMENT", 56, 95], ["severe events", "PROBLEM", 97, 110], ["acute respiratory distress syndrome", "PROBLEM", 145, 180], ["thrombosis", "PROBLEM", 182, 192], ["bleeding", "PROBLEM", 194, 202], ["cardiac arrhythmia", "PROBLEM", 204, 222], ["death", "PROBLEM", 228, 233], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["oxygen", "OBSERVATION_MODIFIER", 21, 27], ["mechanical ventilation", "OBSERVATION", 73, 95], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["respiratory distress", "OBSERVATION", 151, 171], ["thrombosis", "OBSERVATION", 182, 192], ["bleeding", "OBSERVATION", 194, 202], ["cardiac", "ANATOMY", 204, 211], ["arrhythmia", "OBSERVATION", 212, 222]]], ["Dates of admission, transfer to the ICU, mechanical ventilation, discharge from ICU and from hospital were collected.", [["mechanical ventilation", "TREATMENT", 41, 63]]], ["All laboratory tests and radiologic assessments were performed at the discretion of the physician.", [["All laboratory tests", "TEST", 0, 20], ["radiologic assessments", "TEST", 25, 47]]], ["Laboratory data included the result of the SARS-CoV-2 RT-PCR, and the values of biological parameters on admission and during hospitalization (extreme values): serum levels of electrolytes, albumin, lactate dehydrogenases, ferritin, C-reactive protein, procalcitonin, D-Dimers, fibrinogen, and hemoglobin, and lymphocyte, neutrophil, and platelet counts.", [["serum", "ANATOMY", 160, 165], ["lymphocyte", "ANATOMY", 310, 320], ["neutrophil", "ANATOMY", 322, 332], ["platelet", "ANATOMY", 338, 346], ["lactate", "CHEMICAL", 199, 206], ["lactate", "CHEMICAL", 199, 206], ["serum", "ORGANISM_SUBSTANCE", 160, 165], ["electrolytes", "SIMPLE_CHEMICAL", 176, 188], ["albumin", "GENE_OR_GENE_PRODUCT", 190, 197], ["lactate dehydrogenases", "GENE_OR_GENE_PRODUCT", 199, 221], ["ferritin", "GENE_OR_GENE_PRODUCT", 223, 231], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 233, 251], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 253, 266], ["D-Dimers", "SIMPLE_CHEMICAL", 268, 276], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 278, 288], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 294, 304], ["lymphocyte", "CELL", 310, 320], ["neutrophil", "CELL", 322, 332], ["platelet", "CELL", 338, 346], ["albumin", "PROTEIN", 190, 197], ["lactate dehydrogenases", "PROTEIN", 199, 221], ["ferritin", "PROTEIN", 223, 231], ["C-reactive protein", "PROTEIN", 233, 251], ["procalcitonin", "PROTEIN", 253, 266], ["D-Dimers", "PROTEIN", 268, 276], ["fibrinogen", "PROTEIN", 278, 288], ["hemoglobin", "PROTEIN", 294, 304], ["lymphocyte", "CELL_TYPE", 310, 320], ["neutrophil", "CELL_TYPE", 322, 332], ["Laboratory data", "TEST", 0, 15], ["the SARS", "TEST", 39, 47], ["CoV", "TEST", 48, 51], ["PCR", "TEST", 57, 60], ["extreme values", "TEST", 143, 157], ["serum levels", "TEST", 160, 172], ["electrolytes", "TEST", 176, 188], ["albumin", "TEST", 190, 197], ["lactate dehydrogenases", "TEST", 199, 221], ["ferritin", "TEST", 223, 231], ["C", "TEST", 233, 234], ["reactive protein", "TEST", 235, 251], ["procalcitonin", "TEST", 253, 266], ["D-Dimers", "TEST", 268, 276], ["fibrinogen", "TEST", 278, 288], ["hemoglobin", "TEST", 294, 304], ["lymphocyte", "TEST", 310, 320], ["neutrophil", "TEST", 322, 332], ["platelet counts", "TEST", 338, 353], ["lymphocyte", "ANATOMY", 310, 320], ["platelet counts", "OBSERVATION", 338, 353]]], ["The administration of antibiotics and other notable drugs, such as anti-IL6 antibodies, hydroxychloroquine was also recorded.", [["hydroxychloroquine", "CHEMICAL", 88, 106], ["hydroxychloroquine", "CHEMICAL", 88, 106], ["anti-IL6", "GENE_OR_GENE_PRODUCT", 67, 75], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 88, 106], ["anti-IL6 antibodies", "PROTEIN", 67, 86], ["antibiotics", "TREATMENT", 22, 33], ["other notable drugs", "TREATMENT", 38, 57], ["anti-IL6 antibodies", "TREATMENT", 67, 86], ["hydroxychloroquine", "TREATMENT", 88, 106]]], ["Patient data were censored at the time of data cutoff, which occurred on May 11, 2020.Statistical analysisDescriptive statistics were used to summarize the data.", [["Patient", "SPECIES", 0, 7], ["data cutoff", "TEST", 42, 53]]], ["Results are reported as medians with interquartile range [IQR] for continuous variables and counts and percentages for categorical variables.", [["continuous variables", "TEST", 67, 87], ["counts", "TEST", 92, 98], ["percentages", "TEST", 103, 114], ["categorical variables", "TEST", 119, 140]]], ["Analysis was performed with STATA 11.2 software (StataCorp).", [["Analysis", "TEST", 0, 8], ["STATA", "TEST", 28, 33]]], ["Univariate analyses were performed using the Kruskal-Wallis test, and the \u03c72 or Fisher exact test, as appropriate.", [["Univariate analyses", "TEST", 0, 19], ["the Kruskal-Wallis test", "TEST", 41, 64], ["Fisher exact test", "TEST", 80, 97]]], ["A p-value < 0.05 was considered as significant.", [["A p-value", "TEST", 0, 9], ["significant", "OBSERVATION_MODIFIER", 35, 46]]], ["Kaplan-Meier curves were used to illustrate the survival rate according to relevant covariates.", [["the survival rate", "TREATMENT", 44, 61]]], ["Survival analysis was performed using Cox regression method.Statistical analysisCovariates with a p-value < 0.10 in the univariate Cox analysis were included in the multivariate Cox proportional hazard ratio model.", [["Survival analysis", "TEST", 0, 17], ["Cox regression method", "TREATMENT", 38, 59], ["a p-value", "TEST", 96, 105], ["the univariate Cox analysis", "TEST", 116, 143]]], ["A backward method was applied to identify covariates independently associated with survival, with or without adjusting for age, known to be a major risk factor for COVID-related death.", [["COVID", "DISEASE", 164, 169], ["death", "DISEASE", 178, 183], ["A backward method", "TREATMENT", 0, 17], ["COVID-related death", "PROBLEM", 164, 183]]], ["Statistical significance was assumed at p-value < 0.05.Diagnosis of COVID-19 in patients on dialysisDuring the study period, 44 patients with COVID-19 infection, including 29 men and 15 women, were admitted to our in-patient dialysis center (Figure 1) .", [["infection", "DISEASE", 151, 160], ["patients", "ORGANISM", 80, 88], ["patients", "ORGANISM", 128, 136], ["men", "ORGANISM", 175, 178], ["women", "ORGANISM", 186, 191], ["patient", "ORGANISM", 217, 224], ["patients", "SPECIES", 80, 88], ["patients", "SPECIES", 128, 136], ["men", "SPECIES", 175, 178], ["women", "SPECIES", 186, 191], ["patient", "SPECIES", 217, 224], ["p-value", "TEST", 40, 47], ["COVID", "TEST", 68, 73], ["COVID-19 infection", "PROBLEM", 142, 160], ["infection", "OBSERVATION", 151, 160]]], ["Only symptomatic patients were screened for SARS-CoV-2 infection before being referred to our unit irrespectively of the initial requirement of oxygen therapy.", [["SARS-CoV-2 infection", "DISEASE", 44, 64], ["oxygen", "CHEMICAL", 144, 150], ["oxygen", "CHEMICAL", 144, 150], ["patients", "ORGANISM", 17, 25], ["CoV-2", "ORGANISM", 49, 54], ["oxygen", "SIMPLE_CHEMICAL", 144, 150], ["patients", "SPECIES", 17, 25], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["2 infection", "PROBLEM", 53, 64], ["oxygen therapy", "TREATMENT", 144, 158], ["symptomatic", "OBSERVATION_MODIFIER", 5, 16], ["infection", "OBSERVATION", 55, 64], ["oxygen therapy", "OBSERVATION", 144, 158]]], ["RT-PCR assay of a nasopharyngeal swab was positive in all but one patient, who had highly suspicious chest CT-scan findings.Diagnosis of COVID-19 in patients on dialysisPatients were referred from 11 other dialysis facilities (Supplementary Figure S1) .", [["nasopharyngeal swab", "ANATOMY", 18, 37], ["nasopharyngeal swab", "CANCER", 18, 37], ["patient", "ORGANISM", 66, 73], ["chest", "ORGAN", 101, 106], ["patients", "ORGANISM", 149, 157], ["patient", "SPECIES", 66, 73], ["patients", "SPECIES", 149, 157], ["RT-PCR assay", "TEST", 0, 12], ["a nasopharyngeal swab", "TEST", 16, 37], ["suspicious chest CT", "TEST", 90, 109], ["scan findings", "TEST", 110, 123], ["COVID", "TEST", 137, 142], ["nasopharyngeal", "ANATOMY", 18, 32], ["positive", "OBSERVATION", 42, 50], ["chest", "ANATOMY", 101, 106]]], ["No official policy was established for referring dialyzed patients with COVID-19 to hospital.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66]]], ["Patients were most often hospitalized because of clinical severity, coexisting comorbidities, and other medical issues.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["clinical severity", "PROBLEM", 49, 66], ["coexisting comorbidities", "PROBLEM", 68, 92], ["other medical issues", "PROBLEM", 98, 118]]], ["Overall, only three patients with mild symptoms, no oxygen requirement, and no inflammatory syndrome were not admitted to hospital but maintained in our dialysis unit as outpatients.Clinical characteristics and Radiologic findingsMedian age at diagnosis was 61 years old, IQR [51,5-72,5] with 65.9% men.", [["oxygen", "CHEMICAL", 52, 58], ["oxygen", "CHEMICAL", 52, 58], ["patients", "ORGANISM", 20, 28], ["oxygen", "SIMPLE_CHEMICAL", 52, 58], ["men", "ORGANISM", 299, 302], ["patients", "SPECIES", 20, 28], ["men", "SPECIES", 299, 302], ["mild symptoms", "PROBLEM", 34, 47], ["oxygen requirement", "PROBLEM", 52, 70], ["inflammatory syndrome", "PROBLEM", 79, 100], ["Radiologic findings", "TEST", 211, 230], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["symptoms", "OBSERVATION", 39, 47], ["no", "UNCERTAINTY", 49, 51], ["oxygen requirement", "OBSERVATION", 52, 70], ["no", "UNCERTAINTY", 76, 78], ["inflammatory syndrome", "OBSERVATION", 79, 100]]], ["The demographic and clinical characteristics of the patients, and the underlying causes of chronic kidney disease are listed in Table 1 .", [["kidney", "ANATOMY", 99, 105], ["chronic kidney disease", "DISEASE", 91, 113], ["patients", "ORGANISM", 52, 60], ["kidney", "ORGAN", 99, 105], ["patients", "SPECIES", 52, 60], ["chronic kidney disease", "PROBLEM", 91, 113], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["kidney", "ANATOMY", 99, 105], ["disease", "OBSERVATION", 106, 113]]], ["Median duration of maintenance dialysis before COVID-19 was 36.5 months IQR .", [["maintenance dialysis", "TREATMENT", 19, 39], ["COVID", "TEST", 47, 52]]], ["Main coexisting conditions were hypertension (97.7%), dyslipidemia (59.1%), diabetes mellitus (50%), smoking (34.1%) and obesity (34.1%).", [["hypertension", "DISEASE", 32, 44], ["dyslipidemia", "DISEASE", 54, 66], ["diabetes mellitus", "DISEASE", 76, 93], ["smoking", "CHEMICAL", 101, 108], ["obesity", "DISEASE", 121, 128], ["hypertension", "PROBLEM", 32, 44], ["dyslipidemia", "PROBLEM", 54, 66], ["diabetes mellitus", "PROBLEM", 76, 93], ["obesity", "PROBLEM", 121, 128], ["hypertension", "OBSERVATION", 32, 44]]], ["Almost 40% and 30% of patients had a history of chronic cardiac or respiratory disease, respectively.Clinical characteristics and Radiologic findingsThirty-eight patients (86.4%) had more than one coexisting medical conditions.", [["cardiac", "ANATOMY", 56, 63], ["respiratory", "ANATOMY", 67, 78], ["chronic cardiac or respiratory disease", "DISEASE", 48, 86], ["patients", "ORGANISM", 22, 30], ["cardiac", "ORGAN", 56, 63], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 162, 170], ["chronic cardiac or respiratory disease", "PROBLEM", 48, 86], ["Radiologic findings", "TEST", 130, 149], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["cardiac", "ANATOMY", 56, 63], ["respiratory disease", "OBSERVATION", 67, 86]]], ["The most common symptoms on admission are detailed in Table 2 and included fever and chills (79.5%), cough (43.2%), shortness of breath (29.5%), and diarrhea (13.6%).", [["fever", "DISEASE", 75, 80], ["chills", "DISEASE", 85, 91], ["cough", "DISEASE", 101, 106], ["shortness of breath", "DISEASE", 116, 135], ["diarrhea", "DISEASE", 149, 157], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 75, 80], ["chills", "PROBLEM", 85, 91], ["cough", "PROBLEM", 101, 106], ["shortness of breath", "PROBLEM", 116, 135], ["diarrhea", "PROBLEM", 149, 157]]], ["Most patients (59.1%) presented with anorexia and weigh loss.Clinical characteristics and Radiologic findingsChest CT-scan was performed in 41 patients (93.2%) within the first two days IQR [0-5] after initial symptoms and showed bilateral ground glass opacities with or without consolidations in 80.5% of cases.", [["anorexia", "DISEASE", 37, 45], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 143, 151], ["anorexia", "PROBLEM", 37, 45], ["weigh loss", "PROBLEM", 50, 60], ["Radiologic findings", "TEST", 90, 109], ["Chest CT-scan", "TEST", 109, 122], ["initial symptoms", "PROBLEM", 202, 218], ["bilateral ground glass opacities", "PROBLEM", 230, 262], ["consolidations", "PROBLEM", 279, 293], ["anorexia", "OBSERVATION", 37, 45], ["bilateral", "ANATOMY_MODIFIER", 230, 239], ["ground glass opacities", "OBSERVATION", 240, 262], ["without", "UNCERTAINTY", 271, 278], ["consolidations", "OBSERVATION", 279, 293]]], ["Radiological findings were classified as mild, moderate or severe in 22%, 26.8%, and 31.7% of cases respectively.", [["Radiological findings", "TEST", 0, 21], ["mild", "OBSERVATION_MODIFIER", 41, 45], ["moderate", "OBSERVATION_MODIFIER", 47, 55], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["22%", "OBSERVATION_MODIFIER", 69, 72]]], ["Eight CT-scans were normal and were performed within the two days following initial symptoms.Laboratory FindingsLaboratory findings on admission and during hospitalization are detailed in the Table 2 and Table 3 .", [["Eight CT-scans", "TEST", 0, 14], ["initial symptoms", "PROBLEM", 76, 92], ["normal", "OBSERVATION", 20, 26]]], ["Oxygen-free patients (WHO score = [2] [3] [4] ) had only mild biological abnormalities compared to those requiring oxygen (WHO score = 5 and \u2265 6).", [["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 115, 121], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 115, 121], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 12, 20], ["oxygen", "SIMPLE_CHEMICAL", 115, 121], ["patients", "SPECIES", 12, 20], ["Oxygen", "TEST", 0, 6], ["WHO score", "TEST", 22, 31], ["only mild biological abnormalities", "PROBLEM", 52, 86], ["oxygen (WHO score", "TEST", 115, 132], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["abnormalities", "OBSERVATION", 73, 86]]], ["Hematological parameters were also more severe in these patients compared to those who did not require oxygen therapy.", [["oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 103, 109], ["patients", "ORGANISM", 56, 64], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["patients", "SPECIES", 56, 64], ["Hematological parameters", "TEST", 0, 24], ["oxygen therapy", "TREATMENT", 103, 117], ["more severe", "OBSERVATION_MODIFIER", 35, 46], ["oxygen therapy", "OBSERVATION", 103, 117]]], ["Most patients presented with lymphopenia with a median of 0.6 G/L IQR [0.46-1.04], whereas only patients requiring oxygen therapy had a trend for low platelet counts.Laboratory FindingsInterestingly, worsening of hematological and inflammatory markers during disease course was most notable in patients requiring oxygen therapy (Figure 2 ).Initial ManagementOn admission, 20 patients (45.5%) required continuous intermittent nasal catheter oxygen inhalation to reach a saturation of \u2265 94% with a median level of 2 L/min ranging from 1 to 15 L/min.", [["platelet", "ANATOMY", 150, 158], ["hematological", "ANATOMY", 213, 226], ["nasal", "ANATOMY", 425, 430], ["lymphopenia", "DISEASE", 29, 40], ["oxygen", "CHEMICAL", 115, 121], ["oxygen", "CHEMICAL", 313, 319], ["oxygen", "CHEMICAL", 440, 446], ["oxygen", "CHEMICAL", 115, 121], ["oxygen", "CHEMICAL", 313, 319], ["oxygen", "CHEMICAL", 440, 446], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 96, 104], ["oxygen", "SIMPLE_CHEMICAL", 115, 121], ["platelet", "CELL", 150, 158], ["patients", "ORGANISM", 294, 302], ["oxygen", "SIMPLE_CHEMICAL", 313, 319], ["patients", "ORGANISM", 375, 383], ["oxygen", "SIMPLE_CHEMICAL", 440, 446], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 294, 302], ["patients", "SPECIES", 375, 383], ["lymphopenia", "PROBLEM", 29, 40], ["oxygen therapy", "TREATMENT", 115, 129], ["low platelet counts", "PROBLEM", 146, 165], ["hematological and inflammatory markers", "PROBLEM", 213, 251], ["oxygen therapy", "TREATMENT", 313, 327], ["continuous intermittent nasal catheter oxygen inhalation", "TREATMENT", 401, 457], ["a saturation", "TEST", 467, 479], ["lymphopenia", "OBSERVATION", 29, 40], ["oxygen therapy", "OBSERVATION", 115, 129], ["worsening", "OBSERVATION_MODIFIER", 200, 209], ["hematological", "ANATOMY", 213, 226], ["inflammatory", "OBSERVATION_MODIFIER", 231, 243], ["oxygen therapy", "OBSERVATION", 313, 327], ["nasal", "ANATOMY", 425, 430], ["catheter", "OBSERVATION", 431, 439]]], ["By contrast, 24 patients (54.5%) did not require oxygen therapy and had a median oxygen saturation level in ambient air of 98% IQR [96-100].", [["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 81, 87], ["oxygen", "CHEMICAL", 49, 55], ["oxygen", "CHEMICAL", 81, 87], ["patients", "ORGANISM", 16, 24], ["oxygen", "SIMPLE_CHEMICAL", 49, 55], ["oxygen", "SIMPLE_CHEMICAL", 81, 87], ["patients", "SPECIES", 16, 24], ["oxygen therapy", "TREATMENT", 49, 63], ["a median oxygen saturation level", "TEST", 72, 104], ["oxygen therapy", "OBSERVATION", 49, 63]]], ["Overall, 41 patients were hospitalized, including 33 who finally required oxygen therapy during disease course, with a delay ranging from 0 to 9 days after initial symptoms.", [["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 74, 80], ["patients", "ORGANISM", 12, 20], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["patients", "SPECIES", 12, 20], ["oxygen therapy", "TREATMENT", 74, 88], ["a delay", "PROBLEM", 117, 124], ["initial symptoms", "PROBLEM", 156, 172], ["oxygen therapy", "OBSERVATION", 74, 88]]], ["Three patients were maintained on outpatient hemodialysis from initial referral to last follow-up because of only mild symptoms with an oxygen saturation of 99-100% in ambient air and no inflammatory biological syndrome.", [["oxygen", "CHEMICAL", 136, 142], ["oxygen", "CHEMICAL", 136, 142], ["patients", "ORGANISM", 6, 14], ["oxygen", "SIMPLE_CHEMICAL", 136, 142], ["patients", "SPECIES", 6, 14], ["outpatient hemodialysis", "TREATMENT", 34, 57], ["mild symptoms", "PROBLEM", 114, 127], ["an oxygen saturation", "TEST", 133, 153], ["inflammatory biological syndrome", "PROBLEM", 187, 219], ["mild", "OBSERVATION_MODIFIER", 114, 118], ["symptoms", "OBSERVATION", 119, 127], ["no", "UNCERTAINTY", 184, 186], ["inflammatory biological syndrome", "OBSERVATION", 187, 219]]], ["Three patients initially on peritoneal dialysis were switched to hemodialysis at the time of ICU referral.", [["peritoneal", "ANATOMY", 28, 38], ["patients", "ORGANISM", 6, 14], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 28, 38], ["patients", "SPECIES", 6, 14], ["peritoneal dialysis", "TREATMENT", 28, 47], ["hemodialysis", "TREATMENT", 65, 77], ["peritoneal", "ANATOMY", 28, 38], ["dialysis", "OBSERVATION", 39, 47]]], ["Most were administered empiric antibiotherapy during hospitalization, based on penicillin, 3G cephalosporin combined with macrolides ( Table 4) .Initial ManagementOnly a minority of patients received hydroxychloroquine (6.8%) or anti-IL6 antibodies (9.1%), and none had antiviral therapy.", [["penicillin", "CHEMICAL", 79, 89], ["3G cephalosporin", "CHEMICAL", 91, 107], ["macrolides", "CHEMICAL", 122, 132], ["hydroxychloroquine", "CHEMICAL", 200, 218], ["penicillin", "CHEMICAL", 79, 89], ["cephalosporin", "CHEMICAL", 94, 107], ["macrolides", "CHEMICAL", 122, 132], ["hydroxychloroquine", "CHEMICAL", 200, 218], ["penicillin", "SIMPLE_CHEMICAL", 79, 89], ["3G cephalosporin", "SIMPLE_CHEMICAL", 91, 107], ["macrolides", "SIMPLE_CHEMICAL", 122, 132], ["patients", "ORGANISM", 182, 190], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 200, 218], ["IL6", "GENE_OR_GENE_PRODUCT", 234, 237], ["IL6 antibodies", "PROTEIN", 234, 248], ["patients", "SPECIES", 182, 190], ["empiric antibiotherapy", "TREATMENT", 23, 45], ["penicillin", "TREATMENT", 79, 89], ["3G cephalosporin", "TREATMENT", 91, 107], ["macrolides", "TREATMENT", 122, 132], ["hydroxychloroquine", "TREATMENT", 200, 218], ["anti-IL6 antibodies", "TREATMENT", 229, 248], ["antiviral therapy", "TREATMENT", 270, 287], ["antiviral therapy", "OBSERVATION", 270, 287]]], ["All patients were prescribed prophylactic heparin and patients who developed pulmonary embolism or cardiac arrhythmia received therapeutic dosing of heparin.", [["pulmonary", "ANATOMY", 77, 86], ["cardiac", "ANATOMY", 99, 106], ["heparin", "CHEMICAL", 42, 49], ["pulmonary embolism", "DISEASE", 77, 95], ["cardiac arrhythmia", "DISEASE", 99, 117], ["heparin", "CHEMICAL", 149, 156], ["patients", "ORGANISM", 4, 12], ["heparin", "SIMPLE_CHEMICAL", 42, 49], ["patients", "ORGANISM", 54, 62], ["pulmonary", "ORGAN", 77, 86], ["heparin", "SIMPLE_CHEMICAL", 149, 156], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 54, 62], ["prophylactic heparin", "TREATMENT", 29, 49], ["pulmonary embolism", "PROBLEM", 77, 95], ["cardiac arrhythmia", "PROBLEM", 99, 117], ["heparin", "TREATMENT", 149, 156], ["pulmonary", "ANATOMY", 77, 86], ["embolism", "OBSERVATION", 87, 95], ["cardiac", "ANATOMY", 99, 106], ["arrhythmia", "OBSERVATION", 107, 117]]], ["During hospitalization, three profiles of severity could be distinguished on the basis of WHO progression scale, which were correlated with outcome (Figure 3) .", [["severity", "PROBLEM", 42, 50], ["WHO progression scale", "TEST", 90, 111]]], ["Eleven patients (25%) remained oxygen-free during the whole disease course (WHO score between 2 and 4).", [["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 31, 37], ["patients", "ORGANISM", 7, 15], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["patients", "SPECIES", 7, 15], ["oxygen", "TREATMENT", 31, 37]]], ["Fourteen (31.8%) with a WHO score equal to 5 required up to 6 L/min of oxygen therapy, whereas 19 (43.2%) with a WHO score \u2265 6 required higher amounts (\u2265 9/L).", [["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["oxygen therapy", "TREATMENT", 71, 85], ["a WHO score", "TEST", 111, 122]]], ["Of these, 15 (34.1%) were transferred to the ICU for non-invasive (20%) or mechanical (80%) ventilation, with a median delay of 4 days IQR [2] [3] [4] [5] [6] [7] [8] [9] after initial symptoms.", [["[2] [3] [4] [5] [6] [7] [8]", "CHEMICAL", 139, 166], ["3] [4] [5] [6", "SIMPLE_CHEMICAL", 144, 157], ["mechanical (80%) ventilation", "TREATMENT", 75, 103], ["initial symptoms", "PROBLEM", 177, 193]]], ["Four patients with high oxygen requirement were not transferred to the ICU because of a do-not-resuscitate order on admission.OutcomePatients were maintained on hospitalization until complete resolution of clinical symptoms and withdrawal of oxygen therapy for at least 24 hours.", [["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 242, 248], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 242, 248], ["patients", "ORGANISM", 5, 13], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["oxygen", "SIMPLE_CHEMICAL", 242, 248], ["patients", "SPECIES", 5, 13], ["high oxygen requirement", "PROBLEM", 19, 42], ["hospitalization", "TREATMENT", 161, 176], ["clinical symptoms", "PROBLEM", 206, 223], ["oxygen therapy", "TREATMENT", 242, 256], ["high", "OBSERVATION_MODIFIER", 19, 23], ["oxygen requirement", "OBSERVATION", 24, 42]]], ["Patients were then referred home with instructions to minimize the risk of infection transmission at home, including isolation in a separate room at home and use of face masks for 10 days after complete resolution of clinical signs.", [["infection", "DISEASE", 75, 84], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infection transmission", "PROBLEM", 75, 97], ["isolation", "TREATMENT", 117, 126], ["face masks", "TREATMENT", 165, 175], ["clinical signs", "TEST", 217, 231], ["infection", "OBSERVATION", 75, 84]]], ["Discharged patients from hospital were maintained dialyzed in our unit for at least 14 days after initial symptoms and 10 days after complete resolution of clinical signs, before being referred back to their initial outpatient center.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["initial symptoms", "PROBLEM", 98, 114], ["clinical signs", "PROBLEM", 156, 170]]], ["The median duration of hospital stay was 12 days IQR [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] , and the median length of ICU stay was 10 days IQR [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] .", [["[7] [8] [9] [10] [11] [12] [13] [14] [15]", "CHEMICAL", 53, 94], ["8] [9] [10] [11] [12] [13", "SIMPLE_CHEMICAL", 58, 83], ["[10] [11] [12] [13] [14] [15] [16] [17] [18] [19", "SIMPLE_CHEMICAL", 174, 222]]], ["Overall, 58.5% of hospitalized patients, but only four (21.1%) of those patients with a WHO score \u2265 6, were discharged home.", [["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 72, 80]]], ["At the time of data cutoff (May 11, 2020), only 2 patients of those admitted to the ICU were discharged from hospital after 18 and in-ICU mortality was 20.7% in the non-dialyzed population compared to 60% in dialyzed patients (p = 0.002).Identification of prognostic factors associated with deathBy univariate Cox survival analysis, acute respiratory syndrome, neutrophil count \u2265 10 G/L, thrombopenia \u2264 120 G/L, metabolic acidosis < 21 mmol/L, LDH level \u2265 2 times the upper normal limit, blood CRP level \u2265 175 mg/L, and D-dimer level > 4000 UI/L were associated with a higher risk of death ( Table 5) .", [["respiratory", "ANATOMY", 339, 350], ["neutrophil", "ANATOMY", 361, 371], ["blood", "ANATOMY", 488, 493], ["acute respiratory syndrome", "DISEASE", 333, 359], ["thrombopenia", "DISEASE", 388, 400], ["metabolic acidosis", "DISEASE", 412, 430], ["death", "DISEASE", 584, 589], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 217, 225], ["neutrophil", "CELL", 361, 371], ["LDH", "GENE_OR_GENE_PRODUCT", 444, 447], ["blood", "ORGANISM_SUBSTANCE", 488, 493], ["CRP", "GENE_OR_GENE_PRODUCT", 494, 497], ["D-dimer", "GENE_OR_GENE_PRODUCT", 520, 527], ["CRP", "PROTEIN", 494, 497], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 217, 225], ["data cutoff", "TEST", 15, 26], ["prognostic factors", "PROBLEM", 256, 274], ["survival analysis", "TEST", 314, 331], ["acute respiratory syndrome", "PROBLEM", 333, 359], ["neutrophil count", "TEST", 361, 377], ["G", "TEST", 383, 384], ["thrombopenia", "PROBLEM", 388, 400], ["G", "TEST", 407, 408], ["metabolic acidosis", "PROBLEM", 412, 430], ["LDH level", "TEST", 444, 453], ["blood CRP level", "TEST", 488, 503], ["D-dimer level", "TEST", 520, 533], ["death", "PROBLEM", 584, 589], ["acute", "OBSERVATION_MODIFIER", 333, 338], ["respiratory syndrome", "OBSERVATION", 339, 359], ["thrombopenia", "OBSERVATION", 388, 400], ["acidosis", "OBSERVATION", 422, 430], ["upper", "ANATOMY_MODIFIER", 468, 473]]], ["Other variables, including dyspnea, cough, and lymphocyte count \u2264 0.5 G/L also tended to significance (p-value < 0.10).", [["lymphocyte", "ANATOMY", 47, 57], ["dyspnea", "DISEASE", 27, 34], ["cough", "DISEASE", 36, 41], ["lymphocyte", "CELL", 47, 57], ["Other variables", "PROBLEM", 0, 15], ["dyspnea", "PROBLEM", 27, 34], ["cough", "PROBLEM", 36, 41], ["lymphocyte count", "TEST", 47, 63], ["p-value", "TEST", 103, 110], ["cough", "OBSERVATION", 36, 41]]], ["By multivariate analysis ( Table 5 and Figure 4)DISCUSSIONThe present series describes the demographics, clinical course of COVID-19 in patients on maintenance dialysis during the recent epidemic in the Paris region.", [["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["multivariate analysis", "TEST", 3, 24], ["COVID", "TEST", 124, 129], ["maintenance dialysis", "TREATMENT", 148, 168]]], ["We established three profiles of severity based on the WHO progression scale that were tightly correlated with disease outcome and identified prognostic factors significantly associated with death.DISCUSSIONFrance has been on a lockdown since March 17, 2020.", [["death", "DISEASE", 191, 196], ["severity", "PROBLEM", 33, 41], ["prognostic factors", "PROBLEM", 142, 160], ["death", "PROBLEM", 191, 196]]], ["Unlike other individuals, dialyzed patients could not respect strict confinement, and were potentially exposed to circulating coronavirus by going to the dialysis center.", [["patients", "ORGANISM", 35, 43], ["coronavirus", "ORGANISM", 126, 137], ["patients", "SPECIES", 35, 43], ["circulating coronavirus", "PROBLEM", 114, 137]]], ["A significant proportion was likely infected before the measures to mitigate infection spread were effective.", [["infection", "DISEASE", 77, 86], ["infection spread", "PROBLEM", 77, 93], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["likely", "UNCERTAINTY", 29, 35], ["infected", "OBSERVATION", 36, 44], ["infection", "OBSERVATION", 77, 86]]], ["11-13 Data from other parts of the world suggest that around 15% of dialyzed develop symptomatic forms of COVID-19.", [["COVID-19", "CHEMICAL", 106, 114], ["COVID", "TEST", 106, 111]]], ["[14] [15] [16] While more than 50% of patients do not require oxygen therapy on admission, a significant proportion may abruptly worsened, particularly at the end of the first week.", [["oxygen", "CHEMICAL", 62, 68], ["oxygen", "CHEMICAL", 62, 68], ["[14] [15] [16]", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 38, 46], ["oxygen", "SIMPLE_CHEMICAL", 62, 68], ["patients", "SPECIES", 38, 46], ["oxygen therapy", "TREATMENT", 62, 76], ["abruptly", "OBSERVATION_MODIFIER", 120, 128], ["worsened", "OBSERVATION", 129, 137]]], ["17 In our study, only 25% remained oxygen-free along disease course.", [["oxygen", "CHEMICAL", 35, 41], ["oxygen", "CHEMICAL", 35, 41], ["oxygen", "SIMPLE_CHEMICAL", 35, 41], ["our study", "TEST", 6, 15], ["oxygen", "TREATMENT", 35, 41]]], ["Only a few patients received a specific therapy in our series because the local policy was to restrict the off-label use of such treatments and dialyzed patients were most often excluded from randomized trials.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 153, 161], ["a specific therapy", "TREATMENT", 29, 47], ["such treatments", "TREATMENT", 124, 139], ["few", "OBSERVATION_MODIFIER", 7, 10]]], ["By contrast, more than 75% of patients in the Italian, Spanish and New Yorker cohorts received antivirals and hydroxychloroquine.", [["hydroxychloroquine", "CHEMICAL", 110, 128], ["hydroxychloroquine", "CHEMICAL", 110, 128], ["patients", "ORGANISM", 30, 38], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 110, 128], ["patients", "SPECIES", 30, 38], ["antivirals", "TREATMENT", 95, 105], ["hydroxychloroquine", "TREATMENT", 110, 128]]], ["[16] [17] [18] Despite such heterogeneity in the therapeutic approach, the mortality is remarkably consistent across the different cohorts and approximates 30-40%.", [["such heterogeneity in the therapeutic approach", "PROBLEM", 23, 69]]], ["[15] [16] [17] These data contrast with the initial report of only mild 13 disease in China, 19 and a mortality rate of 18.9% in Chinese hemodialyzed patients with COVID-19.", [["COVID-19", "CHEMICAL", 164, 172], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 150, 158], ["These data contrast", "TEST", 15, 34], ["mild 13 disease in China", "PROBLEM", 67, 91], ["a mortality rate", "TEST", 100, 116], ["COVID", "TEST", 164, 169], ["mild", "OBSERVATION_MODIFIER", 67, 71], ["disease", "OBSERVATION", 75, 82]]], ["14 Case fatality rate is also strikingly higher than the 3-4% reported in the general population.", [["Case fatality rate", "TEST", 3, 21], ["strikingly", "OBSERVATION_MODIFIER", 30, 40], ["higher", "OBSERVATION_MODIFIER", 41, 47]]], ["20 Nevertheless, because only symptomatic patients were screened for SARS-CoV-2 infection in most studies, this difference is likely overestimated.", [["SARS-CoV-2 infection", "DISEASE", 69, 89], ["patients", "ORGANISM", 42, 50], ["SARS-CoV-2", "ORGANISM", 69, 79], ["patients", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 69, 77], ["SARS", "PROBLEM", 69, 73], ["CoV-2 infection", "PROBLEM", 74, 89], ["infection", "OBSERVATION", 80, 89]]], ["Interestingly, we were able to compare the rates of ICU transfer and case fatality between non-dialyzed and dialyzed patients admitted to our hospital.", [["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125]]], ["In our series, 34.1% of dialyzed patients were transferred to the ICU with an ICU mortality of 60% compared to 21.4% and 20.7% in the general hospitalized population.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41], ["an ICU mortality", "TEST", 75, 91]]], ["21 Moreover, the ICU case fatality rate due to has been estimated to 24%, which is in line with our results and the ICU mortality rate of 26% reported in other cohorts.", [["the ICU mortality rate", "TEST", 112, 134]]], ["8, 22, 23 The policy for ICU transfer and mechanical ventilation and the rate of a \"do not resuscitate\" order as observed in the Spanish and New Yorker cohorts are also to take into account when interpreting such data.", [["ICU transfer", "TREATMENT", 25, 37], ["mechanical ventilation", "TREATMENT", 42, 64]]], ["17, 18 Such increase in mortality risk in the dialyzed patients could be explained by a greater vulnerability to infections, 9 and the coexistence of multiple comorbidities known to be associated with more severe forms of COVID-19.", [["infections", "DISEASE", 113, 123], ["COVID-19", "CHEMICAL", 222, 230], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["a greater vulnerability to infections", "PROBLEM", 86, 123], ["multiple comorbidities", "PROBLEM", 150, 172], ["COVID", "TEST", 222, 227], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["greater", "OBSERVATION_MODIFIER", 88, 95], ["infections", "OBSERVATION", 113, 123], ["multiple", "OBSERVATION_MODIFIER", 150, 158], ["comorbidities", "OBSERVATION", 159, 172]]], ["10 Our survival analysis showed that cough, thrombopenia \u2264 120 G/L, increased LDH level above 2 times the upper normal limit and blood CRP level above 175 mg/L were independently associated with death.", [["blood", "ANATOMY", 129, 134], ["cough", "DISEASE", 37, 42], ["thrombopenia", "DISEASE", 44, 56], ["death", "DISEASE", 195, 200], ["LDH", "GENE_OR_GENE_PRODUCT", 78, 81], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["CRP", "GENE_OR_GENE_PRODUCT", 135, 138], ["LDH", "PROTEIN", 78, 81], ["CRP", "PROTEIN", 135, 138], ["Our survival analysis", "TEST", 3, 24], ["cough", "PROBLEM", 37, 42], ["thrombopenia", "PROBLEM", 44, 56], ["increased LDH level", "PROBLEM", 68, 87], ["blood CRP level", "TEST", 129, 144], ["death", "PROBLEM", 195, 200], ["cough", "OBSERVATION", 37, 42], ["thrombopenia", "OBSERVATION", 44, 56], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["LDH", "OBSERVATION", 78, 81], ["upper", "ANATOMY_MODIFIER", 106, 111], ["normal", "OBSERVATION", 112, 118]]], ["Dialysis vintage, low lymphocyte count, and high LDH level were identified predictors of mortality in the Spanish series, whereas fever and cough at disease onset, and CRP at baseline > 50 mg/L were significantly associated with death in the Italian series.", [["lymphocyte", "ANATOMY", 22, 32], ["fever", "DISEASE", 130, 135], ["cough", "DISEASE", 140, 145], ["death", "DISEASE", 229, 234], ["lymphocyte", "CELL", 22, 32], ["LDH", "GENE_OR_GENE_PRODUCT", 49, 52], ["CRP", "GENE_OR_GENE_PRODUCT", 168, 171], ["LDH", "PROTEIN", 49, 52], ["CRP", "PROTEIN", 168, 171], ["Dialysis vintage", "TREATMENT", 0, 16], ["low lymphocyte count", "TEST", 18, 38], ["high LDH level", "PROBLEM", 44, 58], ["fever", "PROBLEM", 130, 135], ["cough at disease onset", "PROBLEM", 140, 162], ["CRP", "TEST", 168, 171], ["low lymphocyte count", "OBSERVATION", 18, 38], ["high LDH", "OBSERVATION_MODIFIER", 44, 52], ["cough", "OBSERVATION", 140, 145]]], ["16, 17 It is quite surprising that symptoms as subjective as cough and shortness of breath were associated with poor outcomes, whereas imaging data did not in our series and other cohorts.", [["cough", "DISEASE", 61, 66], ["shortness of breath", "DISEASE", 71, 90], ["symptoms", "PROBLEM", 35, 43], ["cough", "PROBLEM", 61, 66], ["shortness of breath", "PROBLEM", 71, 90], ["poor outcomes", "PROBLEM", 112, 125], ["imaging data", "TEST", 135, 147]]], ["16, 17 Moreover, neither age nor common cardiovascular risk factors were associated with mortality contrary to the general population.", [["cardiovascular", "ANATOMY", 40, 54], ["common cardiovascular risk factors", "PROBLEM", 33, 67]]], ["17 Altogether, our data and recent reports indicate that COVID-19-related mortality in dialyzed patients seems more driven by disease presentation and subsequent severity than patient's comorbid status.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 57, 65], ["patients", "ORGANISM", 96, 104], ["patient", "ORGANISM", 176, 183], ["patients", "SPECIES", 96, 104], ["patient", "SPECIES", 176, 183], ["COVID", "TEST", 57, 62], ["subsequent severity than patient's comorbid status", "PROBLEM", 151, 201]]], ["Our results are thus useful to recognize most at-risk dialyzed patients to die from COVID-19.", [["COVID-19", "CHEMICAL", 84, 92], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 84, 89]]], ["[15] [16] [17] Our study has some limitations mainly due to the retrospective design and the size of the cohort, which increases the risk of overfitting of our multivariate analysis.", [["[15] [16] [17", "SIMPLE_CHEMICAL", 0, 13], ["Our study", "TEST", 15, 24], ["our multivariate analysis", "TEST", 156, 181], ["size", "OBSERVATION_MODIFIER", 93, 97]]], ["Moreover, at data cutoff, several patients were still hospitalized, resulting in a potential underestimation of overall morbidity and mortality.DISCUSSIONIn conclusion, COVID-19 is burdened by a high mortality rate in dialyzed patients compared to the general population and is also associated with dramatic complications and prolonged hospitalization.", [["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 227, 235], ["overall morbidity", "PROBLEM", 112, 129], ["dramatic complications", "PROBLEM", 299, 321], ["prolonged hospitalization", "TREATMENT", 326, 351], ["overall", "OBSERVATION_MODIFIER", 112, 119], ["morbidity", "OBSERVATION", 120, 129], ["dramatic", "OBSERVATION_MODIFIER", 299, 307], ["complications", "OBSERVATION", 308, 321]]], ["The use of clinical and biological parameters as early prognostic markers needs further validation but will be helpful to guide future management strategies.ACKOWLEDGEMENTSWe thank Ms Val\u00e9rie G\u00e9rard and Ms Nadia Corre, and all the colleagues and nurses of our department and institution who were involved in the management of patients during the recent epidemic.", [["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 326, 334], ["further validation", "TEST", 80, 98], ["future management strategies", "TREATMENT", 128, 156]]], ["We also thank Marie Frank and J\u00e9r\u00e9my Laurent from the D\u00e9partement d'Information M\u00e9dicale Paris Saclay for supplying the data regarding the ICU mortality rate in our institution. # At last follow-up (05/11/2020), six patients are still hospitalized, including 3 in the ICU, thus underestimating the median duration of hospital stay, particularly in the group of patients with a WHO score \u2265 6.", [["patients", "ORGANISM", 216, 224], ["patients", "ORGANISM", 361, 369], ["patients", "SPECIES", 216, 224], ["patients", "SPECIES", 361, 369]]], ["NA: not applicable. \"ns\" refers to a non-significant p-value.", [["NA", "CHEMICAL", 0, 2], ["NA", "SIMPLE_CHEMICAL", 0, 2], ["NA", "TEST", 0, 2]]]], "36dfd1ba753f659de6425ea0654588300659dccc": [["The area studied consists of several hundred hectares around BanskP Stiavnica in Central Slovakia, between about 300 and 900m. a d .", [["several", "OBSERVATION_MODIFIER", 29, 36], ["hundred", "OBSERVATION_MODIFIER", 37, 44], ["hectares", "OBSERVATION", 45, 53], ["Central Slovakia", "OBSERVATION", 81, 97]]], ["This division, especially between groups (2) and (3) is artificial, but in the development of the bird community a marked change can be observed about the fifth or sixth year after planting.", [["marked", "OBSERVATION_MODIFIER", 115, 121], ["change", "OBSERVATION", 122, 128]]]], "PMC7454302": [["Patients ::: Materials and MethodsSerum samples were obtained from the following cohorts: (1) hospitalized COVID-19 patients\u2014105 serum samples obtained at different time points from 71 patients with PCR-confirmed SARS-CoV-2 infection and admitted for severe COVID-19 pneumonia from March 1 to April 27, 2020, at our tertiary AZ Delta General Hospital in Roeselare, Belgium; and (2) patients with paucisymptomatic SARS-CoV-2 infections\u201466 serum samples from 64 health care workers with a SARS-CoV-2 infection, PCR-confirmed after developing fever and World Health Organization (WHO)-listed COVID-19 symptoms.", [["samples", "ANATOMY", 40, 47], ["serum samples", "ANATOMY", 129, 142], ["serum samples", "ANATOMY", 438, 451], ["SARS-CoV-2 infection", "DISEASE", 213, 233], ["pneumonia", "DISEASE", 267, 276], ["SARS-CoV-2 infections", "DISEASE", 413, 434], ["SARS-CoV-2 infection", "DISEASE", 487, 507], ["fever", "DISEASE", 540, 545], ["Patients", "ORGANISM", 0, 8], ["MethodsSerum samples", "CANCER", 27, 47], ["patients", "ORGANISM", 116, 124], ["serum samples", "ORGANISM_SUBSTANCE", 129, 142], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 382, 390], ["serum samples", "ORGANISM_SUBSTANCE", 438, 451], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 382, 390], ["SARS-CoV-2", "SPECIES", 213, 223], ["SARS-CoV-2", "SPECIES", 487, 497], ["MethodsSerum samples", "TEST", 27, 47], ["COVID", "TEST", 107, 112], ["serum samples", "TEST", 129, 142], ["PCR", "TEST", 199, 202], ["SARS", "PROBLEM", 213, 217], ["CoV-2 infection", "PROBLEM", 218, 233], ["severe COVID", "PROBLEM", 251, 263], ["pneumonia", "PROBLEM", 267, 276], ["paucisymptomatic SARS", "PROBLEM", 396, 417], ["CoV", "PROBLEM", 418, 421], ["2 infections", "PROBLEM", 422, 434], ["serum samples", "TEST", 438, 451], ["a SARS", "PROBLEM", 485, 491], ["CoV-2 infection", "PROBLEM", 492, 507], ["PCR", "TEST", 509, 512], ["fever", "PROBLEM", 540, 545], ["symptoms", "PROBLEM", 598, 606], ["pneumonia", "OBSERVATION", 267, 276], ["fever", "OBSERVATION", 540, 545]]], ["These patients were home-quarantined without need for hospitalization.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["hospitalization", "TREATMENT", 54, 69]]], ["The study was approved by the AZ Delta ethical committee with a waiver of informed consent from the hospitalized COVID-19 patients and with written informed consent from participants with paucisymptomatic SARS-CoV-2 infections.Patients ::: Materials and MethodsCross-reactivity was evaluated on a panel composed of 57 prepandemic serum samples obtained from patients with PCR-confirmed infection by other HCoV respiratory viruses (HCoV 229E, n = 1; HCoV HKU1, n = 3; HCoV OC43, n = 2; HCoV OC43 + adenovirus, n = 1), other pathogens and viruses (n=42), or presence of autoimmune antibodies (n = 8).", [["serum samples", "ANATOMY", 330, 343], ["SARS-CoV-2 infections", "DISEASE", 205, 226], ["infection", "DISEASE", 386, 395], ["autoimmune antibodies", "DISEASE", 568, 589], ["patients", "ORGANISM", 122, 130], ["CoV-2", "ORGANISM", 210, 215], ["Patients", "ORGANISM", 227, 235], ["serum samples", "ORGANISM_SUBSTANCE", 330, 343], ["patients", "ORGANISM", 358, 366], ["HCoV OC43", "ORGANISM", 467, 476], ["HCoV OC43 + adenovirus", "ORGANISM", 485, 507], ["autoimmune antibodies", "PROTEIN", 568, 589], ["patients", "SPECIES", 122, 130], ["participants", "SPECIES", 170, 182], ["Patients", "SPECIES", 227, 235], ["patients", "SPECIES", 358, 366], ["HCoV respiratory viruses", "SPECIES", 405, 429], ["HCoV", "SPECIES", 431, 435], ["HCoV", "SPECIES", 449, 453], ["HCoV", "SPECIES", 467, 471], ["HCoV", "SPECIES", 485, 489], ["The study", "TEST", 0, 9], ["paucisymptomatic SARS", "PROBLEM", 188, 209], ["CoV-2 infections", "PROBLEM", 210, 226], ["a panel", "TEST", 295, 302], ["prepandemic serum samples", "TEST", 318, 343], ["PCR", "TEST", 372, 375], ["infection", "PROBLEM", 386, 395], ["other HCoV respiratory viruses", "PROBLEM", 399, 429], ["HCoV", "TEST", 431, 435], ["HCoV", "TEST", 449, 453], ["HKU1", "TEST", 454, 458], ["n", "TEST", 460, 461], ["HCoV", "TEST", 467, 471], ["OC43", "TEST", 472, 476], ["n", "TEST", 478, 479], ["HCoV", "TEST", 485, 489], ["OC43", "TEST", 490, 494], ["adenovirus", "TEST", 497, 507], ["other pathogens and viruses", "PROBLEM", 517, 544], ["autoimmune antibodies", "PROBLEM", 568, 589], ["infection", "OBSERVATION", 386, 395], ["respiratory viruses", "OBSERVATION", 410, 429]]], ["Serum samples from patients with other HCoV infections ranged from 0 to 39 days after PCR positivity Table 1.Rapid Tests ::: SARS-CoV-2 Serology Assays ::: Materials and MethodsCOVID-19 IgG/IgM Rapid Test (Zhejiang Orient Gene Biotech) is a solid phase immunochromatographic assay for qualitative detection of IgM and IgG antibodies to recombinant N and S proteins.", [["Serum samples", "ANATOMY", 0, 13], ["HCoV infections", "DISEASE", 39, 54], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["patients", "ORGANISM", 19, 27], ["IgM", "GENE_OR_GENE_PRODUCT", 310, 313], ["IgG antibodies to recombinant N and S proteins", "GENE_OR_GENE_PRODUCT", 318, 364], ["IgG", "PROTEIN", 186, 189], ["IgM", "PROTEIN", 190, 193], ["IgM", "PROTEIN", 310, 313], ["IgG antibodies", "PROTEIN", 318, 332], ["recombinant N and S proteins", "PROTEIN", 336, 364], ["patients", "SPECIES", 19, 27], ["HCoV", "SPECIES", 39, 43], ["Serum samples", "TEST", 0, 13], ["other HCoV infections", "PROBLEM", 33, 54], ["Rapid Tests", "TEST", 109, 120], ["SARS", "PROBLEM", 125, 129], ["CoV", "TEST", 130, 133], ["Materials", "TEST", 156, 165], ["MethodsCOVID", "TEST", 170, 182], ["IgG", "TEST", 186, 189], ["IgM Rapid Test", "TEST", 190, 204], ["a solid phase immunochromatographic assay", "TEST", 239, 280], ["qualitative detection", "TEST", 285, 306], ["IgM", "TEST", 310, 313], ["IgG antibodies", "TEST", 318, 332]]], ["Innovita 2019-nCoV Ab Test (Innovita Biological Technology) is a colloidal gold lateral flow assay for qualitative detection of IgM and IgG antibodies to undisclosed SARS-CoV-2 epitopes.", [["IgM", "GENE_OR_GENE_PRODUCT", 128, 131], ["IgM", "PROTEIN", 128, 131], ["IgG antibodies", "PROTEIN", 136, 150], ["undisclosed SARS-CoV-2 epitopes", "PROTEIN", 154, 185], ["a colloidal gold lateral flow assay", "TEST", 63, 98], ["qualitative detection", "TEST", 103, 124], ["IgM", "TEST", 128, 131], ["IgG antibodies", "TEST", 136, 150], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174]]], ["Rapid tests were considered positive if a line was observed for IgM, IgG, or both.", [["IgM", "GENE_OR_GENE_PRODUCT", 64, 67], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgM", "PROTEIN", 64, 67], ["IgG", "PROTEIN", 69, 72], ["Rapid tests", "TEST", 0, 11], ["a line", "TREATMENT", 40, 46], ["IgM", "PROBLEM", 64, 67], ["IgG", "TEST", 69, 72]]], ["Color intensity was not evaluated.ELISA ::: SARS-CoV-2 Serology Assays ::: Materials and MethodsWantai SARS-COV-2 Ab ELISA (Beijing Wantai Biological Pharmacy Enterprise) is a double-antigen sandwich immunoassay for qualitative detection of all antibody isotypes (IgM, IgA, IgG) against RBD domain of S1 protein.", [["IgM", "GENE_OR_GENE_PRODUCT", 264, 267], ["IgA", "GENE_OR_GENE_PRODUCT", 269, 272], ["IgG", "GENE_OR_GENE_PRODUCT", 274, 277], ["S1", "GENE_OR_GENE_PRODUCT", 301, 303], ["antibody isotypes", "PROTEIN", 245, 262], ["IgM", "PROTEIN", 264, 267], ["IgA", "PROTEIN", 269, 272], ["IgG", "PROTEIN", 274, 277], ["RBD domain", "PROTEIN", 287, 297], ["S1 protein", "PROTEIN", 301, 311], ["SARS", "TEST", 44, 48], ["Materials", "TEST", 75, 84], ["MethodsWantai SARS", "TEST", 89, 107], ["a double-antigen sandwich immunoassay", "TEST", 174, 211], ["qualitative detection", "TEST", 216, 237], ["all antibody isotypes", "TEST", 241, 262], ["IgM", "TEST", 264, 267], ["IgA", "TEST", 269, 272], ["IgG", "TEST", 274, 277], ["RBD domain of S1 protein", "PROBLEM", 287, 311], ["intensity", "OBSERVATION_MODIFIER", 6, 15], ["antibody isotypes", "OBSERVATION", 245, 262]]], ["Samples with a cutoff ratio (absorbance of the sample at 450 nm divided by 0.19) higher than 0.9 were considered positive (classifying gray zone results with cutoff ratio 0.9-1.1 as positive).", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["a cutoff ratio", "TEST", 13, 27], ["the sample", "TEST", 43, 53], ["cutoff ratio", "TEST", 158, 170]]], ["Three indirect ELISAs from EUROIMMUN were tested: Anti-SARS-CoV-2 IgG and IgA assays for semiquantitative detection of IgA and IgG antibodies against S1 protein and Anti-SARS-CoV-2-NCP(IgG) assay for semiquantitative detection of IgG against N protein. (cutoff of 0.8 units, classifying gray zone results of 0.8-1.1 units as positive).", [["Anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 50, 69], ["IgA", "GENE_OR_GENE_PRODUCT", 74, 77], ["IgA", "GENE_OR_GENE_PRODUCT", 119, 122], ["IgG antibodies against S1", "GENE_OR_GENE_PRODUCT", 127, 152], ["2-NCP", "SIMPLE_CHEMICAL", 179, 184], ["IgG", "ORGANISM", 185, 188], ["IgG against N protein", "GENE_OR_GENE_PRODUCT", 230, 251], ["Anti-SARS", "PROTEIN", 50, 59], ["IgG", "PROTEIN", 66, 69], ["IgA", "PROTEIN", 74, 77], ["IgA", "PROTEIN", 119, 122], ["IgG antibodies", "PROTEIN", 127, 141], ["S1 protein", "PROTEIN", 150, 160], ["IgG", "PROTEIN", 185, 188], ["IgG", "PROTEIN", 230, 233], ["N protein", "PROTEIN", 242, 251], ["SARS-CoV", "SPECIES", 170, 178], ["Three indirect ELISAs", "TEST", 0, 21], ["Anti-SARS", "TEST", 50, 59], ["CoV", "TEST", 60, 63], ["IgG", "TEST", 66, 69], ["IgA assays", "TEST", 74, 84], ["semiquantitative detection", "TEST", 89, 115], ["IgA", "TEST", 119, 122], ["IgG antibodies", "TEST", 127, 141], ["S1 protein", "TEST", 150, 160], ["Anti-SARS", "TEST", 165, 174], ["CoV", "TEST", 175, 178], ["NCP(IgG)", "TREATMENT", 181, 189], ["semiquantitative detection", "TEST", 200, 226], ["IgG", "PROBLEM", 230, 233], ["gray zone", "TEST", 287, 296]]], ["All ELISAs were tested using the PhD system (Version EIA 0_16, Bio-Rad Laboratories).Chemiluminescent Immunoassays ::: SARS-CoV-2 Serology Assays ::: Materials and MethodsElecsys Anti-SARS-CoV-2 assay for cobas e601 module (Roche Diagnostics) is a double-antigen sandwich assay for qualitative detection of all antibody isotypes (IgM, IgA, IgG) against N protein (cutoff of 1 cutoff index).", [["IgM", "GENE_OR_GENE_PRODUCT", 330, 333], ["IgA", "GENE_OR_GENE_PRODUCT", 335, 338], ["IgG", "GENE_OR_GENE_PRODUCT", 340, 343], ["antibody isotypes", "PROTEIN", 311, 328], ["IgM", "PROTEIN", 330, 333], ["IgA", "PROTEIN", 335, 338], ["IgG", "PROTEIN", 340, 343], ["N protein", "PROTEIN", 353, 362], ["All ELISAs", "TEST", 0, 10], ["Version EIA", "TEST", 45, 56], ["Chemiluminescent Immunoassays", "TEST", 85, 114], ["Materials", "TEST", 150, 159], ["MethodsElecsys", "TEST", 164, 178], ["Anti-SARS", "TEST", 179, 188], ["CoV", "TEST", 189, 192], ["cobas", "TEST", 205, 210], ["a double-antigen sandwich assay", "TEST", 246, 277], ["qualitative detection", "TEST", 282, 303], ["all antibody isotypes", "TEST", 307, 328], ["IgM", "TEST", 330, 333], ["IgA", "TEST", 335, 338], ["IgG", "TEST", 340, 343], ["N protein", "TEST", 353, 362], ["cutoff", "TEST", 364, 370], ["antibody isotypes", "OBSERVATION", 311, 328]]], ["LIAISON SARS-CoV-2 S1/S2 IgG (DiaSorin) is an indirect chemiluminescent immunoassay for quantitative detection of IgG antibodies against S1/S2 proteins (cutoff of 12 arbitrary units [AU]/mL, classifying gray zone results of 12-15 AU/mL as positive).SARS-CoV-2 PCR ::: SARS-CoV-2 Serology Assays ::: Materials and MethodsThis was done using the Allplex 2019-nCoV assay (Seegene) for E/N/RdRP genes on nasopharyngeal swabs.Statistical Analysis ::: Materials and MethodsStatistical analyses were performed using MedCalc (version 12.2.1).", [["nasopharyngeal swabs", "ANATOMY", 400, 420], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 8, 21], ["S2 IgG", "GENE_OR_GENE_PRODUCT", 22, 28], ["DiaSorin", "GENE_OR_GENE_PRODUCT", 30, 38], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 114, 128], ["S2", "GENE_OR_GENE_PRODUCT", 140, 142], ["E/N", "GENE_OR_GENE_PRODUCT", 382, 385], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 400, 420], ["SARS-CoV-2 S1/S2 IgG", "PROTEIN", 8, 28], ["DiaSorin", "PROTEIN", 30, 38], ["IgG antibodies", "PROTEIN", 114, 128], ["S1", "PROTEIN", 137, 139], ["S2 proteins", "PROTEIN", 140, 151], ["nCoV", "DNA", 357, 361], ["E/N/RdRP genes", "DNA", 382, 396], ["LIAISON SARS", "TEST", 0, 12], ["CoV", "TEST", 13, 16], ["an indirect chemiluminescent immunoassay", "TEST", 43, 83], ["quantitative detection", "TEST", 88, 110], ["IgG antibodies", "TEST", 114, 128], ["S1/S2 proteins", "TEST", 137, 151], ["cutoff", "TEST", 153, 159], ["AU", "TEST", 183, 185], ["gray zone", "TEST", 203, 212], ["SARS-CoV-2 PCR", "TEST", 249, 263], ["the Allplex", "TREATMENT", 340, 351], ["E/N/RdRP genes", "TREATMENT", 382, 396], ["nasopharyngeal swabs", "TREATMENT", 400, 420], ["MethodsStatistical analyses", "TEST", 460, 487], ["S2", "ANATOMY", 140, 142], ["nasopharyngeal", "ANATOMY", 400, 414]]], ["Sensitivities for detection of presence of SARS-CoV-2 antibodies were evaluated on samples obtained from SARS-CoV-2 PCR-positive patients as (1) total fraction of samples showing detectable antibodies and (2) by comparing each individual assay vs consensus outcome obtained by majority of all assays evaluated in this study. \u03c7 2 test was used for comparing proportions for categorical variables.", [["samples", "ANATOMY", 83, 90], ["samples", "ANATOMY", 163, 170], ["SARS", "DISEASE", 43, 47], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 43, 64], ["patients", "ORGANISM", 129, 137], ["samples", "CANCER", 163, 170], ["SARS-CoV-2 antibodies", "PROTEIN", 43, 64], ["antibodies", "PROTEIN", 190, 200], ["patients", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 105, 113], ["Sensitivities", "TEST", 0, 13], ["SARS", "PROBLEM", 43, 47], ["CoV-2 antibodies", "TEST", 48, 64], ["samples", "TEST", 83, 90], ["SARS", "TEST", 105, 109], ["CoV", "TEST", 110, 113], ["PCR", "TEST", 116, 119], ["total fraction of samples", "TEST", 145, 170], ["detectable antibodies", "PROBLEM", 179, 200], ["each individual assay", "TEST", 222, 243], ["all assays", "TEST", 289, 299], ["this study", "TEST", 313, 323], ["2 test", "TEST", 327, 333], ["categorical variables", "TEST", 373, 394]]], ["Not normally quantitative variables are expressed as medians (interquartile range [IQR]), and Mann-Whitney test was used to test for statistical differences between various timeframes after onset symptoms.", [["Whitney test", "TEST", 99, 111], ["onset symptoms", "PROBLEM", 190, 204]]], ["Differences were considered statistically significant if P < .05.", [["P", "TEST", 57, 58]]], ["Kinetics of seroconversion in individual patients in Figure 1 were fitted to a scale from \u20131 to +1, with 0 representing each assays cutoff by subtracting each assay\u2019s cutoff from its raw data signals, and dividing its absolute value by highest (lowest) cutoff-corrected signal for that assay obtained in our data set for positive (negative) samples.Cross-Reactivity (Analytical Specificity) ::: ResultsAnalytical specificity was evaluated on 57 prepandemic samples from individuals infected with other HCoV viruses (229E/HKU1/OC43), other infectious agents, or with positivity to anti\u2013nuclear factor or rheumatoid factor (Table 1).", [["samples", "ANATOMY", 341, 348], ["samples", "ANATOMY", 457, 464], ["patients", "ORGANISM", 41, 49], ["individuals", "ORGANISM", 470, 481], ["HCoV viruses", "ORGANISM", 502, 514], ["OC43", "GENE_OR_GENE_PRODUCT", 526, 530], ["anti\u2013nuclear factor", "GENE_OR_GENE_PRODUCT", 580, 599], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 603, 620], ["anti\u2013nuclear factor", "PROTEIN", 580, 599], ["rheumatoid factor", "PROTEIN", 603, 620], ["patients", "SPECIES", 41, 49], ["HCoV viruses (229E/HKU1/OC43", "SPECIES", 502, 530], ["seroconversion", "TREATMENT", 12, 26], ["cutoff", "TEST", 253, 259], ["that assay", "TEST", 281, 291], ["our data", "TEST", 304, 312], ["prepandemic samples", "TEST", 445, 464], ["other HCoV viruses", "PROBLEM", 496, 514], ["rheumatoid factor", "PROBLEM", 603, 620], ["seroconversion", "OBSERVATION", 12, 26]]], ["Wantai SARS-COV-2 Ab ELISA, Elecsys Anti-SARS-CoV-2 assay, EUROIMMUN Anti-SARS-CoV-2 IgG, and Innovita 2019-nCoV Ab Test showed no cross-reactivity Table 2.", [["IgG", "PROTEIN", 85, 88], ["Innovita 2019", "PROTEIN", 94, 107], ["nCoV Ab", "PROTEIN", 108, 115], ["Wantai SARS", "TEST", 0, 11], ["COV", "TEST", 12, 15], ["Ab ELISA", "TEST", 18, 26], ["Elecsys", "TEST", 28, 35], ["Anti-SARS", "TEST", 36, 45], ["CoV", "TEST", 46, 49], ["EUROIMMUN", "TEST", 59, 68], ["Anti-SARS", "TEST", 69, 78], ["CoV", "TEST", 79, 82], ["IgG", "TEST", 85, 88], ["Innovita", "TEST", 94, 102], ["nCoV Ab Test", "TEST", 108, 120]]], ["EUROIMMUN Anti-SARS-CoV-2 IgA and Orient Gene COVID-19 IgG/IgM Rapid Test showed cross reactivity with common cold HCoV viruses, resulting in respective analytical specificities of 91.1% and 92.9%.", [["Anti-SARS-CoV-2 IgA", "GENE_OR_GENE_PRODUCT", 10, 29], ["IgM", "GENE_OR_GENE_PRODUCT", 59, 62], ["Anti-SARS-CoV-2 IgA", "DNA", 10, 29], ["IgG", "PROTEIN", 55, 58], ["IgM", "PROTEIN", 59, 62], ["HCoV", "SPECIES", 115, 119], ["EUROIMMUN", "TEST", 0, 9], ["Anti-SARS", "TEST", 10, 19], ["CoV", "TEST", 20, 23], ["IgA", "TEST", 26, 29], ["Orient Gene COVID", "TEST", 34, 51], ["IgG/IgM", "TEST", 55, 62], ["Rapid Test", "TEST", 63, 73], ["cross reactivity", "PROBLEM", 81, 97], ["common cold HCoV viruses", "PROBLEM", 103, 127], ["respective analytical specificities", "TEST", 142, 177]]], ["LIAISON SARS-CoV-2 S1/S2 IgG (96.4% analytical specificity) was the only to show interference by rheumatoid factor (Table 1).Study Participants ::: Sensitivity for Detection of Presence of SARS-CoV-2 Antibodies ::: ResultsSensitivities for detection of SARS-CoV-2 antibodies were compared on 171 samples obtained from 135 subjects, all with PCR-confirmed SARS-CoV-2 infections, pooled or grouped in two distinct cohorts: hospitalized and paucisymptomatic COVID-19 patients.", [["samples", "ANATOMY", 296, 303], ["SARS", "DISEASE", 189, 193], ["SARS-CoV-2 infections", "DISEASE", 355, 376], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 8, 21], ["S2", "GENE_OR_GENE_PRODUCT", 22, 24], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 97, 114], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 253, 274], ["SARS-CoV-2", "ORGANISM", 355, 365], ["patients", "ORGANISM", 464, 472], ["CoV-2 S1/S2 IgG", "PROTEIN", 13, 28], ["rheumatoid factor", "PROTEIN", 97, 114], ["SARS-CoV-2 antibodies", "PROTEIN", 253, 274], ["Participants", "SPECIES", 131, 143], ["patients", "SPECIES", 464, 472], ["SARS-CoV", "SPECIES", 189, 197], ["SARS-CoV", "SPECIES", 253, 261], ["SARS-CoV-2", "SPECIES", 355, 365], ["LIAISON SARS", "TEST", 0, 12], ["CoV", "TEST", 13, 16], ["S1/S2 IgG", "TEST", 19, 28], ["analytical specificity", "TEST", 36, 58], ["rheumatoid factor", "PROBLEM", 97, 114], ["Sensitivity", "TEST", 148, 159], ["SARS", "PROBLEM", 189, 193], ["CoV", "TEST", 194, 197], ["SARS", "PROBLEM", 253, 257], ["CoV-2 antibodies", "TEST", 258, 274], ["PCR", "TEST", 341, 344], ["SARS", "PROBLEM", 355, 359], ["CoV", "PROBLEM", 360, 363], ["2 infections", "PROBLEM", 364, 376], ["rheumatoid", "OBSERVATION", 97, 107]]], ["Hospitalized patients included 105 samples from 71 patients hospitalized for severe COVID-19 disease, all with very high level of suspicion of COVID-19 pneumonia on chest computed tomography (COVID-19 Reporting and Data System [CO-RADS] score = 5)13: 48 males (median age, 65 years; IQR, 53-80) and 23 females (median age, 79 years; IQR, 67-86).", [["samples", "ANATOMY", 35, 42], ["COVID-19 disease", "DISEASE", 84, 100], ["pneumonia", "DISEASE", 152, 161], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 51, 59], ["severe COVID-19 disease", "PROBLEM", 77, 100], ["COVID", "TEST", 143, 148], ["pneumonia", "PROBLEM", 152, 161], ["chest computed tomography", "TEST", 165, 190], ["COVID", "TEST", 192, 197], ["IQR", "TEST", 283, 286], ["IQR", "TEST", 333, 336], ["pneumonia", "OBSERVATION", 152, 161], ["chest", "ANATOMY", 165, 170]]], ["Serum samples ranged from 0 to 39 days after patient-reported symptom onset.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["Serum samples", "TEST", 0, 13], ["symptom onset", "PROBLEM", 62, 75]]], ["Paucisymptomatic patients included 66 samples from 64 health care workers with mild (n = 61) or no (n = 3) WHO-listed COVID-19 symptoms: myalgia (present in 62.5%), fever (60.9%), dry cough (56.2%), dyspnea (40.6%), severe fatigue (35.9%), headaches (30.0%), loss of smell or taste (26.6%), or diarrhea (18.8%).", [["samples", "ANATOMY", 38, 45], ["Paucisymptomatic", "DISEASE", 0, 16], ["myalgia", "DISEASE", 137, 144], ["fever", "DISEASE", 165, 170], ["dry cough", "DISEASE", 180, 189], ["dyspnea", "DISEASE", 199, 206], ["fatigue", "DISEASE", 223, 230], ["headaches", "DISEASE", 240, 249], ["loss of smell or taste", "DISEASE", 259, 281], ["diarrhea", "DISEASE", 294, 302], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["mild (n = 61)", "PROBLEM", 79, 92], ["symptoms", "PROBLEM", 127, 135], ["myalgia", "PROBLEM", 137, 144], ["fever", "PROBLEM", 165, 170], ["dry cough", "PROBLEM", 180, 189], ["dyspnea", "PROBLEM", 199, 206], ["severe fatigue", "PROBLEM", 216, 230], ["headaches", "PROBLEM", 240, 249], ["loss of smell or taste", "PROBLEM", 259, 281], ["diarrhea", "PROBLEM", 294, 302], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["myalgia", "OBSERVATION", 137, 144], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["fatigue", "OBSERVATION", 223, 230]]], ["None of these patients were hospitalized.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Serum samples ranged from 11 to 54 days after patient-reported symptom onset.Sensitivity for Detection of SARS-CoV-2 Antibodies ::: Sensitivity for Detection of Presence of SARS-CoV-2 Antibodies ::: ResultsSensitivity was calculated for different patient groups (all patients, hospitalized and paucisymptomatic patients).", [["Serum samples", "ANATOMY", 0, 13], ["SARS", "DISEASE", 173, 177], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["patient", "ORGANISM", 46, 53], ["patient", "ORGANISM", 247, 254], ["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 311, 319], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 247, 254], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 311, 319], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "SPECIES", 173, 181], ["Serum samples", "TEST", 0, 13], ["symptom onset", "PROBLEM", 63, 76], ["Sensitivity", "TEST", 77, 88], ["Detection", "TEST", 93, 102], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["Sensitivity", "TEST", 132, 143], ["SARS", "PROBLEM", 173, 177], ["CoV", "TEST", 178, 181], ["ResultsSensitivity", "TEST", 199, 217]]], ["First, vs SARS-CoV-2 PCR (100% of samples from PCR+ patients) as reference, by measuring the percentage of samples showing antibody titers above the respective assay\u2019s cutoff (Table 2).", [["samples", "ANATOMY", 34, 41], ["samples", "ANATOMY", 107, 114], ["samples", "CANCER", 34, 41], ["patients", "ORGANISM", 52, 60], ["samples", "CANCER", 107, 114], ["patients", "SPECIES", 52, 60], ["SARS-CoV", "SPECIES", 10, 18], ["SARS", "TEST", 10, 14], ["CoV", "TEST", 15, 18], ["PCR", "TEST", 21, 24], ["samples", "TEST", 34, 41], ["PCR", "TEST", 47, 50], ["antibody titers", "TEST", 123, 138]]], ["Wantai SARS-COV-2 Ab ELISA showed highest overall sensitivity for detection of SARS-CoV-2 antibodies: 86.4% (95% confidence interval [CI], 80.3%-91.2%) vs PCR and 100% (95% CI, 97.3%-100%) vs consensus at all time points in both patient cohorts.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 79, 89], ["patient", "ORGANISM", 229, 236], ["patient", "SPECIES", 229, 236], ["SARS-CoV", "SPECIES", 79, 87], ["Wantai SARS", "TEST", 0, 11], ["COV", "TEST", 12, 15], ["Ab ELISA", "TEST", 18, 26], ["SARS", "TEST", 79, 83], ["CoV", "TEST", 84, 87], ["antibodies", "TEST", 90, 100], ["interval", "TEST", 124, 132], ["CI", "TEST", 134, 136], ["PCR", "TEST", 155, 158], ["CI", "TEST", 173, 175]]], ["Its sensitivity was significantly higher (P < .05) than all other assays with the exception of Orient Gene COVID-19 IgG/IgM Rapid Test and EUROIMMUN Anti-SARS-CoV-2 IgG and IgA combined.", [["Anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 149, 168], ["IgA", "GENE_OR_GENE_PRODUCT", 173, 176], ["Orient Gene COVID-19 IgG", "PROTEIN", 95, 119], ["IgM", "PROTEIN", 120, 123], ["Anti-SARS", "PROTEIN", 149, 158], ["CoV", "PROTEIN", 159, 162], ["IgG", "PROTEIN", 165, 168], ["IgA", "PROTEIN", 173, 176], ["Its sensitivity", "TEST", 0, 15], ["all other assays", "TEST", 56, 72], ["Orient Gene COVID", "TEST", 95, 112], ["IgG", "TEST", 116, 119], ["Rapid Test", "TEST", 124, 134], ["EUROIMMUN", "TEST", 139, 148], ["Anti-SARS", "TEST", 149, 158], ["CoV", "TEST", 159, 162], ["IgG", "TEST", 165, 168], ["IgA", "TEST", 173, 176]]], ["In a real-world clinical setting, serology assays might be used at later time stages, eg, more than 20 days after onset of symptoms or to document past SARS-CoV-2 infection in paucisymptomatic patients.", [["infection", "DISEASE", 163, 172], ["paucisymptomatic", "DISEASE", 176, 192], ["SARS-CoV-2", "ORGANISM", 152, 162], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 152, 160], ["serology assays", "TEST", 34, 49], ["symptoms", "PROBLEM", 123, 131], ["past SARS", "PROBLEM", 147, 156], ["CoV", "PROBLEM", 157, 160], ["2 infection in paucisymptomatic patients", "PROBLEM", 161, 201], ["infection", "OBSERVATION", 163, 172]]], ["In these patients, 4 assays showed clinically acceptable sensitivity for detection of SARS-CoV-2 antibodies above 95% vs consensus result (Table 3): Wantai SARS-COV-2 Ab ELISA, Elecsys Anti-SARS-CoV-2 assay, EUROIMMUN Anti-SARS-CoV-2 IgG and IgA combined, and Orient Gene COVID-19 IgG/IgM Rapid Test.", [["SARS", "DISEASE", 86, 90], ["patients", "ORGANISM", 9, 17], ["CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 228, 237], ["IgA", "GENE_OR_GENE_PRODUCT", 242, 245], ["SARS-CoV-2 antibodies", "PROTEIN", 86, 107], ["Anti-SARS", "PROTEIN", 218, 227], ["CoV", "PROTEIN", 228, 231], ["IgG", "PROTEIN", 234, 237], ["IgA", "PROTEIN", 242, 245], ["IgG", "PROTEIN", 281, 284], ["IgM", "PROTEIN", 285, 288], ["patients", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 86, 94], ["4 assays", "TEST", 19, 27], ["SARS", "PROBLEM", 86, 90], ["CoV", "TEST", 91, 94], ["antibodies", "TEST", 97, 107], ["Wantai SARS", "TEST", 149, 160], ["COV", "TEST", 161, 164], ["Ab ELISA", "TEST", 167, 175], ["Elecsys", "TEST", 177, 184], ["Anti-SARS", "TEST", 185, 194], ["CoV", "TEST", 195, 198], ["EUROIMMUN", "TEST", 208, 217], ["Anti-SARS", "TEST", 218, 227], ["CoV", "TEST", 228, 231], ["IgG", "TEST", 234, 237], ["IgA", "TEST", 242, 245], ["Orient Gene COVID", "TEST", 260, 277], ["IgG", "TEST", 281, 284], ["Rapid Test", "TEST", 289, 299]]], ["In comparison with all other assays, LIAISON SARS-CoV-2 S1/S2 IgG showed significantly (P < .05) lower sensitivities of 83.6% (95% CI, 72.5%-91.5%) vs consensus (Table 3) at greater than 20 days post onset of symptoms and of 84.2% (95% CI, 72.1%-92.5%) in paucisymptomatic patients.", [["IgG", "GENE_OR_GENE_PRODUCT", 62, 65], ["patients", "ORGANISM", 273, 281], ["LIAISON SARS-CoV-2 S1/S2 IgG", "PROTEIN", 37, 65], ["patients", "SPECIES", 273, 281], ["all other assays", "TEST", 19, 35], ["LIAISON SARS", "TEST", 37, 49], ["CoV", "TEST", 50, 53], ["S1/S2 IgG", "TEST", 56, 65], ["P", "TEST", 88, 89], ["lower sensitivities", "TEST", 97, 116], ["CI", "TEST", 131, 133], ["symptoms", "PROBLEM", 209, 217], ["CI", "TEST", 236, 238]]], ["Also, EUROIMMUN Anti-SARS-CoV-2-NCP(IgG) and Innovita 2019-nCoV Ab Test showed limited sensitivity at greater than 20 days post onset of symptoms.Kinetics of Seroconversion ::: Sensitivity for Detection of Presence of SARS-CoV-2 Antibodies ::: ResultsWe compared timing of detection of antibodies of the ELISA/CLIA assays on consecutive blood samples of 8 critically ill patients admitted to intensive care units (Figure 1).", [["blood samples", "ANATOMY", 337, 350], ["Anti-SARS-CoV-2-NCP", "CHEMICAL", 16, 35], ["SARS", "DISEASE", 218, 222], ["critically ill", "DISEASE", 356, 370], ["Anti-SARS-CoV-2-NCP", "GENE_OR_GENE_PRODUCT", 16, 35], ["IgG", "ORGANISM", 36, 39], ["blood samples", "ORGANISM_SUBSTANCE", 337, 350], ["patients", "ORGANISM", 371, 379], ["Anti-SARS", "PROTEIN", 16, 25], ["NCP", "PROTEIN", 32, 35], ["IgG", "PROTEIN", 36, 39], ["nCoV Ab", "PROTEIN", 59, 66], ["antibodies", "PROTEIN", 286, 296], ["patients", "SPECIES", 371, 379], ["SARS-CoV", "SPECIES", 218, 226], ["EUROIMMUN", "TEST", 6, 15], ["Anti-SARS", "TEST", 16, 25], ["CoV", "TEST", 26, 29], ["Innovita", "TEST", 45, 53], ["nCoV Ab Test", "TEST", 59, 71], ["limited sensitivity", "PROBLEM", 79, 98], ["symptoms", "PROBLEM", 137, 145], ["Sensitivity", "TEST", 177, 188], ["SARS", "PROBLEM", 218, 222], ["CoV", "TEST", 223, 226], ["antibodies", "TEST", 286, 296], ["the ELISA", "TEST", 300, 309], ["consecutive blood samples", "TEST", 325, 350], ["Seroconversion", "OBSERVATION", 158, 172]]], ["In all 8 patients, Wantai SARS-COV-2 Ab ELISA was first to exceed the predefined assay cutoff, followed by the EUROIMMUN Anti-SARS-CoV-2 IgA assay.", [["patients", "ORGANISM", 9, 17], ["IgA", "GENE_OR_GENE_PRODUCT", 137, 140], ["Anti-SARS", "PROTEIN", 121, 130], ["IgA", "PROTEIN", 137, 140], ["patients", "SPECIES", 9, 17], ["the EUROIMMUN Anti-SARS", "TEST", 107, 130], ["CoV", "TEST", 131, 134]]], ["In this cohort of intensive care patients, of the N-targeting assays, EUROIMMUN Anti-SARS-CoV-2-NCP(IgG) provided positive results more rapidly than Elecsys Anti-SARS-CoV-2 assay.", [["Anti-SARS-CoV-2-NCP", "CHEMICAL", 80, 99], ["patients", "ORGANISM", 33, 41], ["2-NCP", "SIMPLE_CHEMICAL", 94, 99], ["IgG", "ORGANISM", 100, 103], ["NCP", "PROTEIN", 96, 99], ["IgG", "PROTEIN", 100, 103], ["patients", "SPECIES", 33, 41], ["EUROIMMUN", "TEST", 70, 79], ["Anti-SARS", "TEST", 80, 89], ["CoV", "TEST", 90, 93], ["Elecsys", "TEST", 149, 156], ["Anti-SARS", "TEST", 157, 166], ["CoV", "TEST", 167, 170]]], ["LIAISON SARS-CoV-2 S1/S2 IgG was last to detect seroconversion.", [["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 8, 21], ["S2", "GENE_OR_GENE_PRODUCT", 22, 24], ["SARS-CoV-2 S1/S2 IgG", "PROTEIN", 8, 28], ["LIAISON SARS", "TEST", 0, 12], ["CoV", "TEST", 13, 16], ["seroconversion", "PROBLEM", 48, 62]]], ["Seroconversion rates were additionally studied by a pooled analysis in samples from different patients, grouped according to the timeframe after symptom onset ranging from less than 10 days, 10 to 20 days, or more than 20 days post onset of symptoms (Tables 2 and 3).", [["samples", "ANATOMY", 71, 78], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["Seroconversion rates", "TEST", 0, 20], ["a pooled analysis", "TEST", 50, 67], ["symptoms", "PROBLEM", 241, 249]]], ["All tests except Wantai SARS-COV-2 Ab ELISA showed a significantly higher positivity rate between 10 and 20 days post onset of symptoms as compared to less than 10 days post onset of symptoms (P < .05).", [["All tests", "TEST", 0, 9], ["Wantai SARS-COV", "TEST", 17, 32], ["Ab ELISA", "TEST", 35, 43], ["a significantly higher positivity rate", "PROBLEM", 51, 89], ["symptoms", "PROBLEM", 127, 135], ["symptoms", "PROBLEM", 183, 191]]], ["No significant differences were observed in positivity rates between 10 and 20 days post onset of symptoms and more than 20 days post onset of symptoms (Table 2), indicating that serology testing can be performed starting from 10 days after onset symptoms.", [["positivity rates", "TEST", 44, 60], ["symptoms", "PROBLEM", 98, 106], ["symptoms", "PROBLEM", 143, 151], ["serology testing", "TEST", 179, 195], ["onset symptoms", "PROBLEM", 241, 255], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION", 15, 26]]], ["In samples less than 10 days after onset of symptoms, all from hospitalized patients, the Wantai SARS-COV-2 Ab ELISA outperformed all other assays, with a sensitivity of 100% (95% CI, 88.1%-100%) vs consensus and 75.5% (95% CI, 61.7%-86.2%) vs PCR, which was significantly lower than its performance in samples from patients greater than 20 days post onset of symptoms (P < .05).Concordance Analysis of Humoral Immune Response on Individual Samples ::: Sensitivity for Detection of Presence of SARS-CoV-2 Antibodies ::: ResultsFor the assays with acceptable overall sensitivity above 95% (Wantai SARS-COV-2 Ab ELISA, Elecsys Anti-SARS-CoV-2 assay, EUROIMMUN Anti-SARS-CoV-2 IgG and IgA combined, and Orient Gene COVID-19 IgG/IgM Rapid Test) a good overall concordance was seen in samples from patients greater than 10 days post onset of symptoms, with 87.7% and 3.5% of samples positive or negative respectively with all 4 methods.", [["samples", "ANATOMY", 3, 10], ["samples", "ANATOMY", 303, 310], ["samples", "ANATOMY", 780, 787], ["samples", "ANATOMY", 870, 877], ["SARS", "DISEASE", 494, 498], ["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 316, 324], ["IgA", "GENE_OR_GENE_PRODUCT", 682, 685], ["patients", "ORGANISM", 793, 801], ["CoV", "PROTEIN", 668, 671], ["IgG", "PROTEIN", 674, 677], ["IgA", "PROTEIN", 682, 685], ["COVID", "PROTEIN", 712, 717], ["IgG", "PROTEIN", 721, 724], ["IgM", "PROTEIN", 725, 728], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 316, 324], ["patients", "SPECIES", 793, 801], ["SARS-CoV", "SPECIES", 494, 502], ["symptoms", "PROBLEM", 44, 52], ["the Wantai SARS", "TEST", 86, 101], ["a sensitivity", "TEST", 153, 166], ["CI", "TEST", 180, 182], ["consensus", "TEST", 199, 208], ["CI", "TEST", 224, 226], ["PCR", "TEST", 244, 247], ["symptoms", "PROBLEM", 360, 368], ["Sensitivity", "TEST", 453, 464], ["SARS", "PROBLEM", 494, 498], ["CoV", "TEST", 499, 502], ["the assays", "TEST", 531, 541], ["Wantai SARS", "TEST", 589, 600], ["COV", "TEST", 601, 604], ["Ab ELISA", "TEST", 607, 615], ["Elecsys", "TEST", 617, 624], ["Anti-SARS", "TEST", 625, 634], ["CoV", "TEST", 635, 638], ["EUROIMMUN", "TEST", 648, 657], ["Anti-SARS", "TEST", 658, 667], ["CoV", "TEST", 668, 671], ["IgG", "TEST", 674, 677], ["IgA", "TEST", 682, 685], ["Orient Gene COVID", "TEST", 700, 717], ["IgG", "TEST", 721, 724], ["Rapid Test", "TEST", 729, 739], ["symptoms", "PROBLEM", 837, 845], ["samples", "TEST", 870, 877]]], ["No clear differences were observed in kinetics of appearance of antibodies to S or N epitopes.", [["antibodies to S or N epitopes", "PROTEIN", 64, 93], ["clear differences", "PROBLEM", 3, 20], ["N epitopes", "PROBLEM", 83, 93], ["clear", "OBSERVATION", 3, 8]]], ["Beyond 10 days, only 1.4% (1/71) of hospitalized and 4.7% (3/64) paucisymptomatic patients developed no detectable antibodies.DiscussionIn this study we report on the clinical performance characteristics of 7 commercially available serology tests for detection of antibodies against SARS-CoV-2 S protein (S-RBD total antibodies, S1/S2 IgG, S1 IgA and IgG), N protein (N total antibodies, N IgG), and both proteins (N/S IgM and IgG).", [["patients", "ORGANISM", 82, 90], ["S-RBD", "GENE_OR_GENE_PRODUCT", 305, 310], ["IgG", "GENE_OR_GENE_PRODUCT", 335, 338], ["IgA", "GENE_OR_GENE_PRODUCT", 343, 346], ["IgG", "GENE_OR_GENE_PRODUCT", 351, 354], ["N total antibodies, N IgG", "GENE_OR_GENE_PRODUCT", 368, 393], ["N/S IgM", "GENE_OR_GENE_PRODUCT", 415, 422], ["IgG", "GENE_OR_GENE_PRODUCT", 427, 430], ["antibodies", "PROTEIN", 115, 125], ["antibodies", "PROTEIN", 264, 274], ["SARS-CoV-2 S protein", "PROTEIN", 283, 303], ["S", "PROTEIN", 305, 306], ["RBD total antibodies", "PROTEIN", 307, 327], ["S1", "PROTEIN", 329, 331], ["S2", "PROTEIN", 332, 334], ["IgG", "PROTEIN", 335, 338], ["S1", "PROTEIN", 340, 342], ["IgA", "PROTEIN", 343, 346], ["IgG", "PROTEIN", 351, 354], ["N protein", "PROTEIN", 357, 366], ["N total antibodies", "PROTEIN", 368, 386], ["N IgG", "PROTEIN", 388, 393], ["N", "PROTEIN", 415, 416], ["IgM", "PROTEIN", 419, 422], ["IgG", "PROTEIN", 427, 430], ["patients", "SPECIES", 82, 90], ["CoV-", "SPECIES", 288, 292], ["SARS-CoV", "SPECIES", 283, 291], ["detectable antibodies", "PROBLEM", 104, 125], ["this study", "TEST", 139, 149], ["serology tests", "TEST", 232, 246], ["antibodies", "TEST", 264, 274], ["SARS", "TEST", 283, 287], ["CoV", "TEST", 288, 291], ["S protein", "TEST", 294, 303], ["S", "TEST", 305, 306], ["RBD total antibodies", "TEST", 307, 327], ["S1", "TEST", 329, 331], ["S2", "TEST", 332, 334], ["IgG", "TEST", 335, 338], ["S1", "TEST", 340, 342], ["IgA", "TEST", 343, 346], ["IgG", "TEST", 351, 354], ["N protein", "TEST", 357, 366], ["total antibodies", "TEST", 370, 386], ["N IgG", "TEST", 388, 393], ["proteins", "TEST", 405, 413], ["N/S IgM", "TEST", 415, 422], ["IgG", "TEST", 427, 430], ["no", "UNCERTAINTY", 101, 103], ["detectable", "OBSERVATION_MODIFIER", 104, 114], ["antibodies", "OBSERVATION", 115, 125]]], ["To our knowledge, this study is the first to report performance of Elecsys Anti-SARS-CoV-2 assay on the cobas e601 module.", [["cobas e601 module", "DNA", 104, 121], ["this study", "TEST", 18, 28], ["Elecsys", "TEST", 67, 74], ["Anti-SARS", "TEST", 75, 84], ["CoV", "TEST", 85, 88]]], ["We specifically investigated their relative value as a complementary tool to screen for prior SARS-CoV-2 infection in individuals that were not (conclusively) tested by PCR in early stage of active viral replication up to 10 days after onset of symptoms.", [["infection", "DISEASE", 105, 114], ["SARS-CoV-2", "ORGANISM", 94, 104], ["individuals", "ORGANISM", 118, 129], ["SARS-CoV", "SPECIES", 94, 102], ["prior SARS", "PROBLEM", 88, 98], ["CoV", "PROBLEM", 99, 102], ["2 infection", "PROBLEM", 103, 114], ["active viral replication", "TREATMENT", 191, 215], ["symptoms", "PROBLEM", 245, 253], ["infection", "OBSERVATION", 105, 114], ["active", "OBSERVATION_MODIFIER", 191, 197], ["viral replication", "OBSERVATION", 198, 215]]], ["As a working definition for acceptable performance, we propose that such an assay should combine a minimal sensitivity for detection of SARS-CoV-2 antibodies of 95% vs a consensus estimate and a high analytical specificity above 98% in samples taken 20 days or more after onset of symptoms, also in subjects who experienced mild SARS-CoV-2 symptoms.", [["samples", "ANATOMY", 236, 243], ["SARS", "DISEASE", 136, 140], ["SARS", "DISEASE", 329, 333], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["SARS-CoV-2 antibodies", "PROTEIN", 136, 157], ["SARS-CoV", "SPECIES", 136, 144], ["an assay", "TEST", 73, 81], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144], ["antibodies", "TEST", 147, 157], ["symptoms", "PROBLEM", 281, 289], ["mild SARS", "PROBLEM", 324, 333], ["CoV-2 symptoms", "PROBLEM", 334, 348], ["mild", "OBSERVATION_MODIFIER", 324, 328], ["SARS", "OBSERVATION", 329, 333]]], ["Based on these criteria, Wantai SARS-COV-2 Ab ELISA, Elecsys Anti-SARS-CoV-2 assay, and Innovita 2019-nCoV Ab Test all showed acceptable analytical specificity.", [["these criteria", "TEST", 9, 23], ["Wantai SARS", "TEST", 25, 36], ["COV", "TEST", 37, 40], ["Ab ELISA", "TEST", 43, 51], ["Elecsys", "TEST", 53, 60], ["Anti-SARS", "TEST", 61, 70], ["CoV", "TEST", 71, 74], ["Innovita", "TEST", 88, 96], ["nCoV Ab Test", "TEST", 102, 114]]], ["In terms of sensitivity for detection of SARS-CoV-2 antibodies vs consensus result obtained by all tests, Wantai SARS-COV-2 Ab ELISA, Elecsys Anti-SARS-CoV-2 assay, EUROIMMUN Anti-SARS-CoV-2 IgG combined with IgA, and Orient Gene COVID-19 IgG/IgM Rapid Test were acceptable.", [["SARS", "DISEASE", 41, 45], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 185, 194], ["IgA", "GENE_OR_GENE_PRODUCT", 209, 212], ["SARS-CoV-2 antibodies", "PROTEIN", 41, 62], ["CoV", "PROTEIN", 185, 188], ["IgG", "PROTEIN", 191, 194], ["IgA", "PROTEIN", 209, 212], ["IgG", "PROTEIN", 239, 242], ["IgM", "PROTEIN", 243, 246], ["SARS-CoV", "SPECIES", 41, 49], ["sensitivity", "TEST", 12, 23], ["detection", "TEST", 28, 37], ["SARS", "PROBLEM", 41, 45], ["CoV-2 antibodies", "TEST", 46, 62], ["all tests", "TEST", 95, 104], ["Wantai SARS", "TEST", 106, 117], ["COV", "TEST", 118, 121], ["Ab ELISA", "TEST", 124, 132], ["Elecsys", "TEST", 134, 141], ["Anti-SARS", "TEST", 142, 151], ["CoV", "TEST", 152, 155], ["EUROIMMUN", "TEST", 165, 174], ["Anti-SARS", "TEST", 175, 184], ["CoV", "TEST", 185, 188], ["IgA", "TEST", 209, 212], ["Orient Gene COVID", "TEST", 218, 235], ["IgG/IgM Rapid Test", "TEST", 239, 257]]], ["Overall, only Wantai SARS-COV-2 Ab ELISA and Elecsys Anti-SARS-CoV-2 assay fulfilled the proposed acceptance criteria, with Wantai SARS-COV-2 Ab ELISA clearly outperforming all other evaluated assays.DiscussionA strength of this study is that the parallel evaluation of several kits allowed a reliable direct comparison of clinical performance using cutoffs provided by manufacturers.", [["Wantai SARS-COV", "TEST", 14, 29], ["Ab ELISA", "TEST", 32, 40], ["Elecsys", "TEST", 45, 52], ["Anti-SARS", "TEST", 53, 62], ["CoV", "TEST", 63, 66], ["this study", "TEST", 224, 234], ["the parallel evaluation", "TEST", 243, 266]]], ["Also, our patient cohorts, including not only severe COVID-19 patients but also a sizeable cohort of mild SARS-CoV-2 infections, provide a good estimate on assays\u2019 performances in the intended target population.", [["COVID", "DISEASE", 53, 58], ["SARS", "DISEASE", 106, 110], ["infections", "DISEASE", 117, 127], ["patient", "ORGANISM", 10, 17], ["patients", "ORGANISM", 62, 70], ["patient", "SPECIES", 10, 17], ["patients", "SPECIES", 62, 70], ["mild SARS", "PROBLEM", 101, 110], ["CoV-2 infections", "PROBLEM", 111, 127], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["SARS", "OBSERVATION", 106, 110]]], ["We observed no notable differences in timing of seroconversion between severe and milder SARS-CoV-2 infections.DiscussionThere are limitations to our study.", [["SARS-CoV-2 infections", "DISEASE", 89, 110], ["CoV-2", "ORGANISM", 94, 99], ["SARS-CoV-2", "SPECIES", 89, 99], ["notable differences", "PROBLEM", 15, 34], ["seroconversion between severe and milder SARS", "PROBLEM", 48, 93], ["CoV-2 infections", "PROBLEM", 94, 110], ["our study", "TEST", 146, 155], ["no", "UNCERTAINTY", 12, 14], ["notable", "OBSERVATION_MODIFIER", 15, 22], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["milder", "OBSERVATION_MODIFIER", 82, 88], ["SARS", "OBSERVATION", 89, 93]]], ["Cross-reactivity analysis might require more extensive exploration.", [["Cross-reactivity analysis", "TEST", 0, 25], ["extensive exploration", "TEST", 45, 66], ["extensive", "OBSERVATION_MODIFIER", 45, 54], ["exploration", "OBSERVATION", 55, 66]]], ["A higher number of sera from patients with PCR-confirmed HCoV infections and other common cold viruses need to be investigated.", [["sera", "ANATOMY", 19, 23], ["infections", "DISEASE", 62, 72], ["sera", "ORGANISM_SUBSTANCE", 19, 23], ["patients", "ORGANISM", 29, 37], ["HCoV", "ORGANISM", 57, 61], ["patients", "SPECIES", 29, 37], ["HCoV", "SPECIES", 57, 61], ["PCR", "TEST", 43, 46], ["HCoV infections", "PROBLEM", 57, 72], ["other common cold viruses", "PROBLEM", 77, 102], ["infections", "OBSERVATION", 62, 72], ["viruses", "OBSERVATION", 95, 102]]], ["Our study did not include a sizeable cohort of fully asymptomatic SARS-CoV-2 infections, and it focused solely on qualitative analysis.", [["SARS", "DISEASE", 66, 70], ["infections", "DISEASE", 77, 87], ["SARS-CoV-2", "ORGANISM", 66, 76], ["SARS-CoV", "SPECIES", 66, 74], ["Our study", "TEST", 0, 9], ["fully asymptomatic SARS", "PROBLEM", 47, 70], ["2 infections", "PROBLEM", 75, 87], ["qualitative analysis", "TEST", 114, 134], ["asymptomatic", "OBSERVATION_MODIFIER", 53, 65], ["SARS", "OBSERVATION", 66, 70]]], ["Therefore, no investigation of differences in assays\u2019 performance for quantification of antibody titers was performed.DiscussionIn critically ill COVID-19 patients, SARS-CoV-2 antibody levels were reported to correlate to disease severity1 by triggering bradykinin and complement activation pathways.", [["SARS", "DISEASE", 165, 169], ["bradykinin", "CHEMICAL", 254, 264], ["bradykinin", "CHEMICAL", 254, 264], ["patients", "ORGANISM", 155, 163], ["SARS-CoV-2 antibody", "GENE_OR_GENE_PRODUCT", 165, 184], ["bradykinin", "GENE_OR_GENE_PRODUCT", 254, 264], ["patients", "SPECIES", 155, 163], ["SARS-CoV", "SPECIES", 165, 173], ["assays", "TEST", 46, 52], ["quantification of antibody titers", "TEST", 70, 103], ["SARS-CoV-2 antibody levels", "TEST", 165, 191], ["disease severity1", "PROBLEM", 222, 239]]], ["The assays evaluated here show large variations in their dynamic range, ranging from a good linearity for LIAISON SARS-CoV-2 S1/S2 IgG14 to a limited dynamic range with rapid signal saturation for Wantai SARS-COV-2 Ab ELISA.", [["IgG14", "PROTEIN", 131, 136], ["The assays", "TEST", 0, 10], ["large variations", "PROBLEM", 31, 47], ["LIAISON SARS", "TEST", 106, 118], ["CoV", "TEST", 119, 122], ["rapid signal saturation", "TEST", 169, 192], ["Wantai SARS", "TEST", 197, 208], ["large", "OBSERVATION_MODIFIER", 31, 36], ["variations", "OBSERVATION_MODIFIER", 37, 47]]], ["With a sample volume input of 100 \u03bcL that is 10 to 20 times higher than the other evaluated assays, Wantai SARS-COV-2 Ab ELISA is clearly designed toward high sensitivity for detection of SARS-CoV-2 antibodies by maximal antibody capture.", [["sample", "ANATOMY", 7, 13], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 188, 209], ["SARS-CoV-2 antibodies", "PROTEIN", 188, 209], ["SARS-CoV", "SPECIES", 188, 196], ["a sample volume input", "TEST", 5, 26], ["assays", "TEST", 92, 98], ["Wantai SARS-COV", "TEST", 100, 115], ["Ab ELISA", "TEST", 118, 126], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["maximal antibody capture", "TREATMENT", 213, 237], ["10 to 20 times higher", "OBSERVATION_MODIFIER", 45, 66], ["antibody capture", "OBSERVATION", 221, 237]]], ["Caution is needed when comparing (semi)quantitative estimates of antibody titers across platforms before certified standards with known titers become available.DiscussionOur data are compatible with other cross-platform evaluations15 indicating superior performance of Wantai SARS-COV-2 Ab ELISA as compared to EUROIMMUN Anti-SARS-CoV-2 IgG and IgA.", [["Anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 321, 340], ["IgA", "GENE_OR_GENE_PRODUCT", 345, 348], ["EUROIMMUN Anti-SARS-CoV-2 IgG", "PROTEIN", 311, 340], ["IgA", "PROTEIN", 345, 348], ["antibody titers", "TEST", 65, 80], ["known titers", "PROBLEM", 130, 142], ["other cross-platform evaluations", "TEST", 199, 231], ["Wantai SARS", "PROBLEM", 269, 280], ["COV", "TEST", 281, 284], ["Ab ELISA", "TEST", 287, 295], ["EUROIMMUN", "TEST", 311, 320], ["Anti-SARS", "TEST", 321, 330], ["CoV", "TEST", 331, 334]]], ["The results are, however, discrepant with another study reporting a sensitivity of 100% and 99% specificity for LIAISON SARS-CoV-2 S1/S2 IgG14 obtained on a small set of 125 samples including only 40 PCR-confirmed patients and after receiver operating characteristic optimization of assay cutoffs.", [["samples", "ANATOMY", 174, 181], ["IgG14", "GENE_OR_GENE_PRODUCT", 137, 142], ["samples", "CANCER", 174, 181], ["patients", "ORGANISM", 214, 222], ["IgG14", "PROTEIN", 137, 142], ["patients", "SPECIES", 214, 222], ["SARS-CoV", "SPECIES", 120, 128], ["another study", "TEST", 42, 55], ["a sensitivity", "TEST", 66, 79], ["LIAISON SARS", "TEST", 112, 124], ["CoV", "TEST", 125, 128], ["40 PCR", "TEST", 197, 203], ["assay cutoffs", "TEST", 283, 296]]], ["Since we observed considerable lot-to-lot variations in raw signals of the 2 LIAISON SARS-CoV-2 S1/S2 IgG kits tested, we believe that caution is warranted and cutoffs should only be optimized on better data sets and proper assessment of different lots.DiscussionIt was reported that antibodies against S protein appear later in infection than antibodies against N protein.1,9 We also observed faster seroconversion of N vs S1 targeting IgG in EUROIMMUN assays.", [["infection", "DISEASE", 329, 338], ["1,9", "CHEMICAL", 373, 376], ["antibodies against S protein", "GENE_OR_GENE_PRODUCT", 284, 312], ["antibodies against N protein", "GENE_OR_GENE_PRODUCT", 344, 372], ["IgG", "GENE_OR_GENE_PRODUCT", 437, 440], ["LIAISON SARS-CoV-2 S1/S2 IgG kits", "DNA", 77, 110], ["antibodies", "PROTEIN", 284, 294], ["S protein", "PROTEIN", 303, 312], ["antibodies", "PROTEIN", 344, 354], ["N protein", "PROTEIN", 363, 372], ["IgG", "PROTEIN", 437, 440], ["CoV", "TEST", 90, 93], ["S1/S2 IgG kits", "TEST", 96, 110], ["cutoffs", "TEST", 160, 167], ["proper assessment", "TEST", 217, 234], ["S protein", "PROBLEM", 303, 312], ["infection", "PROBLEM", 329, 338], ["faster", "OBSERVATION_MODIFIER", 394, 400], ["seroconversion", "OBSERVATION", 401, 415]]], ["On the other hand, we observed a much faster seroconversion of total antibodies (IgA/IgM/IgG) against S-RBD (Wantai) than N protein (Elecsys).", [["IgA", "GENE_OR_GENE_PRODUCT", 81, 84], ["IgM", "GENE_OR_GENE_PRODUCT", 85, 88], ["IgG", "GENE_OR_GENE_PRODUCT", 89, 92], ["S-RBD", "GENE_OR_GENE_PRODUCT", 102, 107], ["Wantai", "SIMPLE_CHEMICAL", 109, 115], ["N protein", "GENE_OR_GENE_PRODUCT", 122, 131], ["total antibodies", "PROTEIN", 63, 79], ["IgA", "PROTEIN", 81, 84], ["IgM", "PROTEIN", 85, 88], ["IgG", "PROTEIN", 89, 92], ["RBD", "PROTEIN", 104, 107], ["Wantai", "PROTEIN", 109, 115], ["N protein", "PROTEIN", 122, 131], ["total antibodies", "TEST", 63, 79], ["IgA/IgM", "TEST", 81, 88], ["IgG", "TEST", 89, 92], ["RBD", "PROBLEM", 104, 107]]], ["Within the same epitope/assay format (EUROIMMUN to S1), IgA antibodies clearly precede IgG.", [["IgA antibodies", "GENE_OR_GENE_PRODUCT", 56, 70], ["IgG", "GENE_OR_GENE_PRODUCT", 87, 90], ["epitope", "PROTEIN", 16, 23], ["S1", "PROTEIN", 51, 53], ["IgA antibodies", "PROTEIN", 56, 70], ["IgG", "PROTEIN", 87, 90], ["IgA antibodies", "TEST", 56, 70]]], ["Overall, our data suggest that timing of seroconversion depends more on assay design, recombinant viral epitope, and antibody isotypes covered, and that overall sensitivity for detection of antibodies is likely enhanced when both IgA and IgG isotypes are measured.DiscussionIn conclusion, this study supports clinical use of both Wantai SARS-COV-2 Ab ELISA and Elecsys Anti-SARS-CoV-2 assay for sensitive and specific screening of SARS-CoV-2 antibodies from 10 days after onset of symptoms.", [["IgA", "GENE_OR_GENE_PRODUCT", 230, 233], ["IgG isotypes", "GENE_OR_GENE_PRODUCT", 238, 250], ["SARS-CoV-2 antibodies", "GENE_OR_GENE_PRODUCT", 431, 452], ["recombinant viral epitope", "PROTEIN", 86, 111], ["antibody isotypes", "PROTEIN", 117, 134], ["antibodies", "PROTEIN", 190, 200], ["IgA", "PROTEIN", 230, 233], ["IgG isotypes", "PROTEIN", 238, 250], ["SARS-CoV-2 antibodies", "PROTEIN", 431, 452], ["SARS-CoV", "SPECIES", 431, 439], ["our data", "TEST", 9, 17], ["seroconversion", "TREATMENT", 41, 55], ["recombinant viral epitope", "PROBLEM", 86, 111], ["antibody isotypes", "TEST", 117, 134], ["detection of antibodies", "TEST", 177, 200], ["IgA", "TEST", 230, 233], ["IgG isotypes", "TEST", 238, 250], ["this study", "TEST", 289, 299], ["both Wantai SARS", "TEST", 325, 341], ["COV", "TEST", 342, 345], ["Ab ELISA", "TEST", 348, 356], ["Elecsys", "TEST", 361, 368], ["Anti-SARS", "TEST", 369, 378], ["CoV", "TEST", 379, 382], ["specific screening", "TEST", 409, 427], ["SARS", "TEST", 431, 435], ["CoV", "TEST", 436, 439], ["symptoms", "PROBLEM", 481, 489], ["IgG isotypes", "OBSERVATION", 238, 250]]]]}